<?xml version="1.0" encoding="ISO-8859-1"?><COCHRANE_REVIEW DESCRIPTION="For publication" DOI="10.1002/14651858.CD006254.pub2" GROUP_ID="RENAL" ID="418505092616032051" MERGED_FROM="" MODIFIED="2014-12-09 17:47:14 +1100" MODIFIED_BY="Narelle Willis" REVIEW_NO="085" REVMAN_SUB_VERSION="5.3.5 " REVMAN_VERSION="5" SPLIT_FROM="" STAGE="R" STATUS="A" TYPE="INTERVENTION" VERSION_NO="8.2">
<COVER_SHEET MODIFIED="2014-12-09 17:46:46 +1100" MODIFIED_BY="Narelle Willis">
<TITLE>Calcimimetics for secondary hyperparathyroidism in chronic kidney disease patients</TITLE>
<CONTACT>
<PERSON ID="16154" ROLE="AUTHOR">
<PREFIX>Dr</PREFIX>
<FIRST_NAME>Giovanni</FIRST_NAME>
<MIDDLE_INITIALS>FM</MIDDLE_INITIALS>
<LAST_NAME>Strippoli</LAST_NAME>
<SUFFIX/>
<POSITION>Editor and Regional Coordinator</POSITION>
<EMAIL_1>strippoli@negrisud.it</EMAIL_1>
<EMAIL_2>gfmstrippoli@gmail.com</EMAIL_2>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Cochrane Renal Group, Centre for Kidney Research</DEPARTMENT>
<ORGANISATION>The Children's Hospital at Westmead</ORGANISATION>
<ADDRESS_1>Locked Bag 4001</ADDRESS_1>
<ADDRESS_2/>
<CITY>Westmead</CITY>
<ZIP>2145</ZIP>
<REGION>NSW</REGION>
<COUNTRY CODE="AU">Australia</COUNTRY>
<PHONE_1>+39 080 5580776</PHONE_1>
<PHONE_2>+39 349 5705884</PHONE_2>
<FAX_1>+39 080 5580776</FAX_1>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
</CONTACT>
<CREATORS MODIFIED="2014-12-09 17:46:46 +1100" MODIFIED_BY="Narelle Willis">
<PERSON ID="65703978595573372637111109061948" ROLE="AUTHOR">
<PREFIX>Ms</PREFIX>
<FIRST_NAME>Angela</FIRST_NAME>
<MIDDLE_INITIALS>E</MIDDLE_INITIALS>
<LAST_NAME>Ballinger</LAST_NAME>
<SUFFIX/>
<POSITION>Medical Student</POSITION>
<EMAIL_1>balan836@student.otago.ac.nz</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Department of Medicine</DEPARTMENT>
<ORGANISATION>University of Otago Christchurch</ORGANISATION>
<ADDRESS_1>2 Riccarton Ave</ADDRESS_1>
<ADDRESS_2/>
<CITY>Christchurch</CITY>
<ZIP>8041</ZIP>
<REGION/>
<COUNTRY CODE="NZ">New Zealand</COUNTRY>
<PHONE_1/>
<PHONE_2/>
<FAX_1/>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
<PERSON ID="19787" ROLE="AUTHOR">
<PREFIX>Dr</PREFIX>
<FIRST_NAME>Suetonia</FIRST_NAME>
<MIDDLE_INITIALS>C</MIDDLE_INITIALS>
<LAST_NAME>Palmer</LAST_NAME>
<SUFFIX>MBChB</SUFFIX>
<POSITION/>
<EMAIL_1>suetonia.palmer@otago.ac.nz</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Department of Medicine</DEPARTMENT>
<ORGANISATION>University of Otago Christchurch</ORGANISATION>
<ADDRESS_1>2 Riccarton Ave</ADDRESS_1>
<ADDRESS_2>PO Box 4345</ADDRESS_2>
<CITY>Christchurch</CITY>
<ZIP>8140</ZIP>
<REGION/>
<COUNTRY CODE="NZ">New Zealand</COUNTRY>
<PHONE_1>+64 21626008</PHONE_1>
<PHONE_2/>
<FAX_1>+64 3 3253368</FAX_1>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
<PERSON ID="33825053211215209688111117004628" ROLE="AUTHOR">
<PREFIX>Dr</PREFIX>
<FIRST_NAME>Ionut</FIRST_NAME>
<MIDDLE_INITIALS/>
<LAST_NAME>Nistor</LAST_NAME>
<SUFFIX/>
<POSITION>Nephrology Consultant</POSITION>
<EMAIL_1>ionutni@yahoo.com</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE>+40740092080</MOBILE_PHONE>
<ADDRESS>
<DEPARTMENT>Nephrology Department</DEPARTMENT>
<ORGANISATION>"Gr. T. Popa" University of Medicine and Pharmacy</ORGANISATION>
<ADDRESS_1>Bdul Carol I, No 50</ADDRESS_1>
<ADDRESS_2/>
<CITY>Iasi</CITY>
<ZIP>700503</ZIP>
<REGION>Iasi</REGION>
<COUNTRY CODE="RO">Romania</COUNTRY>
<PHONE_1>+4 0232-267 555</PHONE_1>
<PHONE_2>+4 0332-409 876</PHONE_2>
<FAX_1>+4 0232-211 752</FAX_1>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
<PERSON ID="4552" ROLE="AUTHOR">
<PREFIX>Prof</PREFIX>
<FIRST_NAME>Jonathan</FIRST_NAME>
<MIDDLE_INITIALS>C</MIDDLE_INITIALS>
<LAST_NAME>Craig</LAST_NAME>
<SUFFIX/>
<POSITION/>
<EMAIL_1>jonathan.craig@sydney.edu.au</EMAIL_1>
<EMAIL_2>JonC@health.usyd.edu.au</EMAIL_2>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Sydney School of Public Health</DEPARTMENT>
<ORGANISATION>The University of Sydney</ORGANISATION>
<ADDRESS_1>Edward Ford Building A27</ADDRESS_1>
<ADDRESS_2/>
<CITY>Sydney</CITY>
<ZIP>2006</ZIP>
<REGION>NSW</REGION>
<COUNTRY CODE="AU">Australia</COUNTRY>
<PHONE_1/>
<PHONE_2/>
<FAX_1/>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
<PERSON ID="16154" ROLE="AUTHOR">
<PREFIX>Dr</PREFIX>
<FIRST_NAME>Giovanni</FIRST_NAME>
<MIDDLE_INITIALS>FM</MIDDLE_INITIALS>
<LAST_NAME>Strippoli</LAST_NAME>
<SUFFIX/>
<POSITION>Editor and Regional Coordinator</POSITION>
<EMAIL_1>strippoli@negrisud.it</EMAIL_1>
<EMAIL_2>gfmstrippoli@gmail.com</EMAIL_2>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Cochrane Renal Group, Centre for Kidney Research</DEPARTMENT>
<ORGANISATION>The Children's Hospital at Westmead</ORGANISATION>
<ADDRESS_1>Locked Bag 4001</ADDRESS_1>
<ADDRESS_2/>
<CITY>Westmead</CITY>
<ZIP>2145</ZIP>
<REGION>NSW</REGION>
<COUNTRY CODE="AU">Australia</COUNTRY>
<PHONE_1>+39 080 5580776</PHONE_1>
<PHONE_2>+39 349 5705884</PHONE_2>
<FAX_1>+39 080 5580776</FAX_1>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
</CREATORS>
<DATES MODIFIED="2014-12-09 17:46:46 +1100" MODIFIED_BY="Narelle Willis">
<UP_TO_DATE>
<DATE DAY="13" MONTH="2" YEAR="2013"/>
</UP_TO_DATE>
<LAST_SEARCH>
<DATE DAY="7" MONTH="2" YEAR="2013"/>
</LAST_SEARCH>
<NEXT_STAGE>
<DATE DAY="1" MONTH="12" YEAR="2015"/>
</NEXT_STAGE>
<PROTOCOL_PUBLISHED ISSUE="4" YEAR="2006"/>
<REVIEW_PUBLISHED ISSUE="4" YEAR="2006"/>
<LAST_CITATION_ISSUE ISSUE="12" YEAR="2014"/>
</DATES>
<WHATS_NEW MODIFIED="2014-06-11 15:31:35 +1000" MODIFIED_BY="Narelle Willis">
<WHATS_NEW_ENTRY EVENT="UPDATE" MODIFIED="2014-06-11 15:31:35 +1000" MODIFIED_BY="Narelle Willis">
<DATE DAY="11" MONTH="6" YEAR="2014"/>
<DESCRIPTION>
<P>Methods updated, authorship change</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="NEW_CITATION_NEW_CONCLUSIONS" MODIFIED="2014-06-11 15:31:03 +1000" MODIFIED_BY="Narelle Willis">
<DATE DAY="11" MONTH="6" YEAR="2014"/>
<DESCRIPTION>
<P>New studies added</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="AMENDMENT" MODIFIED="2014-06-11 15:29:51 +1000" MODIFIED_BY="Narelle Willis">
<DATE DAY="7" MONTH="2" YEAR="2013"/>
<DESCRIPTION>
<P>Search updated</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</WHATS_NEW>
<HISTORY MODIFIED="2014-06-11 15:29:51 +1000" MODIFIED_BY="Narelle Willis">
<WHATS_NEW_ENTRY EVENT="AMENDMENT" MODIFIED="2010-01-14 11:45:26 +1100" MODIFIED_BY="Narelle Willis">
<DATE DAY="13" MONTH="8" YEAR="2009"/>
<DESCRIPTION>
<P>Contact details updated.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="AMENDMENT" MODIFIED="2009-08-13 14:58:03 +1000" MODIFIED_BY="Narelle Willis">
<DATE DAY="13" MONTH="5" YEAR="2009"/>
<DESCRIPTION>
<P>Contact details updated.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="AMENDMENT" MODIFIED="2009-05-13 17:51:14 +1000" MODIFIED_BY="Narelle Willis">
<DATE DAY="16" MONTH="9" YEAR="2008"/>
<DESCRIPTION>
<P>Converted to new review format.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</HISTORY>
<SOURCES_OF_SUPPORT MODIFIED="2014-06-02 16:27:49 +1000" MODIFIED_BY="Narelle Willis">
<INTERNAL_SOURCES MODIFIED="2013-06-01 14:20:36 +1000" MODIFIED_BY="Suetonia Palmer">
<SOURCE MODIFIED="2013-06-01 14:20:36 +1000" MODIFIED_BY="Suetonia Palmer">
<NAME>Cochrane Renal Group</NAME>
<COUNTRY CODE="AU">Australia</COUNTRY>
<DESCRIPTION/>
</SOURCE>
</INTERNAL_SOURCES>
<EXTERNAL_SOURCES MODIFIED="2014-06-02 16:27:49 +1000" MODIFIED_BY="Narelle Willis">
<SOURCE MODIFIED="2014-06-02 16:27:16 +1000" MODIFIED_BY="Narelle Willis">
<NAME>Suetonia Palmer receives a Fellowship from the Consorzio Mario Negri Sud from an unrestricted grant from Amgen Dompe</NAME>
<COUNTRY CODE="IT">Italy</COUNTRY>
<DESCRIPTION/>
</SOURCE>
<SOURCE MODIFIED="2014-06-02 16:27:21 +1000" MODIFIED_BY="Narelle Willis">
<NAME>Angela Ballinger completed this review as a University of Otago summer studentship project 2012/2013 supported by the Canterbury Medical Research Foundation</NAME>
<COUNTRY CODE="NZ">New Zealand</COUNTRY>
<DESCRIPTION/>
</SOURCE>
<SOURCE MODIFIED="2014-06-02 16:27:49 +1000" MODIFIED_BY="Narelle Willis">
<NAME>Ionut Nistor was the recipient of a grant from European Renal Best Practice (ERBP) and the European Renal Association-European Dialysis Transplantation Association (ERA-EDTA)</NAME>
<COUNTRY CODE="NONE">Other</COUNTRY>
<DESCRIPTION/>
</SOURCE>
</EXTERNAL_SOURCES>
</SOURCES_OF_SUPPORT>
<MESH_TERMS VERIFIED="NO"/>
<KEYWORDS/>
</COVER_SHEET>
<MAIN_TEXT MODIFIED="2014-12-09 17:47:14 +1100" MODIFIED_BY="Narelle Willis">
<SUMMARY MODIFIED="2014-06-10 15:41:29 +1000" MODIFIED_BY="Narelle Willis">
<TITLE MODIFIED="2008-09-17 17:39:43 +1000" MODIFIED_BY="[Empty name]">Calcimimetics for secondary hyperparathyroidism in chronic kidney disease patients</TITLE>
<SUMMARY_BODY MODIFIED="2014-06-10 15:41:29 +1000" MODIFIED_BY="Narelle Willis">
<P>Abnormal calcium and phosphorous levels in the blood and tissues occur in chronic kidney disease. These changes are linked to shorter survival and hardening of the arteries leading to heart disease. Standard therapy for abnormal calcium and other mineral levels includes dietary restrictions, phosphorous binders and vitamin D compounds. A newer treatment called cinacalcet showed promise for improving abnormal mineral levels but the effects of this drug on patient outcomes (the way patients feel function and survive) were unclear from early studies. We have updated an earlier review dated 2006 to include studies that assessed the effects of cinacalcet in about 7500 people with chronic kidney disease. While cinacalcet improves some blood abnormalities, it does not improve risk of death or heart disease in people treated with dialysis. In addition, people who take cinacalcet may experience increased nausea, vomiting and the need for blood tests to check blood calcium levels. The current research is high-quality and means that additional new studies are unlikely to change our confidence in these results. Information for the use of cinacalcet in people with milder forms of kidney disease and those with a kidney transplant is insufficient to guide decision making.</P>
</SUMMARY_BODY>
</SUMMARY>
<ABSTRACT MODIFIED="2014-07-22 10:16:25 +1000" MODIFIED_BY="Suetonia C Palmer">
<ABS_BACKGROUND MODIFIED="2014-06-11 16:01:34 +1000" MODIFIED_BY="Narelle Willis">
<P>Calcimimetic agents lower abnormal serum parathyroid hormone (PTH) levels in people who have chronic kidney disease (CKD), but the benefits and harms on patient-level outcomes are uncertain. Since this review was first published in 2006 showing that evidence for calcimimetics was largely restricted to biochemical outcomes, additional studies have been conducted. This is an update of a review first published in 2006.</P>
</ABS_BACKGROUND>
<ABS_OBJECTIVES MODIFIED="2014-06-10 17:40:25 +1000" MODIFIED_BY="Narelle Willis">
<P>To evaluate the benefits and harms of cinacalcet on patient-level outcomes in adults with CKD.</P>
</ABS_OBJECTIVES>
<ABS_SEARCH_STRATEGY MODIFIED="2014-06-11 16:43:23 +1000" MODIFIED_BY="Narelle Willis">
<P>MEDLINE, EMBASE, CENTRAL and conference proceedings were searched for randomised controlled trials (RCTs) evaluating any calcimimetic against placebo or another agent in adults with CKD (persistent albuminuria &gt; 30 mg/g with or without reduced glomerular filtration rate (GFR) (below 60 mL/min/1.73 m²)). We updated searches to 7 February 2013 including the Cochrane Renal Group's Specialised Register to complete this update.</P>
</ABS_SEARCH_STRATEGY>
<ABS_SELECTION_CRITERIA MODIFIED="2014-06-10 15:41:11 +1000" MODIFIED_BY="Narelle Willis">
<P>We included all RCTs of a calcimimetic administered to patients with CKD for the treatment of elevated serum PTH levels.</P>
</ABS_SELECTION_CRITERIA>
<ABS_DATA_COLLECTION MODIFIED="2014-06-07 23:50:47 +1000" MODIFIED_BY="[Empty name]">
<P>Data were extracted on all relevant patient-centred and surrogate outcomes. We summarised treatment estimates using random effects and expressed treatment effects as a risk ratio (RR) or mean difference (MD) with 95% confidence intervals (CI).</P>
</ABS_DATA_COLLECTION>
<ABS_RESULTS MODIFIED="2014-07-22 10:16:17 +1000" MODIFIED_BY="Suetonia C Palmer">
<P>Eighteen studies (7446 participants) compared cinacalcet in addition to standard therapy with no treatment or placebo plus standard therapy. In adults with GFR category G5 (GFR below 15 mL/min/1.73 m²) treated with dialysis, routine cinacalcet treatment had little or no effect on all-cause mortality (RR 0.97, 95% CI 0.89 to 1.05), imprecise effects on cardiovascular mortality (RR 0.67, 95% CI 0.16 to 2.87), and prevented surgical parathyroidectomy (RR 0.49, 95% CI 0.40 to 0.59) and hypercalcaemia (RR 0.23, 95% CI 0.05 to 0.97), but increased hypocalcaemia (RR 6.98, 95% CI 5.10 to 9.53), nausea (RR 2.02, 95% CI 1.45 to 2.81) and vomiting (RR 1.97, 95% CI 95% CI 1.73 to 2.24). Cinacalcet decreased serum PTH (MD -281.39 pg/mL, 95% CI -325.84 to -234.94) and calcium (MD -0.87 mg/dL, 95% CI -0.96 to -0.77) levels, but had little or no effect on serum phosphorous levels (MD -0.23 mg/dL, 95% CI -0.58 to 0.12).</P>
<P>Data were sparse for adults with GFR categories G3a to G4 (GFR 15 to 60 mL/min/1.73 m²) and kidney transplant recipients.</P>
<P>Overall, based on GRADE criteria, evidence for cinacalcet in adults with GFR category G5 treated with dialysis (mortality, parathyroidectomy, hypocalcaemia, and nausea) is of high or moderate quality. High quality evidence suggests "further research is very unlikely to change our confidence in the estimate of treatment effect" and moderate quality evidence is "further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate". Information for adults with less severe CKD GFR category G3a to G4 is of low or very low quality. This means that further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate</P>
</ABS_RESULTS>
<ABS_CONCLUSIONS MODIFIED="2013-06-03 05:29:50 +1000" MODIFIED_BY="Suetonia Palmer">
<P>Routine cinacalcet therapy reduced the need for parathyroidectomy in adults treated with dialysis and elevated PTH levels but does not improve all-cause or cardiovascular mortality. Cinacalcet increases risks of nausea, vomiting and hypocalcaemia, suggesting harms may outweigh benefits in this population.</P>
</ABS_CONCLUSIONS>
</ABSTRACT>
<BODY MODIFIED="2014-12-08 16:15:06 +1100" MODIFIED_BY="Narelle Willis">
<BACKGROUND MODIFIED="2014-06-11 16:34:49 +1000" MODIFIED_BY="Narelle Willis">
<CONDITION MODIFIED="2014-06-11 16:05:38 +1000" MODIFIED_BY="Narelle Willis">
<P>Abnormal calcium and phosphorous metabolism occurs with kidney failure and is associated with bone and vascular disease. In addition to causing reduced quality of life, these complications of chronic kidney disease (CKD) are associated with increased mortality and major cardiovascular events (<LINK REF="REF-Block-2004b" TYPE="REFERENCE">Block 2004b</LINK>; <LINK REF="REF-Ganesh-2001" TYPE="REFERENCE">Ganesh 2001</LINK>; <LINK REF="REF-Malluche-2004b" TYPE="REFERENCE">Malluche 2004b</LINK>; <LINK REF="REF-Marco-2003" TYPE="REFERENCE">Marco 2003</LINK>; <LINK REF="REF-Martin-2004" TYPE="REFERENCE">Martin 2004</LINK>; <LINK REF="REF-Stehman_x002d_Breen-2004" TYPE="REFERENCE">Stehman-Breen 2004</LINK>). Standard management of patients with CKD, particularly those with glomerular filtration rate (GFR) category G5 (<LINK REF="REF-KDIGO-CKD-2013" TYPE="REFERENCE">KDIGO CKD 2013</LINK>) includes treatment to control serum levels of calcium, phosphorous and parathyroid hormone (PTH) to prevent bone and soft-tissue complications. Based on a number of association studies (<LINK REF="REF-Block-2004b" TYPE="REFERENCE">Block 2004b</LINK>; <LINK REF="REF-Ganesh-2001" TYPE="REFERENCE">Ganesh 2001</LINK>; <LINK REF="REF-Kestenbaum-2005" TYPE="REFERENCE">Kestenbaum 2005</LINK>; <LINK REF="REF-Marco-2003" TYPE="REFERENCE">Marco 2003</LINK>; <LINK REF="REF-Stevens-2004" TYPE="REFERENCE">Stevens 2004</LINK>), including studies of bone histomorphometry (<LINK REF="REF-Hutchison-1993" TYPE="REFERENCE">Hutchison 1993</LINK>; <LINK REF="REF-Qi-1995" TYPE="REFERENCE">Qi 1995</LINK>; <LINK REF="REF-Wang-1995" TYPE="REFERENCE">Wang 1995</LINK>; <LINK REF="REF-Ziolkowska-2000" TYPE="REFERENCE">Ziolkowska 2000</LINK>), optimal ranges for serum phosphorous, calcium, the calcium by phosphorous product and PTH have been suggested (<LINK REF="REF-KHA_x002d_CARI-2014" TYPE="REFERENCE">KHA-CARI 2014</LINK>; <LINK REF="REF-NKF-2003" TYPE="REFERENCE">NKF 2003</LINK>).</P>
</CONDITION>
<THEORY MODIFIED="2014-06-11 16:34:14 +1000" MODIFIED_BY="Narelle Willis">
<P>Specific management of elevated serum PTH levels in people with GFR categories G3a to G5 (estimated GFR below 60 mL/min/1.73 m²) may be accomplished by restriction of dietary phosphorous, calcium supplementation, or the use of vitamin D compounds or both (<LINK REF="REF-Albaaj-2003" TYPE="REFERENCE">Albaaj 2003</LINK>; <LINK REF="REF-Courant-1993" TYPE="REFERENCE">Courant 1993</LINK>). A novel class of drugs called calcimimetic agents have been developed to reduce PTH secretion and parathyroid cell proliferation, while decreasing levels of serum calcium, phosphorous and the calcium by phosphorous product (<LINK REF="REF-Mentaverri-2006" TYPE="REFERENCE">Mentaverri 2006</LINK>; <LINK REF="REF-Mizobuchi-2007" TYPE="REFERENCE">Mizobuchi 2007</LINK>). Cinacalcet, a calcimimetic agent, was first approved in the United States in 2004 to lower elevated serum PTH levels in dialysis patients (<LINK REF="REF-FDA-2004" TYPE="REFERENCE">FDA 2004</LINK>). Cinacalcet mimics the action of calcium on calcium-sensing receptors in the parathyroid gland to suppress PTH secretion. In an earlier version of this review that included eight studies (1,429 participants) published in late 2005 or earlier, cinacalcet markedly reduced serum levels of PTH (290 pg/mL), calcium (-0.85 mg/dL) and phosphorous (-0.29 mg/dL), that have all been shown to be associated with poorer outcomes in adults with CKD (<LINK REF="REF-Block-2004b" TYPE="REFERENCE">Block 2004b</LINK>)</P>
</THEORY>
<IMPORTANCE MODIFIED="2014-06-11 16:34:49 +1000" MODIFIED_BY="Narelle Willis">
<P>However, while cinacalcet reduces biochemical parameters (serum PTH, calcium, and phosphorous), our earlier meta-analysis found insufficient evidence for benefit on clinical outcomes. Despite this lack of evidence for patient-level outcomes, cinacalcet has become the largest single drug cost for dialysis patients in the United States with annual prescribing costs of at least USD 260 million (<LINK REF="REF-USRDS-2012" TYPE="REFERENCE">USRDS 2012</LINK>). A pooled analysis of four placebo-controlled randomised controlled trials (RCTs) of cinacalcet in 2005 showed a large reduction in cardiovascular-related hospitalisation which may have led to uncertainty for clinicians about the therapy benefits of cinacalcet treatment (<LINK REF="REF-Cunningham-2005a" TYPE="REFERENCE">Cunningham 2005a</LINK>).</P>
<P>This systematic review now updates an earlier review that was performed at an early phase of calcimimetic usage, but one year after licensing by the FDA (<LINK REF="REF-FDA-2004" TYPE="REFERENCE">FDA 2004</LINK>). In the light of recent studies of cinacalcet, high prescribing costs in some regions and insufficient existing evidence for cinacalcet on patient-level outcomes in an earlier review, we have updated the evidence summary for the benefits and harms of cinacalcet therapy in people with CKD to early 2013.</P>
</IMPORTANCE>
</BACKGROUND>
<OBJECTIVES MODIFIED="2014-06-07 23:51:29 +1000" MODIFIED_BY="[Empty name]">
<P>To evaluate the benefits and harms of cinacalcet on patient-level outcomes in adults with CKD.</P>
</OBJECTIVES>
<METHODS MODIFIED="2014-06-11 16:45:38 +1000" MODIFIED_BY="Narelle Willis">
<SELECTION_CRITERIA MODIFIED="2014-06-10 15:42:16 +1000" MODIFIED_BY="Narelle Willis">
<CRIT_STUDIES MODIFIED="2014-06-10 15:42:16 +1000" MODIFIED_BY="Narelle Willis">
<P>We included all RCTs of any calcimimetic agent (cinacalcet HCl (AMG-073, Sensipar®), NPS R-467 or NPS R-568) administered to patients with CKD and elevated serum PTH levels.</P>
</CRIT_STUDIES>
<CRIT_PARTICIPANTS MODIFIED="2014-06-07 23:51:34 +1000" MODIFIED_BY="[Empty name]">
<P>Patients with CKD of any severity and elevated serum parathyroid levels.</P>
</CRIT_PARTICIPANTS>
<CRIT_INTERVENTIONS>
<P>Any calcimimetic agent (e.g. cinacalcet HCl (AMG-073, Sensipar®), NPS R-467 or NPS R-568).</P>
</CRIT_INTERVENTIONS>
<CRIT_OUTCOMES MODIFIED="2014-06-10 15:34:48 +1000" MODIFIED_BY="Narelle Willis">
<CRIT_OUTCOMES_PRIMARY MODIFIED="2013-06-01 18:41:25 +1000" MODIFIED_BY="Suetonia Palmer">
<UL>
<LI>All-cause mortality</LI>
<LI>Cardiovascular mortality</LI>
<LI>Parathyroidectomy</LI>
<LI>Fractures</LI>
<LI>Adverse events (hypocalcaemia, hypercalcaemia, nausea, vomiting, upper respiratory tract infection, dyspnoea, muscle weakness, headache, paraesthesia, abdominal pain, diarrhoea)</LI>
</UL>
</CRIT_OUTCOMES_PRIMARY>
<CRIT_OUTCOMES_SECONDARY MODIFIED="2014-06-10 15:34:48 +1000" MODIFIED_BY="Narelle Willis">
<UL>
<LI>At least 30% decrease in serum PTH level</LI>
<LI>Fractures</LI>
<LI>Mixed uraemic osteodystrophy</LI>
<LI>Bone histomorphometry</LI>
<LI>End of treatment PTH levels (any measure)</LI>
<LI>End of treatment serum calcium concentrations (mg/dL)</LI>
<LI>End of treatment serum phosphorous concentrations (mg/dL)</LI>
<LI>End of treatment calcium x phosphorous product (mg²/dL²)</LI>
</UL>
</CRIT_OUTCOMES_SECONDARY>
</CRIT_OUTCOMES>
</SELECTION_CRITERIA>
<SEARCH_METHODS MODIFIED="2014-06-11 16:37:07 +1000" MODIFIED_BY="Narelle Willis">
<P>For this review update we searched EMBASE and the Cochrane Renal Group's Specialised Register (to 7 February 2013) through contact with the Trials' Search Co-ordinator using search terms relevant to this review. The Cochrane Renal Group&#8217;s Specialised Register contains studies identified from the following sources.</P>
<OL>
<LI>Monthly searches of the Cochrane Central Register of Controlled Trials (CENTRAL)</LI>
<LI>Weekly searches of MEDLINE OVID SP</LI>
<LI>Handsearching of renal-related journals &amp; the proceedings of major renal conferences</LI>
<LI>Searching of the current year of EMBASE OVID SP</LI>
<LI>Weekly current awareness alerts for selected renal-journals</LI>
<LI>Searches of the International Clinical Trials Register (ICTRP) Search Portal &amp; ClinicalTrials.gov.</LI>
</OL>
<P>Studies contained in the Specialised Register were identified through search strategies for CENTRAL, MEDLINE, and EMBASE based on the scope of the Cochrane Renal Group. Details of these strategies as well as a list of handsearched journals, conference proceedings and current awareness alerts are available in the 'Specialised Register' section of information about the <A HREF="http://onlinelibrary.wiley.com/o/cochrane/clabout/articles/RENAL/frame.html">Cochrane Renal Group</A>.</P>
<P>See <LINK REF="APP-01" TYPE="APPENDIX">Appendix 1</LINK> for search terms used in strategies for this review.</P>
<P>Previous search strategies can be found in <LINK REF="REF-Strippoli-2006a" TYPE="REFERENCE">Strippoli 2006a</LINK>.</P>
</SEARCH_METHODS>
<DATA_COLLECTION MODIFIED="2014-06-11 16:45:38 +1000" MODIFIED_BY="Narelle Willis">
<STUDY_SELECTION MODIFIED="2014-06-10 15:42:25 +1000" MODIFIED_BY="Narelle Willis">
<P>The search strategy described was used to obtain titles and abstracts of studies that might have been relevant to the review. The titles and abstracts were screened independently by two or more authors, who discarded studies that were not applicable; however studies and reviews that might have included relevant data or information on studies were retained initially. Two authors independently assessed retrieved abstracts and, if necessary the full text, of these studies to determine which studies satisfied the inclusion criteria.</P>
</STUDY_SELECTION>
<DATA_EXTRACTION MODIFIED="2014-06-11 16:07:37 +1000" MODIFIED_BY="Narelle Willis">
<P>Data extraction for population characteristics, interventions, non-randomised co-interventions, and risk of bias was carried out independently by two or more authors using standard data extraction forms in a purpose-built database. Each author double-checked data extraction and data entry independently and any discrepancies between authors were resolved through discussion.</P>
<P>The following data were extracted.</P>
<UL>
<LI>Population: category of CKD, mean age, proportion of men, baseline serum PTH level</LI>
<LI>Intervention: drug name, dosing strategy, target serum PTH level used, randomised and non-randomised co-interventions</LI>
<LI>Comparison: placebo or no treatment, randomised and non-randomised co-interventions</LI>
<LI>Outcomes: all-cause mortality, cardiovascular mortality, parathyroidectomy, fracture, and treatment related adverse events</LI>
<LI>Study design: inclusion criteria; exclusion criteria, primary endpoint; duration of treatment, duration of follow-up, number of participants, date of publication, number of centres, source of funding; study registration (for studies published after 2005); publication (full text publication, abstract publication, unpublished data); period of collection of clinical outcomes (total duration of follow-up, specific phase(s) of follow-up)</LI>
<LI>Risk of bias: sequence generation; allocation concealment; blinding of participants and investigators, blinding of outcome assessment, attrition, selective outcome reporting, other sources of bias (reporting only in conference proceedings, early termination of study, marked imbalance in baseline characteristics, sponsor on authorship or involved with data handling and analysis)</LI>
</UL>
<P>Data were cross checked between authors and discussed. Studies reported in non-English language journals were translated before assessment. Where more than one publication of one study existed, reports were grouped together and the publication with the most complete data was used in the analyses. Where relevant outcomes were only published in earlier versions, these data were used. Any discrepancy between published versions was highlighted. Any disagreements in data extraction were discussed with a third author.</P>
</DATA_EXTRACTION>
<QUALITY_ASSESSMENT MODIFIED="2014-06-11 15:10:06 +1000" MODIFIED_BY="Narelle Willis">
<P>The following items were independently assessed by two authors using the risk of bias assessment tool (<LINK REF="REF-Higgins-2011" TYPE="REFERENCE">Higgins 2011</LINK>). The specific attributes of each risk of bias considered in the adjudication process are described in <LINK REF="APP-02" TYPE="APPENDIX">Appendix 2</LINK>.</P>
<UL>
<LI>Was there adequate sequence generation (selection bias)?</LI>
<LI>Was allocation adequately concealed (selection bias)?</LI>
<LI>Was knowledge of the allocated interventions adequately prevented during the study (detection bias)?</LI>
<UL>
<LI>Participants and personnel</LI>
<LI>Outcome assessors</LI>
</UL>
<LI>Were incomplete outcome data adequately addressed (attrition bias)?</LI>
<LI>Are reports of the study free of suggestion of selective outcome reporting (reporting bias)?</LI>
<LI>Was the study apparently free of other problems that could put it at a risk of bias?</LI>
</UL>
</QUALITY_ASSESSMENT>
<EFFECT_MEASURES MODIFIED="2014-06-11 15:08:53 +1000" MODIFIED_BY="Narelle Willis">
<P>The estimate of effect of an experimental versus a control intervention on categorical outcomes (e.g. all-cause mortality, one or more fractures, parathyroidectomy, one or more episodes of nausea) was analysed using the risk ratio (RR) measure and its 95% confidence interval (CI) for each study. Where proportions of participants experiencing an event were provided in the study reports only (instead of raw event data), we estimated the number of participants experiencing one or more events by multiplying the proportion affected by the sample size and contacted the authors or sponsors for additional information.</P>
<P>For continuous variables (end of treatment serum PTH, calcium, phosphorous, calcium x phosphorous), the mean difference (MD), and its 95% CI were calculated using the end of treatment values of the variable in the treatment and control groups.</P>
</EFFECT_MEASURES>
<HETEROGENEITY_ASSESSMENT MODIFIED="2014-06-11 15:09:20 +1000" MODIFIED_BY="Narelle Willis">
<P>We assessed for heterogeneity in summary effect estimates using the Cochran <I>Q </I>test and the I² test (<LINK REF="REF-Higgins-2003" TYPE="REFERENCE">Higgins 2003</LINK>). We considered a P value &lt; 0.10 to indicate significant heterogeneity.</P>
</HETEROGENEITY_ASSESSMENT>
<DATA_SYNTHESIS MODIFIED="2014-06-11 16:45:38 +1000" MODIFIED_BY="Narelle Willis">
<P>When appropriate and feasible, treatment effects were summarised using random effects meta-analysis and results were expressed as a RR or MD and the 95% confidence interval.</P>
<P>We summarised the quality of the evidence together with absolute treatment effects based on estimated baseline risks by using the Grading of Recommendations Assessment, Development, and Evaluation guidelines (<LINK REF="REF-Guyatt-2008" TYPE="REFERENCE">Guyatt 2008</LINK>). To estimate the absolute number of people with CKD who avoided death or parathyroidectomy and incurred hypocalcaemia or nausea with calcimimetic therapy, the risk estimate and 95% CI were obtained from the corresponding meta-analyses, together with the absolute population risk for people with each category of CKD derived from cohort studies and registry data for all-cause mortality and parathyroidectomy (<LINK REF="REF-Kestenbaum-2004" TYPE="REFERENCE">Kestenbaum 2004</LINK>; <LINK REF="REF-USRDS-2012" TYPE="REFERENCE">USRDS 2012</LINK>; <LINK REF="REF-Weiner-2006" TYPE="REFERENCE">Weiner 2006</LINK>) and event rates in the control arm of meta-analyses for hypocalcaemia and nausea.</P>
</DATA_SYNTHESIS>
<SUBGROUP_ANALYSIS MODIFIED="2014-06-11 15:47:02 +1000" MODIFIED_BY="Narelle Willis">
<P>We analysed data for all-cause mortality, cardiovascular mortality, parathyroidectomy, hypocalcaemia, and nausea and vomiting within stratified analyses comprising adults with GFR category G5 treated with dialysis and GFR categories G33-G4 (using the KDIGO nomenclature - see <LINK REF="TBL-01" TYPE="TABLE">Table 1</LINK> for more details) (<LINK REF="REF-KDIGO-CKD-2013" TYPE="REFERENCE">KDIGO CKD 2013</LINK>).</P>
</SUBGROUP_ANALYSIS>
<SENSITIVITY_ANALYSIS MODIFIED="2014-06-10 15:42:48 +1000" MODIFIED_BY="Narelle Willis">
<P>We conducted additional analyses excluding studies in which randomised co-interventions strategies (vitamin D compounds) were not comparable between treatment arms.</P>
</SENSITIVITY_ANALYSIS>
</DATA_COLLECTION>
</METHODS>
<RESULTS MODIFIED="2014-12-08 16:15:05 +1100" MODIFIED_BY="Narelle Willis">
<STUDY_DESCRIPTION MODIFIED="2014-12-08 16:15:05 +1100" MODIFIED_BY="Narelle Willis">
<SEARCH_RESULTS MODIFIED="2014-12-08 16:15:05 +1100" MODIFIED_BY="Narelle Willis">
<SUBSECTION>
<HEADING LEVEL="4">Initial search to November 2005</HEADING>
<P>Our search for RCTs of calcimimetic interventions identified 186 records (see <LINK REF="FIG-01" TYPE="FIGURE">Figure 1</LINK> - Study flow diagram). Of these, 148 were excluded after title and abstract review because they were clearly ineligible (non-RCTs, RCTs of interventions not relevant to treatment of elevated PTH levels, not calcimimetic interventions, duplicate articles of the same study, or review articles). Of the remaining 38 potentially eligible studies (either full-text or abstract publications), 30 were excluded because we could not confirm from the full-text analysis or from contacting authors that they were RCTs, or that they were not a duplicate publication. Two attempts were made to contact all authors of the studies for clarifications of study designs and request supplemental data but we were not able to obtain some of the data nor to ascertain if some reports (presented in abstract form at the American Society of Nephrology (ASN) and the European Renal Association-European Dialysis and Transplantation Association (ERA-EDTA) meetings of years 2003 and 2004)) were subsets of other publications which had subsequently appeared as full-text articles in scientific journals or were unique unpublished studies. These studies could therefore not be included and were listed under <LINK TAG="CHARACTERISTICS_OF_AWAITING_STUDIES" TYPE="SECTION">Characteristics of studies awaiting classification</LINK>. We have subsequently reviewed these studies and ascertained all but <LINK REF="STD-Coburn-2003" TYPE="STUDY">Coburn 2003</LINK> are clearly duplicate reports of primary studies and these have been moved to the relevant studies.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Search update to February 2013</HEADING>
<P>The updated search to February 7, 2013 is detailed in <LINK REF="FIG-01" TYPE="FIGURE">Figure 1</LINK>.</P>
<P>We identified 78 records from the Cochrane Renal Group Specialised Register and 167 from EMBASE. After title and abstract review we excluded 134 reports (duplicate reports, not randomised, wrong population or intervention).</P>
<P>We screened 111 full-text records and excluded 66 reports as they were not RCTs, did not investigate relevant interventions, or did not include the relevant population. Two ongoing studies from the original review could now be excluded as they are not randomised studies (<LINK REF="STD-CONTROL-Study-2006" TYPE="STUDY">CONTROL Study 2006</LINK>; <LINK REF="STD-TARGET-Study-2008" TYPE="STUDY">TARGET Study 2008</LINK>) and three studies are awaiting classification.</P>
<OL>
<LI>The URL describing the report is no longer linked to the article and the authors could not be contacted to obtain additional information (<LINK REF="STD-UPen-2004a" TYPE="STUDY">UPen 2004a</LINK>)</LI>
<LI>Two studies state they are subgroup analyses of three studies; however we were unable to determine which three studies (<LINK REF="STD-Drueke-2001a" TYPE="STUDY">Drueke 2001a</LINK>; <LINK REF="STD-Fournier-2004a" TYPE="STUDY">Fournier 2004a</LINK>).</LI>
</OL>
</SUBSECTION>
</SEARCH_RESULTS>
<INCLUDED_STUDIES_DESCR MODIFIED="2014-06-12 16:36:21 +1000" MODIFIED_BY="Ruth L Mitchell">
<SUBSECTION>
<HEADING LEVEL="4">Initial review including search to November 2005</HEADING>
<P>In the initial review publication we included eight studies (in eight publications) enrolling 1429 patients (<LINK REF="REF-Block-2004b" TYPE="REFERENCE">Block 2004b</LINK>; <LINK REF="STD-Goodman-2000" TYPE="STUDY">Goodman 2000</LINK>; <LINK REF="STD-Goodman-2002" TYPE="STUDY">Goodman 2002</LINK>; <LINK REF="STD-Harris-2004" TYPE="STUDY">Harris 2004</LINK>; <LINK REF="STD-Lindberg-2003" TYPE="STUDY">Lindberg 2003</LINK>; <LINK REF="STD-Lindberg-2005" TYPE="STUDY">Lindberg 2005</LINK>; <LINK REF="STD-Malluche-2008" TYPE="STUDY">Malluche 2008</LINK> (included as Malluche 2004 in original review); <LINK REF="STD-Quarles-2003a" TYPE="STUDY">Quarles 2003a</LINK>). These studies compared cinacalcet HCl (845 patients) to placebo (584 patients). Three of these studies reported cinacalcet HCl as AMG-073. One study reported on the first-generation calcimimetic R-568. This drug has been withdrawn from clinical use because of poor bioavailability, variable serum concentrations and potential drug interactions caused by cytochrome P-450 activity (<LINK REF="STD-Goodman-2000" TYPE="STUDY">Goodman 2000</LINK>; <LINK REF="REF-Urena-2003" TYPE="REFERENCE">Urena 2003</LINK>).</P>
<P>In addition to these randomised interventions, patients received vitamin D for suppression of PTH and phosphate binders for management of hyperphosphataemia as co-interventions in all studies in a non-randomised fashion. There were no significant differences in the proportions of patients who were prescribed calcitriol, vitamin D analogues and phosphate binders as co-interventions between the calcimimetic and placebo groups of the studies. Entry to some studies was restricted when patients had severely elevated PTH levels (e.g. iPTH &gt; 800 pg/mL) while other studies stratified patients according to the severity of hyperparathyroidism. The mean age of patients enrolled in the studies ranged from 47 to 55 years. All patients had elevated PTH levels. On average, a higher proportion of males were enrolled in the studies (388 males compared to 220 females in the six studies that reported gender distribution). Follow-up of the studies ranged from three to 26 weeks. All studies were supported by Amgen Inc., Thousand Oaks, CA, which holds the cinacalcet HCl patent. Of note, the largest report published (<LINK REF="STD-Goodman-2002" TYPE="STUDY">Goodman 2002</LINK>) was based on the pooled results of two separate studies.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Updated review including search to February 2013</HEADING>
<P>We included 10 additional studies in this review update (<LINK REF="STD-ACHIEVE-Study-2008" TYPE="STUDY">ACHIEVE Study 2008</LINK>; <LINK REF="STD-ADVANCE-Study-2010" TYPE="STUDY">ADVANCE Study 2010</LINK>; <LINK REF="STD-Akiba-2008" TYPE="STUDY">Akiba 2008</LINK>; <LINK REF="STD-Charytan-2005" TYPE="STUDY">Charytan 2005</LINK>; <LINK REF="STD-Chonchol-2009" TYPE="STUDY">Chonchol 2009</LINK>; <LINK REF="STD-El-Shafey-2011" TYPE="STUDY">El Shafey 2011</LINK>; <LINK REF="STD-EVOLVE-study-2007" TYPE="STUDY">EVOLVE study 2007</LINK>; <LINK REF="STD-Fukagawa-2008" TYPE="STUDY">Fukagawa 2008</LINK>; <LINK REF="STD-IMPACT-SHPT-Study-2012" TYPE="STUDY">IMPACT SHPT Study 2012</LINK>; <LINK REF="STD-OPTIMA-Study-2008" TYPE="STUDY">OPTIMA Study 2008</LINK>). One study from the original review (known as Malluche 2004) was updated using data from a newer publication report (<LINK REF="STD-Malluche-2008" TYPE="STUDY">Malluche 2008</LINK>). Overall, the updated review included 18 studies comprising 7446 adults with CKD comparing a calcimimetic plus conventional therapy with placebo or no treatment with conventional therapy. We could include 17 studies in 7424 participants in the meta-analyses. The characteristics of the included studies are described in <LINK TAG="CHARACTERISTICS_OF_INCLUDED_STUDIES" TYPE="SECTION">Characteristics of included studies</LINK>.</P>
<P>All included studies evaluated cinacalcet hydrochloride (referred to as R-568 or AMG-073 in the four earliest studies) (<LINK REF="STD-Goodman-2000" TYPE="STUDY">Goodman 2000</LINK>; <LINK REF="STD-Goodman-2002" TYPE="STUDY">Goodman 2002</LINK>; <LINK REF="STD-Quarles-2003a" TYPE="STUDY">Quarles 2003a</LINK>; <LINK REF="STD-Lindberg-2003" TYPE="STUDY">Lindberg 2003</LINK>). Cinacalcet in additional to conventional therapy (vitamin D compounds and phosphorous binding agents) was compared to placebo or conventional therapy or both in all studies. In three studies, the strategy for vitamin D therapy differed between treatment groups (<LINK REF="STD-ACHIEVE-Study-2008" TYPE="STUDY">ACHIEVE Study 2008</LINK>; <LINK REF="STD-ADVANCE-Study-2010" TYPE="STUDY">ADVANCE Study 2010</LINK>; <LINK REF="STD-IMPACT-SHPT-Study-2012" TYPE="STUDY">IMPACT SHPT Study 2012</LINK>). The two earliest studies were short-term evaluations of cinacalcet therapy (eight days (<LINK REF="STD-Goodman-2002" TYPE="STUDY">Goodman 2002</LINK>) and 15 days (<LINK REF="STD-Goodman-2000" TYPE="STUDY">Goodman 2000</LINK>)) in adults with GFR category G5 (treated with dialysis). Following these earliest studies of safety and biochemical efficacy, the first larger-scale study of cinacalcet therapy was reported in 2004 in 741 adults with GFR category G5 (treated with dialysis) and measured treatment efficacy based on PTH concentrations (<LINK REF="STD-Block-2004a" TYPE="STUDY">Block 2004a</LINK>). Between 2004 and 2012, 11 additional studies were reported (<LINK REF="STD-ACHIEVE-Study-2008" TYPE="STUDY">ACHIEVE Study 2008</LINK>; <LINK REF="STD-ADVANCE-Study-2010" TYPE="STUDY">ADVANCE Study 2010</LINK>; <LINK REF="STD-Akiba-2008" TYPE="STUDY">Akiba 2008</LINK>; <LINK REF="STD-Charytan-2005" TYPE="STUDY">Charytan 2005</LINK>; <LINK REF="STD-Chonchol-2009" TYPE="STUDY">Chonchol 2009</LINK>; <LINK REF="STD-El-Shafey-2011" TYPE="STUDY">El Shafey 2011</LINK>; <LINK REF="STD-Fukagawa-2008" TYPE="STUDY">Fukagawa 2008</LINK>; <LINK REF="STD-IMPACT-SHPT-Study-2012" TYPE="STUDY">IMPACT SHPT Study 2012</LINK>; <LINK REF="STD-Lindberg-2005" TYPE="STUDY">Lindberg 2005</LINK>; <LINK REF="STD-Malluche-2008" TYPE="STUDY">Malluche 2008</LINK>; <LINK REF="STD-OPTIMA-Study-2008" TYPE="STUDY">OPTIMA Study 2008</LINK>) although none was powered to evaluate treatment effects on mortality. In late 2012, the Evaluation of Cinacalcet Therapy to Lower Cardiovascular Events (<LINK REF="STD-EVOLVE-study-2007" TYPE="STUDY">EVOLVE study 2007</LINK>) in 3883 participants with GFR category G5 treated with dialysis was the first study specifically designed to evaluate calcimimetic therapy on a primary composite outcome of all-cause mortality or non-fatal cardiovascular event.</P>
<P>Cinacalcet therapy was given in the included studies generally at increasing doses (usually 30 to 180 mg/d) targeted to serum PTH concentrations. In one study, the cinacalcet dose prescribed was unclear (<LINK REF="STD-IMPACT-SHPT-Study-2012" TYPE="STUDY">IMPACT SHPT Study 2012</LINK>). Overall, 16 studies comprised 6988 participants with GFR category G5 treatment with dialysis (<LINK REF="STD-ACHIEVE-Study-2008" TYPE="STUDY">ACHIEVE Study 2008</LINK>; <LINK REF="STD-ADVANCE-Study-2010" TYPE="STUDY">ADVANCE Study 2010</LINK>; <LINK REF="STD-Akiba-2008" TYPE="STUDY">Akiba 2008</LINK>; <LINK REF="STD-Block-2004a" TYPE="STUDY">Block 2004a</LINK>; <LINK REF="STD-El-Shafey-2011" TYPE="STUDY">El Shafey 2011</LINK>; <LINK REF="STD-EVOLVE-study-2007" TYPE="STUDY">EVOLVE study 2007</LINK>; <LINK REF="STD-Fukagawa-2008" TYPE="STUDY">Fukagawa 2008</LINK>; <LINK REF="STD-Goodman-2000" TYPE="STUDY">Goodman 2000</LINK>; <LINK REF="STD-Goodman-2002" TYPE="STUDY">Goodman 2002</LINK>; <LINK REF="STD-Harris-2004" TYPE="STUDY">Harris 2004</LINK>; <LINK REF="STD-IMPACT-SHPT-Study-2012" TYPE="STUDY">IMPACT SHPT Study 2012</LINK>; <LINK REF="STD-Lindberg-2003" TYPE="STUDY">Lindberg 2003</LINK>; <LINK REF="STD-Lindberg-2005" TYPE="STUDY">Lindberg 2005</LINK>; <LINK REF="STD-Malluche-2008" TYPE="STUDY">Malluche 2008</LINK>; <LINK REF="STD-OPTIMA-Study-2008" TYPE="STUDY">OPTIMA Study 2008</LINK>; <LINK REF="STD-Quarles-2003a" TYPE="STUDY">Quarles 2003a</LINK>) and two studies comprised 458 participants with GFR category G3a to G5 (<LINK REF="STD-Charytan-2005" TYPE="STUDY">Charytan 2005</LINK>; <LINK REF="STD-Chonchol-2009" TYPE="STUDY">Chonchol 2009</LINK>). Of studies in dialysis, 15 enrolled haemodialysis patients and one enrolled patients treated with either haemodialysis or peritoneal dialysis. Follow-up duration was between eight days and 21.2 months (median: 6.5 months)</P>
</SUBSECTION>
</INCLUDED_STUDIES_DESCR>
<EXCLUDED_STUDIES_DESCR MODIFIED="2014-06-11 15:52:23 +1000" MODIFIED_BY="Narelle Willis">
<P>We excluded studies as they were not evaluating a calcimimetic with or without standard therapy versus placebo or standard therapy or both, did not provide data for relevant outcomes, were not RCTs, or were not in the CKD population. The details of reasons for exclusions are provided in the table for <LINK TAG="CHARACTERISTICS_OF_EXCLUDED_STUDIES" TYPE="SECTION">Characteristics of excluded studies</LINK>.</P>
</EXCLUDED_STUDIES_DESCR>
</STUDY_DESCRIPTION>
<STUDY_QUALITY MODIFIED="2014-06-12 16:36:21 +1000" MODIFIED_BY="Ruth L Mitchell">
<P>Risk of bias in the included studies is summarised in <LINK REF="FIG-02" TYPE="FIGURE">Figure 2</LINK> (individual studies) and <LINK REF="FIG-03" TYPE="FIGURE">Figure 3</LINK> (overall summary).</P>
<ALLOCATION MODIFIED="2014-06-10 16:11:29 +1000" MODIFIED_BY="Narelle Willis">
<P>Four studies reported adequate sequence generation (22%) (<LINK REF="STD-Akiba-2008" TYPE="STUDY">Akiba 2008</LINK>; <LINK REF="STD-Fukagawa-2008" TYPE="STUDY">Fukagawa 2008</LINK>; <LINK REF="STD-Lindberg-2005" TYPE="STUDY">Lindberg 2005</LINK>; <LINK REF="STD-Malluche-2008" TYPE="STUDY">Malluche 2008</LINK>) and reporting on this item was unclear in the remainder. Allocation was adequately concealed in seven studies (39%) (<LINK REF="STD-Charytan-2005" TYPE="STUDY">Charytan 2005</LINK>; <LINK REF="STD-Chonchol-2009" TYPE="STUDY">Chonchol 2009</LINK>; <LINK REF="STD-EVOLVE-study-2007" TYPE="STUDY">EVOLVE study 2007</LINK>; <LINK REF="STD-IMPACT-SHPT-Study-2012" TYPE="STUDY">IMPACT SHPT Study 2012</LINK>; <LINK REF="STD-Lindberg-2005" TYPE="STUDY">Lindberg 2005</LINK>; <LINK REF="STD-Malluche-2008" TYPE="STUDY">Malluche 2008</LINK>; <LINK REF="STD-Quarles-2003a" TYPE="STUDY">Quarles 2003a</LINK>) and unclear in the remainder.</P>
</ALLOCATION>
<BLINDING MODIFIED="2014-06-12 16:36:21 +1000" MODIFIED_BY="Ruth L Mitchell">
<P>Participants and investigators were adequately blinded to treatment assignment in 13 studies (72%) (<LINK REF="STD-Akiba-2008" TYPE="STUDY">Akiba 2008</LINK>; <LINK REF="STD-Block-2004a" TYPE="STUDY">Block 2004a</LINK>; <LINK REF="STD-Charytan-2005" TYPE="STUDY">Charytan 2005</LINK>; <LINK REF="STD-Chonchol-2009" TYPE="STUDY">Chonchol 2009</LINK>; <LINK REF="STD-EVOLVE-study-2007" TYPE="STUDY">EVOLVE study 2007</LINK>; <LINK REF="STD-Fukagawa-2008" TYPE="STUDY">Fukagawa 2008</LINK>; <LINK REF="STD-Goodman-2000" TYPE="STUDY">Goodman 2000</LINK>; <LINK REF="STD-Goodman-2002" TYPE="STUDY">Goodman 2002</LINK>; <LINK REF="STD-Harris-2004" TYPE="STUDY">Harris 2004</LINK>; <LINK REF="STD-Lindberg-2003" TYPE="STUDY">Lindberg 2003</LINK>; <LINK REF="STD-Lindberg-2005" TYPE="STUDY">Lindberg 2005</LINK>; <LINK REF="STD-Malluche-2008" TYPE="STUDY">Malluche 2008</LINK>; <LINK REF="STD-Quarles-2003a" TYPE="STUDY">Quarles 2003a</LINK>), and not blinded in five studies (<LINK REF="STD-ACHIEVE-Study-2008" TYPE="STUDY">ACHIEVE Study 2008</LINK>; <LINK REF="STD-ADVANCE-Study-2010" TYPE="STUDY">ADVANCE Study 2010</LINK>; <LINK REF="STD-El-Shafey-2011" TYPE="STUDY">El Shafey 2011</LINK>; <LINK REF="STD-IMPACT-SHPT-Study-2012" TYPE="STUDY">IMPACT SHPT Study 2012</LINK>; <LINK REF="STD-OPTIMA-Study-2008" TYPE="STUDY">OPTIMA Study 2008</LINK>). Outcome assessment was blinded in two studies (11%) (<LINK REF="STD-Akiba-2008" TYPE="STUDY">Akiba 2008</LINK>; <LINK REF="STD-EVOLVE-study-2007" TYPE="STUDY">EVOLVE study 2007</LINK>), not blinded in one study (<LINK REF="STD-ACHIEVE-Study-2008" TYPE="STUDY">ACHIEVE Study 2008</LINK>), and unclear in the remainder.</P>
</BLINDING>
<EXCLUSIONS MODIFIED="2014-06-10 15:44:31 +1000" MODIFIED_BY="Narelle Willis">
<P>Six studies were at low risk of attrition bias (33%) (<LINK REF="STD-Chonchol-2009" TYPE="STUDY">Chonchol 2009</LINK>; <LINK REF="STD-El-Shafey-2011" TYPE="STUDY">El Shafey 2011</LINK>; <LINK REF="STD-EVOLVE-study-2007" TYPE="STUDY">EVOLVE study 2007</LINK>; <LINK REF="STD-Fukagawa-2008" TYPE="STUDY">Fukagawa 2008</LINK>; <LINK REF="STD-Goodman-2002" TYPE="STUDY">Goodman 2002</LINK>; <LINK REF="STD-Quarles-2003a" TYPE="STUDY">Quarles 2003a</LINK>) and the remainder were considered at high risk.</P>
</EXCLUSIONS>
<SELECTIVE_REPORTING MODIFIED="2014-06-10 15:44:32 +1000" MODIFIED_BY="Narelle Willis">
<P>Eleven studies reported all expected outcomes (61%) including mortality, hypocalcaemia, and two or more of nausea, vomiting or diarrhoea (<LINK REF="STD-ACHIEVE-Study-2008" TYPE="STUDY">ACHIEVE Study 2008</LINK>; <LINK REF="STD-Akiba-2008" TYPE="STUDY">Akiba 2008</LINK>; <LINK REF="STD-Block-2004a" TYPE="STUDY">Block 2004a</LINK>; <LINK REF="STD-Charytan-2005" TYPE="STUDY">Charytan 2005</LINK>; <LINK REF="STD-Chonchol-2009" TYPE="STUDY">Chonchol 2009</LINK>; <LINK REF="STD-El-Shafey-2011" TYPE="STUDY">El Shafey 2011</LINK>; <LINK REF="STD-EVOLVE-study-2007" TYPE="STUDY">EVOLVE study 2007</LINK>; <LINK REF="STD-Fukagawa-2008" TYPE="STUDY">Fukagawa 2008</LINK>; <LINK REF="STD-Goodman-2002" TYPE="STUDY">Goodman 2002</LINK>; <LINK REF="STD-IMPACT-SHPT-Study-2012" TYPE="STUDY">IMPACT SHPT Study 2012</LINK>; <LINK REF="STD-OPTIMA-Study-2008" TYPE="STUDY">OPTIMA Study 2008</LINK>).</P>
</SELECTIVE_REPORTING>
<OTHER_BIAS_SOURCES MODIFIED="2014-06-12 16:36:21 +1000" MODIFIED_BY="Ruth L Mitchell">
<P>One study described uneven treatment comparisons at baseline (<LINK REF="STD-El-Shafey-2011" TYPE="STUDY">El Shafey 2011</LINK>). The study sponsor was on the authorship and/or involved in data collection, analysis and/or interpretation in 15 studies (<LINK REF="STD-ACHIEVE-Study-2008" TYPE="STUDY">ACHIEVE Study 2008</LINK>; <LINK REF="STD-ADVANCE-Study-2010" TYPE="STUDY">ADVANCE Study 2010</LINK>; <LINK REF="STD-Block-2004a" TYPE="STUDY">Block 2004a</LINK>; <LINK REF="STD-Charytan-2005" TYPE="STUDY">Charytan 2005</LINK>; <LINK REF="STD-Chonchol-2009" TYPE="STUDY">Chonchol 2009</LINK>; <LINK REF="STD-EVOLVE-study-2007" TYPE="STUDY">EVOLVE study 2007</LINK>; <LINK REF="STD-Goodman-2000" TYPE="STUDY">Goodman 2000</LINK>; <LINK REF="STD-Goodman-2002" TYPE="STUDY">Goodman 2002</LINK>; <LINK REF="STD-Harris-2004" TYPE="STUDY">Harris 2004</LINK>; <LINK REF="STD-IMPACT-SHPT-Study-2012" TYPE="STUDY">IMPACT SHPT Study 2012</LINK>; <LINK REF="STD-Lindberg-2003" TYPE="STUDY">Lindberg 2003</LINK>; <LINK REF="STD-Lindberg-2005" TYPE="STUDY">Lindberg 2005</LINK>; <LINK REF="STD-Malluche-2008" TYPE="STUDY">Malluche 2008</LINK>; <LINK REF="STD-OPTIMA-Study-2008" TYPE="STUDY">OPTIMA Study 2008</LINK>; <LINK REF="STD-Quarles-2003a" TYPE="STUDY">Quarles 2003a</LINK>). Of 10 studies reported since 2005, five (50%) reported evidence of study registration within a studies registry before publication (<LINK REF="STD-ADVANCE-Study-2010" TYPE="STUDY">ADVANCE Study 2010</LINK>; <LINK REF="STD-Chonchol-2009" TYPE="STUDY">Chonchol 2009</LINK>; <LINK REF="STD-EVOLVE-study-2007" TYPE="STUDY">EVOLVE study 2007</LINK>; <LINK REF="STD-Fukagawa-2008" TYPE="STUDY">Fukagawa 2008</LINK>; <LINK REF="STD-IMPACT-SHPT-Study-2012" TYPE="STUDY">IMPACT SHPT Study 2012</LINK>).</P>
</OTHER_BIAS_SOURCES>
</STUDY_QUALITY>
<INTERVENTION_EFFECTS MODIFIED="2014-12-08 16:15:05 +1100" MODIFIED_BY="Narelle Willis">
<SUBSECTION>
<HEADING LEVEL="3">Clinical outcomes</HEADING>
<SUBSECTION>
<HEADING LEVEL="4">All-cause and cardiovascular mortality</HEADING>
<P>Compared to placebo or no treatment, cinacalcet had little or no effect on all-cause mortality (<LINK REF="CMP-001.01" TYPE="ANALYSIS">Analysis 1.1</LINK>.1 (14 studies, 6893 participants): RR 0.97, 95% CI 0.89 to 1.05; I² = 0%) in adults with GFR category G5 treated with dialysis and imprecise effects on all-cause mortality in adults with GFR categories G3a to G4 (<LINK REF="CMP-001.01" TYPE="ANALYSIS">Analysis 1.1</LINK>.2 (2 studies, 458 participants): RR 0.29, 95% CI 0.06 to 1.48; I² = 0%). There was no heterogeneity in treatment effects across studies in either subgroup and no statistical difference in treatment effects in the different stages of CKD.</P>
<P>Cinacalcet had uncertain effects on cardiovascular mortality for participants with GFR category G5 treated with dialysis (<LINK REF="CMP-001.02" TYPE="ANALYSIS">Analysis 1.2</LINK>.1 (7 studies, 4542 participants): RR 0.67, 95% CI 0.16 to 2.87; I² = 37%) and GFR category G3a-G4 (<LINK REF="CMP-001.02" TYPE="ANALYSIS">Analysis 1.2</LINK>.2 (2 studies, 458 participants): RR 0.29, 95% CI 0.06 to 1.48; I² = 0%). There was no significant heterogeneity in treatment effects across studies in either subgroup and no statistical difference in treatment effects in the different stages of CKD.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Parathyroidectomy</HEADING>
<P>Cinacalcet reduced the risk of parathyroidectomy (<LINK REF="CMP-001.03" TYPE="ANALYSIS">Analysis 1.3</LINK> (5 studies, 4893 participants): RR 0.49, 95% CI 0.40 to 0.59; I² = 0%) without evidence of heterogeneity in treatment estimates.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Fractures</HEADING>
<P>The risk of one of more fractures was reported in extractable format in two studies. Cinacalcet had uncertain effects on risk of one or more fractures (<LINK REF="CMP-001.04" TYPE="ANALYSIS">Analysis 1.4</LINK> (2 studies, 3965 participants): RR 0.52, 95% CI 0.12 to 2.27) with significant heterogeneity in the treatment effect estimates of contributing studies (P = 0.05, I²; I² = 73%).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Hypocalcaemia and hypercalcaemia</HEADING>
<P>Definitions of hypocalcaemia and hypercalcaemia in the included studies are provided in <LINK REF="TBL-02" TYPE="TABLE">Table 2</LINK>. The cut-off for the definition of hypocalcaemia generally ranged between 7.1 and 8.4 mg/dL and that of hypercalcaemia was 10.2 to 10.5 mg/dL. Cinacalcet increased hypocalcaemia in both adults with GFR category G5 treated with dialysis (<LINK REF="CMP-001.05" TYPE="ANALYSIS">Analysis 1.5</LINK>.1 (12 studies, 6415 participants): RR 6.98, 95% CI 5.10 to 9.53; I² = 0%) and those with GFR category G3 to G4 (<LINK REF="CMP-001.05" TYPE="ANALYSIS">Analysis 1.5</LINK>.2 (2 studies, 449 participants): RR 31.90, 95% CI 5.28 to 192.60; I² = 16%) without significant heterogeneity in treatment estimates between studies.</P>
<P>Cinacalcet reduced risks of one or more episodes of hypercalcaemia in adults with GFR category G5 treated with dialysis (<LINK REF="CMP-001.06" TYPE="ANALYSIS">Analysis 1.6</LINK> (4 studies, 4662 participants): RR 0.23, 95% CI 0.05 to 0.97) although there was significant heterogeneity in treatment estimates in the available studies (P = 0.005, I² = 77%).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Nausea and vomiting</HEADING>
<P>Cinacalcet increased nausea in participants with GFR category G5 treated with dialysis (<LINK REF="CMP-001.07" TYPE="ANALYSIS">Analysis 1.7</LINK>.1 (12 studies, 6450 participants): RR 2.02, 95% CI 1.45 to 2.81; I² = 66%) and those with GFR category G3 to G4 (<LINK REF="CMP-001.07" TYPE="ANALYSIS">Analysis 1.7</LINK>.2 (2 studies, 449 participants): RR 2.26, 95% CI 1.29 to 3.95; I² = 6%). There was no statistical evidence that treatment effects were different in the different categories of CKD but there was significant heterogeneity in treatment estimates in studies including dialysis patients (P &lt; 0.0006; I² = 66%).</P>
<P>Cinacalcet also increased vomiting in participants with GFR category G5 treated with dialysis (<LINK REF="CMP-001.08" TYPE="ANALYSIS">Analysis 1.8</LINK>.1 (9 studies, 6323 participants): RR 1.97, 95% CI 1.73 to 2.24; I² = 3%) and those with GFR category G3 to G4 (<LINK REF="CMP-001.08" TYPE="ANALYSIS">Analysis 1.8</LINK>.2 (1 study, 395 participants): RR 1.77, 95% CI 0.90 to 3.48). There was no statistical evidence that treatment effects were different in the different categories of CKD or significant heterogeneity in treatment estimates between studies.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Other adverse events</HEADING>
<UL>
<LI>Cinacalcet consistently increased diarrhoea in the available studies (<LINK REF="CMP-001.09" TYPE="ANALYSIS">Analysis 1.9</LINK> (8 studies, 5639 participants): RR 1.15, 95% CI 1.02 to 1.29; I² = 0%).</LI>
<LI>Cinacalcet had uncertain effects on abdominal pain (<LINK REF="CMP-001.10" TYPE="ANALYSIS">Analysis 1.10</LINK> (4 studies, 831 participants): RR 1.62, 95% CI 0.55 to 4.82) with significant heterogeneity in the treatment effect estimates of contributing studies (P = 0.02, I² = 70%)</LI>
<LI>Cinacalcet had uncertain effects on the risk of upper respiratory tract infection (<LINK REF="CMP-001.11" TYPE="ANALYSIS">Analysis 1.11</LINK> (4 studies, 1856 participants): RR 0.95, 95% CI 0.39 to 2.33) with statistically significant heterogeneity in estimated treatment effects between studies (P = 0.002, I² = 80%)</LI>
<LI>Cinacalcet had uncertain effects on asthenia (<LINK REF="CMP-001.12" TYPE="ANALYSIS">Analysis 1.12</LINK>.1 (2 studies, 790 participants): RR 1.54, 95% CI 0.26 to 8.98) with statistically significant heterogeneity in the estimated treatment effects in available studies (P = 0.04, I² = 77%)</LI>
<LI>Cinacalcet increased muscle weakness (<LINK REF="CMP-001.12" TYPE="ANALYSIS">Analysis 1.12</LINK>.2 (4 studies, 589 participants): RR 1.78, 95% CI 1.00 to 3.14; I² = 0%) without heterogeneity in treatment effects.</LI>
<LI>Cinacalcet had uncertain effects on dyspnoea (<LINK REF="CMP-001.13" TYPE="ANALYSIS">Analysis 1.13</LINK> (2 studies, 250 participants): RR 1.02, 95% CI 0.49 to 2.12; I² = 0%) without heterogeneity in treatment effects.</LI>
<LI>Cinacalcet had uncertain effects on headache (<LINK REF="CMP-001.14" TYPE="ANALYSIS">Analysis 1.14</LINK> (3 studies, 1115 participants): RR 1.11, 95% CI 0.65 to 1.91; I² = 25%) without significant heterogeneity in treatment effects.</LI>
</UL>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Biochemical parameters</HEADING>
<SUBSECTION>
<HEADING LEVEL="4">Achieved serum PTH value target</HEADING>
<P>Target serum PTH values are described in <LINK REF="TBL-02" TYPE="TABLE">Table 2</LINK>. Most PTH values targeted by cinacalcet therapy were a reduction of 30% or more from baseline or a reduction to below 250 pg/mL, 279 pg/mL or 300 pg/mL or a target value between 150 to 300 pg/mL. Cinacalcet increased the likelihood that serum PTH values were reduced to a target value (<LINK REF="CMP-001.15" TYPE="ANALYSIS">Analysis 1.15</LINK> (11 studies, 2853 participants): RR 3.06, 95% CI 1.89 to 4.98), although there was marked heterogeneity in the treatment estimates between studies (P &lt; 0.00001, I² = 92%).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">End of treatment serum PTH</HEADING>
<P>Cinacalcet lowered serum PTH levels (<LINK REF="CMP-001.16" TYPE="ANALYSIS">Analysis 1.16</LINK> (7 studies, 1935 participants): MD -280.39 pg/mL, 95% CI -326.84 to -235.94) with moderate heterogeneity in the analysis (P = 0.16, I² = 34%).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">End of treatment serum calcium</HEADING>
<P>Cinacalcet lowered end of treatment serum calcium levels (<LINK REF="CMP-001.17" TYPE="ANALYSIS">Analysis 1.17</LINK> (7 study, 1556 participants): MD -0.87 mg/dL, 95% CI -0.96 to -0.77; I² = 18%) without significant heterogeneity in the analysis.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">End of treatment serum phosphorous</HEADING>
<P>Cinacalcet had little or no effect on end of treatment serum phosphorous levels (<LINK REF="CMP-001.18" TYPE="ANALYSIS">Analysis 1.18</LINK> (8 studies, 2300 participants): MD -0.23 mg/dL, 95% CI -0.58 to 0.12) with marked heterogeneity in treatment effects between studies (P &lt; 0.00001, I² = 88%).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">End of treatment serum calcium by phosphorous product</HEADING>
<P>Cinacalcet significantly lowered the serum calcium by phosphorous product (<LINK REF="CMP-001.19" TYPE="ANALYSIS">Analysis 1.19</LINK> (8 studies, 2395 participants): MD -5.25 mg²/dL², 95% CI -9.16 to -1.34) with marked heterogeneity in treatment effects between studies (P &lt; 0.00001, I² = 91%).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Bone outcomes</HEADING>
<P>Effects of calcimimetic therapy on bone structure and function was not consistently reported in available studies (<LINK REF="CMP-001.02" TYPE="ANALYSIS">Analysis 1.2</LINK>0; <LINK REF="CMP-001.02" TYPE="ANALYSIS">Analysis 1.2</LINK>1).</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Sensitivity analyses</HEADING>
<P>When we excluded the three studies in which randomised co-intervention strategies for vitamin D compounds were not comparable between treatment arms, we observed similar treatment estimates in dialysis patients (all-cause mortality: RR, 0.97, 95% CI 0.89 to 1.05; cardiovascular mortality: RR 0.95, 95% CI 0.84 to 1.08; hypocalcaemia: RR 6.72, 95% CI 4.88 to 9.25; nausea: RR 1.89, 95% CI 1.38 to 2.60; vomiting: RR 1.98 95% CI 1.71 to 2.30), although risks of hypercalcaemia became less certain (RR 0.88, 95% CI 0.55 to 1.41).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Absolute treatment effects</HEADING>
<P>Estimated absolute treatment effects of cinacalcet (taking into consideration baseline event rates) combined with an overall grading of evidence quality are summarised in the <LINK REF="SOF-01" TYPE="SOF">Summary of findings table 1</LINK>. Overall, treating 1000 patients with GFR category G5 (treated with dialysis) with cinacalcet might be expected to prevent three experiencing parathyroidectomy, and 60 and 150 more to experience hypocalcaemia and nausea respectively, without altering mortality. In adults with less severe kidney disease (GFR category G3a to G5), treating 1000 patients for one year would result in approximately 300 and 120 experiencing hypocalcaemia and nausea respectively, without evidence for benefits on mortality or parathyroidectomy.</P>
</SUBSECTION>
</INTERVENTION_EFFECTS>
</RESULTS>
<DISCUSSION MODIFIED="2014-06-11 16:09:59 +1000" MODIFIED_BY="Narelle Willis">
<SUMMARY_OF_RESULTS MODIFIED="2014-06-11 16:09:59 +1000" MODIFIED_BY="Narelle Willis">
<P>High- to moderate-quality evidence for cinacalcet treatment in adults with GFR category G5 treated with dialysis and elevated PTH levels is available in 16 RCTs (6,988 participants). Routine cinacalcet therapy in dialysis patients at doses between 30 and 180 mg/d decreases serum PTH levels (281 pg/mL) and infrequently reduces surgical parathyroidectomy, but has little or no effect on total mortality, uncertain effects on cardiovascular-related death, and is commonly associated with adverse events including nausea, vomiting, hypocalcaemia and diarrhoea. Evidence for adults with GFR category G3a to G4 is scant and generally low or very low quality. Because of lower absolute risks of parathyroidectomy in earlier stages of CKD, the benefits of cinacalcet identified by studies in dialysis populations are likely to be smaller if generalised to people who have less severe CKD. Data for adults with a functioning kidney transplant and those treated with peritoneal dialysis were largely absent. It should be noted that adverse treatment effects including nausea, vomiting and hypocalcaemia may have been transient and additional information about patient experiences of these outcomes would inform clinical decision-making.</P>
<P>Although it is possible that routine cinacalcet prescribing has a beneficial effect on all-cause mortality, consistent treatment effects across all available studies suggest that, at best, any benefit for mortality is likely to be small. Given that lag censoring analyses for outcomes (where data were censored six months after patients stopped using the study drug) were reported as prespecified secondary analyses in the <LINK REF="STD-EVOLVE-study-2007" TYPE="STUDY">EVOLVE study 2007</LINK> and suggested a potential benefit for cinacalcet on total mortality (hazard ratio 0.83, 95% CI 0.73 to 0.96), it might be argued that additional studies of cinacalcet are now needed or that cinacalcet lowers mortality. However, we suggest that these lag-censoring approaches were secondary analyses only, and that existing evidence for all-cause mortality is high-quality according to GRADE criteria (<LINK REF="REF-Guyatt-2008" TYPE="REFERENCE">Guyatt 2008</LINK>). This means that additional studies are unlikely to change the treatment estimates we observed or our confidence in these estimates.</P>
<P>By contrast, evidence for GFR categories G3a to G4 (estimated GFR 15 to 60 mL/min/1.73 m²) was low or very low quality indicating that further data for this specific group of patients would be informative.</P>
</SUMMARY_OF_RESULTS>
<APPLICABILITY_OF_FINDINGS MODIFIED="2014-06-11 15:42:46 +1000" MODIFIED_BY="Narelle Willis">
<P>Despite widespread adoption into clinical practice and approval by the FDA, the efficacy and tolerability of cinacalcet in available studies is now better understood and suggests routine cinacalcet therapy has little or no benefit for dialysis patients. Notably, all available studies of cinacalcet investigating cinacalcet used it as "routine" or "first-line" therapy in patients with elevated serum PTH levels. The findings in these studies therefore do not assess the possibility that cinacalcet may improve patient outcomes when used as treatment of elevated PTH levels resistant to other therapy including vitamin D compounds and phosphorous binders. The National Health Service National Institute for Health and Clinical Excellence (NICE) Clinical practice guidelines have suggested that cinacalcet should be used when serum PTH levels are very high, other treatments have been ineffective and when surgical parathyroidectomy is contraindicated (<LINK REF="REF-NICE-2007" TYPE="REFERENCE">NICE 2007</LINK>). However, we advise caution in this clinical setting, as available studies for this approach to cinacalcet therapy are not available and, in particular, outcomes and adverse events comparing parathyroidectomy versus cinacalcet treatment are not available.</P>
<P>This updated review has provided additional evidence for patient-level outcomes, beyond surrogate outcomes of efficacy that dominated earlier studies and our earlier review (<LINK REF="REF-Strippoli-2006a" TYPE="REFERENCE">Strippoli 2006a</LINK>). A surrogate is a measurable outcome such as a laboratory or imaging test, which is responsive to the effect of an intervention (e.g. reduction of total cholesterol with statins) and is also causally associated with a clinically important outcome (e.g. reduction in all-cause or cardiovascular mortality with statins). A valid surrogate end-point therefore captures the full effect of an intervention but earlier in the causal chain of events (<LINK REF="REF-Bucher-1999" TYPE="REFERENCE">Bucher 1999</LINK>; <LINK REF="REF-Psaty-1999" TYPE="REFERENCE">Psaty 1999</LINK>; <LINK REF="REF-Temple-1999" TYPE="REFERENCE">Temple 1999</LINK>). Surrogate end points are used in preference to hard end points in RCTs because cost and sample size can be reduced and feasibility increased substantially. Compared with hard endpoints, surrogates allow for shorter study duration, and either occur more commonly or are continuous measures and so more sensitive to differences in treatment. In kidney disease, surrogates are commonly used in studies, and include dialysis adequacy, haemoglobin levels, left ventricular hypertrophy, and episodes of acute rejection, which have been the basis for the regulatory approval and clinical use of various drugs (<LINK REF="REF-Besarab-1998" TYPE="REFERENCE">Besarab 1998</LINK>; <LINK REF="REF-Borrows-2004" TYPE="REFERENCE">Borrows 2004</LINK>; <LINK REF="REF-Churchill-1997" TYPE="REFERENCE">Churchill 1997</LINK>; <LINK REF="REF-McMahon-2004" TYPE="REFERENCE">McMahon 2004</LINK>). However, not all surrogates are valid proxies of clinically important patient-entered outcomes. In order for a surrogate to be valid, two criteria must be met. First, there must be a strong, independent and consistent association between the surrogate and the clinically important outcome, which comes from observational studies. For calcium, phosphorous and PTH this criterion has been met from a number of large-scale cohort and cross sectional studies (<LINK REF="REF-Avram-1996" TYPE="REFERENCE">Avram 1996</LINK>; <LINK REF="REF-Ganesh-2001" TYPE="REFERENCE">Ganesh 2001</LINK>; <LINK REF="REF-Kestenbaum-2005" TYPE="REFERENCE">Kestenbaum 2005</LINK>; <LINK REF="REF-Stevens-2004" TYPE="REFERENCE">Stevens 2004</LINK>). Second, and more importantly, for a surrogate to be valid there must also be evidence that using an intervention changes a surrogate (e.g. reduction of PTH with a calcimimetic) and results in an expected change in the patient-based outcome distal to the surrogate in the same causal pathway for the disease in question (e.g. reduction of deaths with a calcimimetic). This criterion requires a RCT, which measures both the surrogate and the hard endpoint. In the available studies for cinacalcet, we have shown that despite large and clinically-relevant improvements in serum PTH and serum calcium levels, mortality is not reduced and effects on cardiovascular mortality remain uncertain, suggesting that serum PTH and calcium are not sufficiently proven to be valid proxies of hard patient endpoints in studies of novel agents in CKD.</P>
<P>To date, cinacalcet has uncertain effects on fracture in CKD. The treatment effect we observed (RR 0.53) was similar in magnitude to, but less certain than the risk estimate measured in a pooled analysis of 4 similarly designed, RCTs of cinacalcet comprising 1184 participants with GFR category G5 treated with dialysis and serum PTH levels of 300 pg/mL or greater, in which the reported risk of fracture was 0.46 (95% CI 0.22 to 0.95) (<LINK REF="REF-Cunningham-2005a" TYPE="REFERENCE">Cunningham 2005a</LINK>). It was unclear in that publication which studies were included in the analysis, and which included data for extended treatment in two studies that included only about half of the initially randomised participants. While it is possible that cinacalcet has beneficial effects on fracture, at present available evidence provides uncertain estimates of effect.</P>
<P>At this stage, data for cinacalcet in adults with earlier stages of CKD, peritoneal dialysis patients and those with a functioning kidney transplant are scarce or absent. There is currently no strong evidence to support the use of cinacalcet in these clinical settings.</P>
</APPLICABILITY_OF_FINDINGS>
<QUALITY_OF_EVIDENCE MODIFIED="2013-06-03 05:40:54 +1000" MODIFIED_BY="Suetonia Palmer">
<P>Overall, based on GRADE criteria considering risks of bias in individual studies consistency of the evidence between studies, directness of the evidence to clinical populations, precision of estimates and publication bias, (<LINK REF="SOF-01" TYPE="SOF">Summary of findings table 1</LINK>) evidence for cinacalcet in adults with GFR category G5 treated with dialysis (mortality, parathyroidectomy, hypocalcaemia, and nausea) is of high or moderate quality. High quality evidence suggests "further research is very unlikely to change our confidence in the estimate of treatment effect" and moderate quality evidence is "further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate".</P>
<P>Information for adults with less severe CKD GFR category G3a to G4 is of low or very low quality. This means that further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate. Very low quality evidence suggests any estimate of effect is very uncertain.</P>
</QUALITY_OF_EVIDENCE>
<POTENTIAL_BIASES MODIFIED="2014-06-11 15:32:59 +1000" MODIFIED_BY="Narelle Willis">
<P>First, to illustrate the importance of prospective registration of studies recently adopted by all major biomedical journals and kidney journals, in order to ensure that all studies evaluating an intervention can be known and linked with publications to avoid publication bias (<LINK REF="REF-Simes-1986" TYPE="REFERENCE">Simes 1986</LINK>) and duplication bias (<LINK REF="REF-Egger-1998" TYPE="REFERENCE">Egger 1998</LINK>), we found it very difficult to link publications with specific studies. This was an issue with the first publication of this review in 2006 and continues with this update. While we believe we have eighteen unequivocally separate studies with unique data, we found numerous reports for which we believe data were duplicates of that already available in full-text published reports. Duplicate reporting is known to be associated with an overestimation of true treatment effects and spurious precision if the studies are incorporated in meta-analysis (<LINK REF="REF-Egger-1998" TYPE="REFERENCE">Egger 1998</LINK>). Prospective registration with a unique identification number for each study would avoid this; despite the recommendation for study registration, only 50% of the 10 included studies published after 2005 (when this requirement commenced) had clearly reported studies registration in the primary published report.</P>
<P>Second, sponsor involvement in authorship, data management and statistical analysis may influence study reporting and lead to a greater likelihood of positive results (<LINK REF="REF-Lexchin-2003" TYPE="REFERENCE">Lexchin 2003</LINK>). The sponsor played a role in the authorship or analysis of over 80% of available studies for cinacalcet suggesting a potential for over-estimation of treatment benefits.</P>
<P>Third, the investigators of one large study (<LINK REF="STD-Block-2004a" TYPE="STUDY">Block 2004a</LINK>) combined the results of two separate but similar studies, a method used by the CLASS investigators that has been widely criticized (<LINK REF="REF-Juni-2003" TYPE="REFERENCE">Juni 2003</LINK>). When the cinacalcet group of one study is compared both with the placebo group of the same study (random allocation) but also the placebo group of the other study (non-random allocation), outcome differences between the cinacalcet and placebo groups may be due to differences in study populations or co-interventions; which are unknown and therefore cannot be adjusted for. Having identical study designs does not prevent these effects. Such study results would be better reported separately. Data could then be combined using meta-analysis to provide a summary weighted estimate of the effects shown in the individual studies.</P>
</POTENTIAL_BIASES>
<AGREEMENT MODIFIED="2014-06-11 15:43:32 +1000" MODIFIED_BY="Narelle Willis">
<P>This review disagrees with the findings of a pooled analyses of four studies of cinacalcet reported in 2005 (<LINK REF="REF-Cunningham-2005a" TYPE="REFERENCE">Cunningham 2005a</LINK>) comprising 1184 dialysis patients with an elevated serum PTH level. That study combined four studies without meta-analysis and evaluated parathyroidectomy, fracture, hospitalisations and mortality to find marked reductions in the risk of parathyroidectomy (RR 0.07, 95% CI 0.01 to 0.55), fracture (RR 0.46, 95% CI 0.22 to 0.95) and cardiovascular hospitalisation (RR 0.61, 95% CI 0.43 to 0.86). These findings were in contrast to our meta-analysis in 2006 which found no significant effects on patient-based endpoints (<LINK REF="REF-Strippoli-2006a" TYPE="REFERENCE">Strippoli 2006a</LINK>). Our current update which includes all available studies, indicates a similar but more uncertain effect on fracture, a smaller effect on parathyroidectomy, and could not provide estimates for hospitalisation.</P>
</AGREEMENT>
</DISCUSSION>
<CONCLUSIONS MODIFIED="2014-06-10 15:45:32 +1000" MODIFIED_BY="Narelle Willis">
<IMPLICATIONS_PRACTICE MODIFIED="2014-06-07 23:51:45 +1000" MODIFIED_BY="[Empty name]">
<P>Evidence for benefits of routine cinacalcet treatment in adults with CKD and elevated PTH levels are limited to small absolute reductions in parathyroidectomy. Routine cinacalcet therapy in people with CKD does not appear warranted and benefits may be limited to preventing parathyroidectomy in the small number of patients for whom surgery is contraindicated. Nausea, vomiting and hypocalcaemia are commonly experienced by patients treated with cinacalcet.</P>
</IMPLICATIONS_PRACTICE>
<IMPLICATIONS_RESEARCH MODIFIED="2014-06-10 15:45:32 +1000" MODIFIED_BY="Narelle Willis">
<UL>
<LI>Additional studies of cinacalcet in adults with earlier stages of CKD, kidney transplant recipients and peritoneal dialysis patients would inform practice. Until then, widespread prescribing in these populations is not warranted.</LI>
<LI>Further studies in haemodialysis patients is unlikely to change the estimates of effect or our confidence in the current evidence</LI>
<LI>Studies comparing cinacalcet with surgical parathyroidectomy might be informative for patients who have elevated PTH levels resistant to standard therapies.</LI>
</UL>
</IMPLICATIONS_RESEARCH>
</CONCLUSIONS>
</BODY>
<ACKNOWLEDGEMENTS MODIFIED="2014-12-08 09:34:11 +1100" MODIFIED_BY="Ann Jones">
<P>The authors wish to acknowledge the editorial and administrative support of Narelle Willis and Sandra Puckeridge. Ruth Mitchell, Linda Heslop and Gail Higgins, Trial Search Co-ordinators of the Cochrane Renal Group, provided search strategies for this review.</P>
<P>We also wish to acknowledge Drs Allison Tong and Grahame Elder who were authors on previous versions of this review.</P>
</ACKNOWLEDGEMENTS>
<CONFLICT_OF_INTEREST MODIFIED="2014-12-09 17:47:14 +1100" MODIFIED_BY="Narelle Willis">
<UL>
<LI>Angela Ballinger received a student stipend for a summer studentship 2012/2013 from the University of Otago to assist with completing this research.</LI>
<LI>Suetonia Palmer: none known</LI>
<LI>Jonathan Craig: none known</LI>
<LI>Ionut Nistor: is a fellow of the Methods Support Team of European Renal Best Practice (ERBP), supported by a grant of the European Renal Association - European Dialysis Transplantation Association (ERA-EDTA)</LI>
<LI>Giovanni Strippoli: none known.</LI>
</UL>
</CONFLICT_OF_INTEREST>
<CONTRIBUTIONS MODIFIED="2014-12-08 09:35:26 +1100" MODIFIED_BY="Ann Jones">
<UL>
<LI>Angela Ballinger: search screening, data extraction and analysis and input into writing of the review</LI>
<LI>Suetonia Palmer: design, conduct, data extraction and analysis, primary drafting and revisions of the review</LI>
<LI>Ionut Nistor: search screening, data extraction and analysis and input into writing of the review</LI>
<LI>Jonathan Craig: design, data analysis, writing the review</LI>
<LI>Giovanni Strippoli: design, conduct, data-extraction and analysis, writing the review.</LI>
</UL>
</CONTRIBUTIONS>
<PRO_REV_DIFF MODIFIED="2014-12-08 09:34:42 +1100" MODIFIED_BY="Ann Jones">
<P>The outcomes of cardiovascular mortality and one or more episodes of hypercalcaemia have been added to the review in the update to February 2013.</P>
<P>The study included in the review published in 2006 called Malluche 2004 has been updated to include data from a 2008 full text publication and renamed <LINK REF="STD-Malluche-2008" TYPE="STUDY">Malluche 2008</LINK>.</P>
</PRO_REV_DIFF>
<PUBLIC_NOTES MODIFIED="2014-06-11 15:44:30 +1000" MODIFIED_BY="Narelle Willis">
<P>A systematic review and meta-analysis that includes sequential meta-analysis and meta-regression of these data has been published in PLoS Medicine (<LINK REF="REF-Palmer-2013" TYPE="REFERENCE">Palmer 2013</LINK>).</P>
</PUBLIC_NOTES>
</MAIN_TEXT>
<STUDIES_AND_REFERENCES MODIFIED="2014-12-08 16:15:06 +1100" MODIFIED_BY="Narelle Willis">
<STUDIES MODIFIED="2014-12-08 16:15:06 +1100" MODIFIED_BY="Narelle Willis">
<INCLUDED_STUDIES MODIFIED="2014-12-08 16:15:06 +1100" MODIFIED_BY="Narelle Willis">
<STUDY DATA_SOURCE="PUB" ID="STD-ACHIEVE-Study-2008" MODIFIED="2014-12-08 16:15:06 +1100" MODIFIED_BY="Narelle Willis" NAME="ACHIEVE Study 2008" YEAR="">
<REFERENCE MODIFIED="2014-06-01 14:56:24 +1000" MODIFIED_BY="Narelle S Willis" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Charytan C, Corry D, Roppolo M, Ling X, Droge J, Fishbane S</AU>
<TI>Assessing the use of the calcimimetic cinacalcet with low dose vitamin D versus escalating doses of vitamin D alone in the treatment of secondary hyperparathyroidism (HPT) - The ACHIEVE Study [abstract no: 39]</TI>
<SO>American Journal of Kidney Diseases</SO>
<YR>2007</YR>
<VL>49</VL>
<NO>4</NO>
<PG>A34</PG>
<IDENTIFIERS MODIFIED="2014-06-01 14:56:24 +1000" MODIFIED_BY="Narelle S Willis">
<IDENTIFIER MODIFIED="2014-06-01 14:56:24 +1000" MODIFIED_BY="Narelle S Willis" TYPE="CENTRAL" VALUE="CN-00615830"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2014-06-01 14:57:41 +1000" MODIFIED_BY="Narelle S Willis" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Charytan C, Wetmore J, Moustafa M, Martinez C, Stewart T, Ling X, et al</AU>
<TI>Efficacy of treatments targeting the calcium-sensing receptor (CaR) and vitamin D receptor (VDR) in controlling parathyroid hormone (PTH) in hemodialysis (HD) patients: cinacalcet HCI plus low-dose vitamin D vs flexible vitamin D alone [abstract no: SU-PO812]</TI>
<SO>Journal of the American Society of Nephrology</SO>
<YR>2007</YR>
<VL>18</VL>
<NO>Abstracts Issue</NO>
<PG>764A</PG>
<IDENTIFIERS MODIFIED="2014-06-01 14:57:41 +1000" MODIFIED_BY="Narelle S Willis"/>
</REFERENCE>
<REFERENCE MODIFIED="2014-06-01 14:58:35 +1000" MODIFIED_BY="Narelle S Willis" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Fishbane S, Shapiro W, Corry D, Rappaport K, Vicks S, Ling X, et al</AU>
<TI>A comparison of cinacalcet HCI and low-dose vitamin D vs escalating doses of vitamin D alone - the ACHIEVE study [abstract no: PUB354]</TI>
<SO>Journal of the American Society of Nephrology</SO>
<YR>2006</YR>
<VL>17</VL>
<NO>Abstracts</NO>
<PG>891A</PG>
<IDENTIFIERS MODIFIED="2014-06-01 14:58:35 +1000" MODIFIED_BY="Narelle S Willis">
<IDENTIFIER MODIFIED="2014-06-01 14:58:35 +1000" MODIFIED_BY="Narelle S Willis" TYPE="CENTRAL" VALUE="CN-00615831"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2014-06-01 15:00:31 +1000" MODIFIED_BY="Narelle S Willis" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Fishbane S, Shapiro WB, Corry DB, Vicks SL, Roppolo M, Rappaport K, et al</AU>
<TI>Cinacalcet HCl and concurrent low-dose vitamin D improves treatment of secondary hyperparathyroidism in dialysis patients compared with vitamin D alone: the ACHIEVE study results</TI>
<SO>Clinical Journal of The American Society of Nephrology: CJASN</SO>
<YR>2008</YR>
<VL>3</VL>
<NO>6</NO>
<PG>1718-25</PG>
<IDENTIFIERS MODIFIED="2014-06-01 15:00:31 +1000" MODIFIED_BY="Narelle S Willis">
<IDENTIFIER MODIFIED="2014-06-01 15:00:31 +1000" MODIFIED_BY="Narelle S Willis" TYPE="MEDLINE" VALUE="18945995"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2014-06-01 15:01:24 +1000" MODIFIED_BY="Narelle S Willis" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Fishbane S, Vicks S, Ling X, Turner S, Charytan C</AU>
<TI>Cinacalcet with low dose vitamin D provides improved control of parathyroid hormone, calcium, and calcium-phosphorus product in hemodialysis patients with secondary hyperparathyroidism compared with vitamin D alone [abstract no: SaP383]</TI>
<SO>Nephrology Dialysis Transplantation</SO>
<YR>2007</YR>
<VL>22</VL>
<NO>Suppl 6</NO>
<PG>vi363</PG>
<IDENTIFIERS MODIFIED="2014-06-01 15:01:24 +1000" MODIFIED_BY="Narelle S Willis">
<IDENTIFIER MODIFIED="2014-06-01 15:01:24 +1000" MODIFIED_BY="Narelle S Willis" TYPE="CENTRAL" VALUE="CN-00671779"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2012-11-05 11:19:56 +1100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Fishbane S, Wetmore J, Moustafa M, Martinez C, Ling X, Turner S, et al</AU>
<TI>Treatment with cinacalcet HC1 and concurrent low-dose vitamin D improved management of secondary hyperparathyroidism (SHPT) compared with vitamin D alone [abstract no: SU-FC100]</TI>
<SO>Journal of the American Society of Nephrology</SO>
<YR>2007</YR>
<VL>18</VL>
<NO>Abstracts</NO>
<PG>89A</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2014-06-01 15:02:37 +1000" MODIFIED_BY="Narelle S Willis" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Shireman TI, Almehmi A, Wetmore JB, Lu J, Pregenzer M, Quarles LD</AU>
<TI>Economic analysis of cinacalcet in combination with low-dose vitamin D versus flexible-dose vitamin D in treating secondary hyperparathyroidism in hemodialysis patients</TI>
<SO>American Journal of Kidney Diseases</SO>
<YR>2010</YR>
<VL>56</VL>
<NO>6</NO>
<PG>1108-16</PG>
<IDENTIFIERS MODIFIED="2014-06-01 15:02:37 +1000" MODIFIED_BY="Narelle S Willis">
<IDENTIFIER MODIFIED="2014-06-01 15:02:37 +1000" MODIFIED_BY="Narelle S Willis" TYPE="MEDLINE" VALUE="20951487"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2014-06-11 16:22:10 +1000" MODIFIED_BY="Narelle Willis" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Wetmore JB, Liu S, Krebill R, Menard R, Quarles D</AU>
<TI>Treatment with cinacalcet plus vitamin D results in lower FGF23 levels than vitamin D alone [abstract no: SA-PO2779]</TI>
<SO>Journal of the American Society of Nephrology</SO>
<YR>2008</YR>
<VL>19</VL>
<NO>Abstracts Issue</NO>
<PG>739A</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2014-12-08 16:15:06 +1100" MODIFIED_BY="Narelle Willis" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Wetmore JB, Liu S, Krebill R, Menard R, Quarles LD</AU>
<TI>Effects of cinacalcet and concurrent low-dose vitamin D on FGF23 levels in ESRD</TI>
<SO>Clinical Journal of The American Society of Nephrology: CJASN</SO>
<YR>2010</YR>
<VL>5</VL>
<NO>1</NO>
<PG>110-6</PG>
<IDENTIFIERS MODIFIED="2014-06-01 15:05:36 +1000" MODIFIED_BY="Narelle S Willis">
<IDENTIFIER MODIFIED="2014-06-01 15:05:36 +1000" MODIFIED_BY="Narelle S Willis" TYPE="MEDLINE" VALUE="19965548"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-ADVANCE-Study-2010" MODIFIED="2014-12-08 16:15:05 +1100" MODIFIED_BY="Narelle Willis" NAME="ADVANCE Study 2010" YEAR="2010">
<REFERENCE MODIFIED="2014-12-08 16:15:05 +1100" MODIFIED_BY="Narelle Willis" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Floege J, Raggi P, Block GA, Torres PU, Csiky B, Naso A, et al</AU>
<TI>Study design and subject baseline characteristics in the ADVANCE Study: effects of cinacalcet on vascular calcification in haemodialysis patients</TI>
<SO>Nephrology Dialysis Transplantation</SO>
<YR>2010</YR>
<VL>25</VL>
<NO>6</NO>
<PG>1916-23</PG>
<IDENTIFIERS MODIFIED="2014-06-01 15:07:15 +1000" MODIFIED_BY="Narelle S Willis">
<IDENTIFIER MODIFIED="2014-06-01 15:07:15 +1000" MODIFIED_BY="Narelle S Willis" TYPE="MEDLINE" VALUE="20110249"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2014-06-01 15:14:35 +1000" MODIFIED_BY="Narelle S Willis" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Floege J, Sprague S, Droge J, Banos A, Chertow G</AU>
<TI>ADVANCE: the effect of cinacalcet + low-dose vitamin D on vascular calcification in hemodialysis patients - methods [abstract no: 60]</TI>
<SO>American Journal of Kidney Diseases</SO>
<YR>2007</YR>
<VL>49</VL>
<NO>4</NO>
<PG>A39</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2014-06-01 15:15:22 +1000" MODIFIED_BY="Narelle S Willis" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Raggi P, Chertow GM, Torres PU, Csiky B, Naso A, Nossuli K, et al</AU>
<TI>The ADVANCE study: a randomized study to evaluate the effects of cinacalcet plus low-dose vitamin D on vascular calcification in patients on hemodialysis</TI>
<SO>Nephrology Dialysis Transplantation</SO>
<YR>2011</YR>
<VL>26</VL>
<NO>4</NO>
<PG>1327-39</PG>
<IDENTIFIERS MODIFIED="2014-06-01 15:15:22 +1000" MODIFIED_BY="Narelle S Willis">
<IDENTIFIER MODIFIED="2014-06-01 15:15:22 +1000" MODIFIED_BY="Narelle S Willis" TYPE="MEDLINE" VALUE="21148030"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2014-05-28 13:52:08 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Urena PA, Kopyt NP, Rodriguez M, Bridges IM, Dehmel B, Cooper K, et al</AU>
<TI>Efficacy of cinacalcet combined with low dose vitamin D in incident hemodialysis subjects with secondary hyperparathyroidism [abstract no: LB-PO3145]</TI>
<SO>Journal of the American Society of Nephrology</SO>
<YR>2011</YR>
<VL>22</VL>
<NO>Abstracts</NO>
<PG>3B</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Akiba-2008" MODIFIED="2014-06-01 15:20:46 +1000" MODIFIED_BY="Narelle S Willis" NAME="Akiba 2008" YEAR="2008">
<REFERENCE MODIFIED="2014-06-01 15:19:24 +1000" MODIFIED_BY="Narelle S Willis" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Akiba T, Akizawa T, Tsukamoto Y, Uchida E, Iwasaki M, Koshikawa S, et al</AU>
<TI>Dose determination of cinacalcet hydrochloride in Japanese hemodialysis patients with secondary hyperparathyroidism</TI>
<SO>Therapeutic Apheresis &amp; Dialysis</SO>
<YR>2008</YR>
<VL>12</VL>
<NO>2</NO>
<PG>117-25</PG>
<IDENTIFIERS MODIFIED="2014-06-01 15:19:24 +1000" MODIFIED_BY="Narelle S Willis">
<IDENTIFIER MODIFIED="2014-06-01 15:19:24 +1000" MODIFIED_BY="Narelle S Willis" TYPE="OTHER" VALUE="18387159"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2013-06-02 08:10:26 +1000" MODIFIED_BY="Suetonia Palmer" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Akiba T, Akizawa T, Uchida E, Tsukamoto Y, Koshikawa S, KRN1493 Study Group</AU>
<TI>Randomized, double blind, placebo-controlled, dose-finding parallel study for KRN1493 (cinacalcet HC1) in Japanese hemodialysis patients [abstract no: F-PO764]</TI>
<SO>Journal of the American Society of Nephrology</SO>
<YR>2005</YR>
<VL>16</VL>
<PG>503A</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2014-06-01 15:20:46 +1000" MODIFIED_BY="Narelle S Willis" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Akizawa T, Koshikawa S</AU>
<TI>Clinical study of cinacalcet in Japan</TI>
<SO>Therapeutic Apheresis &amp; Dialysis</SO>
<YR>2008</YR>
<VL>12 Suppl 1</VL>
<PG>S13-5</PG>
<IDENTIFIERS MODIFIED="2014-06-01 15:20:46 +1000" MODIFIED_BY="Narelle S Willis">
<IDENTIFIER MODIFIED="2014-06-01 15:20:46 +1000" MODIFIED_BY="Narelle S Willis" TYPE="MEDLINE" VALUE="19032520"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Block-2004a" MODIFIED="2014-06-11 16:24:36 +1000" MODIFIED_BY="Narelle Willis" NAME="Block 2004a" YEAR="2004">
<REFERENCE MODIFIED="2014-06-01 15:23:03 +1000" MODIFIED_BY="Narelle S Willis" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Block GA, Martin KJ, Turner SA, Avram MM, Hercz G, Abu-Alfa AK, et al</AU>
<TI>Phase 3 study results demonstrate efficacy and safety of the calcimimetic cinacalcet HCI in hemodialysis patients with secondary hyperparathyroidism (HPT) [abstract no: SA-PO743]</TI>
<SO>Journal of the American Society of Nephrology</SO>
<YR>2003</YR>
<VL>14</VL>
<NO>Nov</NO>
<PG>461A</PG>
<IDENTIFIERS MODIFIED="2014-06-01 15:23:03 +1000" MODIFIED_BY="Narelle S Willis">
<IDENTIFIER MODIFIED="2014-06-01 15:23:03 +1000" MODIFIED_BY="Narelle S Willis" TYPE="CENTRAL" VALUE="CN-00644280"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2014-06-02 18:30:25 +1000" MODIFIED_BY="Narelle Willis" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Block GA, Martin KJ, de Francisco AL, Turner SA, Avram MM, Suranyi MG, et al</AU>
<TI>Cinacalcet for secondary hyperparathyroidism in patients receiving hemodialysis</TI>
<SO>New England Journal of Medicine</SO>
<YR>2004</YR>
<VL>350</VL>
<NO>15</NO>
<PG>1516-25</PG>
<IDENTIFIERS MODIFIED="2014-06-02 18:30:25 +1000" MODIFIED_BY="Narelle Willis">
<IDENTIFIER MODIFIED="2014-06-02 18:30:25 +1000" MODIFIED_BY="Narelle Willis" TYPE="MEDLINE" VALUE="15071126"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2014-05-28 13:10:39 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Coyne DW, Stegman MH, Azad H, Joy MS, Mischel SF, Pokroy N, et al</AU>
<TI>Cinacalcet HCI controls secondary hyperparathyroidism (HPT) regardless of gender, race, age, and geography in patients with chronic kidney disease (CKD) receiving dialysis. [abstract no: SA-PO754]</TI>
<SO>Journal of the American Society of Nephrology</SO>
<YR>2003</YR>
<VL>14</VL>
<NO>Nov</NO>
<PG>464A</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2014-05-28 13:22:22 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Cunningham J, Chertow G, Goodman W, Danese M, Olson K, Klassen P et al</AU>
<TI>The effect of cinacalcet HCl on parathyroidectomy, fracture, hospitalisation, and mortality in dialysis subjects with secondary hyperparathyroidism (HPT) [abstract]</TI>
<SO>41st ERA-EDTA Congress; 2004; May 15-18; Lisbon (Portugal)</SO>
<YR>2004</YR>
<PG>219</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="OTHER" VALUE="CN-00509144"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2014-06-08 00:14:57 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Cunningham J, Danese M, Olson K, Klassen P, Chertow GM</AU>
<TI>Effects of the calcimimetic cinacalcet HCl on cardiovascular disease, fracture, and health-related quality of life in secondary hyperparathyroidism</TI>
<SO>Kidney international</SO>
<YR>2005</YR>
<VL>68</VL>
<NO>4</NO>
<PG>1793-800</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="16164656"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2014-05-28 13:27:37 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Frazao JM, Holzer H, Stummvoll HK, Bahner U, Wilkie M, Zani V, et al</AU>
<TI>Cinacalcet (Mimpara©/Sensipar©) maintains achievement of NKF-K/DOQI treatment targets for secondary hyperparathyroidism (HPT) in patients on dialysis [abstract no: SP209]</TI>
<SO>Nephrology Dialysis Transplantation</SO>
<YR>2005</YR>
<VL>20</VL>
<NO>Suppl 5</NO>
<PG>v89</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2014-05-28 13:27:37 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Frazao JM, Messa P, Cunningham J, Evenepoel P, Shahapuni I, Urena P, et al</AU>
<TI>Early use of cinacalcet (Mimpara©/Sensipar©) in dialysis patients enables greatest achievement of NKF-KDOQITM treatment targets for bone metabolism [abstract no: SO016]</TI>
<SO>Nephrology Dialysis Transplantation</SO>
<YR>2006</YR>
<VL>21</VL>
<NO>Suppl 4</NO>
<PG>iv8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2014-06-01 15:26:57 +1000" MODIFIED_BY="Narelle S Willis" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Frazao JM, Nicolini M, Torresgrossa JV, Kerr P, Jaeger PH, Sprague SM, et al</AU>
<TI>Cinacalcet HCl effectively reduces intact parathyroid hormone (iPTH) and Ca x P irrespective of the severity of secondary hyperparathyroidism (HPT) [abstract]</TI>
<SO>41st ERA-EDTA Congress; 2004; May 15-18; Lisbon (Portugal)</SO>
<YR>2004</YR>
<PG>219</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2014-06-01 15:27:34 +1000" MODIFIED_BY="Narelle S Willis" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Goodman WG, Fadda GZ, Finkelstein FO Mittman N, Lien YH, LeBlanc M, et al</AU>
<TI>Cinacalcet HCl is an effective primary therapy for the management of secondary hyperparathyroidism [abstract]</TI>
<SO>Journal of the American Society of Nephrology</SO>
<YR>2003</YR>
<VL>14</VL>
<NO>Program &amp; Abstracts</NO>
<PG>460A</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2014-06-04 18:57:46 +1000" MODIFIED_BY="Narelle Willis" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Goodman WG, de Francisco AL, Mittman N, Messa P, Lien YH, Leblanc M, et al</AU>
<TI>Cinacalcet HCI (SensiparTM) effectively manages secondary hyperparathyroidism (HPT) in new to dialysis patients [abstract no: PUB477]</TI>
<SO>Journal of the American Society of Nephrology</SO>
<YR>2004</YR>
<VL>15</VL>
<NO>Oct</NO>
<PG>863A</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="CENTRAL" VALUE="CN-00644149"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2014-06-04 18:59:27 +1000" MODIFIED_BY="Narelle Willis" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Goodman WG, de Francisco AL, Moe SM, Cunningham J, Martin KJ, McCary LC, et al</AU>
<TI>Cinacalcet HCI (SensiparTM) is an effective treatment for secondary hyperparathyroidism (HPT) in CKD patients on dialysis [abstract no: F-PO984]</TI>
<SO>Journal of the American Society of Nephrology</SO>
<YR>2004</YR>
<VL>15</VL>
<NO>Oct</NO>
<PG>280A</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="CENTRAL" VALUE="CN-00644151"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2013-06-02 08:09:40 +1000" MODIFIED_BY="Suetonia Palmer" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Lien YH, Silva AL, Whittman D</AU>
<TI>Effects of cinacalcet on bone mineral density in patients with secondary hyperparathyroidism [abstract no: W-PO40084]</TI>
<SO>Nephrology</SO>
<YR>2005</YR>
<VL>10</VL>
<NO>Suppl 1</NO>
<PG>A301</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2014-06-01 15:29:15 +1000" MODIFIED_BY="Narelle S Willis" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Lien YH, Silva AL, Whittman D</AU>
<TI>Effects of cinacalcet on bone mineral density in patients with secondary hyperparathyroidism</TI>
<SO>Nephrology Dialysis Transplantation</SO>
<YR>2005</YR>
<VL>20</VL>
<NO>6</NO>
<PG>1232-7</PG>
<IDENTIFIERS MODIFIED="2014-06-01 15:29:15 +1000" MODIFIED_BY="Narelle S Willis">
<IDENTIFIER MODIFIED="2014-06-01 15:29:15 +1000" MODIFIED_BY="Narelle S Willis" TYPE="MEDLINE" VALUE="15840675"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2014-06-11 16:24:03 +1000" MODIFIED_BY="Narelle Willis" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Martin KJ, Sherrard DJ, Nassar G, Campbell P, Curzi M, McCary KJ, et al</AU>
<TI>Control of bio-intact parathyroid hormone (PTH) levels with the calcimimetic Cinacalcet HCl in hemodialysis patients with secondary hyperparathyroidism (HPT) [abstract no: SA-PO747]</TI>
<SO>Journal of the American Society of Nephrology</SO>
<YR>2003</YR>
<VL>14</VL>
<NO>Nov</NO>
<PG>462A</PG>
<IDENTIFIERS MODIFIED="2014-06-01 22:10:43 +1000" MODIFIED_BY="Narelle S Willis">
<IDENTIFIER MODIFIED="2014-06-01 22:10:43 +1000" MODIFIED_BY="Narelle S Willis" TYPE="CENTRAL" VALUE="CN-00583599"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2014-05-28 13:43:28 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Mittman N, de Francisco ALM, Drueke T, Fadda GZ, Arruda JA, Abu-Alfa AK, et al</AU>
<TI>Phase 3 studies demonstrate effective control of PTH and Ca x P in patients treated with cinacalcet HCI [abstract no: 73]</TI>
<SO>American Journal of Kidney Diseases</SO>
<YR>2004</YR>
<VL>43</VL>
<NO>4</NO>
<PG>A33</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2014-06-01 22:12:24 +1000" MODIFIED_BY="Narelle S Willis" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Moe SM, Chertow GM, Coburn JW, Quarles LD, Goodman WG, Block GA, et al</AU>
<TI>Achieving NKF-K/DOQI bone metabolism and disease treatment goals with cinacalcet HCl</TI>
<SO>Kidney international</SO>
<YR>2005</YR>
<VL>67</VL>
<NO>2</NO>
<PG>760-71</PG>
<IDENTIFIERS MODIFIED="2014-06-01 22:12:24 +1000" MODIFIED_BY="Narelle S Willis">
<IDENTIFIER MODIFIED="2014-06-01 22:12:24 +1000" MODIFIED_BY="Narelle S Willis" TYPE="CENTRAL" VALUE="15673327"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2014-06-11 16:24:36 +1000" MODIFIED_BY="Narelle Willis" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Sterrett JF, Strom J, Stummvoll HK, Bahner U, Disney A Soroka SD, et al</AU>
<TI>Long-term treatment of secondary hyperparathyroidism (HPT) with cinacalcet (SensiparTM) in patients receiving dialysis [abstract]</TI>
<SO>Journal of the American Society of Nephrology</SO>
<YR>2004</YR>
<VL>15</VL>
<NO>Abstracts</NO>
<PG>275A</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="CENTRAL" VALUE="CN-00583604"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2014-06-01 22:13:11 +1000" MODIFIED_BY="Narelle S Willis" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Sterrett JR, Strom J, Stummvoll HK, Bahner U, Disney A, Soroka SD, et al</AU>
<TI>Cinacalcet HCI (Sensipar/Mimpara) is an effective chronic therapy for hemodialysis patients with secondary hyperparathyroidism</TI>
<SO>Clinical Nephrology</SO>
<YR>2007</YR>
<VL>68</VL>
<NO>1</NO>
<PG>10-7</PG>
<IDENTIFIERS MODIFIED="2014-06-01 22:13:11 +1000" MODIFIED_BY="Narelle S Willis">
<IDENTIFIER MODIFIED="2014-06-01 22:13:11 +1000" MODIFIED_BY="Narelle S Willis" TYPE="MEDLINE" VALUE="17703830"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2014-06-01 22:13:41 +1000" MODIFIED_BY="Narelle S Willis" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>de Francisco A, Suranyi M, Cunningham J, Messa P, Locatelli F, Evenepoel P et al</AU>
<TI>Greater achievement of NKF-K/DOQI bone metabolism and disease targets with oral cinacalcet HCL in an EU/Australian phase 3 study in haemodialysis subjects [abstract]</TI>
<SO>41st ERA-EDTA Congress; 2004; May 15-18; Lisbon (Portugal)</SO>
<YR>2004</YR>
<PG>319</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2014-06-07 21:12:26 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>de Francisco AL, Suranyi M, Cunningham J, Messa P, Locatelli F, Evenepoel P, et al</AU>
<TI>Oral cinacalcet HCI (AMG 073) for the treatment of hemodialysis patients with secondary hyperparathyroidism (HPT): results of a European/Australian phase 3 study. [abstract no: SA-PO742]</TI>
<SO>Journal of the American Society of Nephrology</SO>
<YR>2003</YR>
<VL>14</VL>
<NO>Nov</NO>
<PG>461A</PG>
<IDENTIFIERS MODIFIED="2014-06-01 22:15:35 +1000" MODIFIED_BY="Narelle S Willis">
<IDENTIFIER MODIFIED="2014-06-01 22:15:35 +1000" MODIFIED_BY="Narelle S Willis" TYPE="CENTRAL" VALUE="CN-00583675"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Charytan-2005" MODIFIED="2014-06-02 18:52:53 +1000" MODIFIED_BY="Narelle Willis" NAME="Charytan 2005" YEAR="2005">
<REFERENCE MODIFIED="2014-06-02 18:52:53 +1000" MODIFIED_BY="Narelle Willis" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Charytan C, Coburn JW, Chonchol M, Herman J, Lien YH, Liu W, et al</AU>
<TI>Cinacalcet hydrochloride is an effective treatment for secondary hyperparathyroidism in patients with CKD not receiving dialysis</TI>
<SO>American Journal of Kidney Diseases</SO>
<YR>2005</YR>
<VL>46</VL>
<NO>1</NO>
<PG>58-67</PG>
<IDENTIFIERS MODIFIED="2014-06-02 18:52:53 +1000" MODIFIED_BY="Narelle Willis">
<IDENTIFIER MODIFIED="2014-06-02 18:52:53 +1000" MODIFIED_BY="Narelle Willis" TYPE="MEDLINE" VALUE="15983958"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2014-06-01 22:16:46 +1000" MODIFIED_BY="Narelle S Willis" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Coburn JW, Charytan C, Chonchol M, Herman J, Lien YH, Liu W, et al</AU>
<TI>Cinacalcet HCl is an effective treatment for secondary hyperparathyroidism (HPT) in patients with chronic kidney disease (CKD) not yet receiving dialysis [abstract]</TI>
<SO>Journal of the American Society of Nephrology</SO>
<YR>2003</YR>
<VL>14</VL>
<NO>Program &amp; Abstracts</NO>
<PG>460A</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Chonchol-2009" MODIFIED="2014-06-01 22:19:38 +1000" MODIFIED_BY="Narelle S Willis" NAME="Chonchol 2009" YEAR="2009">
<REFERENCE MODIFIED="2014-06-01 22:17:36 +1000" MODIFIED_BY="Narelle S Willis" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Chonchol M, Kopyt N, Herman J, Charytan C, Pischette V, Olson KA, et al</AU>
<TI>Cinacalcet HCI reduces parathyroid hormone (PTH) in patients with stage 3 and 4 chronic kidney disease (CKD) [abstract no: 18]</TI>
<SO>American Journal of Kidney Diseases</SO>
<YR>2004</YR>
<VL>43</VL>
<NO>4</NO>
<PG>A19</PG>
<IDENTIFIERS MODIFIED="2014-06-01 22:17:36 +1000" MODIFIED_BY="Narelle S Willis">
<IDENTIFIER MODIFIED="2014-06-01 22:17:36 +1000" MODIFIED_BY="Narelle S Willis" TYPE="CENTRAL" VALUE="CN-00602122"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2014-06-01 22:19:01 +1000" MODIFIED_BY="Narelle S Willis" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Chonchol M, Locatelli F, Abboud H, Charytan C, De Francisco A, Jolly S, et al</AU>
<TI>A randomized, double-blind, placebo-controlled study of cinacalcet in CKD not on dialysis [abstract no: SA-PO867]</TI>
<SO>Journal of the American Society of Nephrology</SO>
<YR>2007</YR>
<VL>18</VL>
<NO>Abstracts</NO>
<PG>533A</PG>
<IDENTIFIERS MODIFIED="2014-06-01 22:19:01 +1000" MODIFIED_BY="Narelle S Willis">
<IDENTIFIER MODIFIED="2014-06-01 22:19:01 +1000" MODIFIED_BY="Narelle S Willis" TYPE="CENTRAL" VALUE="CN-00583853"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2014-06-01 22:19:38 +1000" MODIFIED_BY="Narelle S Willis" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Chonchol M, Locatelli F, Abboud HE, Charytan C, de Francisco AL, Jolly S, et al</AU>
<TI>A randomized, double-blind, placebo-controlled study to assess the efficacy and safety of cinacalcet HCl in participants with CKD not receiving dialysis</TI>
<SO>American Journal of Kidney Diseases</SO>
<YR>2009</YR>
<VL>53</VL>
<NO>2</NO>
<PG>197-207</PG>
<IDENTIFIERS MODIFIED="2014-06-01 22:19:38 +1000" MODIFIED_BY="Narelle S Willis">
<IDENTIFIER MODIFIED="2014-06-01 22:19:38 +1000" MODIFIED_BY="Narelle S Willis" TYPE="MEDLINE" VALUE="19110359"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-El-Shafey-2011" MODIFIED="2014-12-08 16:15:06 +1100" MODIFIED_BY="Narelle Willis" NAME="El Shafey 2011" YEAR="2011">
<REFERENCE MODIFIED="2014-12-08 16:15:06 +1100" MODIFIED_BY="Narelle Willis" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>El-Shafey EM, Alsahow AE, Alsaran K, Sabry AA, Atia M</AU>
<TI>Cinacalcet hydrochloride therapy for secondary hyperparathyroidism in hemodialysis patients</TI>
<SO>Therapeutic Apheresis &amp; Dialysis</SO>
<YR>2011</YR>
<VL>15</VL>
<NO>6</NO>
<PG>547-55</PG>
<IDENTIFIERS MODIFIED="2014-06-01 22:20:14 +1000" MODIFIED_BY="Narelle S Willis">
<IDENTIFIER MODIFIED="2014-06-01 22:20:14 +1000" MODIFIED_BY="Narelle S Willis" TYPE="MEDLINE" VALUE="22107691"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-EVOLVE-study-2007" MODIFIED="2014-12-08 16:15:06 +1100" MODIFIED_BY="Narelle Willis" NAME="EVOLVE study 2007" YEAR="2007">
<REFERENCE MODIFIED="2014-06-11 16:24:59 +1000" MODIFIED_BY="Narelle Willis" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Chertow G, Block G, Correa-Rotter R, Drueke T, Floege J, Goodman W, et al</AU>
<TI>Evaluation of cinacalcet HCI therapy to lower cardiovascular events (EVOLVE) trial [abstract no: PUB359]</TI>
<SO>Journal of the American Society of Nephrology</SO>
<YR>2006</YR>
<VL>17</VL>
<NO>Abstracts</NO>
<PG>893A</PG>
<IDENTIFIERS MODIFIED="2014-06-01 22:21:08 +1000" MODIFIED_BY="Narelle S Willis">
<IDENTIFIER MODIFIED="2014-06-01 22:21:08 +1000" MODIFIED_BY="Narelle S Willis" TYPE="CENTRAL" VALUE="CN-00601998"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2014-12-08 16:15:06 +1100" MODIFIED_BY="Narelle Willis" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Chertow GM, Correa-Rotter R, Block GA, Drueke TB, Floege J, Goodman WG, et al</AU>
<TI>Baseline characteristics of subjects enrolled in the Evaluation of Cinacalcet HCl Therapy to Lower Cardiovascular Events (EVOLVE) trial</TI>
<SO>Nephrology Dialysis Transplantation</SO>
<YR>2012</YR>
<VL>27</VL>
<NO>7</NO>
<PG>2872-9</PG>
<IDENTIFIERS MODIFIED="2014-06-01 22:21:58 +1000" MODIFIED_BY="Narelle S Willis">
<IDENTIFIER MODIFIED="2014-06-01 22:21:58 +1000" MODIFIED_BY="Narelle S Willis" TYPE="MEDLINE" VALUE="22529163"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2014-12-08 16:15:05 +1100" MODIFIED_BY="Narelle Willis" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Chertow GM, Pupim LB, Block GA, Correa-Rotter R, Drueke TB, Floege J, et al</AU>
<TI>Evaluation of Cinacalcet Therapy to Lower Cardiovascular Events (EVOLVE): rationale and design overview</TI>
<SO>Clinical Journal of The American Society of Nephrology: CJASN</SO>
<YR>2007</YR>
<VL>2</VL>
<NO>5</NO>
<PG>898-905</PG>
<IDENTIFIERS MODIFIED="2014-06-01 22:23:37 +1000" MODIFIED_BY="Narelle S Willis">
<IDENTIFIER MODIFIED="2014-06-01 22:23:37 +1000" MODIFIED_BY="Narelle S Willis" TYPE="MEDLINE" VALUE="17702710"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2014-12-08 16:15:06 +1100" MODIFIED_BY="Narelle Willis" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Evolve Trial Investigators, Chertow GM, Block GA, Correa-Rotter R, Drueke TB, Floege J, et al</AU>
<TI>Effect of cinacalcet on cardiovascular disease in patients undergoing dialysis</TI>
<SO>New England Journal of Medicine</SO>
<YR>2012</YR>
<VL>367</VL>
<NO>26</NO>
<PG>2482-94</PG>
<IDENTIFIERS MODIFIED="2014-06-01 22:25:07 +1000" MODIFIED_BY="Narelle S Willis">
<IDENTIFIER MODIFIED="2014-06-01 22:25:07 +1000" MODIFIED_BY="Narelle S Willis" TYPE="MEDLINE" VALUE="23121374"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Fukagawa-2008" MODIFIED="2014-06-01 22:27:17 +1000" MODIFIED_BY="Narelle S Willis" NAME="Fukagawa 2008" YEAR="2008">
<REFERENCE MODIFIED="2014-06-01 22:25:52 +1000" MODIFIED_BY="Narelle S Willis" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Akizawa T, Koshikawa S</AU>
<TI>Clinical study of cinacalcet in Japan</TI>
<SO>Therapeutic Apheresis &amp; Dialysis</SO>
<YR>2008</YR>
<VL>12 Suppl 1</VL>
<PG>S13-5</PG>
<IDENTIFIERS MODIFIED="2014-06-01 22:25:52 +1000" MODIFIED_BY="Narelle S Willis">
<IDENTIFIER MODIFIED="2014-06-01 22:25:52 +1000" MODIFIED_BY="Narelle S Willis" TYPE="MEDLINE" VALUE="19032520"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2012-11-05 11:26:50 +1100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Fukagawa M, Yumita S, Akizawa T, Tsukamoto Y, Uchida E, Iwasaki M, et al</AU>
<TI>Randomized, placebo-controlled trial of cinacalcet (KRN1493) in Japanese dialysis patients with more severe hyperparathyroidism and longer dialysis vintage [abstract no: FP453]</TI>
<SO>Nephrology Dialysis Transplantation</SO>
<YR>2007</YR>
<VL>22</VL>
<NO>Suppl 6</NO>
<PG>vi171</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2014-06-01 22:27:17 +1000" MODIFIED_BY="Narelle S Willis" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Fukagawa M, Yumita S, Akizawa T, Uchida E, Tsukamoto Y, Iwasaki M, et al</AU>
<TI>Cinacalcet (KRN1493) effectively decreases the serum intact PTH level with favorable control of the serum phosphorus and calcium levels in Japanese dialysis patients</TI>
<SO>Nephrology Dialysis Transplantation</SO>
<YR>2008</YR>
<VL>23</VL>
<NO>1</NO>
<PG>328-35</PG>
<IDENTIFIERS MODIFIED="2014-06-01 22:27:17 +1000" MODIFIED_BY="Narelle S Willis">
<IDENTIFIER MODIFIED="2014-06-01 22:27:17 +1000" MODIFIED_BY="Narelle S Willis" TYPE="MEDLINE" VALUE="17717030"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2014-05-28 13:55:18 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Yumita S, Akizawa T, Uchida E, Tsukamoto Y, Koshikawa S, KRN1493 Study Group</AU>
<TI>A randomized, double blind, placebo-controlled, 14 week study to assess the efficacy and safety of cinacalcet HCI in Japanese hemodialysis patients [abstract no: PUB348]</TI>
<SO>Journal of the American Society of Nephrology</SO>
<YR>2006</YR>
<VL>17</VL>
<NO>Abstracts</NO>
<PG>889A</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Goodman-2000" MODIFIED="2014-06-04 15:22:45 +1000" MODIFIED_BY="Narelle Willis" NAME="Goodman 2000" YEAR="2000">
<REFERENCE MODIFIED="2014-06-01 22:29:11 +1000" MODIFIED_BY="Narelle S Willis" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Goodman WG, Frazao JM, Goodkin DA, Turner S, Liu W, Coburn JW</AU>
<TI>The calcimimetic, R-568, lowers plasma parathyroid hormone levels in hemodialysis patients with secondary hyperparathyroidism [abstract]</TI>
<SO>Journal of the American Society of Nephrology</SO>
<YR>1999</YR>
<VL>10</VL>
<NO>Program &amp; Abstracts</NO>
<PG>619A-20A</PG>
<IDENTIFIERS MODIFIED="2014-06-01 22:29:11 +1000" MODIFIED_BY="Narelle S Willis">
<IDENTIFIER MODIFIED="2014-06-01 22:29:11 +1000" MODIFIED_BY="Narelle S Willis" TYPE="CENTRAL" VALUE="CN-00626084"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2014-06-04 15:22:45 +1000" MODIFIED_BY="Narelle Willis" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Goodman WG, Frazao JM, Goodkin DA, Turner SA, Liu W, Coburn JW</AU>
<TI>A calcimimetic agent lowers plasma parathyroid hormone levels in patients with secondary hyperparathyroidism</TI>
<SO>Kidney International</SO>
<YR>2000</YR>
<VL>58</VL>
<NO>1</NO>
<PG>436-45</PG>
<IDENTIFIERS MODIFIED="2014-06-04 15:22:45 +1000" MODIFIED_BY="Narelle Willis">
<IDENTIFIER MODIFIED="2014-06-04 15:22:45 +1000" MODIFIED_BY="Narelle Willis" TYPE="MEDLINE" VALUE="10886592"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Goodman-2002" MODIFIED="2014-06-11 16:25:26 +1000" MODIFIED_BY="Narelle Willis" NAME="Goodman 2002" YEAR="2002">
<REFERENCE MODIFIED="2014-06-11 16:25:26 +1000" MODIFIED_BY="Narelle Willis" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Goodman WG, Hladik GA, Turner SA, Blaisdell PW, Goodkin DA, Liu W, et al</AU>
<TI>Multiple doses of the calcimimetic AMG 073 reduce plasma parathyroid hormone in hemodialysis patients with secondary hyperparathyroidism (SHPT) [abstract]</TI>
<SO>Journal of the American Society of Nephrology</SO>
<YR>2000</YR>
<VL>11</VL>
<NO>Sept</NO>
<PG>576A</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2014-06-04 15:35:35 +1000" MODIFIED_BY="Narelle Willis" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Goodman WG, Hladik GA, Turner SA, Blaisdell PW, Goodkin DA, Liu W, et al</AU>
<TI>The calcimimetic agent AMG 073 lowers plasma parathyroid hormone levels in hemodialysis patients with secondary hyperparathyroidism</TI>
<SO>Journal of the American Society of Nephrology</SO>
<YR>2002</YR>
<VL>13</VL>
<NO>4</NO>
<PG>1017-24</PG>
<IDENTIFIERS MODIFIED="2014-06-04 15:35:35 +1000" MODIFIED_BY="Narelle Willis">
<IDENTIFIER MODIFIED="2014-06-04 15:35:35 +1000" MODIFIED_BY="Narelle Willis" TYPE="MEDLINE" VALUE="11912261"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Harris-2004" MODIFIED="2014-06-04 15:51:24 +1000" MODIFIED_BY="Narelle Willis" NAME="Harris 2004" YEAR="2004">
<REFERENCE MODIFIED="2014-06-04 15:51:24 +1000" MODIFIED_BY="Narelle Willis" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Harris RZ, Padhi D, Marbury TC, Novelck RJ, Salfi M, Sullivan JT</AU>
<TI>Pharmacokinetics, pharmacodynamics and safety of cinacalcet hydrochloride in hemodialysis patients at doses up to 200 mg once daily</TI>
<SO>American Journal of Kidney Diseases</SO>
<YR>2004</YR>
<VL>44</VL>
<NO>6</NO>
<PG>1070-6</PG>
<IDENTIFIERS MODIFIED="2014-06-04 15:51:24 +1000" MODIFIED_BY="Narelle Willis">
<IDENTIFIER MODIFIED="2014-06-04 15:51:24 +1000" MODIFIED_BY="Narelle Willis" TYPE="MEDLINE" VALUE="15558528"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-IMPACT-SHPT-Study-2012" MODIFIED="2014-12-08 16:15:06 +1100" MODIFIED_BY="Narelle Willis" NAME="IMPACT SHPT Study 2012" YEAR="2012">
<REFERENCE MODIFIED="2014-12-08 16:15:06 +1100" MODIFIED_BY="Narelle Willis" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ketteler M, Martin KJ, Cozzolino M, Goldsmith D, Sharma A, Khan S, et al</AU>
<TI>Paricalcitol versus cinacalcet plus low-dose vitamin D for the treatment of secondary hyperparathyroidism in patients receiving haemodialysis: study design and baseline characteristics of the IMPACT SHPT study</TI>
<SO>Nephrology Dialysis Transplantation</SO>
<YR>2012</YR>
<VL>27</VL>
<NO>5</NO>
<PG>1942-9</PG>
<IDENTIFIERS MODIFIED="2014-06-01 22:31:46 +1000" MODIFIED_BY="Narelle S Willis">
<IDENTIFIER MODIFIED="2014-06-01 22:31:46 +1000" MODIFIED_BY="Narelle S Willis" TYPE="MEDLINE" VALUE="21931122"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2014-06-01 22:33:41 +1000" MODIFIED_BY="Narelle S Willis" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Ketteler M, Martin KJ, Wolf M, Amdahl M, Cozzolino M, Goldsmith D, et al</AU>
<TI>Paricalcitol versus cinacalcet plus low-dose vitamin D therapy for the treatment of secondary hyperparathyroidism in patients receiving haemodialysis: results of the IMPACT SHPT study</TI>
<SO>Nephrology Dialysis Transplantation</SO>
<YR>2012</YR>
<VL>27</VL>
<NO>8</NO>
<PG>3270-8</PG>
<IDENTIFIERS MODIFIED="2014-06-01 22:33:41 +1000" MODIFIED_BY="Narelle S Willis">
<IDENTIFIER MODIFIED="2014-06-01 22:33:41 +1000" MODIFIED_BY="Narelle S Willis" TYPE="MEDLINE" VALUE="22387567"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Lindberg-2003" MODIFIED="2014-06-04 16:30:08 +1000" MODIFIED_BY="Narelle Willis" NAME="Lindberg 2003" YEAR="2003">
<REFERENCE MODIFIED="2014-06-04 16:30:08 +1000" MODIFIED_BY="Narelle Willis" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Lindberg JS, Moe SM, Goodman WG, Coburn JW, Sprague SM, Liu W, et al</AU>
<TI>The calcimimetic AMG 073 reduces parathyroid hormone and calcium x phosphorus in secondary hyperparathyroidism</TI>
<SO>Kidney International</SO>
<YR>2003</YR>
<VL>63</VL>
<NO>1</NO>
<PG>248-54</PG>
<IDENTIFIERS MODIFIED="2014-06-04 16:30:08 +1000" MODIFIED_BY="Narelle Willis">
<IDENTIFIER MODIFIED="2014-06-04 16:30:08 +1000" MODIFIED_BY="Narelle Willis" TYPE="MEDLINE" VALUE="12472790"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2014-06-01 22:35:23 +1000" MODIFIED_BY="Narelle S Willis" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Lindberg JS, Moe SM, Goodman WG, Coburn JW, Turner SA, Blaisdell PW, et al</AU>
<TI>The calcimimetic AMG073 reduces parathyroid hormone (PTH), phosphorus (P), and calcium x phosphorus product (Ca x P) in patients with ESRD and secondary hyperparathyroidism (SHPT) [abstract]</TI>
<SO>Journal of the American Society of Nephrology</SO>
<YR>2000</YR>
<VL>11</VL>
<NO>Sept</NO>
<PG>578A</PG>
<IDENTIFIERS MODIFIED="2014-06-01 22:35:23 +1000" MODIFIED_BY="Narelle S Willis">
<IDENTIFIER MODIFIED="2014-06-01 22:35:23 +1000" MODIFIED_BY="Narelle S Willis" TYPE="CENTRAL" VALUE="CN-00626121"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Lindberg-2005" MODIFIED="2014-06-08 00:14:39 +1000" MODIFIED_BY="[Empty name]" NAME="Lindberg 2005" YEAR="2005">
<REFERENCE MODIFIED="2014-05-28 13:10:46 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Coyne DW, Stegman MH, Azad H, Joy MS, Mischel SF, Pokroy N, et al</AU>
<TI>Cinacalcet HCI controls secondary hyperparathyroidism (HPT) regardless of gender, race, age, and geography in patients with chronic kidney disease (CKD) receiving dialysis. [abstract no: SA-PO754]</TI>
<SO>Journal of the American Society of Nephrology</SO>
<YR>2003</YR>
<VL>14</VL>
<NO>Nov</NO>
<PG>464A</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2014-06-01 22:37:12 +1000" MODIFIED_BY="Narelle S Willis" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Cunningham J, Chertow G, Goodman W, Danese M, Olson K, Klassen P, et al</AU>
<TI>The effect of cinacalcet HCl on parathyroidectomy, fracture, hospitalisation, and mortality in dialysis subjects with secondary hyperparathyroidism (HPT) [abstract]</TI>
<SO>41st ERA-EDTA Congress; 2004; May 15-18; Lisbon (Portugal)</SO>
<YR>2004</YR>
<PG>219</PG>
<IDENTIFIERS MODIFIED="2014-06-01 22:37:12 +1000" MODIFIED_BY="Narelle S Willis">
<IDENTIFIER MODIFIED="2014-06-01 22:37:12 +1000" MODIFIED_BY="Narelle S Willis" TYPE="CENTRAL" VALUE="CN-00509144"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2014-06-08 00:14:39 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Cunningham J, Danese M, Olson K, Klassen P, Chertow GM</AU>
<TI>Effects of the calcimimetic cinacalcet HCl on cardiovascular disease, fracture, and health-related quality of life in secondary hyperparathyroidism</TI>
<SO>Kidney international</SO>
<YR>2005</YR>
<VL>68</VL>
<NO>4</NO>
<PG>1793-800</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="16164656"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2014-05-28 13:27:20 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Frazao JM, Holzer H, Stummvoll HK, Bahner U, Wilkie M, Zani V, et al</AU>
<TI>Cinacalcet (Mimpara©/Sensipar©) maintains achievement of NKF-K/DOQI treatment targets for secondary hyperparathyroidism (HPT) in patients on dialysis [abstract no: SP209]</TI>
<SO>Nephrology Dialysis Transplantation</SO>
<YR>2005</YR>
<VL>20</VL>
<NO>Suppl 5</NO>
<PG>v89</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2014-05-28 13:27:20 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Frazao JM, Messa P, Cunningham J, Evenepoel P, Shahapuni I, Urena P, et al</AU>
<TI>Early use of cinacalcet (Mimpara©/Sensipar©) in dialysis patients enables greatest achievement of NKF-KDOQITM treatment targets for bone metabolism [abstract no: SO016]</TI>
<SO>Nephrology Dialysis Transplantation</SO>
<YR>2006</YR>
<VL>21</VL>
<NO>Suppl 4</NO>
<PG>iv8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2014-06-01 22:39:11 +1000" MODIFIED_BY="Narelle S Willis" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Frazao JM, Nicolini M, Torresgrossa JV, Kerr P, Jaeger PH, Sprague SM, et al</AU>
<TI>Cinacalcet HCl effectively reduces intact parathyroid hormone (iPTH) and Ca x P irrespective of the severity of secondary hyperparathyroidism (HPT)</TI>
<SO>41st ERA-EDTA Congress; 2004; May 15-18; Lisbon (Portugal)</SO>
<YR>2004</YR>
<PG>219</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2014-06-01 22:39:43 +1000" MODIFIED_BY="Narelle S Willis" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Goodman WG, Fadda GZ, Finkelstein FO, Mittman N, Lien YH, LeBlanc M, et al</AU>
<TI>Cinacalcet HCl is an effective primary therapy for the management of secondary hyperparathyroidism [abstract]</TI>
<SO>Journal of the American Society of Nephrology</SO>
<YR>2003</YR>
<VL>14</VL>
<NO>Program &amp; Abstracts</NO>
<PG>460A</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2014-06-04 18:57:31 +1000" MODIFIED_BY="Narelle Willis" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Goodman WG, de Francisco AL, Mittman N, Messa P, Lien YH, Leblanc M, et al</AU>
<TI>Cinacalcet HCI (SensiparTM) effectively manages secondary hyperparathyroidism (HPT) in new to dialysis patients [abstract no: PUB477]</TI>
<SO>Journal of the American Society of Nephrology</SO>
<YR>2004</YR>
<VL>15</VL>
<NO>Oct</NO>
<PG>863A</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="CENTRAL" VALUE="CN-00644149"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2014-06-04 18:59:15 +1000" MODIFIED_BY="Narelle Willis" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Goodman WG, de Francisco AL, Moe SM, Cunningham J, Martin KJ, McCary LC, et al</AU>
<TI>Cinacalcet HCI (SensiparTM) is an effective treatment for secondary hyperparathyroidism (HPT) in CKD patients on dialysis [abstract no: F-PO984]</TI>
<SO>Journal of the American Society of Nephrology</SO>
<YR>2004</YR>
<VL>15</VL>
<NO>Oct</NO>
<PG>280A</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="CENTRAL" VALUE="CN-00644151"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2014-06-04 16:40:41 +1000" MODIFIED_BY="Narelle Willis" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Lindberg JS, Culleton B, Wong G, Borah MF, Clark RV, Shapiro WB, et al</AU>
<TI>Cinacalcet HCl, an oral calcimimetic agent for the treatment of secondary hyperparathyroidism in hemodialysis and peritoneal dialysis: a randomized, double-blind, multicenter study</TI>
<SO>Journal of the American Society of Nephrology</SO>
<YR>2005</YR>
<VL>16</VL>
<NO>3</NO>
<PG>800-7</PG>
<IDENTIFIERS MODIFIED="2014-06-04 16:40:41 +1000" MODIFIED_BY="Narelle Willis">
<IDENTIFIER MODIFIED="2014-06-04 16:40:41 +1000" MODIFIED_BY="Narelle Willis" TYPE="MEDLINE" VALUE="15689407"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2014-06-01 22:41:03 +1000" MODIFIED_BY="Narelle S Willis" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Lindberg JS, Culleton B, Wong G, Borah MF, Clark RV, Shapiro WB, et al</AU>
<TI>Phase 3 experience with cinacalcet HCI in hemodialysis (HD) and peritoneal dialysis (PD) patients with secondary HPT [abstract no: SA-PO752]</TI>
<SO>Journal of the American Society of Nephrology</SO>
<YR>2003</YR>
<VL>14</VL>
<NO>Nov</NO>
<PG>463A</PG>
<IDENTIFIERS MODIFIED="2014-06-01 22:40:58 +1000" MODIFIED_BY="Narelle S Willis">
<IDENTIFIER MODIFIED="2014-06-01 22:40:58 +1000" MODIFIED_BY="Narelle S Willis" TYPE="CENTRAL" VALUE="CN-00626029"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2014-06-01 22:41:56 +1000" MODIFIED_BY="Narelle S Willis" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Mittman N, Finkelstein F, Culleton B, Charytan C, Agarwal A, Albizem MA, et al</AU>
<TI>Cinacalcet HCI (SensiparTM) for the management of secondary hyperparathyroidism (HPT) in patients receiving peritoneal dialysis (PD) [abstract no: F-PO985]</TI>
<SO>Journal of the American Society of Nephrology</SO>
<YR>2004</YR>
<VL>15</VL>
<NO>Oct</NO>
<PG>280A</PG>
<IDENTIFIERS MODIFIED="2014-06-01 22:41:56 +1000" MODIFIED_BY="Narelle S Willis">
<IDENTIFIER MODIFIED="2014-06-01 22:41:56 +1000" MODIFIED_BY="Narelle S Willis" TYPE="CENTRAL" VALUE="CN-00626108"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2014-06-01 22:42:32 +1000" MODIFIED_BY="Narelle S Willis" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Mittman N, de Francisco AL, Drueke T, Fadda GZ, Arruda JA, Abu-Alfa AK, et al</AU>
<TI>Phase 3 studies demonstrate effective control of PTH and Ca x P in patients treated with cinacalcet HCI [abstract no: 73]</TI>
<SO>American Journal of Kidney Diseases</SO>
<YR>2004</YR>
<VL>43</VL>
<NO>4</NO>
<PG>A33</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2014-06-01 22:43:07 +1000" MODIFIED_BY="Narelle S Willis" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Moe SM, Chertow GM, Coburn JW, Quarles LD, Goodman WG, Block GA, et al</AU>
<TI>Achieving NKF-K/DOQI bone metabolism and disease treatment goals with cinacalcet HCl</TI>
<SO>Kidney international</SO>
<YR>2005</YR>
<VL>67</VL>
<NO>2</NO>
<PG>760-71</PG>
<IDENTIFIERS MODIFIED="2014-06-01 22:43:07 +1000" MODIFIED_BY="Narelle S Willis">
<IDENTIFIER MODIFIED="2014-06-01 22:43:07 +1000" MODIFIED_BY="Narelle S Willis" TYPE="MEDLINE" VALUE="15673327"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Malluche-2008" MODIFIED="2014-06-08 00:14:46 +1000" MODIFIED_BY="[Empty name]" NAME="Malluche 2008" YEAR="2008">
<REFERENCE MODIFIED="2014-06-01 22:43:33 +1000" MODIFIED_BY="Narelle S Willis" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Cunningham J, Chertow G, Goodman W, Danese M, Olson K, Klassen P et al</AU>
<TI>The effect of cinacalcet HCl on parathyroidectomy, fracture, hospitalisation, and mortality in dialysis subjects with secondary hyperparathyroidism (HPT) [abstract]</TI>
<SO>41st ERA-EDTA Congress; 2004; May 15-18; Lisbon (Portugal)</SO>
<YR>2004</YR>
<PG>219</PG>
<IDENTIFIERS MODIFIED="2014-06-01 22:43:33 +1000" MODIFIED_BY="Narelle S Willis">
<IDENTIFIER MODIFIED="2014-06-01 22:43:33 +1000" MODIFIED_BY="Narelle S Willis" TYPE="CENTRAL" VALUE="CN-00509144"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2014-06-08 00:14:46 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Cunningham J, Danese M, Olson K, Klassen P, Chertow GM</AU>
<TI>Effects of the calcimimetic cinacalcet HCl on cardiovascular disease, fracture, and health-related quality of life in secondary hyperparathyroidism</TI>
<SO>Kidney international</SO>
<YR>2005</YR>
<VL>68</VL>
<NO>4</NO>
<PG>1793-800</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="16164656"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2014-06-04 18:57:09 +1000" MODIFIED_BY="Narelle Willis" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Goodman WG, de Francisco AL, Mittman N, Messa P, Lien YH, Leblanc M, et al</AU>
<TI>Cinacalcet HCI (SensiparTM) effectively manages secondary hyperparathyroidism (HPT) in new to dialysis patients [abstract no: PUB477]</TI>
<SO>Journal of the American Society of Nephrology</SO>
<YR>2004</YR>
<VL>15</VL>
<NO>Oct</NO>
<PG>863A</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="CENTRAL" VALUE="CN-00644149"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2014-06-04 18:59:07 +1000" MODIFIED_BY="Narelle Willis" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Goodman WG, de Francisco AL, Moe SM, Cunningham J, Martin KJ, McCary LC, et al</AU>
<TI>Cinacalcet HCI (SensiparTM) is an effective treatment for secondary hyperparathyroidism (HPT) in CKD patients on dialysis [abstract no: F-PO984]</TI>
<SO>Journal of the American Society of Nephrology</SO>
<YR>2004</YR>
<VL>15</VL>
<NO>Oct</NO>
<PG>280A</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="CENTRAL" VALUE="CN-00644151"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2014-06-01 22:44:05 +1000" MODIFIED_BY="Narelle S Willis" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Malluche HH, Monier-Faugere MC, Wang G, Fraza OJ, Charytan C, Coburn JW, et al</AU>
<TI>An assessment of cinacalcet HCl effects on bone histology in dialysis patients with secondary hyperparathyroidism</TI>
<SO>Clinical Nephrology</SO>
<YR>2008</YR>
<VL>69</VL>
<NO>4</NO>
<PG>269-78</PG>
<IDENTIFIERS MODIFIED="2014-06-01 22:44:05 +1000" MODIFIED_BY="Narelle S Willis">
<IDENTIFIER MODIFIED="2014-06-01 22:44:05 +1000" MODIFIED_BY="Narelle S Willis" TYPE="MEDLINE" VALUE="18397701"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2014-06-01 22:44:50 +1000" MODIFIED_BY="Narelle S Willis" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Malluche HH, Monier-Faugere MC, Wang G, Frazao JM, Charytan C, Coburn JW, et al</AU>
<TI>Cinacalcet HCl reduces bone turnover and bone marrow fibrosis in hemodialysis patients with secondary hyperparathyroidism (HPT) [abstract]</TI>
<SO>41st ERA-EDTA Congress; 2004; May 15-18; Lisbon (Portugal)</SO>
<YR>2004</YR>
<PG>218-9</PG>
<IDENTIFIERS MODIFIED="2014-06-01 22:44:50 +1000" MODIFIED_BY="Narelle S Willis">
<IDENTIFIER MODIFIED="2014-06-01 22:44:50 +1000" MODIFIED_BY="Narelle S Willis" TYPE="CENTRAL" VALUE="CN-00509338"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-OPTIMA-Study-2008" MODIFIED="2014-12-08 16:15:06 +1100" MODIFIED_BY="Narelle Willis" NAME="OPTIMA Study 2008" YEAR="">
<REFERENCE MODIFIED="2014-12-08 16:15:06 +1100" MODIFIED_BY="Narelle Willis" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Frazao JM, Braun J, Messa P, Dehmel B, Mattin C, Wilkie M</AU>
<TI>Is serum phosphorus control related to parathyroid hormone control in dialysis patients with secondary hyperparathyroidism?</TI>
<SO>BMC Nephrology</SO>
<YR>2012</YR>
<VL>13</VL>
<PG>76</PG>
<IDENTIFIERS MODIFIED="2014-06-01 22:44:53 +1000" MODIFIED_BY="Narelle S Willis">
<IDENTIFIER TYPE="MEDLINE" VALUE="22863242"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2014-06-11 16:26:30 +1000" MODIFIED_BY="Narelle Willis" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Frazao JM, Macario F, Yaqoob M, Bouman K, Braun J, von Albertini B, et al</AU>
<TI>The Optima Study: earlier intervention of cinacalcet HCL (Sensipar©/Mimpara©) enables greater achievement of KDOQIT secondary hyperparathyroidism (SHPT) targets in dialysis patients [abstract no: 45]</TI>
<SO>American Journal of Kidney Diseases</SO>
<YR>2006</YR>
<VL>47</VL>
<NO>4</NO>
<PG>A30</PG>
<IDENTIFIERS MODIFIED="2014-06-01 22:45:41 +1000" MODIFIED_BY="Narelle S Willis">
<IDENTIFIER MODIFIED="2014-06-01 22:45:41 +1000" MODIFIED_BY="Narelle S Willis" TYPE="CENTRAL" VALUE="CN-00644220"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2014-05-28 13:28:46 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Gonzalez MT, Hutchison AJ, Girndt M, Stahl-Nilsson A, Zani V, Carter D, et al</AU>
<TI>Secondary hyperparathyroidism (HPT) in patients receiving peritoneal dialysis (PD) can be effectively managed with cinacalcet (Mimpara©/Sensipar©) [abstract no: SP359]</TI>
<SO>Nephrology Dialysis Transplantation</SO>
<YR>2006</YR>
<VL>21</VL>
<NO>Suppl 4</NO>
<PG>iv134</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2014-06-11 16:27:10 +1000" MODIFIED_BY="Narelle Willis" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Locatelli F, Macario F, Brink HS, Dhaene M, Pai P, Holzer H, et al</AU>
<TI>The OPTIMA study: efficacy of a cinacalcet (Mimpara©/Sensipar©) treatment algorithm to treat dialysis patients with elevated PTH and calcium-phosphorus product (Ca x P) [abstract no: SP357]</TI>
<SO>Nephrology Dialysis Transplantation</SO>
<YR>2006</YR>
<VL>21</VL>
<NO>Suppl 4</NO>
<PG>iv133</PG>
<IDENTIFIERS MODIFIED="2014-06-01 22:47:09 +1000" MODIFIED_BY="Narelle S Willis">
<IDENTIFIER MODIFIED="2014-06-01 22:47:09 +1000" MODIFIED_BY="Narelle S Willis" TYPE="CENTRAL" VALUE="CN-00644212"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2014-06-04 16:56:36 +1000" MODIFIED_BY="Narelle Willis" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Messa P, Macario F, Yaqoob M, Bouman K, Braun J, von Albertini B, et al</AU>
<TI>The OPTIMA study: assessing a new cinacalcet (Sensipar/Mimpara) treatment algorithm for secondary hyperparathyroidism</TI>
<SO>Clinical Journal of The American Society of Nephrology: CJASN</SO>
<YR>2008</YR>
<VL>3</VL>
<NO>1</NO>
<PG>36-45</PG>
<IDENTIFIERS MODIFIED="2014-06-04 16:56:36 +1000" MODIFIED_BY="Narelle Willis">
<IDENTIFIER MODIFIED="2014-06-04 16:56:36 +1000" MODIFIED_BY="Narelle Willis" TYPE="MEDLINE" VALUE="18178780"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2014-06-01 22:48:36 +1000" MODIFIED_BY="Narelle S Willis" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Messa P, Motellon JL, OPTIMA Study Group</AU>
<TI>Optimizing the use of cinacalcet (Mimpara©/Sensipar©) and vitamin D: interim results from the OPTIMA study [abstract no: F-PO758]</TI>
<SO>Journal of the American Society of Nephrology</SO>
<YR>2005</YR>
<VL>16</VL>
<PG>501A-2A</PG>
<IDENTIFIERS MODIFIED="2014-06-01 22:48:36 +1000" MODIFIED_BY="Narelle S Willis">
<IDENTIFIER MODIFIED="2014-06-01 22:48:36 +1000" MODIFIED_BY="Narelle S Willis" TYPE="CENTRAL" VALUE="CN-00644221"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2014-06-01 22:49:14 +1000" MODIFIED_BY="Narelle S Willis" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Messa P, Villa G, Braun J, Maduell F, Cruz J, Martin PY, et al</AU>
<TI>The OPTIMA study: lower doses of cinacalcet (Mimpara©/Sensipar©) are required to achieve KDOQITM secondary hyperparathyroidism (HPT) targets in dialysis patients with less severe disease [abstract no: MP324]</TI>
<SO>Nephrology Dialysis Transplantation</SO>
<YR>2006</YR>
<VL>21</VL>
<NO>Suppl 4</NO>
<PG>iv407</PG>
<IDENTIFIERS MODIFIED="2014-06-01 22:49:14 +1000" MODIFIED_BY="Narelle S Willis">
<IDENTIFIER MODIFIED="2014-06-01 22:49:14 +1000" MODIFIED_BY="Narelle S Willis" TYPE="CENTRAL" VALUE="CN-00583842"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2014-05-28 13:47:53 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Perrault L, Carter D, Molemans B, Maetzel A</AU>
<TI>Use of cinacalcet HCL (Mimpara©/Sensipar©) to control mineral metabolism in patients with end-stage renal disease (ESRD) on dialysis complicated by secondary hyperparathyroidism (SHPT): a cost-consequence analysis of cinacalcet HCL versus standard of care (SC) [abstract no: SP363]</TI>
<SO>Nephrology Dialysis Transplantation</SO>
<YR>2006</YR>
<VL>21</VL>
<NO>Suppl 4</NO>
<PG>iv136</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2014-06-01 22:50:31 +1000" MODIFIED_BY="Narelle S Willis" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Wilkie M, Pontoriero G, Macario F, Yaqoob M, Bouman K, Braun J, et al</AU>
<TI>Impact of vitamin D dose on biochemical parameters in patients with secondary hyperparathyroidism receiving cinacalcet</TI>
<SO>Nephron</SO>
<YR>2009</YR>
<VL>112</VL>
<NO>1</NO>
<PG>c41-50</PG>
<IDENTIFIERS MODIFIED="2014-06-01 22:50:31 +1000" MODIFIED_BY="Narelle S Willis">
<IDENTIFIER MODIFIED="2014-06-01 22:50:31 +1000" MODIFIED_BY="Narelle S Willis" TYPE="MEDLINE" VALUE="19365139"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2014-06-01 22:51:09 +1000" MODIFIED_BY="Narelle S Willis" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Wilkie M, Salvadori M, De Meester J, Jofre R, Koopman MG, Leidig FM, et al</AU>
<TI>The OPTIMA study: optimising the dose of vitamin D (vit D) in the presence of cinacalcet (Mimpara©/Sensipar©) to obtain maximum clinical benefit [abstract no: SP358]</TI>
<SO>Nephrology Dialysis Transplantation</SO>
<YR>2006</YR>
<VL>21</VL>
<NO>Suppl 4</NO>
<PG>iv134</PG>
<IDENTIFIERS MODIFIED="2014-06-01 22:51:09 +1000" MODIFIED_BY="Narelle S Willis">
<IDENTIFIER MODIFIED="2014-06-01 22:51:09 +1000" MODIFIED_BY="Narelle S Willis" TYPE="CENTRAL" VALUE="CN-00583844"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2014-06-01 22:56:19 +1000" MODIFIED_BY="Narelle S Willis" PRIMARY="NO" TYPE="OTHER">
<AU>Wilkie M</AU>
<TI>A multi-centre, randomised, open-label study to compare the efficacy and safety of an oral calcimimetic agent (AMG 073) when two different vitamin D regimens are used in subjects with secondary hyperparathyroidism of end-stage renal disease (ESRD)</TI>
<SO>http://www.nihr.ac.uk/Profile/Pages/NRRResults.aspx?publication_id=N0059124801</SO>
<YR>(accessed 1 June 2014)</YR>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Quarles-2003a" MODIFIED="2014-06-04 17:20:17 +1000" MODIFIED_BY="Narelle Willis" NAME="Quarles 2003a" YEAR="2003">
<REFERENCE MODIFIED="2014-06-04 17:20:17 +1000" MODIFIED_BY="Narelle Willis" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Quarles LD, Sherrard DJ, Adler S, Rosansky SJ, McCary LC, Liu W, et al</AU>
<TI>The calcimimetic AMG 073 as a potential treatment for secondary hyperparathyroidism of end-stage renal disease</TI>
<SO>Journal of the American Society of Nephrology</SO>
<YR>2003</YR>
<VL>14</VL>
<NO>3</NO>
<PG>575-83</PG>
<IDENTIFIERS MODIFIED="2014-06-04 17:20:17 +1000" MODIFIED_BY="Narelle Willis">
<IDENTIFIER MODIFIED="2014-06-04 17:20:17 +1000" MODIFIED_BY="Narelle Willis" TYPE="MEDLINE" VALUE="12595492"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</INCLUDED_STUDIES>
<EXCLUDED_STUDIES MODIFIED="2014-12-08 16:15:06 +1100" MODIFIED_BY="Narelle Willis">
<STUDY DATA_SOURCE="PUB" ID="STD-Al_x002d_Hilali-2011" MODIFIED="2014-06-04 17:54:59 +1000" MODIFIED_BY="Narelle Willis" NAME="Al-Hilali 2011" YEAR="2011">
<REFERENCE MODIFIED="2014-06-02 15:24:42 +1000" MODIFIED_BY="Narelle Willis" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Al-Hilali N, Hussain N, Kawy YA, Al-Azmi M</AU>
<TI>A novel dose regimen of cinacalcet in the treatment of severe hyperparathyroidism in hemodialysis patients</TI>
<SO>Saudi Journal of Kidney Diseases &amp; Transplantation</SO>
<YR>2011</YR>
<VL>22</VL>
<NO>3</NO>
<PG>448-55</PG>
<IDENTIFIERS MODIFIED="2014-06-02 15:24:42 +1000" MODIFIED_BY="Narelle Willis">
<IDENTIFIER MODIFIED="2014-06-02 15:24:42 +1000" MODIFIED_BY="Narelle Willis" TYPE="MEDLINE" VALUE="21566299"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Coburn-2000a" MODIFIED="2014-06-02 15:25:33 +1000" MODIFIED_BY="Narelle Willis" NAME="Coburn 2000a" YEAR="2000">
<REFERENCE MODIFIED="2014-06-02 15:25:33 +1000" MODIFIED_BY="Narelle Willis" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Coburn JW, Barri YM, Turner SA, Blaisdell PW, Goodkin DA, Liu W, et al</AU>
<TI>Single doses of the calcimimetic AMG 073 reduce parathyroid hormone levels in a dose dependent manner in hemodialysis patients with secondary hyperparathyroidism [abstract]</TI>
<SO>Journal of the American Society of Nephrology</SO>
<YR>2000</YR>
<VL>11</VL>
<NO>Sept</NO>
<PG>573A-4A</PG>
<IDENTIFIERS MODIFIED="2014-06-02 15:25:33 +1000" MODIFIED_BY="Narelle Willis">
<IDENTIFIER MODIFIED="2014-06-02 15:25:33 +1000" MODIFIED_BY="Narelle Willis" TYPE="CENTRAL" VALUE="CN-00550686"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-CONTROL-Study-2006" MODIFIED="2014-12-08 16:15:06 +1100" MODIFIED_BY="Narelle Willis" NAME="CONTROL Study 2006" YEAR="2006">
<REFERENCE MODIFIED="2014-12-08 16:15:06 +1100" MODIFIED_BY="Narelle Willis" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Chertow GM, Blumenthal S, Turner S, Roppolo M, Stern L, Chi EM, et al</AU>
<TI>Cinacalcet hydrochloride (Sensipar) in hemodialysis patients on active vitamin D derivatives with controlled PTH and elevated calcium x phosphate</TI>
<SO>Clinical Journal of The American Society of Nephrology: CJASN</SO>
<YR>2006</YR>
<VL>1</VL>
<NO>2</NO>
<PG>305-12</PG>
<IDENTIFIERS MODIFIED="2014-06-02 15:26:30 +1000" MODIFIED_BY="Narelle Willis">
<IDENTIFIER MODIFIED="2014-06-02 15:26:30 +1000" MODIFIED_BY="Narelle Willis" TYPE="MEDLINE" VALUE="17699221"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2014-06-02 15:27:37 +1000" MODIFIED_BY="Narelle Willis" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Reed J, Keightley G, Blumenthal S, Bradley C, LaBrecque J, Turner S, et al</AU>
<TI>The CONTROL STUDY: enhanced achievement of NKF-K/DOQI bone metabolism and disease targets using cinacalcet HCL (Sensipar) [abstract]</TI>
<SO>Journal of the American Society of Nephrology</SO>
<YR>2004</YR>
<VL>15</VL>
<NO>Abstracts</NO>
<PG>280A</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Cunningham-2003" MODIFIED="2014-06-11 16:28:04 +1000" MODIFIED_BY="Narelle Willis" NAME="Cunningham 2003" YEAR="2003">
<REFERENCE MODIFIED="2014-06-11 16:28:04 +1000" MODIFIED_BY="Narelle Willis" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Cunningham J, Holzer H, Reichel H, Braun J, Hawley C, Urena P, et al</AU>
<TI>Sustained, long-term reductions in parathyroid hormone (iPTH) after 3 years of treatment with calcimimetic cinacalcet HCl in patients with secondary hyperparathyroidism (SPTH) [abstract no: M479]</TI>
<SO>Nephrology Dialysis Transplantation</SO>
<YR>2003</YR>
<VL>18</VL>
<NO>Suppl 4</NO>
<PG>150-1</PG>
<IDENTIFIERS MODIFIED="2014-06-02 15:29:45 +1000" MODIFIED_BY="Narelle Willis">
<IDENTIFIER MODIFIED="2014-06-02 15:29:45 +1000" MODIFIED_BY="Narelle Willis" TYPE="CENTRAL" VALUE="CN-00583594"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Cunningham-2005" MODIFIED="2012-11-05 11:25:27 +1100" MODIFIED_BY="[Empty name]" NAME="Cunningham 2005" YEAR="2005">
<REFERENCE MODIFIED="2012-11-05 11:25:27 +1100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Cunningham J, Urena P, Reichel H, Holzer H, Drueke T, Zani V, et al</AU>
<TI>Long term efficacy of cinacalcet in secondary hyperparathyroidism (HPT) of end stage renal disease (ESRD) [abstract no: SP210]</TI>
<SO>Nephrology Dialysis Transplantation</SO>
<YR>2005</YR>
<VL>20</VL>
<NO>Suppl 5</NO>
<PG>v89</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-de-Francisco-2005" MODIFIED="2014-06-07 21:11:59 +1000" MODIFIED_BY="[Empty name]" NAME="de Francisco 2005" YEAR="2005">
<REFERENCE MODIFIED="2012-11-05 11:25:38 +1100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>De Francisco A, Evenepoel P, Brink HS, Mellotte G, Barata JD, Zani V, et al</AU>
<TI>Cinacalcet (Mimpara©/Sensipar©) effectively reduces intact parathyroid hormone (iPTH) and serum calcium (CA) regardless of serum calcium level in patients with secondary hyperparathyroidism (HPT) [abstract no: MO30]</TI>
<SO>Nephrology Dialysis Transplantation</SO>
<YR>2005</YR>
<VL>20</VL>
<NO>Suppl 5</NO>
<PG>v197</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Harris-2003" MODIFIED="2014-06-02 15:38:22 +1000" MODIFIED_BY="Narelle Willis" NAME="Harris 2003" YEAR="2003">
<REFERENCE MODIFIED="2014-06-02 15:38:22 +1000" MODIFIED_BY="Narelle Willis" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Harris R, Padhi D, Salfi M, Yates W, Simiens MA, Sulivan JT</AU>
<TI>Pharmacokinetics (PK), pharmacodynamics (PD), and safety of daily administration of cinacalcet HCI up to 300 mg in chronic kidney disease (CKD) patients on hemodialysis (HD) [abstract no: SA-PO746]</TI>
<SO>Journal of the American Society of Nephrology</SO>
<YR>2003</YR>
<VL>14</VL>
<NO>Nov</NO>
<PG>462A</PG>
<IDENTIFIERS MODIFIED="2014-06-02 15:38:22 +1000" MODIFIED_BY="Narelle Willis">
<IDENTIFIER MODIFIED="2014-06-02 15:38:22 +1000" MODIFIED_BY="Narelle Willis" TYPE="CENTRAL" VALUE="CN-00583298"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kaperonis-2012" MODIFIED="2014-12-08 16:15:06 +1100" MODIFIED_BY="Narelle Willis" NAME="Kaperonis 2012" YEAR="2012">
<REFERENCE MODIFIED="2014-12-08 16:15:06 +1100" MODIFIED_BY="Narelle Willis" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kaperonis N, Kourvelou C, Sgantzos A, Nastou D, Ntatsis G, Ziakka S, et al</AU>
<TI>Cinacalcet vs. paricalcitol in hemodialysis patients [abstract]</TI>
<SO>Nephrology Dialysis Transplantation</SO>
<YR>2012</YR>
<VL>27</VL>
<NO>Suppl 2</NO>
<PG>ii497-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Moe-2003a" MODIFIED="2014-06-02 15:40:22 +1000" MODIFIED_BY="Narelle Willis" NAME="Moe 2003a" YEAR="2003">
<REFERENCE MODIFIED="2014-06-02 15:40:22 +1000" MODIFIED_BY="Narelle Willis" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Moe SM, Sprague SM, Cunningham J, Drueke T, Adler S, Rosansky SJ, et al</AU>
<TI>Long-term treatment of secondary hyperparathyroidism (HPT) with the calcimimetic cinacalcet HCI [abstract no: SA-PO753]</TI>
<SO>Journal of the American Society of Nephrology</SO>
<YR>2003</YR>
<VL>14</VL>
<PG>463A-4A</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Moe-2005" MODIFIED="2014-06-04 19:08:06 +1000" MODIFIED_BY="Narelle Willis" NAME="Moe 2005" YEAR="2005">
<REFERENCE MODIFIED="2014-05-28 13:07:11 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Belozeroff V, Goodman W, Ren L, Kalantar-Zadeh K</AU>
<TI>Cinacalcet lowers serum alkaline phosphatase (alkPhos) in maintenance hemodialysis (MHD) patients [abstract no: SA-PO698]</TI>
<SO>Journal of the American Society of Nephrology</SO>
<YR>2007</YR>
<VL>18</VL>
<NO>Abstracts Issue</NO>
<PG>495A-6A</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2014-06-02 15:41:28 +1000" MODIFIED_BY="Narelle Willis" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Bushinsky DA, Avram MM, Abu-Alfa AK, Borah MF, Shapiro WB, Olson KA, et al</AU>
<TI>Characterization of the effects of cinacalcet HC1 (Sensipar©/Mimpara©) on serum calcium in dialysis patients with secondary hyperparathyroidism (HPT) [abstract no: F-PO756]</TI>
<SO>Journal of the American Society of Nephrology</SO>
<YR>2005</YR>
<VL>16</VL>
<PG>501A</PG>
<IDENTIFIERS MODIFIED="2014-06-02 15:41:28 +1000" MODIFIED_BY="Narelle Willis">
<IDENTIFIER MODIFIED="2014-06-02 15:41:28 +1000" MODIFIED_BY="Narelle Willis" TYPE="CENTRAL" VALUE="CN-00583862"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2014-06-04 19:08:06 +1000" MODIFIED_BY="Narelle Willis" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Moe SM, Coburn JW, Quarles LD, Goodman WG, Chertow GM, Block GA, et al</AU>
<TI>Achievement of proposed NKF-K/DOQI bone metabolism and disease targets: treatment with cinacalcet HCl in dialysis patients with uncontrolled secondary hyperparathyroidism (HPT) [abstract no: SU-FC217]</TI>
<SO>Journal of the American Society of Nephrology</SO>
<YR>2003</YR>
<VL>14</VL>
<NO>Nov</NO>
<PG>48A</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2012-11-05 11:32:45 +1100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Moe SM, Goodman WG, Cunningham J, Drueke T, Adler S, Rosansky SJ, et al</AU>
<TI>Cinacalcet HC1 sustains long-term control of secondary hyperparathyroidism (HPT) [abstract no: F-PO755]</TI>
<SO>Journal of the American Society of Nephrology</SO>
<YR>2005</YR>
<VL>16</VL>
<PG>501A</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Moe-2005b" MODIFIED="2014-06-02 15:43:15 +1000" MODIFIED_BY="Narelle Willis" NAME="Moe 2005b" YEAR="2005">
<REFERENCE MODIFIED="2014-06-02 15:43:15 +1000" MODIFIED_BY="Narelle Willis" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Moe SM, Cunningham J, Bommer J, Adler S, Rosansky SJ, Urena-Torres P, et al</AU>
<TI>Long-term treatment of secondary hyperparathyroidism with the calcimimetic cinacalcet HCl</TI>
<SO>Nephrology Dialysis Transplantation</SO>
<YR>2005</YR>
<VL>20</VL>
<NO>10</NO>
<PG>2186-93</PG>
<IDENTIFIERS MODIFIED="2014-06-02 15:43:15 +1000" MODIFIED_BY="Narelle Willis">
<IDENTIFIER MODIFIED="2014-06-02 15:43:15 +1000" MODIFIED_BY="Narelle Willis" TYPE="MEDLINE" VALUE="16030053"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Padhi-2003" MODIFIED="2014-06-11 16:28:40 +1000" MODIFIED_BY="Narelle Willis" NAME="Padhi 2003" YEAR="2003">
<REFERENCE MODIFIED="2014-06-11 16:28:40 +1000" MODIFIED_BY="Narelle Willis" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Padhi D, Harris R, Salfi M, Yates W, Hansen J, Flynn J, et al</AU>
<TI>Cinacalcet HCI absorption in study subjects is not affected by coadministration of medications commonly prescribed to chronic kidney disease (CKD) patients (pantoprazole, sevelamer HCI, and calcium carbonate). [abstract no: SA-PO744]</TI>
<SO>Journal of the American Society of Nephrology</SO>
<YR>2003</YR>
<VL>14</VL>
<PG>461A</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Pahl-1996" MODIFIED="2014-06-02 15:44:03 +1000" MODIFIED_BY="Narelle Willis" NAME="Pahl 1996" YEAR="1996">
<REFERENCE MODIFIED="2014-06-02 15:44:03 +1000" MODIFIED_BY="Narelle Willis" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Pahl M, Jara A, Bover J, Rodriguez M, Felsenfeld AJ</AU>
<TI>The set point of calcium and the reduction of parathyroid hormone in hemodialysis patients</TI>
<SO>Kidney international</SO>
<YR>1996</YR>
<VL>49</VL>
<NO>1</NO>
<PG>226-31</PG>
<IDENTIFIERS MODIFIED="2014-06-02 15:44:03 +1000" MODIFIED_BY="Narelle Willis">
<IDENTIFIER MODIFIED="2014-06-02 15:44:03 +1000" MODIFIED_BY="Narelle Willis" TYPE="MEDLINE" VALUE="8770972"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Quarles-2003" MODIFIED="2014-06-02 15:44:22 +1000" MODIFIED_BY="Narelle Willis" NAME="Quarles 2003" YEAR="2003">
<REFERENCE MODIFIED="2014-06-02 15:44:22 +1000" MODIFIED_BY="Narelle Willis" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Quarles LD, Zeig S, Spiegel DM, Silver MR, Vokes TJ, Torregrosa JV, et al</AU>
<TI>Cinacalcet HCl controls secondary hyperparathyroidism (HPT) in dialysis patients regardless of disease severity [abstract]</TI>
<SO>Journal of the American Society of Nephrology</SO>
<YR>2003</YR>
<VL>14</VL>
<NO>Program &amp; Abstracts</NO>
<PG>463A</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Schaefer-2008" MODIFIED="2014-06-11 16:29:20 +1000" MODIFIED_BY="Narelle Willis" NAME="Schaefer 2008" YEAR="2008">
<REFERENCE MODIFIED="2014-06-02 15:45:06 +1000" MODIFIED_BY="Narelle Willis" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Schaefer RM, Bover J, Dellanna F, Sanz D, Asensio C, Sanchez GM, et al</AU>
<TI>Efficacy of cinacalcet administered with the first meal after dialysis: the SENSOR Study</TI>
<SO>Clinical Nephrology</SO>
<YR>2008</YR>
<VL>70</VL>
<NO>2</NO>
<PG>126-34</PG>
<IDENTIFIERS MODIFIED="2014-06-02 15:45:06 +1000" MODIFIED_BY="Narelle Willis">
<IDENTIFIER MODIFIED="2014-06-02 15:45:06 +1000" MODIFIED_BY="Narelle Willis" TYPE="MEDLINE" VALUE="18793528"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2014-06-11 16:29:20 +1000" MODIFIED_BY="Narelle Willis" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Schaefer RM, Bover J, Kleophas W, Sanz D, Asensio C, Alonso JL, et al</AU>
<TI>The SENSOR study: a study to evaluate the efficacy of administering cinacalcet (Mimpara©/Sensipar©) with the first meal after dialysis [abstract no: MO003]</TI>
<SO>Nephrology Dialysis Transplantation</SO>
<YR>2006</YR>
<VL>21</VL>
<NO>Suppl 4</NO>
<PG>iv288</PG>
<IDENTIFIERS MODIFIED="2014-06-02 15:45:35 +1000" MODIFIED_BY="Narelle Willis">
<IDENTIFIER MODIFIED="2014-06-02 15:45:35 +1000" MODIFIED_BY="Narelle Willis" TYPE="CENTRAL" VALUE="CN-00671819"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Sezer-2012" MODIFIED="2014-12-08 16:15:06 +1100" MODIFIED_BY="Narelle Willis" NAME="Sezer 2012" YEAR="2012">
<REFERENCE MODIFIED="2014-12-08 16:15:06 +1100" MODIFIED_BY="Narelle Willis" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Sezer S, Tutal E, Bal Z, Ozelsancak R, Demirci BG, Torun D, et al</AU>
<TI>Treatment of secondary hyperparathyroidism in maintenance hemodialysis patients: a randomised clinical trial comparing paricalcitol, calcitriol and cinacalcet [abstract]</TI>
<SO>Nephrology Dialysis Transplantation</SO>
<YR>2012</YR>
<VL>27</VL>
<NO>Suppl 2</NO>
<PG>ii509-10</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-TARGET-Study-2008" MODIFIED="2014-12-08 16:15:05 +1100" MODIFIED_BY="Narelle Willis" NAME="TARGET Study 2008" YEAR="2008">
<REFERENCE MODIFIED="2014-12-08 16:15:05 +1100" MODIFIED_BY="Narelle Willis" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Block GA, Zeig S, Sugihara J, Chertow GM, Chi EM, Turner SA, et al</AU>
<TI>Combined therapy with cinacalcet and low doses of vitamin D sterols in patients with moderate to severe secondary hyperparathyroidism</TI>
<SO>Nephrology Dialysis Transplantation</SO>
<YR>2008</YR>
<VL>23</VL>
<NO>7</NO>
<PG>2311-8</PG>
<IDENTIFIERS MODIFIED="2014-06-02 15:48:32 +1000" MODIFIED_BY="Narelle Willis">
<IDENTIFIER MODIFIED="2014-06-02 15:48:32 +1000" MODIFIED_BY="Narelle Willis" TYPE="MEDLINE" VALUE="18310602"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2014-06-02 15:48:53 +1000" MODIFIED_BY="Narelle Willis" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Chertow GM, Corpier C, Zieg S, Stegman M, Lynn R, Abu-Alfa AK, et al</AU>
<TI>Preliminary results from TARGET: treatment strategies to achieve recommended K/DOQI goals in ESRD patients on Cinacalcet [abstract]</TI>
<SO>Journal of the American Society of Nephrology</SO>
<YR>2004</YR>
<VL>15</VL>
<NO>Abstracts</NO>
<PG>863A</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2014-06-02 15:50:19 +1000" MODIFIED_BY="Narelle Willis" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Chertow GM, Lu ZJ, Xu X, Knight TG, Goodman WG, Bushinsky DA, et al</AU>
<TI>Self-reported symptoms in patients on hemodialysis with moderate to severe secondary hyperparathyroidism receiving combined therapy with cinacalcet and low-dose vitamin D sterols</TI>
<SO>Hemodialysis International</SO>
<YR>2012</YR>
<VL>16</VL>
<NO>2</NO>
<PG>188-97</PG>
<IDENTIFIERS MODIFIED="2014-06-02 15:50:19 +1000" MODIFIED_BY="Narelle Willis">
<IDENTIFIER MODIFIED="2014-06-02 15:50:19 +1000" MODIFIED_BY="Narelle Willis" TYPE="MEDLINE" VALUE="22118402"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</EXCLUDED_STUDIES>
<AWAITING_STUDIES MODIFIED="2014-12-08 16:15:06 +1100" MODIFIED_BY="Narelle Willis">
<STUDY DATA_SOURCE="PUB" ID="STD-Coburn-2003" MODIFIED="2014-06-02 15:51:06 +1000" MODIFIED_BY="Narelle Willis" NAME="Coburn 2003" YEAR="2003">
<REFERENCE MODIFIED="2014-06-02 15:51:06 +1000" MODIFIED_BY="Narelle Willis" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Coburn JW, Charytan C, Chonchol M, Herman J, Lien YH, Liu W, et al</AU>
<TI>Cinacalcet HCl is an effective treatment for secondary hyperparathyroidism (HPT) in patients with chronic kidney diseases (CKD) not receiving dialysis [abstract]</TI>
<SO>Journal of the American Society of Nephrology</SO>
<YR>2003</YR>
<VL>14</VL>
<NO>Program &amp; Abstracts</NO>
<PG>460A</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Drueke-2001a" MODIFIED="2014-12-08 16:15:06 +1100" MODIFIED_BY="Narelle Willis" NAME="Drueke 2001a" YEAR="2001">
<REFERENCE MODIFIED="2014-06-07 21:24:29 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Drueke T, Cunningham J, Goodman WG, Horl WH, Braun J, Chen MG, et al</AU>
<TI>Short-term treatment of secondary hyperparathyroidism (SHPT) with the calcimimetic agent AMG 073 [abstract]</TI>
<SO>Journal of the American Society of Nephrology</SO>
<YR>2001</YR>
<VL>12</VL>
<NO>Program &amp; Abstracts</NO>
<PG>764A</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="CENTRAL" VALUE="CN-00550690"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Fournier-2004a" MODIFIED="2014-12-08 16:15:06 +1100" MODIFIED_BY="Narelle Willis" NAME="Fournier 2004a" YEAR="2004">
<REFERENCE MODIFIED="2014-06-07 21:24:57 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Fournier A, Pontoiero G, Walker R, Martin-Malo A, Wilkie M, Coyne DW, et al</AU>
<TI>Cinacalcet HCL reduces parathyroid hormone (PTH) and calcium-phosphate product (Ca x P) regardless of concurrent changes in vitamin D administration [abstract]</TI>
<SO>41st ERA-EDTA Congress; 2004; May 15-18; Lisbon (Portugal)</SO>
<YR>2004</YR>
<PG>319</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="CENTRAL" VALUE="CN-00509198"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-UPen-2004a" MODIFIED="2014-06-02 15:55:21 +1000" MODIFIED_BY="Narelle Willis" NAME="UPen 2004a" YEAR="2004">
<REFERENCE MODIFIED="2014-06-02 15:55:21 +1000" MODIFIED_BY="Narelle Willis" PRIMARY="NO" TYPE="OTHER">
<AU>University of Pennsylvania, Renal Electrolyte and Hypertension Division. 2004</AU>
<TI>A randomized, double-blind, placebo-controlled study to assess the safety and efficacy of a calcimimetic agent (AMG 073) in subjects with secondary hyperparathyroidism of chronic renal insufficiency</TI>
<SO>http://www.uphs.upenn.edu/renal/research/clinical_research_chronic_kidney.html</SO>
<YR>(accessed 2 June 2014)</YR>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</AWAITING_STUDIES>
<ONGOING_STUDIES MODIFIED="2013-06-03 11:56:28 +1000" MODIFIED_BY="[Empty name]"/>
</STUDIES>
<OTHER_REFERENCES MODIFIED="2014-12-08 11:03:08 +1100" MODIFIED_BY="Suetonia C Palmer">
<ADDITIONAL_REFERENCES MODIFIED="2014-06-11 15:41:05 +1000" MODIFIED_BY="Narelle Willis">
<REFERENCE ID="REF-Albaaj-2003" NAME="Albaaj 2003" TYPE="JOURNAL_ARTICLE">
<AU>Albaaj F, Hutchison A</AU>
<TI>Hyperphosphataemia in renal failure: causes, consequences and current management</TI>
<SO>Drugs</SO>
<YR>2003</YR>
<VL>63</VL>
<NO>6</NO>
<PG>577-96</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="12656655"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Avram-1996" NAME="Avram 1996" TYPE="JOURNAL_ARTICLE">
<AU>Avram MM, Sreedhara R, Avram DK, Muchnick RA, Fein P</AU>
<TI>Enrollment parathyroid hormone level is a new marker of survival in hemodialysis and peritoneal dialysis therapy for uremia</TI>
<SO>American Journal of Kidney Diseases</SO>
<YR>1996</YR>
<VL>28</VL>
<NO>6</NO>
<PG>924-30</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="8957048"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Besarab-1998" MODIFIED="2014-06-02 15:56:03 +1000" MODIFIED_BY="Narelle Willis" NAME="Besarab 1998" TYPE="JOURNAL_ARTICLE">
<AU>Besarab A, Bolton WK, Browne JK, Egrie JC, Nissenson AR, Okamoto DM, et al</AU>
<TI>The effects of normal, as compared with low, hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin</TI>
<SO>New England Journal of Medicine</SO>
<YR>1998</YR>
<VL>339</VL>
<NO>9</NO>
<PG>584-90</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="9718377"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Block-2004b" NAME="Block 2004b" TYPE="JOURNAL_ARTICLE">
<AU>Block GA, Klassen PS, Lazarus LM, Ofsthun N, Lowrie EG, Chertow GM</AU>
<TI>Mineral metabolism, mortality and morbidity in maintenance hemodialysis</TI>
<SO>Journal of the American Society of Nephrology</SO>
<YR>2004</YR>
<VL>15</VL>
<NO>8</NO>
<PG>2208-10</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="15284307"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Borrows-2004" MODIFIED="2014-06-02 15:56:22 +1000" MODIFIED_BY="Narelle Willis" NAME="Borrows 2004" TYPE="JOURNAL_ARTICLE">
<AU>Borrows R, Loucaidou M, Van Tromp J, Cairns T, Griffith M, Hakim N, et al</AU>
<TI>Steroid sparing with tacrolimus and mycophenolate mofetil in renal transplantation</TI>
<SO>American Journal of Transplantation</SO>
<YR>2004</YR>
<VL>4</VL>
<NO>11</NO>
<PG>1845-51</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="15476485"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Bucher-1999" MODIFIED="2014-06-02 15:57:00 +1000" MODIFIED_BY="Narelle Willis" NAME="Bucher 1999" TYPE="JOURNAL_ARTICLE">
<AU>Bucher HC, Guyatt GH, Cook DJ, Holbrook A, McAlister FA</AU>
<TI>Users' guides to the medical literature: XIX. Applying clinical trial results. A. How to use an article measuring the effect of an intervention on surrogate end points. Evidence-Based Medicine Working Group</TI>
<SO>JAMA</SO>
<YR>1999</YR>
<VL>282</VL>
<NO>8</NO>
<PG>771-8</PG>
<IDENTIFIERS MODIFIED="2014-06-02 15:57:00 +1000" MODIFIED_BY="Narelle Willis">
<IDENTIFIER MODIFIED="2014-06-02 15:57:00 +1000" MODIFIED_BY="Narelle Willis" TYPE="MEDLINE" VALUE="10463714"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Churchill-1997" MODIFIED="2014-06-02 15:58:58 +1000" MODIFIED_BY="Narelle Willis" NAME="Churchill 1997" TYPE="JOURNAL_ARTICLE">
<AU>Churchill DN, Thorpe KE, Vonesh EF, Keshaviah PR</AU>
<TI>Lower probability of patient survival with continuous peritoneal dialysis in the united states compared with Canada. Canada-USA (CANUSA) Peritoneal Dialysis Study Group</TI>
<SO>Journal of the American Society of Nephrology</SO>
<YR>1997</YR>
<VL>8</VL>
<NO>6</NO>
<PG>965-71</PG>
<IDENTIFIERS MODIFIED="2014-06-02 15:58:45 +1000" MODIFIED_BY="Narelle Willis">
<IDENTIFIER MODIFIED="2014-06-02 15:58:45 +1000" MODIFIED_BY="Narelle Willis" TYPE="MEDLINE" VALUE="9189865"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Courant-1993" MODIFIED="2014-06-02 15:59:31 +1000" MODIFIED_BY="Narelle Willis" NAME="Courant 1993" TYPE="JOURNAL_ARTICLE">
<AU>Courant O, Letessier E, Moutel MG, Hamy A, Paineau J, Visset J</AU>
<TI>Surgical treatment of secondary hyperparathyroidism in chronic kidney failure. Results of total parathyroidectomy with parathyroid autotransplantation</TI>
<SO>Journal de Chirurgie</SO>
<YR>1993</YR>
<VL>130</VL>
<NO>8-9</NO>
<PG>327-34</PG>
<IDENTIFIERS MODIFIED="2014-06-02 15:59:31 +1000" MODIFIED_BY="Narelle Willis">
<IDENTIFIER MODIFIED="2014-06-02 15:59:31 +1000" MODIFIED_BY="Narelle Willis" TYPE="MEDLINE" VALUE="8253879"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Cunningham-2005a" MODIFIED="2014-06-11 15:40:25 +1000" MODIFIED_BY="Narelle Willis" NAME="Cunningham 2005a" TYPE="JOURNAL_ARTICLE">
<AU>Cunningham J, Danese M, Olson K, Klassen P, Chertow GM</AU>
<TI>Effects of the calcimimetic cinacalcet HCl on cardiovascular disease, fracture, and health-related quality of life in secondary hyperparathyroidism</TI>
<SO>Kidney international</SO>
<YR>2005</YR>
<VL>68</VL>
<NO>4</NO>
<PG>1793-800</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="16164656"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Egger-1998" MODIFIED="2008-09-17 17:46:51 +1000" MODIFIED_BY="[Empty name]" NAME="Egger 1998" TYPE="JOURNAL_ARTICLE">
<AU>Egger M, Smith GD</AU>
<TI>Bias in location and selection of studies</TI>
<SO>BMJ</SO>
<YR>1998</YR>
<VL>316</VL>
<NO>7124</NO>
<PG>61-6</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="9451274"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-FDA-2004" MODIFIED="2014-06-02 16:01:15 +1000" MODIFIED_BY="Narelle Willis" NAME="FDA 2004" TYPE="OTHER">
<AU>US Food and Drug Administration</AU>
<TI>Sensipar (cinacalcet HCl) tablets</TI>
<SO>http://www.fda.gov/safety/medwatch/safetyinformation/ucm194427.htm</SO>
<YR>(accessed 2 June 2014)</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Ganesh-2001" NAME="Ganesh 2001" TYPE="JOURNAL_ARTICLE">
<AU>Ganesh SK, Stack AG, Levin NW, Hulbert-Shearon T, Port FK</AU>
<TI>Association of elevated serum PO(4), Ca x PO(4) product, and parathyroid hormone with cardiac mortality risk in chronic hemodialysis patient</TI>
<SO>Journal of the American Society of Nephrology</SO>
<YR>2001</YR>
<VL>12</VL>
<NO>10</NO>
<PG>2131-8</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="11562412"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Guyatt-2008" MODIFIED="2014-06-02 16:02:19 +1000" MODIFIED_BY="Narelle Willis" NAME="Guyatt 2008" TYPE="JOURNAL_ARTICLE">
<AU>Guyatt GH, Oxman A D, Vist GE, Kunz R, Falck-Ytter Y, Alonso-Coello P, et al</AU>
<TI>GRADE: an emerging consensus on rating quality of evidence and strength of recommendations</TI>
<SO>BMJ</SO>
<YR>2008</YR>
<VL>336</VL>
<NO>7650</NO>
<PG>924-6</PG>
<IDENTIFIERS MODIFIED="2014-06-02 16:02:19 +1000" MODIFIED_BY="Narelle Willis">
<IDENTIFIER MODIFIED="2014-06-02 16:02:19 +1000" MODIFIED_BY="Narelle Willis" TYPE="MEDLINE" VALUE="18436948"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Higgins-2003" MODIFIED="2008-09-17 17:46:55 +1000" MODIFIED_BY="[Empty name]" NAME="Higgins 2003" TYPE="JOURNAL_ARTICLE">
<AU>Higgins JP, Thompson SG, Deeks JJ, Altman DG</AU>
<TI>Measuring inconsistency in meta-analyses</TI>
<SO>BMJ</SO>
<YR>2003</YR>
<VL>327</VL>
<NO>7414</NO>
<PG>557-60</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="12958120"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Higgins-2011" MODIFIED="2013-06-01 19:04:07 +1000" MODIFIED_BY="Suetonia Palmer" NAME="Higgins 2011" TYPE="OTHER">
<AU>Higgins JP, Green S (editors)</AU>
<TI>Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011</TI>
<SO>Available from www.cochrane-handbook.org</SO>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Hutchison-1993" MODIFIED="2014-06-02 16:03:28 +1000" MODIFIED_BY="Narelle Willis" NAME="Hutchison 1993" TYPE="JOURNAL_ARTICLE">
<AU>Hutchison AJ, Whitehouse RW, Boulton HF, Adams JE, Mawer EB, Freemont TJ, et al</AU>
<TI>Correlation of bone histology with parathyroid hormone, vitamin D3, and radiology in end-stage renal disease</TI>
<SO>Kidney international</SO>
<YR>1995</YR>
<VL>26</VL>
<NO>5</NO>
<PG>622-31</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="8264137"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Juni-2003" MODIFIED="2014-06-02 16:03:38 +1000" MODIFIED_BY="Narelle Willis" NAME="Juni 2003" TYPE="JOURNAL_ARTICLE">
<AU>Juni P, Sterchi R, Dieppe P</AU>
<TI>Systematic review of celecoxib for osteoarthritis and rheumatoid arthritis. Problems compromise review's validity</TI>
<SO>BMJ</SO>
<YR>2003</YR>
<VL>326</VL>
<NO>7384</NO>
<PG>334</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="12574052"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-KDIGO-CKD-2013" MODIFIED="2014-06-02 16:06:41 +1000" MODIFIED_BY="Narelle Willis" NAME="KDIGO CKD 2013" TYPE="JOURNAL_ARTICLE">
<AU>Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group</AU>
<TI>KDIGO 2012 clinical practice guideline for the evaluation and management of chronic kidney disease</TI>
<SO>Kidney International - Supplement</SO>
<YR>2013</YR>
<VL>3</VL>
<PG>1-150</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Kestenbaum-2004" MODIFIED="2014-06-02 16:07:32 +1000" MODIFIED_BY="Narelle Willis" NAME="Kestenbaum 2004" TYPE="JOURNAL_ARTICLE">
<AU>Kestenbaum B, Seliger SL, Gillen DL, Wasse H, Young B, Sherrard DJ, et al</AU>
<TI>Parathyroidectomy rates among United States dialysis patients: 1990-1999</TI>
<SO>Kidney International</SO>
<YR>2004</YR>
<VL>65</VL>
<NO>1</NO>
<PG>282-8</PG>
<IDENTIFIERS MODIFIED="2014-06-02 16:07:07 +1000" MODIFIED_BY="Narelle Willis">
<IDENTIFIER MODIFIED="2014-06-02 16:07:07 +1000" MODIFIED_BY="Narelle Willis" TYPE="MEDLINE" VALUE="14675061"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Kestenbaum-2005" MODIFIED="2014-06-02 16:07:50 +1000" MODIFIED_BY="Narelle Willis" NAME="Kestenbaum 2005" TYPE="JOURNAL_ARTICLE">
<AU>Kestenbaum B, Sampson JN, Rudser KD, Patterson DJ, Seliger SL, Young B, et al</AU>
<TI>Serum phosphate levels and mortality risk among people with chronic kidney disease</TI>
<SO>Journal of the American Society of Nephrology</SO>
<YR>2005</YR>
<VL>16</VL>
<NO>2</NO>
<PG>520-8</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="15615819"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-KHA_x002d_CARI-2014" MODIFIED="2014-06-02 15:58:21 +1000" MODIFIED_BY="Narelle Willis" NAME="KHA-CARI 2014" TYPE="OTHER">
<TI>KHA-CARI guidelines</TI>
<SO>http://www.cari.org.au/</SO>
<YR>(accessed 2 June 2014)</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Lexchin-2003" MODIFIED="2014-06-02 16:08:40 +1000" MODIFIED_BY="Narelle Willis" NAME="Lexchin 2003" TYPE="JOURNAL_ARTICLE">
<AU>Lexchin J, Bero LA, Djulbegovic B, Clark O</AU>
<TI>Pharmaceutical industry sponsorship and research outcome and quality: systematic review</TI>
<SO>BMJ</SO>
<YR>2003</YR>
<VL>326</VL>
<NO>7400</NO>
<PG>1167-70</PG>
<IDENTIFIERS MODIFIED="2014-06-02 16:08:40 +1000" MODIFIED_BY="Narelle Willis">
<IDENTIFIER MODIFIED="2014-06-02 16:08:40 +1000" MODIFIED_BY="Narelle Willis" TYPE="MEDLINE" VALUE="12775614"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Malluche-2004b" MODIFIED="2008-09-17 17:47:07 +1000" MODIFIED_BY="[Empty name]" NAME="Malluche 2004b" TYPE="JOURNAL_ARTICLE">
<AU>Malluche HH, Mawad H, Monier-Faugere MC</AU>
<TI>The importance of bone health in end-stage renal disease: out of the frying pan, into the fire?</TI>
<SO>Nephrology Dialysis Transplantation</SO>
<YR>2004</YR>
<VL>19 Suppl 1</VL>
<PG>i9-13</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="15126648"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Marco-2003" MODIFIED="2013-06-02 08:03:49 +1000" MODIFIED_BY="[Empty name]" NAME="Marco 2003" TYPE="JOURNAL_ARTICLE">
<AU>Marco MP, Craver L, Betriu A, Belart M, Fibla J, Fernandez E</AU>
<TI>Higher impact of mineral metabolism on cardiovascular mortality in a European hemodialysis population</TI>
<SO>Kidney International - Supplement</SO>
<YR>2003</YR>
<VL>85</VL>
<PG>S111-4</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="12753279"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Martin-2004" MODIFIED="2014-06-02 16:09:10 +1000" MODIFIED_BY="Narelle Willis" NAME="Martin 2004" TYPE="JOURNAL_ARTICLE">
<AU>Martin KJ, Olgaard K, Coburn JW, Coen GM, Fukagawa M, Langman C, et al</AU>
<TI>Diagnosis, assessment and treatment of bone turnover abnormalities in renal osteodystrophy</TI>
<SO>American Journal of Kidney Diseases</SO>
<YR>2004</YR>
<VL>43</VL>
<NO>3</NO>
<PG>558-65</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="14981615"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-McMahon-2004" MODIFIED="2014-06-02 16:09:45 +1000" MODIFIED_BY="Narelle Willis" NAME="McMahon 2004" TYPE="JOURNAL_ARTICLE">
<AU>McMahon LP, Roger SD, Levin A, SLIMHEART Investigators Group</AU>
<TI>Development, prevention and potential reversal of left ventricular hypertrophy in chronic kidney disease</TI>
<SO>Journal of the American Society of Nephrology</SO>
<YR>2004</YR>
<VL>15</VL>
<NO>6</NO>
<PG>1640-7</PG>
<IDENTIFIERS MODIFIED="2014-06-02 16:09:45 +1000" MODIFIED_BY="Narelle Willis">
<IDENTIFIER MODIFIED="2014-06-02 16:09:45 +1000" MODIFIED_BY="Narelle Willis" TYPE="MEDLINE" VALUE="15153576"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Mentaverri-2006" MODIFIED="2014-06-02 16:10:21 +1000" MODIFIED_BY="Narelle Willis" NAME="Mentaverri 2006" TYPE="JOURNAL_ARTICLE">
<AU>Mentaverri R, Yano S, Chattopadhyay N, Petit L, Kifor O, Kamel S, et al</AU>
<TI>The calcium sensing receptor is directly involved in both osteoclast differentiation and apoptosis</TI>
<SO>FASEB Journal</SO>
<YR>2006</YR>
<VL>20</VL>
<NO>14</NO>
<PG>2562-4</PG>
<IDENTIFIERS MODIFIED="2014-06-02 16:10:21 +1000" MODIFIED_BY="Narelle Willis">
<IDENTIFIER MODIFIED="2014-06-02 16:10:21 +1000" MODIFIED_BY="Narelle Willis" TYPE="MEDLINE" VALUE="17077282"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Mizobuchi-2007" MODIFIED="2014-06-02 16:11:09 +1000" MODIFIED_BY="Narelle Willis" NAME="Mizobuchi 2007" TYPE="JOURNAL_ARTICLE">
<AU>Mizobuchi M, Ogata H, Hatamura I, Saji F, Koiwa F, Kinugasa E, et al</AU>
<TI>Activation of calcium-sensing receptor accelerates apoptosis in hyperplastic parathyroid cells</TI>
<SO>Biochemical &amp; Biophysical Research Communications</SO>
<YR>2007</YR>
<VL>362</VL>
<NO>1</NO>
<PG>11-6</PG>
<IDENTIFIERS MODIFIED="2014-06-02 16:11:00 +1000" MODIFIED_BY="Narelle Willis">
<IDENTIFIER MODIFIED="2014-06-02 16:11:00 +1000" MODIFIED_BY="Narelle Willis" TYPE="MEDLINE" VALUE="17706605"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-NICE-2007" MODIFIED="2014-06-02 16:13:53 +1000" MODIFIED_BY="Narelle Willis" NAME="NICE 2007" TYPE="OTHER">
<AU>NICE: National Institute for Health and Care Excellence</AU>
<TI>TA117 Hyperparathyroidism - cinacalcet guidance (24 January 2007)</TI>
<SO>http://guidance.nice.org.uk/TA117/Guidance/</SO>
<YR>(accessed 2 June 2014)</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-NKF-2003" MODIFIED="2008-09-17 17:47:23 +1000" MODIFIED_BY="[Empty name]" NAME="NKF 2003" TYPE="JOURNAL_ARTICLE">
<AU>National Kidney Foundation</AU>
<TI>K/DOQI clinical practice guidelines for bone metabolism and disease in chronic kidney disease</TI>
<SO>American Journal of Kidney Diseases</SO>
<YR>2003</YR>
<VL>42</VL>
<NO>4 Suppl 3</NO>
<PG>S1-210</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="14520607"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Psaty-1999" MODIFIED="2014-06-02 16:14:34 +1000" MODIFIED_BY="Narelle Willis" NAME="Psaty 1999" TYPE="JOURNAL_ARTICLE">
<AU>Psaty BM, Weiss NS, Furberg CD, Koepsell TD, Siscovick DS, Rosendaal FR, et al</AU>
<TI>Surrogate end points, health outcomes, and the drug-approval process for the treatment of risk factors for cardiovascular disease</TI>
<SO>JAMA</SO>
<YR>1999</YR>
<VL>282</VL>
<NO>8</NO>
<PG>786-90</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="10463718"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Qi-1995" MODIFIED="2008-09-17 17:47:31 +1000" MODIFIED_BY="[Empty name]" NAME="Qi 1995" TYPE="JOURNAL_ARTICLE">
<AU>Qi Q, Monier-Faugere MC, Geng Z, Malluche HH</AU>
<TI>Predictive value of serum parathyroid hormone levels for bone turnover in patients on chronic maintenance dialysis</TI>
<SO>American Journal of Kidney Diseases</SO>
<YR>1995</YR>
<VL>26</VL>
<NO>4</NO>
<PG>622-31</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="7573017"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Simes-1986" MODIFIED="2008-09-17 17:47:38 +1000" MODIFIED_BY="[Empty name]" NAME="Simes 1986" TYPE="JOURNAL_ARTICLE">
<AU>Simes RJ</AU>
<TI>Publication bias: the case for an international registry of clinical trials</TI>
<SO>Journal of Clinical Oncology</SO>
<YR>1986</YR>
<VL>4</VL>
<NO>10</NO>
<PG>1529-41</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="3760920"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Stehman_x002d_Breen-2004" MODIFIED="2008-09-17 17:47:41 +1000" MODIFIED_BY="[Empty name]" NAME="Stehman-Breen 2004" TYPE="JOURNAL_ARTICLE">
<AU>Stehman-Breen C</AU>
<TI>Osteoporosis and chronic kidney disease</TI>
<SO>Seminars in Nephrology</SO>
<YR>2004</YR>
<VL>24</VL>
<NO>1</NO>
<PG>78-81</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="14730513"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Stevens-2004" MODIFIED="2008-09-17 17:47:43 +1000" MODIFIED_BY="[Empty name]" NAME="Stevens 2004" TYPE="JOURNAL_ARTICLE">
<AU>Stevens LA, Djurdjev O, Cardew S, Cameron EC, Levin A</AU>
<TI>Calcium, phosphate, and parathyroid hormone levels in combination and as a function of dialysis duration predict mortality: evidence for the complexity of the association between mineral metabolism and outcomes</TI>
<SO>Journal of the American Society of Nephrology</SO>
<YR>2004</YR>
<VL>15</VL>
<NO>3</NO>
<PG>770-9</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="14978180"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Temple-1999" NAME="Temple 1999" TYPE="JOURNAL_ARTICLE">
<AU>Temple R</AU>
<TI>Are surrogate markers adequate to assess cardiovascular disease drugs?</TI>
<SO>JAMA</SO>
<YR>1999</YR>
<VL>282</VL>
<NO>8</NO>
<PG>790-5</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="10463719"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Urena-2003" MODIFIED="2013-06-02 08:04:02 +1000" MODIFIED_BY="[Empty name]" NAME="Urena 2003" TYPE="JOURNAL_ARTICLE">
<AU>Urena P, Frazao JM</AU>
<TI>Calcimimetic agents: review and perspectives</TI>
<SO>Kidney International - Supplement</SO>
<YR>2003</YR>
<VL>85</VL>
<PG>S91-6</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="12753275"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-USRDS-2012" MODIFIED="2014-06-02 16:21:53 +1000" MODIFIED_BY="Narelle Willis" NAME="USRDS 2012" TYPE="JOURNAL_ARTICLE">
<AU>Collins AJ, Foley RN, Herzog C, Chavers B, Gilbertson D, Herzog C, et al</AU>
<TI>United States Renal Data System 2012 annual data report: atlas of chronic kidney disease and end-stage renal disease in the United States</TI>
<SO>American Journal of Kidney Diseases</SO>
<YR>2013</YR>
<VL>61</VL>
<NO>1 Suppl 1</NO>
<PG>e1-e480</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Wang-1995" MODIFIED="2008-09-17 17:47:49 +1000" MODIFIED_BY="[Empty name]" NAME="Wang 1995" TYPE="JOURNAL_ARTICLE">
<AU>Wang M, Hercz G, Sherrard DJ, Maloney NA, Segre GV, Pei Y</AU>
<TI>Relationship between intact 1-84 parathyroid hormone and bone histomorphometric parameters in dialysis patients without aluminum toxicity</TI>
<SO>American Journal of Kidney Diseases</SO>
<YR>1995</YR>
<VL>26</VL>
<NO>5</NO>
<PG>836-44</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="7485142"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Weiner-2006" MODIFIED="2014-06-02 16:22:57 +1000" MODIFIED_BY="Narelle Willis" NAME="Weiner 2006" TYPE="JOURNAL_ARTICLE">
<AU>Weiner DE, Tabatabai S, Tighiouart H, Elsayed E, Bansal N, Griffith J, et al</AU>
<TI>Cardiovascular outcomes and all-cause mortality: exploring the interaction between CKD and cardiovascular disease</TI>
<SO>American Journal of Kidney Diseases</SO>
<YR>2006</YR>
<VL>48</VL>
<NO>3</NO>
<PG>392-401</PG>
<IDENTIFIERS MODIFIED="2014-06-02 16:22:57 +1000" MODIFIED_BY="Narelle Willis">
<IDENTIFIER MODIFIED="2014-06-02 16:22:57 +1000" MODIFIED_BY="Narelle Willis" TYPE="MEDLINE" VALUE="16931212"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Ziolkowska-2000" MODIFIED="2014-06-02 16:23:11 +1000" MODIFIED_BY="Narelle Willis" NAME="Ziolkowska 2000" TYPE="JOURNAL_ARTICLE">
<AU>Ziolkowska H, Paniczyk-Tomaszewska M, Debinski A, Polowiec Z, Sawicki A, Sieniawska M</AU>
<TI>Bone biopsy results and serum bone turnover parameters in uremic children</TI>
<SO>Acta Paediatrica</SO>
<YR>2000</YR>
<VL>89</VL>
<NO>6</NO>
<PG>666-71</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="10914959"/>
</IDENTIFIERS>
</REFERENCE>
</ADDITIONAL_REFERENCES>
<OTHER_VERSIONS_REFERENCES MODIFIED="2014-06-11 15:41:42 +1000" MODIFIED_BY="Narelle Willis">
<REFERENCE ID="REF-Palmer-2013" MODIFIED="2014-06-02 16:25:41 +1000" MODIFIED_BY="Narelle Willis" NAME="Palmer 2013" TYPE="JOURNAL_ARTICLE">
<AU>Palmer SC, Nistor I, Craig JC, Pellegrini F, Messa P, Tonelli M, et al</AU>
<TI>Cinacalcet in patients with chronic kidney disease: a cumulative meta-analysis of randomized controlled trials</TI>
<SO>PLoS Medicine</SO>
<YR>2013</YR>
<VL>10</VL>
<NO>4</NO>
<PG>e1001436</PG>
<IDENTIFIERS MODIFIED="2014-06-02 16:25:39 +1000" MODIFIED_BY="Narelle Willis">
<IDENTIFIER MODIFIED="2014-06-02 16:25:39 +1000" MODIFIED_BY="Narelle Willis" TYPE="MEDLINE" VALUE="23637579"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Strippoli-2006a" MODIFIED="2014-06-11 15:41:42 +1000" MODIFIED_BY="Narelle Willis" NAME="Strippoli 2006a" TYPE="COCHRANE_REVIEW">
<AU>Strippoli GF, Tong A, Palmer SC, Elder G, Craig JC</AU>
<TI>Calcimimetics for secondary hyperparathyroidism in chronic kidney disease patients</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2006</YR>
<NO>4</NO>
<IDENTIFIERS MODIFIED="2014-06-02 16:24:42 +1000" MODIFIED_BY="Narelle Willis">
<IDENTIFIER MODIFIED="2014-06-02 16:24:42 +1000" MODIFIED_BY="Narelle Willis" TYPE="DOI" VALUE="10.1002/14651858.CD006254"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Strippoli-2006b" MODIFIED="2014-06-02 16:25:09 +1000" MODIFIED_BY="Narelle Willis" NAME="Strippoli 2006b" TYPE="JOURNAL_ARTICLE">
<AU>Strippoli GF, Palmer S, Tong A, Elder G, Messa P, Craig JC</AU>
<TI>Meta-analysis of biochemical and patient-level effects of calcimimetic therapy</TI>
<SO>American Journal of Kidney Diseases</SO>
<YR>2006</YR>
<VL>47</VL>
<NO>5</NO>
<PG>715-26</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="16632010"/>
</IDENTIFIERS>
</REFERENCE>
</OTHER_VERSIONS_REFERENCES>
<PENDING_REFERENCES MODIFIED="2014-12-08 11:03:08 +1100" MODIFIED_BY="Suetonia C Palmer"/>
</OTHER_REFERENCES>
</STUDIES_AND_REFERENCES>
<CHARACTERISTICS_OF_STUDIES MODIFIED="2014-12-08 16:15:06 +1100" MODIFIED_BY="Narelle Willis">
<CHARACTERISTICS_OF_INCLUDED_STUDIES MODIFIED="2014-12-08 16:15:06 +1100" MODIFIED_BY="Narelle Willis" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<INCLUDED_CHAR MODIFIED="2014-06-10 15:47:07 +1000" MODIFIED_BY="Narelle Willis" STUDY_ID="STD-ACHIEVE-Study-2008">
<CHAR_METHODS MODIFIED="2014-06-03 15:43:00 +1000" MODIFIED_BY="Narelle Willis">
<UL>
<LI>Study design: parallel, open-label RCT</LI>
<LI>Study duration: NS</LI>
<LI>Study follow-up: 27 weeks</LI>
</UL>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2014-06-10 15:47:07 +1000" MODIFIED_BY="Narelle Willis">
<UL>
<LI>Country: USA</LI>
<LI>Setting: multicentre (42 centres)</LI>
<LI>Patients &#8805; 18 years; received HD for &#8805; 3 mo; were receiving either paricalcitol or doxercalciferol to manage SHPT; historical plasma PTH values between 150 and 800 pg/mL (confirmed during screening); albumin-corrected serum total calcium concentrations &#8805; 8.4 mg/dL. Patients with PTH levels between 300 to 800 pg/mL were considered without regard to serum Ca x P levels, whereas those with PTH levels between 150 to 300 pg/mL were considered only if Ca x P &gt; 55 mg²/dL². After a 3-wk washout period during which vitamin D therapy was withheld, PTH and calcium levels were measured again on at least 2 occasions. Patients with mean PTH values &gt; 300 pg/mL and mean calcium levels &#8805; 8.4 mg/dL qualified for study</LI>
<LI>Number: treatment group (87); control group (86)</LI>
<LI>Mean age ± SD (years): treatment group (57.7 ± SD 14.9); control group (59 ± 12.4)</LI>
<LI>Sex (M/F): treatment group (52/35); control group (45/41)</LI>
<LI>Exclusion criteria: pregnant or nursing; undergone a parathyroidectomy within the previous 3 mo; involved in any other clinical study within the past 30 d; had received cinacalcet previously</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2014-06-04 17:24:33 +1000" MODIFIED_BY="Narelle Willis">
<P>Treatment group</P>
<UL>
<LI>Cinacalcet</LI>
<LI>Low dose vitamin D</LI>
<LI>Duration: 16 weeks titration, 11 weeks maintenance</LI>
</UL>
<P>Control group</P>
<UL>
<LI>Vitamin D</LI>
</UL>
<P>Co-interventions: NS</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2014-06-10 15:38:03 +1000" MODIFIED_BY="Narelle Willis">
<UL>
<LI>Simultaneously achieved a mean PTH between 150 and 300 pg/mL and a mean Ca x P value &lt; 55 mg²/dL²</LI>
<LI>Achieved KDOQI targets for PTH, calcium, phosphorous, and Ca x P individually</LI>
<LI>Absolute and percentage change from baseline in values for PTH, calcium, phosphorous, and Ca x P</LI>
<LI>Proportion with 30% reduction in PTH</LI>
</UL>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2014-06-02 18:38:58 +1000" MODIFIED_BY="Narelle Willis">
<UL>
<LI>ITT: yes</LI>
<LI>Funding: "The ACHIEVE study (Study ID Number 20050102) and the preparation of this manuscript were funded by Amgen, Inc. The authors wish to thank Nelson Erlick, DPM, MS, on behalf of Amgen Inc. and Jane Mannion, MS, Amgen Inc. for their assistance in the preparation of this manuscript (Ms Mannion is currently employed by Baxter International, Inc.)"</LI>
</UL>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2014-06-10 15:38:05 +1000" MODIFIED_BY="Narelle Willis" STUDY_ID="STD-ADVANCE-Study-2010">
<CHAR_METHODS MODIFIED="2014-06-03 15:43:09 +1000" MODIFIED_BY="Narelle Willis">
<UL>
<LI>Study design: parallel, open-label RCT</LI>
<LI>Study duration: NS</LI>
<LI>Study follow-up: 52 weeks</LI>
</UL>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2014-06-02 17:48:47 +1000" MODIFIED_BY="Narelle Willis">
<UL>
<LI>Country: multinational </LI>
<LI>Setting: multicentre (90 centres)</LI>
<LI>HD &#8805; 3 mo; iPTH &gt; 300 pg/mL; serum calcium &#8805; 8.4 mg/dL; serum Ca x P &gt; 50 mg²/dL²</LI>
<LI>Number: treatment group (180); control group (180)</LI>
<LI>Mean age ± SD (years): treatment group (61.2 ± 12.6); control group (61.8 ± 12.8)</LI>
<LI>Sex (M/F): treatment group (112/68); control group (95/85)</LI>
<LI>Exclusion criteria: previous cinacalcet treatment; calcium-free phosphate binding agents; bisphosphonate therapy; lipid lowering within 30 d; atrial fibrillation; coronary artery bypass grafting or stent; valve replacement; heart transplant; pacemaker; aortic aneurysm; parathyroidectomy within 3 mo or in next 6 mo; scheduled kidney transplant; body weight &gt; 136 kg; inability to absorb oral medications; sensitivity to cinacalcet; unstable medical condition</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2014-06-04 17:24:49 +1000" MODIFIED_BY="Narelle Willis">
<P>Treatment group</P>
<UL>
<LI>Cinacalcet</LI>
<LI>Low dose vitamin D</LI>
<LI>Duration: 20-week dose-titration phase, 32-week follow-up phase</LI>
</UL>
<P>Control group</P>
<UL>
<LI>Vitamin D at the same dose prescribed before randomisation</LI>
<LI>Duration: 52 weeks</LI>
</UL>
<P>Co-interventions</P>
<UL>
<LI>Treatment group: vitamin D (75%); phosphate binders (calcium-based (83%); sevelamer (26%); lanthanum (4%); other (11%))</LI>
<LI>Control group: vitamin D (79%); phosphate binders (calcium-based (84%); sevelamer (26%); lanthanum (7%); other (8%))</LI>
</UL>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2014-06-10 15:38:05 +1000" MODIFIED_BY="Narelle Willis">
<UL>
<LI>% change in CAC score from baseline to week 52</LI>
<LI>Absolute change in CAC score from baseline to week 52</LI>
<LI>Absolute and percentage change in calcification scores for the thoracic aorta, aortic valve and mitral valve from baseline to week 52</LI>
<LI>&gt; 15% progression of CAC from baseline to week 52</LI>
<LI>Absolute and percentage change in PTH, calcium, phosphorous and Ca × P from baseline to the end of study as assessed during weeks 44 to 52 of follow-up</LI>
<LI>Safety of cinacalcet as measured by the type, frequency and severity of adverse events and their reported relationship to treatment</LI>
<LI>Absolute and percent changes in mean PTH, calcium, phosphorous and Ca × P values from baseline to end of study as assessed at week 44&#8211;52 in the efficacy analysis set</LI>
</UL>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2014-06-02 18:39:09 +1000" MODIFIED_BY="Narelle Willis">
<UL>
<LI>ITT: yes</LI>
<LI>Funding: "This study was sponsored by Amgen Inc. J.F. has received speaker and consultant honoraria from Amgen, Genzyme, Shire and has received grant support from Amgen and Fresenius. P.R. has received research grants from Amgen and Genzyme. G.A.B. has received research grants from Amgen, Genzyme, Shire, Novartis, DaVita, and Fresenius; has received fees for expert consultancy and/or advice from Amgen, Genzyme, Shire, Mitsubishi, and Theraclion. P.U.T. has received fees for clinical research, speaking and expert consultancy from Amgen, Shire, Novartis, Roche, Fresenius, Roche, HAS, and Hemotech. G.M.C. has received research funding from Amgen. W.G.G., N.L., G.D. and B.D. are employees and stockholders in Amgen"</LI>
</UL>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2014-12-08 16:15:06 +1100" MODIFIED_BY="Narelle Willis" STUDY_ID="STD-Akiba-2008">
<CHAR_METHODS MODIFIED="2014-06-03 15:43:16 +1000" MODIFIED_BY="Narelle Willis">
<UL>
<LI>Study design: parallel RCT</LI>
<LI>Study duration: April 2003 to October 2003</LI>
<LI>Study follow-up: 5 weeks</LI>
</UL>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2014-06-02 18:11:23 +1000" MODIFIED_BY="Narelle Willis">
<UL>
<LI>Country: Japan</LI>
<LI>Setting: multicentre (2 centres)</LI>
<LI>Aged 20 to 74 years; serum iPTH &#8805; 300 pg/mL, serum calcium 9.0&#8211;11.5 mg/dL; treatment with HD for at least 12 weeks before the screening period. Patients receiving vitamin D sterols or phosphate binders were required to be on a stable dose during the screening period. Dialysate calcium concentration and the size of the dialyzer membrane surface area could not be changed during the 14 days before enrolment.</LI>
<LI>Number: treatment group (91 randomised, 79 completed); control group (30)</LI>
<LI>Mean age ± SD (years): treatment group (56.7 ± 9.2; 55.8 ± 7.7; 53.2 ± 7.0); control group (51.8 ± 7.5)</LI>
<LI>Sex (M/F): treatment group (54/25); control group (25/5)</LI>
<LI>Exclusion criteria: severe hepatic diseases; cirrhosis, severe heart failure; uncontrolled hypertension; uncontrolled DM; malignant neoplasm; serious infectious diseases; undergone a parathyroidectomy within 24 weeks before enrolment; parathyroid intervention therapies (percutaneous ethanol injection therapy (PEIT) during the screening period; pregnant or lactating females</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2014-06-03 15:34:22 +1000" MODIFIED_BY="Narelle Willis">
<P>Treatment group</P>
<UL>
<LI>Cinacalcet: 12.5 to 50 mg/d</LI>
<LI>Duration: 3 weeks maintenance, 2 weeks follow-up</LI>
</UL>
<P>Control group</P>
<UL>
<LI>Placebo</LI>
</UL>
<P>Co-interventions</P>
<UL>
<LI>Treatment group: vitamin D (67%); phosphate binders (96%)</LI>
<LI>Control group: vitamin D (70%); phosphate binders (100%)</LI>
</UL>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2014-06-10 15:38:06 +1000" MODIFIED_BY="Narelle Willis">
<UL>
<LI>Percentage changes from baseline in serum iPTH levels at the end of dosing (week 3)</LI>
<LI>Percentage changes from baseline in serum calcium, phosphorous, Ca x P and bone metabolism markers (BSAP, osteocalcin, TRACP and NTx) levels at the end of dosing</LI>
</UL>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2014-12-08 16:15:05 +1100" MODIFIED_BY="Narelle Willis">
<UL>
<LI>ITT: per-protocol analysis was used to analyse efficacy endpoints</LI>
<LI>Three treatment groups were combined</LI>
<LI>Funding: "This study was supported by Kirin Brewery. Drs Akizawa, Tsukamoto, Uchida, Iwasaki and Koshikawa are scientific advisors for Kirin Brewery"</LI>
</UL>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2014-06-11 16:12:08 +1000" MODIFIED_BY="Narelle Willis" STUDY_ID="STD-Block-2004a">
<CHAR_METHODS MODIFIED="2014-06-03 15:43:26 +1000" MODIFIED_BY="Narelle Willis">
<UL>
<LI>Study design: parallel RCT</LI>
<LI>Study duration: December 2001 to January 2003</LI>
<LI>Study follow-up: 26 weeks</LI>
</UL>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2014-06-02 18:30:38 +1000" MODIFIED_BY="Narelle Willis">
<UL>
<LI>Country: multinational</LI>
<LI>Setting: multicentre (125 centres)</LI>
<LI>Medically stable patients with secondary hyperparathyroidism; &#8805; 18 years; treated with thrice-weekly HD for at least three mo; mean plasma PTH of at least 300 pg/mL; established by 3 measurements obtained within a 30-day screening period. Dialysate calcium levels remained unchanged throughout the study.</LI>
<LI>Number: treatment group (371); control group (370)</LI>
<LI>Mean age ± SD (years): treatment group (54 ± 14); control group (55 ± 15)</LI>
<LI>Sex (M/F): treatment group (226/145); control group (229/141)</LI>
<LI>Exclusion criteria: evidence of cancer; active infection; diseases known to cause hypercalcaemia; serum Ca &lt; 8.4 mg/dL corrected for albumin; receiving drugs such as flecainide, thioridazine, and most tricyclic antidepressants</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2014-06-11 16:12:08 +1000" MODIFIED_BY="Narelle Willis">
<P>Treatment group</P>
<UL>
<LI>Cinacalcet: 30 to 180 mg/d</LI>
<LI>Duration: 12 weeks titration, 14 weeks maintenance</LI>
</UL>
<P>Control group</P>
<UL>
<LI>Placebo</LI>
</UL>
<P>Co-interventions</P>
<UL>
<LI>Treatment group: vitamin D (66%); phosphate binders (92%)</LI>
<LI>Control group: vitamin D (67%); phosphate binders (93%)</LI>
</UL>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2014-06-10 15:38:06 +1000" MODIFIED_BY="Narelle Willis">
<UL>
<LI>Mean PTH &#8804; 250 pg/mL</LI>
<LI>Reduction from base line of at least 30% in mean PTH levels</LI>
<LI>Percent change in the values for PTH, calcium, phosphorous, Ca x P</LI>
</UL>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2014-06-02 18:39:32 +1000" MODIFIED_BY="Narelle Willis">
<UL>
<LI>Stop/endpoints: iPTH &lt; 250 pg/mL</LI>
<LI>ITT: no</LI>
<LI>Pooled data from 2 studies</LI>
<LI>Funding: "Supported by Amgen"</LI>
</UL>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2014-06-11 16:12:21 +1000" MODIFIED_BY="Narelle Willis" STUDY_ID="STD-Charytan-2005">
<CHAR_METHODS MODIFIED="2014-06-03 15:43:32 +1000" MODIFIED_BY="Narelle Willis">
<UL>
<LI>Study design: parallel RCT</LI>
<LI>Study duration: June 2002 and March 2003</LI>
<LI>Study follow-up: 18 weeks</LI>
</UL>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2014-06-11 16:12:21 +1000" MODIFIED_BY="Narelle Willis">
<UL>
<LI>Country: USA and Canada</LI>
<LI>Setting: multicentre (16 centres)</LI>
<LI>Men and women, &#8805; 18 years with CKD and SHPT but were not receiving dialysis; GFR of 15 to 50 mL/min/1.73 m²; one iPTH &lt; 130 pg/mL; serum Ca &#8805; 9.0 mg/dL</LI>
<LI>Number: treatment group (27); control group (27)</LI>
<LI>Mean age ± SD (years): treatment group (60.6 ± 15.6); control group (61.9 ± 15.1)</LI>
<LI>Sex (M/F): treatment group (16/11); control group (22/5)</LI>
<LI>Exclusion criteria: any unstable medical condition; pregnant or lactating; undergone parathyroidectomy or experienced MI in the previous 3 months; kidney transplantation at any time; changed vitamin D therapy in the previous 30 days; were likely to begin dialysis therapy or receive a kidney transplant within 18 weeks</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2014-06-04 17:24:05 +1000" MODIFIED_BY="Narelle Willis">
<P>Treatment group</P>
<UL>
<LI>Cinacalcet: 30 to 180 mg/d</LI>
<LI>Duration: 12 weeks titration, 6 weeks maintenance</LI>
</UL>
<P>Control group</P>
<UL>
<LI>Placebo: 30 to 180 mg/d</LI>
<LI>Duration: 12 weeks titration, 6 weeks maintenance</LI>
</UL>
<P>Co-interventions</P>
<UL>
<LI>Treatment group: vitamin D (22%); phosphate binders (37%)</LI>
<LI>Control group: vitamin D (33%); phosphate binders (48%)</LI>
</UL>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2014-06-03 15:38:44 +1000" MODIFIED_BY="Narelle Willis">
<UL>
<LI>&#8805; 30% reduction from baseline in mean iPTH</LI>
<LI>Percentage change in mean iPTH within each treatment group (efficacy)</LI>
<LI>Collection of adverse events and laboratory parameters (safety)</LI>
</UL>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2014-06-02 18:55:05 +1000" MODIFIED_BY="Narelle Willis">
<UL>
<LI>ITT: yes</LI>
<LI>Funding: "Supported in part by a grant from Amgen Inc. WL, PSK, and LCM are employees of Amgen Inc"</LI>
</UL>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2014-06-11 16:13:03 +1000" MODIFIED_BY="Narelle Willis" STUDY_ID="STD-Chonchol-2009">
<CHAR_METHODS MODIFIED="2014-06-03 15:43:39 +1000" MODIFIED_BY="Narelle Willis">
<UL>
<LI>Study design: parallel RCT</LI>
<LI>Study duration: December 2004 to August 2006</LI>
<LI>Study follow-up: 32 weeks</LI>
</UL>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2014-06-10 15:47:11 +1000" MODIFIED_BY="Narelle Willis">
<UL>
<LI>Country: multinational</LI>
<LI>Setting: multicentre (73 centres)</LI>
<LI>Adults with an iPTH &#8805; 100 pg/mL (CKD stage 3) or &#8805; 160 pg/mL (CKD stage 4); eGFR 15 to 59 mL/min/1.73 m²; albumin-corrected serum calcium concentration &#8805; 9.0 mg/dL</LI>
<LI>Number: treatment group (302); control group (102)</LI>
<LI>Mean age ± SD (years): treatment group (64.7 ± 13.3); control group (66.2 ± 12.2)</LI>
<LI>Sex (M/F): treatment group (177/125); control group (60/42)</LI>
<LI>Exclusion criteria: kidney transplantation; pregnancy; lactation; laboratory evidence of primary hyperparathyroidism; unstable medical condition; participation in a previous cinacalcet clinical study; likelihood of dialysis or scheduled for kidney transplantation within 28 weeks after day 1; MI within 3 months before day 1; participation in another investigational study; prior treatment with cinacalcet; change in active vitamin D sterol treatment in the previous 30 days</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2014-06-04 17:23:53 +1000" MODIFIED_BY="Narelle Willis">
<P>Treatment group</P>
<UL>
<LI>Cinacalcet: 30 to 180 mg/d</LI>
<LI>Duration: 16 weeks titration, 16 weeks maintenance</LI>
</UL>
<P>Control group</P>
<UL>
<LI>Placebo</LI>
</UL>
<P>Co-interventions</P>
<UL>
<LI>Treatment group: vitamin D (21%); phosphate binders (19%)</LI>
<LI>Control group: vitamin D (21%); phosphate binders (18%)</LI>
</UL>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2014-06-11 16:12:44 +1000" MODIFIED_BY="Narelle Willis">
<UL>
<LI>Mean &#8805; 30% decrease in iPTH level</LI>
<LI>iPTH &#8804; 70 pg/mL (CKD stage 3) or &#8804; 110 pg/mL (CKD stage 4)</LI>
<LI>Mean percentages of change in iPTH levels from baseline</LI>
<LI>Adverse events</LI>
<LI>Changes in haematology, clinical chemistry and urine calcium and phosphorous results</LI>
</UL>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2014-06-11 16:13:03 +1000" MODIFIED_BY="Narelle Willis">
<UL>
<LI>ITT: no</LI>
<LI>Funding: "The writing of this manuscript was supported by Amgen Inc; see Financial Disclosure for further information." "This trial (20000178) was sponsored by Amgen Inc, which markets cinacalcet. Dr Chonchol is a member of advisory boards for Amgen; Dr Locatelli is a member of advisory boards for Amgen-Dompé, Shire, and Mitsubishi; Dr Charytan receives research and/or consultation support from Amgen; Dr de Francisco is a clinical advisor for Amgen and lectures for Amgen, Roche, Jansen Cilag, and Abbott; Dr Jolly is a stockholder of Amgen; Drs Albizem and Mix and Ms Kubo are employees of and stockholders of Amgen; and Dr Block is an advisor for Amgen and has received research support from Amgen."</LI>
</UL>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2014-06-11 16:13:41 +1000" MODIFIED_BY="Narelle Willis" STUDY_ID="STD-El-Shafey-2011">
<CHAR_METHODS MODIFIED="2014-06-03 15:42:50 +1000" MODIFIED_BY="Narelle Willis">
<UL>
<LI>Study design: parallel RCT</LI>
<LI>Study duration: July 2009 to August 2010</LI>
<LI>Study follow-up: 36 weeks</LI>
</UL>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2014-06-11 16:13:21 +1000" MODIFIED_BY="Narelle Willis">
<UL>
<LI>Country: Kuwait; Saudi Arabia</LI>
<LI>Setting: multicentre (2 centres)</LI>
<LI>Adults &#8805; 18 years; ESKD with SHPT; receiving maintenance HD 3 times/week for &#8805; 3 months; iPTH &#8805; 31.8 pmol/L; albumin-corrected serum calcium &#8805; 2.1 mmol/L; no more than 20% of the study population could have iPTH levels exceeding 84.8 pmol/L</LI>
<LI>Number: treatment group (55); control group (27)</LI>
<LI>Mean age ± SD (years): treatment group (51.5 ± 12.7); control group (51.8 ± 15)</LI>
<LI>Sex (M/F): treatment group (27/28); control group (14/13)</LI>
<LI>Exclusion criteria: any unstable medical condition; breastfeeding; experienced a MI within 3 month of study day 1; undergone a parathyroidectomy within 6 month of study day 1; gastrointestinal disorder associated with impaired absorption of oral medications or an inability to swallow tablets; received vitamin D therapy for &lt; 21 d; change in prescribed vitamin D brand or dose within 21 d before study day 1; enrolled in other studies; previously enrolled or participated in other cinacalcet clinical studies</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2014-06-04 17:23:45 +1000" MODIFIED_BY="Narelle Willis">
<P>Treatment group</P>
<UL>
<LI>Cinacalcet: 30 to 180 mg/d</LI>
<LI>Duration: 12 weeks titration, 24 weeks maintenance</LI>
</UL>
<P>Control group</P>
<UL>
<LI>Conventional therapy</LI>
</UL>
<P>Co-interventions</P>
<UL>
<LI>Treatment group: vitamin D (50%); phosphate binders (86%)</LI>
<LI>Control group: vitamin D (52%); phosphate binders (89%)</LI>
</UL>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2014-06-11 16:13:41 +1000" MODIFIED_BY="Narelle Willis">
<UL>
<LI>Mean iPTH &#8804; 31.8 pmol/L</LI>
<LI>Both mean Ca x P &lt; 4.44 mmol²/L² and iPTH &#8804; 31.8 pmol/L</LI>
<LI>Mean calcium &lt; 2.37 mmol/L</LI>
<LI>Mean phosphorous &lt; 1.78 mmol/L</LI>
<LI>Mean Ca x P &lt; 4.44 mmol²/L²</LI>
<LI>Adverse events</LI>
<LI>Changes in safety laboratory parameters (including clinical chemistry and haematology)</LI>
</UL>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2014-06-03 15:42:13 +1000" MODIFIED_BY="Narelle Willis">
<UL>
<LI>ITT: no</LI>
<LI>Funding: NS</LI>
</UL>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2014-06-11 16:14:20 +1000" MODIFIED_BY="Narelle Willis" STUDY_ID="STD-EVOLVE-study-2007">
<CHAR_METHODS MODIFIED="2014-06-03 15:59:34 +1000" MODIFIED_BY="Narelle Willis">
<UL>
<LI>Study design: parallel RCT</LI>
<LI>Study duration: 22 August 2006, to 31 January 2008</LI>
<LI>Study follow-up: treatment group (21.2 months); control group (17.5 months)</LI>
</UL>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2014-06-11 16:13:51 +1000" MODIFIED_BY="Narelle Willis">
<UL>
<LI>Country: multinational (USA, Canada, Argentina, Brazil, Mexico, Australia, Austria, Belgium, Denmark, France, Germany, Hungary, Ireland, Italy, Netherlands, Poland, Portugal, Russia, Spain, Sweden, Switzerland, UK)</LI>
<LI>Setting: multicentre (approx. 500 centres)</LI>
<LI>Men or women &#8805;18 years of age at screening; treated with maintenance HD 3 times/wk for &#8805; 3 months before randomisation; PTH &#8805; 300 pg/mL; serum calcium &#8805; 8.4 mg/dL; Ca x P &#8805;45 mg²/dL²; available during the follow-up phase of the study; agree to be followed for study endpoints until the end of study; appropriate written informed consent must be obtained.</LI>
<LI>Number: treatment group (1948); control group (1935)</LI>
<LI>Mean age ± SD: 54 ± 14 years</LI>
<LI>Sex (M/F): treatment group (1140/808); control group (1167/768)</LI>
<LI>Exclusion criteria: unstable medical condition; parathyroidectomy; severe concomitant disease, including life-threatening malignancy or acquired immune deficiency syndrome, or any other life-threatening concomitant disease; received therapy with cinacalcet within 3 months of randomisation; hospitalization within 12 weeks of randomisation for any of the following events (MI, unstable angina, heart failure, peripheral vascular disease, stroke; history of seizure within 12 weeks prior to randomisation); scheduled date for kidney transplant from a known living donor; anticipated parathyroidectomy within 6 months after randomisation; currently enrolled in or has not yet completed at least 30 days since ending other investigational device or drug study(s); receiving other investigational agent(s); known sensitivity or intolerance to any of the products to be administered; any kind of disorder that compromises the ability of the subject to give written informed consent and/or to comply with study procedures; pregnant; breast feeding; child-bearing potential and not using adequate contraceptive precautions</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2014-06-03 16:01:04 +1000" MODIFIED_BY="Narelle Willis">
<P>Treatment group</P>
<UL>
<LI>Cinacalcet: 30 to 180 mg/d</LI>
<LI>Duration: 21.2 months</LI>
</UL>
<P>Control group</P>
<UL>
<LI>Placebo</LI>
<LI>Duration: 17.5 months</LI>
</UL>
<P>Co-interventions</P>
<UL>
<LI>Treatment group: vitamin D (59.3%); phosphate binders (87.8%)</LI>
<LI>Control group: vitamin D (59.6%); phosphate binders (89%)</LI>
</UL>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2014-06-03 16:02:06 +1000" MODIFIED_BY="Narelle Willis">
<UL>
<LI>Composite endpoint of time to death or first nonfatal cardiovascular event (MI, hospitalisation for unstable angina, heart failure, or a peripheral vascular event)</LI>
<LI>Time to individual components of primary composite endpoint</LI>
<LI>Death from cardiovascular causes</LI>
<LI>Stroke</LI>
<LI>Bone fracture</LI>
<LI>Parathyroidectomy</LI>
</UL>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2014-06-11 16:14:20 +1000" MODIFIED_BY="Narelle Willis">
<UL>
<LI>ITT: yes</LI>
<LI>Funding: "This study was funded by Amgen, Inc and led by an executive committee composed of academic members, two sponsor members (nonvoting), and statisticians. The executive committee oversaw the design, conduct, and all analyses. Data were collected by the sponsor and shared with the executive committee throughout the study and after unblinding. The analysis was performed by the sponsor and confirmed by an independent biostatistician at Stanford University School of Medicine. The sponsor provided the active medication and matching placebo. The lead author wrote the first draft of the manuscript, and the executive committee was responsible for data interpretation and manuscript completion. The sponsor reviewed the manuscript, but decisions about the final manuscript were made by the lead author and academic members of the executive committee only."</LI>
</UL>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2014-12-08 16:15:06 +1100" MODIFIED_BY="Narelle Willis" STUDY_ID="STD-Fukagawa-2008">
<CHAR_METHODS MODIFIED="2014-06-03 16:10:27 +1000" MODIFIED_BY="Narelle Willis">
<UL>
<LI>Study design: parallel RCT</LI>
<LI>Study duration: April to December 2004</LI>
<LI>Study follow-up: 14 weeks</LI>
</UL>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2014-06-03 16:07:28 +1000" MODIFIED_BY="Narelle Willis">
<UL>
<LI>Country: Japan</LI>
<LI>Setting: multicentre (29 centres)</LI>
<LI>Patients &gt; 20 years of age with ESRD and SHPT who were undergoing HD 3 times/wk for at least 16 weeks and were in a medically stable condition; serum iPTH level &#8805;300 pg/mL both at 1 and 2 weeks prior to the cinacalcet administration; serum calcium level &#8805; 9.0 mg/dL at 1 week prior to the cinacalcet administration</LI>
<LI>Number: treatment group (72); control group (71)</LI>
<LI>Mean age ± SD (years): treatment group (54.7 ± 11); control group (55.7 ± 11.7)</LI>
<LI>Sex (M/F): treatment group (40/32); control group (37/34)</LI>
<LI>Exclusion criteria: parathyroidectomy within 24 weeks prior to the treatment; percutaneous ethanol injection therapy into the parathyroid gland during the 4 weeks&#8217; screening period; severe impairment of hepatic function; severe hypertension; uncontrolled DM; cancer; severe infection; severe cardiac failure</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2014-06-03 16:08:41 +1000" MODIFIED_BY="Narelle Willis">
<P>Treatment group</P>
<UL>
<LI>Cinacalcet: 30 to 180 mg/d</LI>
<LI>Duration: 14 weeks</LI>
</UL>
<P>Control group</P>
<UL>
<LI>Placebo</LI>
</UL>
<P>Co-interventions</P>
<UL>
<LI>Treatment group: vitamin D (87.5%); phosphate binders (93.1%)</LI>
<LI>Control group: vitamin D (88.7%); phosphate binders (95.8%)</LI>
</UL>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2014-06-03 16:09:28 +1000" MODIFIED_BY="Narelle Willis">
<UL>
<LI>Percentage with serum iPTH levels &#8804; 250 pg/mL at the end of the dosing</LI>
<LI>Adverse events</LI>
<LI>Laboratory variables</LI>
<LI>Vital signs</LI>
</UL>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2014-12-08 16:15:06 +1100" MODIFIED_BY="Narelle Willis">
<UL>
<LI>ITT: yes</LI>
<LI>Funding: "This study was supported by Kirin Pharma Co., Ltd."</LI>
</UL>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2014-12-08 16:15:06 +1100" MODIFIED_BY="Narelle Willis" STUDY_ID="STD-Goodman-2000">
<CHAR_METHODS MODIFIED="2014-06-04 15:32:24 +1000" MODIFIED_BY="Narelle Willis">
<UL>
<LI>Study design: parallel RCT</LI>
<LI>Study duration: NS</LI>
<LI>Study follow-up: 24 days</LI>
</UL>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2014-06-10 15:38:10 +1000" MODIFIED_BY="Narelle Willis">
<UL>
<LI>Country: USA</LI>
<LI>Setting: multicentre</LI>
<LI>Medically stable individuals &#8805; 18 years undergoing HD 3 times/wk for at least 3 months with biochemical evidence of secondary hyperparathyroidism as judged by serum PTH levels between 300 and 1200 pg/mL; calcium levels &gt; 9.0 mg/dL; serum phosphorous levels &gt; 3.0 mg/dL; serum aluminium levels &lt; 40 mg/L; serum CO<SUB>2</SUB> levels &gt; 15 mEq/L; serum potassium concentrations &lt; 6.2 mEq/L; HCT values &gt; 30%; serum ferritin levels &gt; 100 ng/mL; transferrin saturation values &gt; 20%; urea reduction rate &#8805; 65% and/or measured Kt/V values &gt; 1.2.</LI>
<LI>Number: treatment group (16); control group (5 randomised, 4 analysed)</LI>
<LI>Mean age ± SD (years): treatment group (48.6 ± 12.4); control group (54.7 ± 16.8)</LI>
<LI>Sex (M/F): treatment group (13/3); control group (1/3)</LI>
<LI>Exclusion criteria: women of childbearing age unless they were using effective contraceptive measures or had previously been rendered sterile surgically; serum levels of hepatic transaminases or bilirubin were more than twice the upper limit of normal or if they were using medication such as selective serotonin reuptake inhibitors, tricyclic antidepressants, or B-adrenergic blocking agents that are metabolized extensively by the P450 pathway; history of seizures; malignancy; hyperthyroidism; granulomatous diseases that could cause hypercalcaemia; MI within the previous 6 months; corrected QT interval (QTc) on electrocardiogram that exceeded 450 milliseconds</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2014-06-04 15:45:14 +1000" MODIFIED_BY="Narelle Willis">
<P>Treatment group</P>
<UL>
<LI>R-568: 100 mg/d</LI>
<LI>Duration: 15 days maintenance</LI>
</UL>
<P>Control group</P>
<UL>
<LI>Placebo</LI>
</UL>
<P>Co-interventions</P>
<UL>
<LI>Treatment group: vitamin D (38%); phosphate binders (31%)</LI>
<LI>Control group: vitamin D (50%); phosphate binders (50%)</LI>
</UL>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2014-12-08 16:15:06 +1100" MODIFIED_BY="Narelle Willis">
<UL>
<LI>Plasma PTH</LI>
<LI>Blood-ionized calcium</LI>
<LI>Pharmacokinetic data</LI>
<LI>Adverse effects</LI>
</UL>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2014-06-04 15:30:47 +1000" MODIFIED_BY="Narelle Willis">
<UL>
<LI>ITT: no</LI>
<LI>Funding: "This work was supported by Amgen, Inc., and by USPHS grants RR-00865 and DK-52905"</LI>
</UL>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2014-06-10 17:23:49 +1000" MODIFIED_BY="Narelle Willis" STUDY_ID="STD-Goodman-2002">
<CHAR_METHODS MODIFIED="2014-06-04 15:45:07 +1000" MODIFIED_BY="Narelle Willis">
<UL>
<LI>Study design: parallel RCT</LI>
<LI>Study duration: NS</LI>
<LI>Study follow-up: 16 days</LI>
</UL>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2014-06-10 17:23:47 +1000" MODIFIED_BY="Narelle Willis">
<UL>
<LI>Country: USA</LI>
<LI>Setting: multicentre</LI>
<LI>Patients &#8805; 18 years; medically stable, and had been treated for at least 3 months with thrice-weekly HD with evidence of secondary hyperparathyroidism as judged by two plasma PTH determinations obtained at least a week apart within 21 d of the initial dose of AMG-073 that were between 250 and 1500 pg/mL; serum total calcium values of &#8805; 9.0 mg/dL after correcting for serum albumin concentrations; serum phosphorous levels of &#8805; 2.5 mg/dL; serum aluminium levels &lt; 40 ug/L; Hb level &#8805; 10 g/dL or a blood HCT &#8805; 30%; chest radiograph within the past 6 months showing no evidence of active parenchymal disease; body mass index between 15 and 40 kg/m²</LI>
<LI>Number: treatment group (23); control group (7)</LI>
<LI>Mean age ± SD: 46 ± 16 years</LI>
<LI>Sex (M/F): NS</LI>
<LI>Exclusion criteria: women of childbearing age unless they had previously been rendered sterile surgically for other medical reasons; serum levels of hepatic transaminases or bilirubin were more than twice the upper limit of normal; history of seizures within the past 12 months; malignancy within the past 5 years; hyperparathyroidism; MI within the previous 6 months a cardiac ventricular rhythm disturbance requiring active treatment; a gastrointestinal disorder that could affect the absorption of drugs given orally; granulomatous diseases that could cause hypercalcaemia</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2014-06-10 17:23:49 +1000" MODIFIED_BY="Narelle Willis">
<P>Treatment group</P>
<UL>
<LI>AMG-073: 10 to 50 mg/d</LI>
<LI>Duration: 8 days maintenance</LI>
</UL>
<P>Control group</P>
<UL>
<LI>Placebo</LI>
</UL>
<P>Co-interventions: NS</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2014-06-04 15:43:26 +1000" MODIFIED_BY="Narelle Willis">
<UL>
<LI>Serum PTH</LI>
<LI>Serum calcium</LI>
<LI>Dose response</LI>
</UL>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2014-06-04 15:44:06 +1000" MODIFIED_BY="Narelle Willis">
<UL>
<LI>ITT: no</LI>
<LI>Funding: "This work was supported by Amgen Inc. and by USPHS grants DK-52905, DK-60107, and RR-00865"</LI>
</UL>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2014-06-11 16:15:59 +1000" MODIFIED_BY="Narelle Willis" STUDY_ID="STD-Harris-2004">
<CHAR_METHODS MODIFIED="2014-06-04 15:54:20 +1000" MODIFIED_BY="Narelle Willis">
<UL>
<LI>Study design: parallel RCT</LI>
<LI>Study duration: NS</LI>
<LI>Study follow-up: 12 weeks</LI>
</UL>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2014-06-10 15:38:12 +1000" MODIFIED_BY="Narelle Willis">
<UL>
<LI>Country: USA</LI>
<LI>Setting: multicentre (2 centres)</LI>
<LI>Medically stable patients with serum calcium levels corrected for albumin concentration &#8805; 8.4 mg/dL; serum phosphorous levels &#8805; 3.0 mg/dL</LI>
<LI>Number: treatment group (17); control group (5)</LI>
<LI>Mean age ± SD (years): treatment group (48.5 ± 10.4); control group (48 ± 13.1)</LI>
<LI>Sex (M/F): treatment group (14/3); control group (4/1)</LI>
<LI>Exclusion criteria: NS</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2014-06-04 15:52:33 +1000" MODIFIED_BY="Narelle Willis">
<P>Treatment group</P>
<UL>
<LI>Cinacalcet: 25 to 300 mg/d</LI>
<LI>Duration: 12 weeks</LI>
</UL>
<P>Control group</P>
<UL>
<LI>Placebo</LI>
</UL>
<P>Co-interventions</P>
<UL>
<LI>Treatment group: vitamin D (71%); phosphate binders (100%)</LI>
<LI>Control group: vitamin D (60%); phosphate binders (80%)</LI>
</UL>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2014-06-11 16:15:59 +1000" MODIFIED_BY="Narelle Willis">
<UL>
<LI>Pharmacodynamic data at doses &gt; 100 mg</LI>
<LI>Adverse effects</LI>
</UL>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2014-06-04 15:53:53 +1000" MODIFIED_BY="Narelle Willis">
<UL>
<LI>ITT: no</LI>
<LI>Funding: "From Pharmacokinetics and Drug Metabolism, Early Development, and Biostatistics, Amgen Inc, Thousand Oaks, CA; Orlando Clinical Research Center, Orlando, FL; and Clinical Research Center, New Orleans, LA"</LI>
<LI>Not included in meta-analyses</LI>
</UL>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2014-06-11 16:17:13 +1000" MODIFIED_BY="Narelle Willis" STUDY_ID="STD-IMPACT-SHPT-Study-2012">
<CHAR_METHODS MODIFIED="2014-06-04 16:19:22 +1000" MODIFIED_BY="Narelle Willis">
<UL>
<LI>Study design: parallel, open-label RCT</LI>
<LI>Study duration: NS</LI>
<LI>Study follow-up: 28 weeks</LI>
</UL>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2014-06-10 15:38:13 +1000" MODIFIED_BY="Narelle Willis">
<UL>
<LI>Country: multinational</LI>
<LI>Setting: multicentre (89 centres)</LI>
<LI>Eligible patients were aged &#8805; 8 years with Stage 5 CKD receiving maintenance HD 3 times/wk for at least 3 months before screening and were to continue HD during the study; serum iPTH 130 to 700 pg/mL; total alkaline phosphatase &#8805; 0 U/L; calcium &#8804; 10.0 mg/dL; Ca x P &#8804; 5 mg²/dL² for US centres or &#8804; 70 mg²/dL² for non-US centres; iPTH 300&#8211;800 pg/mL; calcium 8.4 to 10.0 mg/ dL; phosphorous &#8804; 6.5 mg/dL</LI>
<LI>Number: treatment group (134); control group (134)</LI>
<LI>Mean age ± SD (years): treatment group-IV (59.9 ± 12.0); treatment group-oral (65.1 ± 12.5); control group-IV (61.2 ± 12.7); control group-oral (65.7 ± 13.5)</LI>
<LI>Sex (M/F): treatment group-IV (38/26); treatment group-oral (43/27); control group-IV (38/26); oral group-oral (49/23)</LI>
<LI>Exclusion criteria: allergic reaction or significant sensitivity to any study drug; expected daily requirement of &gt; 2.0 g of oral elemental calcium; previous parathyroidectomy; chronic gastrointestinal disorders; clinically significant liver disease and use of known inhibitors or inducers of cytochrome P450 3A or of drugs metabolized by cytochrome P450 2D6 within 2 weeks before study drug administration</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2014-06-04 17:25:55 +1000" MODIFIED_BY="Narelle Willis">
<P>Treatment group</P>
<UL>
<LI>Cinacalcet</LI>
<LI>Low dose vitamin D</LI>
<LI>Duration: 28 weeks</LI>
</UL>
<P>Control group</P>
<UL>
<LI>Vitamin D</LI>
</UL>
<P>Co-interventions: NS</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2014-06-04 16:49:35 +1000" MODIFIED_BY="Narelle Willis">
<UL>
<LI>Mean iPTH value of 150 to 300 pg/mL during weeks 21 to 28</LI>
<LI>Achieved &#8805; 30% or &#8805; 50% reduction from baseline in iPTH</LI>
<LI>Hypocalcaemia (mean calcium &lt; 8.4 mg/dL) during weeks 21 to 28</LI>
<LI>Hypercalcaemia (mean calcium &gt; 10.5 mg/dL) during weeks 21 to 28</LI>
<LI>BSAP</LI>
<LI>Alkaline phosphatase</LI>
</UL>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2014-06-11 16:17:13 +1000" MODIFIED_BY="Narelle Willis">
<UL>
<LI>ITT: yes</LI>
<LI>Funding: "The IMPACT SHPT study was funded by Abbott Laboratories Inc. Writing and editorial assistance, funded by Abbott Laboratories Inc., was provided by Roland Tacke, PhD, Marsha Hall and Colleen Hedge of Scientific Connexions, Newtown, PA, USA"</LI>
</UL>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2014-06-11 16:18:09 +1000" MODIFIED_BY="Narelle Willis" STUDY_ID="STD-Lindberg-2003">
<CHAR_METHODS MODIFIED="2014-06-04 16:31:05 +1000" MODIFIED_BY="Narelle Willis">
<UL>
<LI>Study design: parallel RCT</LI>
<LI>Study duration: NS</LI>
<LI>Study follow-up: 18 weeks</LI>
</UL>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2014-06-11 16:17:38 +1000" MODIFIED_BY="Narelle Willis">
<UL>
<LI>Country: USA, Canada</LI>
<LI>Setting: multicentre (23 centres)</LI>
<LI>Patients &#8805; 18 years, treated for at least 3 mo with HD; PTH levels &#8805; 300 pg/mL despite receiving standard of care (phosphate binders and/or vitamin D sterols); serum calcium corrected for serum albumin &#8805; 8.8 mg/dL and &lt; 11.0 mg/dL; serum phosphorous &#8805; 2.5 mg/dL; Ca x P &lt; 70 mg²/dL². Patients receiving vitamin D sterols were required to be on a stable dose for at least 21 days before enrolment; dialysate calcium concentration and calcium supplements/oral phosphate binders dose could not be changed during the 7 days before enrolment</LI>
<LI>Number: treatment group (39); control group (39)</LI>
<LI>Mean age ± SD (years): treatment group (52.7 ± 16.4); control group (48.8 ± 15.6)</LI>
<LI>Sex (M/F): treatment group (24/15); control group (22/17)</LI>
<LI>Exclusion criteria: medically unstable; evidence of an active infectious or malignant process or diseases known to cause hypercalcaemia; Hb concentration &lt; 9.0 g/dL or a HCT &lt; 27%; liver transaminases and bilirubin levels more than twice the upper limit of normal</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2014-06-04 16:26:05 +1000" MODIFIED_BY="Narelle Willis">
<P>Treatment group</P>
<UL>
<LI>AMG-073: 10 to 50 mg/d</LI>
<LI>Duration: 12 weeks titration, 6 weeks maintenance</LI>
</UL>
<P>Control group</P>
<UL>
<LI>Placebo</LI>
</UL>
<P>Co-interventions</P>
<UL>
<LI>Treatment group: vitamin D (67%); phosphate binders (87%)</LI>
<LI>Control group: vitamin D (62%); phosphate binders (87%)</LI>
</UL>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2014-06-11 16:18:09 +1000" MODIFIED_BY="Narelle Willis">
<UL>
<LI>Reduction in PTH &#8805; 30% during the maintenance phase</LI>
<LI>Mean percent change from baseline for PTH, serum calcium, phosphorous, and Ca x P during the maintenance phase</LI>
<LI>Adverse events</LI>
<LI>Laboratory variables (haematology and biochemistry)</LI>
<LI>Vital signs</LI>
</UL>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2014-06-04 16:31:33 +1000" MODIFIED_BY="Narelle Willis">
<UL>
<LI>ITT: no</LI>
<LI>Funding: "Funding for this study was provided by Amgen Inc"</LI>
</UL>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2014-06-11 16:18:52 +1000" MODIFIED_BY="Narelle Willis" STUDY_ID="STD-Lindberg-2005">
<CHAR_METHODS MODIFIED="2014-06-04 16:41:08 +1000" MODIFIED_BY="Narelle Willis">
<UL>
<LI>Study design: parallel RCT</LI>
<LI>Study duration: May 2002 to March 2003</LI>
<LI>Study follow-up: 26 weeks</LI>
</UL>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2014-06-11 16:18:52 +1000" MODIFIED_BY="Narelle Willis">
<UL>
<LI>Country: multinational</LI>
<LI>Setting: multicentre (60 centres)</LI>
<LI>Age &#8805;18 years; mean of two plasma iPTH values &#8805; 300 pg/mL; mean of two serum calcium values &#8805; 8.4 mg/dL during the screening phase; treatment with HD, continuous ambulatory PD, or automated PD for at least 1 mo before beginning study medication; patients who were receiving vitamin D therapy must have been treated with a stable dose for at least 30 d before enrolment</LI>
<LI>Number: treatment group (294); control group (101)</LI>
<LI>Mean age ± SD (years): treatment group (51.8 ± 14.0); control group (53.5 ± 13.9)</LI>
<LI>Sex (M/F): treatment group (181/113); control group (64/37)</LI>
<LI>Exclusion criteria: an unstable medical condition; undergone parathyroidectomy; MI within 3 mo before the study began</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2014-06-04 16:36:02 +1000" MODIFIED_BY="Narelle Willis">
<P>Treatment group</P>
<UL>
<LI>Cinacalcet: 30 to 180 mg/d</LI>
<LI>Duration: 16 weeks titration, 10 weeks maintenance</LI>
</UL>
<P>Control group</P>
<UL>
<LI>Placebo</LI>
</UL>
<P>Co-interventions</P>
<UL>
<LI>Treatment group: vitamin D (65%); phosphate binders (NS)</LI>
<LI>Control group: vitamin D (69%); phosphate binders (NS)</LI>
</UL>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2014-06-10 15:38:16 +1000" MODIFIED_BY="Narelle Willis">
<UL>
<LI>Mean iPTH level &#8804; 250 pg/mL</LI>
<LI>Reduction in iPTH of at least 30% from baseline</LI>
<LI>Mean percentage changes from baseline for iPTH, serum calcium, phosphorous, and Ca x P</LI>
<LI>Mean iPTH &#8804; 300 pg/mL or reductions in iPTH of a least 20%, 40%, or 50% from baseline</LI>
<LI>Ca x P &lt; 55 mg²/dL²</LI>
<LI>Mean reduction in Ca x P of at least 5 or 10 mg²/dL²</LI>
</UL>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2014-06-04 16:41:42 +1000" MODIFIED_BY="Narelle Willis">
<UL>
<LI>ITT: yes</LI>
<LI>Funding: "This study was supported by Amgen Inc. Holly Brenza Zoog assisted in the preparation of the manuscript."</LI>
</UL>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2014-06-04 17:22:14 +1000" MODIFIED_BY="Narelle Willis" STUDY_ID="STD-Malluche-2008">
<CHAR_METHODS MODIFIED="2014-06-04 16:53:58 +1000" MODIFIED_BY="Narelle Willis">
<UL>
<LI>Study design: parallel RCT</LI>
<LI>Study duration: October 2001 to May 2003</LI>
<LI>Study follow-up: 52 weeks</LI>
</UL>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2014-06-04 17:22:14 +1000" MODIFIED_BY="Narelle Willis">
<UL>
<LI>Country: multinational</LI>
<LI>Setting: multicentre (17 centres)</LI>
<LI>Medically stable patients &#8805; 18 years who had received HD for &#8805; 1 month with biochemical evidence of elevated PTH levels; albumin-adjusted serum calcium concentration &#8805; 8.4 mg/dL; either Hb level &gt; 9.0 g/dL or a HCT value &gt; 27%; patients receiving vitamin D sterols had to have been on a constant dose for &#8805; 30 days before beginning the study</LI>
<LI>Number: treatment group (19); control group (13)</LI>
<LI>Mean age ± SD (years): treatment group (50.3 ± 13.3); control group (51.5 ± 14.1)</LI>
<LI>Sex (M/F): treatment group (12/7); control group (9/4)</LI>
<LI>Exclusion criteria: received bisphosphonate or fluoride during the preceding 90 days</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2014-06-04 16:46:23 +1000" MODIFIED_BY="Narelle Willis">
<P>Treatment group</P>
<UL>
<LI>Cinacalcet: 30 to 180 mg/d</LI>
<LI>Duration: 24 weeks titration, 28 weeks maintenance</LI>
</UL>
<P>Control group</P>
<UL>
<LI>Placebo</LI>
</UL>
<P>Co-interventions</P>
<UL>
<LI>Treatment group: vitamin D (47%); phosphate binders (100%)</LI>
<LI>Control group: vitamin D (54%); phosphate binders (77%)</LI>
</UL>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2014-06-04 16:49:51 +1000" MODIFIED_BY="Narelle Willis">
<UL>
<LI>Interval changes in activation frequency, bone formation rate/bone surface, number of osteoblasts and osteoclasts/bone perimeter, fibrosis surface/bone surface and woven osteoid surface/bone surface</LI>
<LI>Absolute and percentage changes from baseline in iPTH, BSAP, NTx and Ca x P</LI>
</UL>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2014-06-04 16:55:03 +1000" MODIFIED_BY="Narelle Willis">
<UL>
<LI>ITT: no</LI>
<LI>Funding: "This study was supported by Amgen Inc (Study 20010141)"</LI>
</UL>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2014-06-11 16:20:13 +1000" MODIFIED_BY="Narelle Willis" STUDY_ID="STD-OPTIMA-Study-2008">
<CHAR_METHODS MODIFIED="2014-06-04 17:05:49 +1000" MODIFIED_BY="Narelle Willis">
<UL>
<LI>Study design: parallel, open-label RCT</LI>
<LI>Study duration: NS</LI>
<LI>Study follow-up: 23 weeks</LI>
</UL>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2014-06-10 15:45:47 +1000" MODIFIED_BY="Narelle Willis">
<UL>
<LI>Country: Europe</LI>
<LI>Setting: multicentre (111 centres)</LI>
<LI>Patients &#8805; 18 years with ESKD with SHPT and had required maintenance dialysis for &#8805; 1 mo; iPTH &#8805; 300 pg/mL and &lt; 800 pg/mL; bio-intact PTH &#8805;150 pg/mL and &lt; 410 pg/mL; albumin-corrected serum calcium &#8805; 8.4 mg/dL</LI>
<LI>Number: treatment group (368); control group (184)</LI>
<LI>Mean age ± SD (years): treatment group (58.5 ± 14.5); control group (58.3 ± 14.5)</LI>
<LI>Sex (M/F): treatment group (224/144); control group (117/67)</LI>
<LI>Exclusion criteria: any unstable medical condition; breastfeeding; MI within 3 mo of study day 1; parathyroidectomy within 6 mo of study day 1; gastrointestinal disorder associated with impaired absorption of oral medications or an inability to swallow tablets; patients who received vitamin D therapy for &lt; 21 d or had a change in their prescribed vitamin D brand or dose within 21 d before study day 1; enrolled in other studies; previously enrolled or participated in other cinacalcet clinical studies</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2014-06-04 17:04:35 +1000" MODIFIED_BY="Narelle Willis">
<P>Treatment group</P>
<UL>
<LI>Cinacalcet: 30 to 180 mg/d</LI>
<LI>Duration: 16 weeks titration, 7 weeks maintenance</LI>
</UL>
<P>Control group</P>
<UL>
<LI>Placebo</LI>
</UL>
<P>Co-interventions</P>
<UL>
<LI>Treatment group: vitamin D (68%); phosphate binders (92%)</LI>
<LI>Control group: vitamin D (68%); phosphate binders (90%)</LI>
</UL>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2014-06-10 15:38:17 +1000" MODIFIED_BY="Narelle Willis">
<UL>
<LI>Mean iPTH &#8804; 300 pg/mL</LI>
<LI>Both mean Ca x P &lt; 55 mg²/dL² and iPTH &#8804; 300 pg/mL</LI>
<LI>Mean Ca × P &lt; 55 mg²/dL²</LI>
<LI>Man calcium &lt; 9.5 mg/dL</LI>
<LI>Mean phosphorous &lt; 5.5 mg/dL</LI>
</UL>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2014-06-11 16:20:13 +1000" MODIFIED_BY="Narelle Willis">
<UL>
<LI>ITT: yes</LI>
<LI>Funding: "This study was sponsored by Amgen Inc."</LI>
</UL>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2014-06-11 16:20:35 +1000" MODIFIED_BY="Narelle Willis" STUDY_ID="STD-Quarles-2003a">
<CHAR_METHODS MODIFIED="2014-06-04 18:31:48 +1000" MODIFIED_BY="Narelle Willis">
<UL>
<LI>Study design: parallel RCT</LI>
<LI>Study duration: NS</LI>
<LI>Study follow-up: 18 weeks</LI>
</UL>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2014-06-11 16:20:35 +1000" MODIFIED_BY="Narelle Willis">
<UL>
<LI>Country: USA</LI>
<LI>Setting: multicentre (17 centres)</LI>
<LI>Patients &#8805; 18 years treated for at least 3 mo with HD and had uncontrolled SHPT (mean PTH &#8805; 300 pg/mL, despite availability of standard care (phosphate binders and/or vitamin D sterols)); serum calcium &#8805; 8.8 mg/dL and &lt; 11.0 mg/dL; serum phosphorous &#8805; 2.5 mg/dL; Ca x P &lt; 70 mg²/dL²; patients receiving vitamin D sterols must have been on a stable dose for at least 21 d before enrolment; dialysis calcium concentration, the dose of any supplements, and the dose of oral phosphate binders must not have been changed during the 7 d before enrolment</LI>
<LI>Number: treatment group (36); control group (35)</LI>
<LI>Mean age ± SD (years): treatment group (49.6 ± 8.5); control group (47.9 ± 14.2)</LI>
<LI>Sex (M/F): treatment group (27/9); control group (17/18)</LI>
<LI>Exclusion criteria: medically unstable; evidence of an active infectious; malignant process; diseases known to cause hypercalcaemia; Hb concentration &lt; 9.0 g/dL or a HCT &lt; 27%; liver transaminases and bilirubin concentrations more than twice the upper limit of normal</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2014-06-04 17:16:31 +1000" MODIFIED_BY="Narelle Willis">
<P>Treatment group</P>
<UL>
<LI>AMG-073: 25 to 100 mg/d</LI>
<LI>Duration: 12 weeks titration, 6 weeks maintenance</LI>
</UL>
<P>Control group</P>
<UL>
<LI>Placebo</LI>
</UL>
<P>Co-interventions</P>
<UL>
<LI>Treatment group: vitamin D (61%); phosphate binders (100%)</LI>
<LI>Control group: vitamin D (69%); phosphate binders (94%)</LI>
</UL>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2014-06-04 18:30:46 +1000" MODIFIED_BY="Narelle Willis">
<UL>
<LI>Mean reduction in PTH of &#8805; 30% during the maintenance phase</LI>
</UL>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2014-06-04 17:20:50 +1000" MODIFIED_BY="Narelle Willis">
<UL>
<LI>Stop/end point: iPTH reduction = 30%</LI>
<LI>ITT: yes</LI>
<LI>Funding: "Funding for this study was provided by Amgen Inc."</LI>
</UL>
</CHAR_NOTES>
</INCLUDED_CHAR>
<FOOTNOTES>
<P>BSAP - bone-specific alkaline phosphatase; Ca x P - calcium-phosphorous product; CAC - coronary artery calcification score; DM - diabetes mellitus; ESKD - end-stage kidney disease; GFR - glomerular filtration rate; Hb - haemoglobin; HCT - haematocrit; HD - haemodialysis; iPTH - intact parathyroid hormone; ITT - Intention-to-treat; MI - myocardial infarction; NA - not available; NS - not stated; NTx - cross-linked N-telopeptides of type I collagen; PTH - parathyroid hormone; RCT - randomised controlled trial; SHPT - secondary hyperparathyroidism; TRACP - tartrate-resistant acid phosphatase</P>
</FOOTNOTES>
</CHARACTERISTICS_OF_INCLUDED_STUDIES>
<CHARACTERISTICS_OF_EXCLUDED_STUDIES MODIFIED="2014-12-08 16:12:36 +1100" MODIFIED_BY="Narelle Willis" SORT_BY="STUDY">
<EXCLUDED_CHAR MODIFIED="2013-06-02 08:11:21 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Al_x002d_Hilali-2011">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-06-02 08:11:21 +1000" MODIFIED_BY="Suetonia Palmer">
<P>Not appropriate intervention</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-06-02 08:13:29 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Coburn-2000a">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-06-02 08:13:29 +1000" MODIFIED_BY="Suetonia Palmer">
<P>Not appropriate outcome</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-06-02 16:56:05 +1000" MODIFIED_BY="Narelle Willis" STUDY_ID="STD-CONTROL-Study-2006">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-06-02 16:56:05 +1000" MODIFIED_BY="Narelle Willis">
<P>Not RCT</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-06-02 08:14:07 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Cunningham-2003">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-06-02 08:14:07 +1000" MODIFIED_BY="Suetonia Palmer">
<P>Observational extension study</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-06-02 08:14:48 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Cunningham-2005">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-06-02 08:14:48 +1000" MODIFIED_BY="Suetonia Palmer">
<P>Observational extension study</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-06-04 18:10:39 +1000" MODIFIED_BY="Narelle Willis" STUDY_ID="STD-de-Francisco-2005">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-06-04 18:10:39 +1000" MODIFIED_BY="Narelle Willis">
<P>Not RCT</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-06-02 08:07:34 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Harris-2003">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-06-02 08:07:34 +1000" MODIFIED_BY="Suetonia Palmer">
<P>Not appropriate outcome</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-06-02 16:56:26 +1000" MODIFIED_BY="Narelle Willis" STUDY_ID="STD-Kaperonis-2012">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-06-02 16:56:26 +1000" MODIFIED_BY="Narelle Willis">
<P>Not RCT</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-06-02 16:56:31 +1000" MODIFIED_BY="Narelle Willis" STUDY_ID="STD-Moe-2003a">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-06-02 16:56:31 +1000" MODIFIED_BY="Narelle Willis">
<P>Not RCT</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-06-02 16:56:35 +1000" MODIFIED_BY="Narelle Willis" STUDY_ID="STD-Moe-2005">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-06-02 16:56:35 +1000" MODIFIED_BY="Narelle Willis">
<P>Not RCT</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-06-02 16:56:38 +1000" MODIFIED_BY="Narelle Willis" STUDY_ID="STD-Moe-2005b">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-06-02 16:56:38 +1000" MODIFIED_BY="Narelle Willis">
<P>Not RCT</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-06-02 08:23:28 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Padhi-2003">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-06-02 08:23:28 +1000" MODIFIED_BY="Suetonia Palmer">
<P>Not CKD population</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-06-02 08:23:38 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Pahl-1996">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-06-02 08:23:38 +1000" MODIFIED_BY="Suetonia Palmer">
<P>Not intervention</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-12-21 00:34:53 +1100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Quarles-2003">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-12-21 00:34:53 +1100" MODIFIED_BY="[Empty name]">
<P>Not RCT</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-06-02 16:56:48 +1000" MODIFIED_BY="Narelle Willis" STUDY_ID="STD-Schaefer-2008">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-06-02 16:56:48 +1000" MODIFIED_BY="Narelle Willis">
<P>Not intervention</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-06-02 08:24:59 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Sezer-2012">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-06-02 08:24:59 +1000" MODIFIED_BY="Suetonia Palmer">
<P>Not intervention</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-06-02 16:56:55 +1000" MODIFIED_BY="Narelle Willis" STUDY_ID="STD-TARGET-Study-2008">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-06-02 16:56:55 +1000" MODIFIED_BY="Narelle Willis">
<P>Not RCT</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<FOOTNOTES>
<P>CKD - chronic kidney disease; RCT - randomised controlled trial</P>
</FOOTNOTES>
</CHARACTERISTICS_OF_EXCLUDED_STUDIES>
<CHARACTERISTICS_OF_AWAITING_STUDIES MODIFIED="2014-12-08 16:15:06 +1100" MODIFIED_BY="Narelle Willis" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<AWAITING_CHAR MODIFIED="2014-12-08 16:06:41 +1100" MODIFIED_BY="Narelle Willis" STUDY_ID="STD-Coburn-2003">
<CHAR_METHODS MODIFIED="2013-06-04 06:42:13 +1000" MODIFIED_BY="Suetonia Palmer">
<P>Randomised double-blind placebo-controlled study</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2014-12-08 16:06:41 +1100" MODIFIED_BY="Narelle Willis">
<P>Patients with CKD not treated with dialysis (GFR 15 to 50 mL/min) and intact PTH levels &gt; 130 ng/mL</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2014-06-07 20:50:25 +1000" MODIFIED_BY="[Empty name]">
<P>Cinacalcet 30 to 180 mg/d titrated to obtain a &#8805; 30% reduction in intact PTH levels</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2014-06-10 15:38:19 +1000" MODIFIED_BY="Narelle Willis">
<P>Mean change in PTH, per cent with reduced PTH &#8805; 30%, calcium and phosphorous levels</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2014-12-08 16:06:26 +1100" MODIFIED_BY="Narelle Willis">
<P>Unclear whether an additional report of <LINK REF="STD-Charytan-2005" TYPE="STUDY">Charytan 2005</LINK>
</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2014-12-08 16:15:06 +1100" MODIFIED_BY="Narelle Willis" STUDY_ID="STD-Drueke-2001a">
<CHAR_METHODS MODIFIED="2014-06-07 21:44:29 +1000" MODIFIED_BY="[Empty name]">
<P>Placebo controlled RCTs (3)</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2014-06-10 17:23:49 +1000" MODIFIED_BY="Narelle Willis">
<P>Dialysis patients</P>
<P>Number: AMG-073 (141); placebo (74)</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2014-06-10 17:23:50 +1000" MODIFIED_BY="Narelle Willis">
<P>AMG-073 (50 to 100 mg/d)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2014-06-07 21:30:26 +1000" MODIFIED_BY="[Empty name]">
<P>Ca x P; mean iPTH</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2014-12-08 16:03:40 +1100" MODIFIED_BY="Narelle Willis">
<P>Abstract only; states combined data of the first 12 weeks of 3 studies - unable to determine which 3 studies</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2014-12-08 16:15:06 +1100" MODIFIED_BY="Narelle Willis" STUDY_ID="STD-Fournier-2004a">
<CHAR_METHODS MODIFIED="2014-06-07 21:44:34 +1000" MODIFIED_BY="[Empty name]">
<P>Placebo controlled RCTs (3)</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2014-06-07 21:46:08 +1000" MODIFIED_BY="[Empty name]">
<P>Dialysis patients with iPTH &#8805; 300 pg/mL</P>
<P>Number: 955</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2014-06-07 21:51:29 +1000" MODIFIED_BY="[Empty name]">
<P>Cinacalcet 30 to 180 mg/d</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2014-06-07 21:44:52 +1000" MODIFIED_BY="[Empty name]">
<P>Ca x P; mean iPTH</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2014-12-08 16:03:53 +1100" MODIFIED_BY="Narelle Willis">
<P>Abstract only; states combined data of 3 studies - unable to determine which 3 studies</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2014-06-10 17:23:51 +1000" MODIFIED_BY="Narelle Willis" STUDY_ID="STD-UPen-2004a">
<CHAR_METHODS MODIFIED="2013-06-02 13:37:58 +1000" MODIFIED_BY="Suetonia Palmer">
<P>Randomised double-blinded placebo controlled study</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-06-02 13:38:21 +1000" MODIFIED_BY="Suetonia Palmer">
<P>Participants with CKD and elevated serum parathyroid hormone levels</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2014-06-10 17:23:51 +1000" MODIFIED_BY="Narelle Willis">
<P>AMG-073</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-06-02 13:38:31 +1000" MODIFIED_BY="Suetonia Palmer">
<P>Unclear</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-06-02 17:38:16 +1000" MODIFIED_BY="Suetonia Palmer">
<P>Reported as published by the University of Pennsylvania at http://renal2.med.upenn.edu/ but URL link broken and unable to obtain information about study to ascertain details and eligibility for this review</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<FOOTNOTES>
<P>Ca x P - calcium phosphorous product; CKD - chronic kidney diease; iPTH - intact parathyroid hormone; RCT - randomised controlled trial</P>
</FOOTNOTES>
</CHARACTERISTICS_OF_AWAITING_STUDIES>
<CHARACTERISTICS_OF_ONGOING_STUDIES MODIFIED="2014-06-07 20:45:38 +1000" MODIFIED_BY="[Empty name]" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_ONGOING_STUDIES>
</CHARACTERISTICS_OF_STUDIES>
<QUALITY_ITEMS MODIFIED="2014-12-08 16:15:05 +1100" MODIFIED_BY="Narelle Willis">
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-01" LEVEL="STUDY" MODIFIED="2014-06-02 17:54:00 +1000" MODIFIED_BY="Narelle Willis" NO="1">
<NAME>Random sequence generation (selection bias)</NAME>
<DESCRIPTION>
<P>Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-06-02 17:26:34 +1000" MODIFIED_BY="Narelle Willis" RESULT="UNKNOWN" STUDY_ID="STD-ACHIEVE-Study-2008">
<DESCRIPTION>
<P>NS</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-06-02 17:53:36 +1000" MODIFIED_BY="Narelle Willis" RESULT="UNKNOWN" STUDY_ID="STD-ADVANCE-Study-2010">
<DESCRIPTION>
<P>NS</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-01-03 06:33:16 +1100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Akiba-2008">
<DESCRIPTION>
<P>Central computerised system </P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-06-02 17:53:38 +1000" MODIFIED_BY="Narelle Willis" RESULT="UNKNOWN" STUDY_ID="STD-Block-2004a">
<DESCRIPTION>
<P>NS</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-06-02 17:53:41 +1000" MODIFIED_BY="Narelle Willis" RESULT="UNKNOWN" STUDY_ID="STD-Charytan-2005">
<DESCRIPTION>
<P>NS</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-06-02 17:53:42 +1000" MODIFIED_BY="Narelle Willis" RESULT="UNKNOWN" STUDY_ID="STD-Chonchol-2009">
<DESCRIPTION>
<P>NS</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-02-03 17:33:55 +1100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-EVOLVE-study-2007">
<DESCRIPTION>
<P>Generated by Amgen</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-06-02 17:53:43 +1000" MODIFIED_BY="Narelle Willis" RESULT="UNKNOWN" STUDY_ID="STD-El-Shafey-2011">
<DESCRIPTION>
<P>NS</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-02-03 17:32:17 +1100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Fukagawa-2008">
<DESCRIPTION>
<P>Centralised computer system</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-06-02 17:53:47 +1000" MODIFIED_BY="Narelle Willis" RESULT="UNKNOWN" STUDY_ID="STD-Goodman-2000">
<DESCRIPTION>
<P>NS</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-06-02 17:53:49 +1000" MODIFIED_BY="Narelle Willis" RESULT="UNKNOWN" STUDY_ID="STD-Goodman-2002">
<DESCRIPTION>
<P>NS</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-06-02 17:53:51 +1000" MODIFIED_BY="Narelle Willis" RESULT="UNKNOWN" STUDY_ID="STD-Harris-2004">
<DESCRIPTION>
<P>NS</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-02-03 17:25:49 +1100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-IMPACT-SHPT-Study-2012">
<DESCRIPTION>
<P>Generated by Clinical Statistics department of Abbott</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-06-02 17:53:54 +1000" MODIFIED_BY="Narelle Willis" RESULT="UNKNOWN" STUDY_ID="STD-Lindberg-2003">
<DESCRIPTION>
<P>NS</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-02-03 16:56:21 +1100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Lindberg-2005">
<DESCRIPTION>
<P>Programmatic algorithm</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-02-03 16:55:02 +1100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Malluche-2008">
<DESCRIPTION>
<P>Computer generated</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-06-02 17:53:57 +1000" MODIFIED_BY="Narelle Willis" RESULT="UNKNOWN" STUDY_ID="STD-OPTIMA-Study-2008">
<DESCRIPTION>
<P>NS</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-06-02 17:54:00 +1000" MODIFIED_BY="Narelle Willis" RESULT="UNKNOWN" STUDY_ID="STD-Quarles-2003a">
<DESCRIPTION>
<P>NS</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-02" LEVEL="STUDY" MODIFIED="2014-06-02 18:48:16 +1000" MODIFIED_BY="Narelle Willis" NO="2">
<NAME>Allocation concealment (selection bias)</NAME>
<DESCRIPTION>
<P>Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-06-02 17:26:39 +1000" MODIFIED_BY="Narelle Willis" RESULT="UNKNOWN" STUDY_ID="STD-ACHIEVE-Study-2008">
<DESCRIPTION>
<P>NS</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-06-02 17:53:36 +1000" MODIFIED_BY="Narelle Willis" RESULT="UNKNOWN" STUDY_ID="STD-ADVANCE-Study-2010">
<DESCRIPTION>
<P>NS</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-06-02 17:53:38 +1000" MODIFIED_BY="Narelle Willis" RESULT="UNKNOWN" STUDY_ID="STD-Akiba-2008">
<DESCRIPTION>
<P>NS</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-06-02 17:53:39 +1000" MODIFIED_BY="Narelle Willis" RESULT="UNKNOWN" STUDY_ID="STD-Block-2004a">
<DESCRIPTION>
<P>NS</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-06-02 18:48:16 +1000" MODIFIED_BY="Narelle Willis" RESULT="YES" STUDY_ID="STD-Charytan-2005">
<DESCRIPTION>
<P>Centralised interactive voice-response system</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-02-03 17:37:30 +1100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Chonchol-2009">
<DESCRIPTION>
<P>Interactive voice-response system</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-02-03 17:34:03 +1100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-EVOLVE-study-2007">
<DESCRIPTION>
<P>Interactive voice-response system</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-06-02 17:53:44 +1000" MODIFIED_BY="Narelle Willis" RESULT="UNKNOWN" STUDY_ID="STD-El-Shafey-2011">
<DESCRIPTION>
<P>NS</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-06-02 17:53:45 +1000" MODIFIED_BY="Narelle Willis" RESULT="UNKNOWN" STUDY_ID="STD-Fukagawa-2008">
<DESCRIPTION>
<P>NS</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-06-02 17:53:47 +1000" MODIFIED_BY="Narelle Willis" RESULT="UNKNOWN" STUDY_ID="STD-Goodman-2000">
<DESCRIPTION>
<P>NS</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-06-02 17:53:49 +1000" MODIFIED_BY="Narelle Willis" RESULT="UNKNOWN" STUDY_ID="STD-Goodman-2002">
<DESCRIPTION>
<P>NS</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-06-02 17:53:52 +1000" MODIFIED_BY="Narelle Willis" RESULT="UNKNOWN" STUDY_ID="STD-Harris-2004">
<DESCRIPTION>
<P>NS</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-02-03 17:26:04 +1100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-IMPACT-SHPT-Study-2012">
<DESCRIPTION>
<P>Interactive voice-response system</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-06-02 17:53:54 +1000" MODIFIED_BY="Narelle Willis" RESULT="UNKNOWN" STUDY_ID="STD-Lindberg-2003">
<DESCRIPTION>
<P>NS</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-02-03 16:56:31 +1100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Lindberg-2005">
<DESCRIPTION>
<P>Interactive voice-response system</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-02-03 16:54:53 +1100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Malluche-2008">
<DESCRIPTION>
<P>Interactive voice-response system</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-06-02 17:53:58 +1000" MODIFIED_BY="Narelle Willis" RESULT="UNKNOWN" STUDY_ID="STD-OPTIMA-Study-2008">
<DESCRIPTION>
<P>NS</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-02-03 16:51:24 +1100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Quarles-2003a">
<DESCRIPTION>
<P>Interactive voice-response system</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-03" LEVEL="GROUP" MODIFIED="2012-11-06 08:58:36 +1100" MODIFIED_BY="[Empty name]" NO="3">
<NAME>Blinding (performance bias and detection bias)</NAME>
<DESCRIPTION>
<P>Performance bias or detection bias due to knowledge of the allocated interventions after assignment</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-03.01" NO="1">
<NAME>All outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-07" LEVEL="GROUP" MODIFIED="2014-06-04 16:32:02 +1000" MODIFIED_BY="Narelle Willis" NO="7">
<NAME>Blinding of participants and personnel (performance bias)</NAME>
<DESCRIPTION>
<P>Performance bias due to knowledge of the allocated interventions by participants and personnel during the study</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-07.01" NO="1">
<NAME>All outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2012-11-06 09:37:35 +1100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-ACHIEVE-Study-2008">
<DESCRIPTION>
<P>Not used</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2014-06-02 17:55:14 +1000" MODIFIED_BY="Narelle Willis" RESULT="NO" STUDY_ID="STD-ADVANCE-Study-2010">
<DESCRIPTION>
<P>Open-label (http://clinicaltrials.gov/show/NCT00379899)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2013-01-03 06:37:18 +1100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Akiba-2008">
<DESCRIPTION>
<P>"Cinacalcet and placebo tablets were identical in appearance in order to maintain the double-blind status of the study."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2013-06-02 17:24:32 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Block-2004a">
<DESCRIPTION>
<P>Blinded study</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2013-06-02 17:24:40 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Charytan-2005">
<DESCRIPTION>
<P>Blinded study</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2013-06-02 17:24:46 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Chonchol-2009">
<DESCRIPTION>
<P>Blinded study</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2013-06-02 17:26:09 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-EVOLVE-study-2007">
<DESCRIPTION>
<P>Double-blinded</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2013-06-02 17:24:57 +1000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-El-Shafey-2011">
<DESCRIPTION>
<P>Not blinded</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2013-06-02 17:26:38 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Fukagawa-2008">
<DESCRIPTION>
<P>Double-blinded</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2013-06-02 17:26:54 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Goodman-2000">
<DESCRIPTION>
<P>Double-blinded</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2013-06-02 17:27:20 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Goodman-2002">
<DESCRIPTION>
<P>Double blinded</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2013-06-02 17:27:38 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Harris-2004">
<DESCRIPTION>
<P>Double-blinded</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2013-06-02 17:28:12 +1000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-IMPACT-SHPT-Study-2012">
<DESCRIPTION>
<P>Not blinded</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2013-06-02 17:28:33 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Lindberg-2003">
<DESCRIPTION>
<P>Double-blinded</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2014-06-04 16:32:02 +1000" MODIFIED_BY="Narelle Willis" RESULT="YES" STUDY_ID="STD-Lindberg-2005">
<DESCRIPTION>
<P>Double-blinded</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2013-06-02 17:29:27 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Malluche-2008">
<DESCRIPTION>
<P>Double-blinded</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2013-06-02 17:29:39 +1000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-OPTIMA-Study-2008">
<DESCRIPTION>
<P>Not blinded</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2013-06-02 17:30:00 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Quarles-2003a">
<DESCRIPTION>
<P>Double blinded</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-08" LEVEL="GROUP" MODIFIED="2014-06-02 17:54:00 +1000" MODIFIED_BY="Narelle Willis" NO="8">
<NAME>Blinding of outcome assessment (detection bias)</NAME>
<DESCRIPTION>
<P>Detection bias due to knowledge of the allocated interventions by outcome assessors</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-08.01" NO="1">
<NAME>All outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2012-11-06 09:37:41 +1100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-ACHIEVE-Study-2008">
<DESCRIPTION>
<P>Not used</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2014-06-02 17:53:37 +1000" MODIFIED_BY="Narelle Willis" RESULT="UNKNOWN" STUDY_ID="STD-ADVANCE-Study-2010">
<DESCRIPTION>
<P>NS</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2013-01-03 06:39:01 +1100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Akiba-2008">
<DESCRIPTION>
<P>"All laboratory determinations, except for hematological assessments, were performed at a central laboratory"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2014-06-02 17:53:40 +1000" MODIFIED_BY="Narelle Willis" RESULT="UNKNOWN" STUDY_ID="STD-Block-2004a">
<DESCRIPTION>
<P>NS</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2014-06-02 17:53:41 +1000" MODIFIED_BY="Narelle Willis" RESULT="UNKNOWN" STUDY_ID="STD-Charytan-2005">
<DESCRIPTION>
<P>NS</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2014-06-02 17:53:43 +1000" MODIFIED_BY="Narelle Willis" RESULT="UNKNOWN" STUDY_ID="STD-Chonchol-2009">
<DESCRIPTION>
<P>NS</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2013-06-02 17:26:11 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-EVOLVE-study-2007">
<DESCRIPTION>
<P>Blinded</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2014-06-02 17:53:45 +1000" MODIFIED_BY="Narelle Willis" RESULT="UNKNOWN" STUDY_ID="STD-El-Shafey-2011">
<DESCRIPTION>
<P>NS</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2014-06-02 17:53:46 +1000" MODIFIED_BY="Narelle Willis" RESULT="UNKNOWN" STUDY_ID="STD-Fukagawa-2008">
<DESCRIPTION>
<P>NS</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2014-06-02 17:53:48 +1000" MODIFIED_BY="Narelle Willis" RESULT="UNKNOWN" STUDY_ID="STD-Goodman-2000">
<DESCRIPTION>
<P>NS</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2014-06-02 17:53:50 +1000" MODIFIED_BY="Narelle Willis" RESULT="UNKNOWN" STUDY_ID="STD-Goodman-2002">
<DESCRIPTION>
<P>NS</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2014-06-02 17:53:52 +1000" MODIFIED_BY="Narelle Willis" RESULT="UNKNOWN" STUDY_ID="STD-Harris-2004">
<DESCRIPTION>
<P>NS</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2014-06-02 17:53:53 +1000" MODIFIED_BY="Narelle Willis" RESULT="UNKNOWN" STUDY_ID="STD-IMPACT-SHPT-Study-2012">
<DESCRIPTION>
<P>NS</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2014-06-02 17:53:55 +1000" MODIFIED_BY="Narelle Willis" RESULT="UNKNOWN" STUDY_ID="STD-Lindberg-2003">
<DESCRIPTION>
<P>NS</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2014-06-02 17:53:56 +1000" MODIFIED_BY="Narelle Willis" RESULT="UNKNOWN" STUDY_ID="STD-Lindberg-2005">
<DESCRIPTION>
<P>NS</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2014-06-02 17:53:57 +1000" MODIFIED_BY="Narelle Willis" RESULT="UNKNOWN" STUDY_ID="STD-Malluche-2008">
<DESCRIPTION>
<P>NS</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2014-06-02 17:53:59 +1000" MODIFIED_BY="Narelle Willis" RESULT="UNKNOWN" STUDY_ID="STD-OPTIMA-Study-2008">
<DESCRIPTION>
<P>NS</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2014-06-02 17:54:00 +1000" MODIFIED_BY="Narelle Willis" RESULT="UNKNOWN" STUDY_ID="STD-Quarles-2003a">
<DESCRIPTION>
<P>NS</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-04" LEVEL="GROUP" MODIFIED="2014-06-02 18:36:07 +1000" MODIFIED_BY="Narelle Willis" NO="4">
<NAME>Incomplete outcome data (attrition bias)</NAME>
<DESCRIPTION>
<P>Attrition bias due to amount, nature or handling of incomplete outcome data</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-04.01" NO="1">
<NAME>All outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2014-06-02 17:26:57 +1000" MODIFIED_BY="Narelle Willis" RESULT="NO" STUDY_ID="STD-ACHIEVE-Study-2008">
<DESCRIPTION>
<P>Lost to follow-up 24% of the patients</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2014-06-02 17:26:57 +1000" MODIFIED_BY="Narelle Willis" RESULT="NO" STUDY_ID="STD-ADVANCE-Study-2010">
<DESCRIPTION>
<P>Loss to follow-up 22.2 % patients</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2014-06-02 18:36:07 +1000" MODIFIED_BY="Narelle Willis" RESULT="NO" STUDY_ID="STD-Akiba-2008">
<DESCRIPTION>
<P>Per-protocol analysis was used to analyse efficacy endpoints. 14.2% lost to follow-up in the active arm. 10.7% lost to follow-up in total</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2014-06-02 17:26:57 +1000" MODIFIED_BY="Narelle Willis" RESULT="NO" STUDY_ID="STD-Block-2004a">
<DESCRIPTION>
<P>Loss to follow-up 22%</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-02-03 17:39:54 +1100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Charytan-2005">
<DESCRIPTION>
<P>Loss to follow-up 30% of patients</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-02-03 17:38:01 +1100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Chonchol-2009">
<DESCRIPTION>
<P>Loss to follow-up 3% of patients</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-02-03 17:34:41 +1100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-EVOLVE-study-2007">
<DESCRIPTION>
<P>Loss to follow-up 7.9% of patients</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-02-03 17:36:14 +1100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-El-Shafey-2011">
<DESCRIPTION>
<P>Loss to follow-up 5% of patients</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-02-03 17:32:48 +1100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Fukagawa-2008">
<DESCRIPTION>
<P>Loss to follow-up 2.8% of patients</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-02-03 17:30:49 +1100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Goodman-2000">
<DESCRIPTION>
<P>Loss to follow-up 38% of patients</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-02-03 17:30:06 +1100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Goodman-2002">
<DESCRIPTION>
<P>No patients lost to follow-up</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-02-03 17:28:29 +1100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Harris-2004">
<DESCRIPTION>
<P>Loss to follow-up 59.1% of patients</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-02-03 17:26:34 +1100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-IMPACT-SHPT-Study-2012">
<DESCRIPTION>
<P>Loss to follow-up 24.3% of patients</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-02-03 17:24:28 +1100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Lindberg-2003">
<DESCRIPTION>
<P>Loss to follow-up 14.1% of patients</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-02-03 16:57:01 +1100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Lindberg-2005">
<DESCRIPTION>
<P>Loss to follow-up 25.3% of patients</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-02-03 16:55:25 +1100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Malluche-2008">
<DESCRIPTION>
<P>Loss to follow-up 31.3% of patients</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-02-03 16:53:47 +1100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-OPTIMA-Study-2008">
<DESCRIPTION>
<P>Loss to follow-up 21.9% of patients</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-02-03 16:52:12 +1100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Quarles-2003a">
<DESCRIPTION>
<P>Loss to follow-up 8.5% of patients</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-05" LEVEL="STUDY" MODIFIED="2014-06-11 16:19:48 +1000" MODIFIED_BY="Narelle Willis" NO="5">
<NAME>Selective reporting (reporting bias)</NAME>
<DESCRIPTION>
<P>Reporting bias due to selective outcome reporting</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-11-06 09:41:35 +1100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-ACHIEVE-Study-2008">
<DESCRIPTION>
<P>Data available for all included outcomes</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-06-11 16:11:26 +1000" MODIFIED_BY="Narelle Willis" RESULT="NO" STUDY_ID="STD-ADVANCE-Study-2010">
<DESCRIPTION>
<P>Not reported systematically (end of treatment calcium, phoshorous, PTH and adverse events)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-01-03 06:42:17 +1100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Akiba-2008">
<DESCRIPTION>
<P>All the prespecified outcomes were reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-01-17 11:27:38 +1100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Block-2004a">
<DESCRIPTION>
<P>All the prespecified outcomes were reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-02-03 17:40:11 +1100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Charytan-2005">
<DESCRIPTION>
<P>All the prespecified outcomes were reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-02-03 17:38:18 +1100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Chonchol-2009">
<DESCRIPTION>
<P>All the prespecified outcomes were reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-02-03 17:35:01 +1100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-EVOLVE-study-2007">
<DESCRIPTION>
<P>All the prespecified outcomes were reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-02-03 17:36:32 +1100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-El-Shafey-2011">
<DESCRIPTION>
<P>All the prespecified outcomes were reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-02-03 17:33:09 +1100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Fukagawa-2008">
<DESCRIPTION>
<P>All the prespecified outcomes were reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-06-11 16:15:25 +1000" MODIFIED_BY="Narelle Willis" RESULT="NO" STUDY_ID="STD-Goodman-2000">
<DESCRIPTION>
<P>Not reported systematically (end of treatment calcium, phoshorous, PTH and adverse events)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-02-03 17:30:09 +1100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Goodman-2002">
<DESCRIPTION>
<P>All the prespecified outcomes were reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-06-11 16:16:40 +1000" MODIFIED_BY="Narelle Willis" RESULT="NO" STUDY_ID="STD-Harris-2004">
<DESCRIPTION>
<P>Not reported systematically (end of treatment calcium, phosphorous, PTH and adverse events)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-02-03 17:27:25 +1100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-IMPACT-SHPT-Study-2012">
<DESCRIPTION>
<P>All the prespecified outcomes were reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-06-11 16:18:43 +1000" MODIFIED_BY="Narelle Willis" RESULT="NO" STUDY_ID="STD-Lindberg-2003">
<DESCRIPTION>
<P>Not reported systematically (end of treatment calcium, phosphorous, PTH and adverse events)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-06-11 16:19:48 +1000" MODIFIED_BY="Narelle Willis" RESULT="NO" STUDY_ID="STD-Lindberg-2005">
<DESCRIPTION>
<P>Not reported systematically (end of treatment calcium, phosphorous, PTH and adverse events)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-06-11 16:19:23 +1000" MODIFIED_BY="Narelle Willis" RESULT="NO" STUDY_ID="STD-Malluche-2008">
<DESCRIPTION>
<P>Not reported systematically (end of treatment calcium, posphorous, PTH and adverse events)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-02-03 16:54:06 +1100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-OPTIMA-Study-2008">
<DESCRIPTION>
<P>All the prespecified outcomes were reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-06-11 16:19:37 +1000" MODIFIED_BY="Narelle Willis" RESULT="NO" STUDY_ID="STD-Quarles-2003a">
<DESCRIPTION>
<P>Not reported systematically (end of treatment calcium, phosphorous, PTH and adverse events)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-06" LEVEL="STUDY" MODIFIED="2014-12-08 16:15:05 +1100" MODIFIED_BY="Narelle Willis" NO="6">
<NAME>Other bias</NAME>
<DESCRIPTION>
<P>Bias due to problems not covered elsewhere in the table</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-11-06 09:40:07 +1100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-ACHIEVE-Study-2008">
<DESCRIPTION>
<P>Sponsor on authorship</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-01-03 06:08:33 +1100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-ADVANCE-Study-2010">
<DESCRIPTION>
<P>Sponsor on authorship</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-01-03 06:42:23 +1100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Akiba-2008">
<DESCRIPTION>
<P>Authors are scientific advisors for sponsor</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-06-02 18:35:57 +1000" MODIFIED_BY="Narelle Willis" RESULT="NO" STUDY_ID="STD-Block-2004a">
<DESCRIPTION>
<P>Pooled data from 2 studies; statistical analyses and data interpretation by sponsor; data held by sponsor; editorial assistance from sponsor</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-02-03 17:40:23 +1100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Charytan-2005">
<DESCRIPTION>
<P>Sponsor on authorship</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-02-03 17:38:34 +1100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Chonchol-2009">
<DESCRIPTION>
<P>Sponsor on authorship; sponsor involved in writing manuscript</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-06-11 16:14:30 +1000" MODIFIED_BY="Narelle Willis" RESULT="NO" STUDY_ID="STD-EVOLVE-study-2007">
<DESCRIPTION>
<P>Sponsor on authorship; sponsor involved in writing manuscript; sponsor held data and analysed data</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-02-03 17:36:44 +1100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-El-Shafey-2011">
<DESCRIPTION>
<P>Uneven comparisons</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-12-08 16:15:05 +1100" MODIFIED_BY="Narelle Willis" RESULT="NO" STUDY_ID="STD-Fukagawa-2008">
<DESCRIPTION>
<P>Study sponsored by Kirin Parma Co. LTD</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-02-03 17:31:35 +1100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Goodman-2000">
<DESCRIPTION>
<P>Sponsor on authorship</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-02-03 17:30:24 +1100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Goodman-2002">
<DESCRIPTION>
<P>Sponsor on authorship</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-06-04 15:53:48 +1000" MODIFIED_BY="Narelle Willis" RESULT="NO" STUDY_ID="STD-Harris-2004">
<DESCRIPTION>
<P>Sponsor on authorship</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-06-02 17:28:22 +1000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-IMPACT-SHPT-Study-2012">
<DESCRIPTION>
<P>Sponsor on authorship; sponsor involved in writing manuscript; sponsor held data and analysed data</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-02-03 17:25:08 +1100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Lindberg-2003">
<DESCRIPTION>
<P>Sponsor on authorship</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-02-03 16:57:09 +1100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Lindberg-2005">
<DESCRIPTION>
<P>Sponsor on authorship</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-02-03 16:55:43 +1100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Malluche-2008">
<DESCRIPTION>
<P>Sponsor authorship</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-02-03 16:54:13 +1100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-OPTIMA-Study-2008">
<DESCRIPTION>
<P>Sponsor on authorship</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-02-03 16:51:55 +1100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Quarles-2003a">
<DESCRIPTION>
<P>Sponsor on authorship</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
</QUALITY_ITEMS>
<SOF_TABLES MODIFIED="2014-12-08 16:10:47 +1100" MODIFIED_BY="Narelle Willis">
<SOF_TABLE ID="SOF-01" MODIFIED="2014-12-08 16:10:47 +1100" MODIFIED_BY="Narelle Willis" NO="1">
<TITLE MODIFIED="2013-06-02 17:49:30 +1000" MODIFIED_BY="Suetonia Palmer">Summary of findings for dialysis patients</TITLE>
<TABLE COLS="6" ROWS="15">
<TR>
<TD COLSPAN="6">
<P>
<B>Cinacalcet plus standard therapy versus placebo or standard therapy or both for patients with CKD and elevated PTH levels</B>
</P>
</TD>
</TR>
<TR>
<TD COLSPAN="6">
<P>
<B>Patient or population: adults with CKD</B>
</P>
</TD>
</TR>
<TR>
<TH VALIGN="BOTTOM">
<P>Outcomes</P>
<P>(median treatment duration)</P>
</TH>
<TH VALIGN="BOTTOM">
<P>*Best estimate of control group risk</P>
</TH>
<TH VALIGN="BOTTOM">
<P>Relative effect<BR/>(95% CI)</P>
</TH>
<TH VALIGN="BOTTOM">
<P>No of participants<BR/>(studies)</P>
</TH>
<TH VALIGN="BOTTOM">
<P>Absolute effect per one year of treatment for 1000 treated (95%CI)</P>
</TH>
<TH VALIGN="BOTTOM">
<P>Quality of the evidence<BR/>(GRADE)</P>
</TH>
</TR>
<TR>
<TD COLSPAN="6">
<P>
<B>GFR category G5 treated with dialysis</B>
</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>All-cause mortality</B>
</P>
<P>(8 months)</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>200 per 1000</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>RR 0.97 </B>(0.89 to 95)</P>
</TD>
<TD VALIGN="TOP">
<P>6893 (14)</P>
</TD>
<TD VALIGN="TOP">
<P>6 fewer (22 fewer to 10 more)</P>
</TD>
<TD VALIGN="TOP">
<P>&#8853;&#8853;&#8853;&#8853;<BR/>
<B>high</B>
</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>Parathyroidectomy</B>
</P>
<P>(9 months)</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>7 per 1000</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>RR 0.49 </B>(0.40 to 0.59)</P>
</TD>
<TD VALIGN="TOP">
<P>4893 (5)</P>
</TD>
<TD VALIGN="TOP">
<P>3 fewer (4 fewer to 3 fewer)</P>
</TD>
<TD VALIGN="TOP">
<P>&#8853;&#8853;&#8853;&#8853;<BR/>
<B>high</B>
</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>Hypocalcaemia</B>
</P>
<P>(7 months)</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>10 per 1000</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>RR 6.98 </B>(5.10 to 9.53)</P>
</TD>
<TD VALIGN="TOP">
<P>6415 (12)</P>
</TD>
<TD VALIGN="TOP">
<P>60 more (41 more to 85 more)</P>
</TD>
<TD VALIGN="TOP">
<P>&#8853;&#8853;&#8853;&#8853;<BR/>
<B>high</B>
</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>Nausea</B>
</P>
<P>(7 months)</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>150 per 1000</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>RR 2.02 </B>(1.45 to 2.81)</P>
</TD>
<TD VALIGN="TOP">
<P>6450 (12)</P>
</TD>
<TD VALIGN="TOP">
<P>153 more (68 more to 272 more)</P>
</TD>
<TD VALIGN="TOP">
<P>&#8853;&#8853;&#8853;<BR/>
<B>moderate</B>
</P>
</TD>
</TR>
<TR>
<TD COLSPAN="6">
<P>
<B>GFR category G3a-G4</B>
</P>
</TD>
</TR>
<TR>
<TD>
<P>
<B>All-cause mortality</B>
</P>
<P>(8 months)</P>
</TD>
<TD>
<P>
<B>25 per 1000</B>
</P>
</TD>
<TD>
<P>
<B>RR 0.29</B> (0.06 to 1.48)</P>
</TD>
<TD>
<P>458 (2)</P>
</TD>
<TD>
<P>18 fewer (23 fewer to 12 more)</P>
</TD>
<TD>
<P>&#8853;&#8853;<BR/>
<B>low</B>
</P>
</TD>
</TR>
<TR>
<TD>
<P>
<B>Parathyroidectomy</B>
</P>
<P>(9 months)</P>
</TD>
<TD>
<P>
<B>7 per 1000</B>
</P>
</TD>
<TD>
<P>
<B>RR not estimable</B>
</P>
</TD>
<TD>
<P>0 (0)</P>
</TD>
<TD>
<P>Not estimable</P>
</TD>
<TD>
<P>
<B>nil</B>
</P>
</TD>
</TR>
<TR>
<TD>
<P>
<B>Hypocalcaemia</B>
</P>
<P>(7 months)</P>
</TD>
<TD>
<P>
<B>10 per 1000</B>
</P>
</TD>
<TD>
<P>
<B>RR 31.9</B> (5.28 to 192.6)</P>
</TD>
<TD>
<P>449 (2)</P>
</TD>
<TD>
<P>310 more (43 more to 1910 more)</P>
</TD>
<TD>
<P>&#8853;<BR/>
<B>very low</B>
</P>
</TD>
</TR>
<TR>
<TD>
<P>
<B>Nausea</B>
</P>
<P>(7 months)</P>
</TD>
<TD>
<P>
<B>100 per 1000</B>
</P>
</TD>
<TD>
<P>
<B>RR 2.26</B> (1.29 to 3.95)</P>
</TD>
<TD>
<P>449 (2)</P>
</TD>
<TD>
<P>126 more (29 more to 295 more)</P>
</TD>
<TD>
<P>&#8853;&#8853;</P>
<P>
<B>low</B>
</P>
</TD>
</TR>
<TR>
<TD COLSPAN="6">
<P/>
<P>*The basis for the <B>assumed risk</B> (e.g. the median control group risk across studies) is provided in footnotes. The <B>corresponding risk</B> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <B>relative effect</B> of the intervention (and its 95% CI).<BR/>
<B>CI:</B> Confidence interval; <B>RR:</B> Risk Ratio;</P>
<P/>
<P>Approximate absolute event rates of outcomes per year are derived from previously published cohort studies and registry data for the outcomes of all-cause mortality (<LINK REF="REF-Weiner-2006" TYPE="REFERENCE">Weiner 2006</LINK>) and parathyroidectomy (<LINK REF="REF-Kestenbaum-2004" TYPE="REFERENCE">Kestenbaum 2004</LINK>) or event rates in the control arm of contributing studies for outcomes of hypocalcaemia and nausea. Absolute numbers of people who had chronic kidney disease with mortality or parathyroidectomy events avoided or nausea or hypocalcaemia events caused per 1000 treated were calculated from the risk estimate for the outcome (and associated 95% confidence interval) obtained from meta-analysis of placebo-controlled studies together with the absolute population risk estimates.</P>
</TD>
</TR>
<TR>
<TD COLSPAN="6">
<P>GRADE Working Group grades of evidence<BR/>
<B>High quality:</B> Further research is very unlikely to change our confidence in the estimate of effect.<BR/>
<B>Moderate quality:</B> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<BR/>
<B>Low quality:</B> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<BR/>
<B>Very low quality:</B> We are very uncertain about the estimate.</P>
<P/>
</TD>
</TR>
</TABLE>
<FOOTNOTES>
<P>CKD - chronic kidney disease; GFR - glomerular filtration rate; PTH- parathyroid hormone</P>
</FOOTNOTES>
</SOF_TABLE>
</SOF_TABLES>
<ADDITIONAL_TABLES MODIFIED="2014-12-08 16:15:06 +1100" MODIFIED_BY="Narelle Willis">
<ADDITIONAL_TABLE ID="TBL-01" MODIFIED="2014-12-08 16:09:24 +1100" MODIFIED_BY="Narelle Willis" NO="1">
<TITLE MODIFIED="2014-12-08 16:09:01 +1100" MODIFIED_BY="Narelle Willis">Current chronic kidney disease nomenclature used by KDIGO nomenclature</TITLE>
<TABLE COLS="7" ROWS="8">
<TR>
<TH ALIGN="CENTER" COLSPAN="4" ROWSPAN="3">
<P>
<B>Prognosis of CKD by GFR and albuminuria categories: KDIGO 2012</B>
</P>
</TH>
<TH ALIGN="CENTER" COLSPAN="3">
<P>
<B>Persistent albuminuria categories</B>
</P>
<P>
<B>Description and range</B>
</P>
</TH>
</TR>
<TR>
<TH ALIGN="CENTER" VALIGN="BOTTOM">
<P>
<B>A1</B>
</P>
<P>Normal to</P>
<P>mildly</P>
<P>increased</P>
</TH>
<TH ALIGN="CENTER" VALIGN="BOTTOM">
<P>
<B>A2</B>
</P>
<P/>
<P>Moderately</P>
<P>increased</P>
</TH>
<TH ALIGN="CENTER" VALIGN="BOTTOM">
<P>
<B>A3</B>
</P>
<P/>
<P>Severely</P>
<P>increased</P>
</TH>
</TR>
<TR>
<TH>
<P>&lt; 30 mg/g</P>
<P>&lt; 3 mg/mmol</P>
</TH>
<TH>
<P>30 to 300 mg/g</P>
<P>3 to 30 mg/mmol</P>
</TH>
<TH>
<P>&gt; 300 mg/g</P>
<P>&gt; 30 mg/mmol</P>
</TH>
</TR>
<TR>
<TD ROWSPAN="5">
<P>
<B>GFR categories</B>
</P>
<P>
<B>(mL/min per 1.73 m²)</B>
</P>
<P>
<B>Description and range</B>
</P>
</TD>
<TD>
<P>
<B>G1</B>
</P>
<P>
<B>G2</B>
</P>
</TD>
<TD>
<P>Normal or high</P>
<P>Mildly decreased</P>
</TD>
<TD>
<P>&gt; 90</P>
<P>60 to 89</P>
</TD>
<TD>
<P>Low</P>
</TD>
<TD>
<P>Moderate</P>
</TD>
<TD>
<P>High</P>
</TD>
</TR>
<TR>
<TD>
<P>
<B>G3a</B>
</P>
</TD>
<TD>
<P>Mild to moderately decreased</P>
</TD>
<TD>
<P>45 to 59</P>
</TD>
<TD>
<P>Moderate</P>
</TD>
<TD>
<P>High</P>
</TD>
<TD ROWSPAN="4">
<P>Very high</P>
</TD>
</TR>
<TR>
<TD>
<P>
<B>G3b</B>
</P>
</TD>
<TD>
<P>Moderate to severely decreased</P>
</TD>
<TD>
<P>30 to 44</P>
</TD>
<TD>
<P>High</P>
</TD>
<TD ROWSPAN="3">
<P>Very high</P>
</TD>
</TR>
<TR>
<TD>
<P>
<B>G4</B>
</P>
</TD>
<TD>
<P>Severely decreased</P>
</TD>
<TD>
<P>15 to 29</P>
</TD>
<TD ROWSPAN="2">
<P>Very high</P>
</TD>
</TR>
<TR>
<TD>
<P>
<B>G5</B>
</P>
</TD>
<TD>
<P>Kidney failure</P>
</TD>
<TD>
<P>&lt; 15</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES>
<P>Description of the Kidney Disease: Improving Global Outcomes (KDIGO) nomenclature for chronic kidney disease used in this review (see the full <LINK REF="REF-KDIGO-CKD-2013" TYPE="REFERENCE">KDIGO CKD 2013</LINK> for additional information).</P>
<P>GFR - glomerular filtration rate</P>
</FOOTNOTES>
</ADDITIONAL_TABLE>
<ADDITIONAL_TABLE ID="TBL-02" MODIFIED="2014-12-08 16:15:06 +1100" MODIFIED_BY="Narelle Willis" NO="2">
<TITLE MODIFIED="2014-12-08 16:08:06 +1100" MODIFIED_BY="Narelle Willis">Definitions of parathyroid hormone target, and hypercalcaemia and hypocalcaemia endpoints</TITLE>
<TABLE COLS="6" ROWS="19">
<TR>
<TH ALIGN="CENTER" VALIGN="MIDDLE">
<P>
<B>Study</B>
</P>
</TH>
<TH ALIGN="CENTER" VALIGN="MIDDLE">
<P>
<B>Participants (treatment/control)</B>
</P>
</TH>
<TH ALIGN="CENTER" VALIGN="MIDDLE">
<P>
<B>PTH level triggering reduction in cinacalcet dose</B>
</P>
</TH>
<TH ALIGN="CENTER" VALIGN="MIDDLE">
<P>
<B>Calcium level triggering reduction in cinacalcet dose</B>
</P>
</TH>
<TH ALIGN="CENTER" VALIGN="MIDDLE">
<P>
<B>Hypocalcaemia (study endpoint)</B>
</P>
</TH>
<TH ALIGN="CENTER" VALIGN="MIDDLE">
<P>
<B>Hypercalcaemia (study endpoint)</B>
</P>
</TH>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-ACHIEVE-Study-2008" TYPE="STUDY">ACHIEVE Study 2008</LINK>
</P>
</TD>
<TD>
<P>173 (87/86)</P>
</TD>
<TD>
<P>&lt; 150 pg/mL</P>
</TD>
<TD>
<P>Symptoms of hypocalcaemia or &lt; 7.5 mg/dL</P>
</TD>
<TD>
<P>&lt; 8.4 mg/dL</P>
</TD>
<TD>
<P>&gt; 10.2 mg/dL</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-ADVANCE-Study-2010" TYPE="STUDY">ADVANCE Study 2010</LINK>
</P>
</TD>
<TD>
<P>360 (180/180)</P>
</TD>
<TD>
<P>--</P>
</TD>
<TD>
<P>--</P>
</TD>
<TD>
<P>Hypocalcaemia</P>
</TD>
<TD>
<P>Hypercalcaemia</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Akiba-2008" TYPE="STUDY">Akiba 2008</LINK>
</P>
</TD>
<TD>
<P>121 (91/30)</P>
</TD>
<TD>
<P>--</P>
</TD>
<TD>
<P>--</P>
</TD>
<TD>
<P>Hypocalcaemia</P>
</TD>
<TD>
<P>--</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Block-2004a" TYPE="STUDY">Block 2004a</LINK>
</P>
</TD>
<TD>
<P>741 (371/370)</P>
</TD>
<TD>
<P>&lt; 100 pg/mL</P>
</TD>
<TD>
<P>Symptoms of hypocalcaemia or &lt; 7.8 mg/dL</P>
</TD>
<TD>
<P>Withdrawal due to hypocalcaemia</P>
</TD>
<TD>
<P>--</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Charytan-2005" TYPE="STUDY">Charytan 2005</LINK>
</P>
</TD>
<TD>
<P>54 (27/27)</P>
</TD>
<TD>
<P>--</P>
</TD>
<TD>
<P>Dose-related adverse event or &lt; 7.8 mg/dL</P>
</TD>
<TD>
<P>&lt; 8.4 mg/dL</P>
</TD>
<TD>
<P>--</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Chonchol-2009" TYPE="STUDY">Chonchol 2009</LINK>
</P>
</TD>
<TD>
<P>404 (302/102)</P>
</TD>
<TD>
<P>PTH &lt; 35 pg/mL for stage 3 and &lt; 70 pg/mL for stage 4</P>
</TD>
<TD>
<P>Symptoms of hypocalcaemia or &lt; 7.5 mg/dL</P>
</TD>
<TD>
<P>&lt; 7.5 mg/dL</P>
</TD>
<TD>
<P>--</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-El-Shafey-2011" TYPE="STUDY">El Shafey 2011</LINK>
</P>
</TD>
<TD>
<P>82 (55/27)</P>
</TD>
<TD>
<P>&lt; 92 pg/mL</P>
</TD>
<TD>
<P>Dose-related adverse event or &lt; 7.5 mg/dL</P>
</TD>
<TD>
<P>Hypocalcaemia</P>
</TD>
<TD>
<P>--</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-EVOLVE-study-2007" TYPE="STUDY">EVOLVE study 2007</LINK>
</P>
</TD>
<TD>
<P>3883 (1948/1935)</P>
</TD>
<TD>
<P>&lt; 150 pg/mL</P>
</TD>
<TD>
<P>&lt; 7.5 mg/dL and/or symptoms of hypocalcaemia</P>
</TD>
<TD>
<P>&lt; 8.0 mg/dL or &lt; 7.5 mg/dL (unclear which threshold reported in study)</P>
</TD>
<TD>
<P>&gt; 10.5 mg/dL</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Fukagawa-2008" TYPE="STUDY">Fukagawa 2008</LINK>
</P>
</TD>
<TD>
<P>145 (72/73)</P>
</TD>
<TD>
<P>Investigators&#8217; discretion or excessive decrease in PTH level</P>
</TD>
<TD>
<P>Investigators&#8217; discretion or &lt; 7.5 mg/dL</P>
</TD>
<TD>
<P>Hypocalcaemia</P>
</TD>
<TD>
<P>--</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Goodman-2000" TYPE="STUDY">Goodman 2000</LINK>
</P>
</TD>
<TD>
<P>21 (16/5)</P>
</TD>
<TD>
<P>--</P>
</TD>
<TD>
<P>Symptoms of hypocalcaemia or ionised calcium &lt; 4 mg/dL</P>
</TD>
<TD>
<P>Ionized calcium &lt; 4 mg/dL</P>
</TD>
<TD>
<P>--</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Goodman-2002" TYPE="STUDY">Goodman 2002</LINK>
</P>
</TD>
<TD>
<P>30 (23/7)</P>
</TD>
<TD>
<P>--</P>
</TD>
<TD>
<P>8.0 mg/dL</P>
</TD>
<TD>
<P>&lt; 8.0 mg/dL</P>
</TD>
<TD>
<P>--</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Harris-2004" TYPE="STUDY">Harris 2004</LINK>
</P>
</TD>
<TD>
<P>23 (17/6)</P>
</TD>
<TD>
<P>--</P>
</TD>
<TD>
<P>--</P>
</TD>
<TD>
<P>--</P>
</TD>
<TD>
<P>--</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-IMPACT-SHPT-Study-2012" TYPE="STUDY">IMPACT SHPT Study 2012</LINK>
</P>
</TD>
<TD>
<P>264 (134/134)</P>
</TD>
<TD>
<P>&lt; 150 pg/mL</P>
</TD>
<TD>
<P>&lt; 7.5 mg/dL</P>
</TD>
<TD>
<P>&lt;8,.4 mg/dL</P>
</TD>
<TD>
<P>&gt; 10.5 mg/dL</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Lindberg-2003" TYPE="STUDY">Lindberg 2003</LINK>
</P>
</TD>
<TD>
<P>78 (39/39)</P>
</TD>
<TD>
<P>&lt; 100 pg/mL</P>
</TD>
<TD>
<P>Symptoms of hypocalcaemia or &lt; 7.8 mg/dL</P>
</TD>
<TD>
<P>&lt; 7.5 mg/dL</P>
</TD>
<TD>
<P>--</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Lindberg-2005" TYPE="STUDY">Lindberg 2005</LINK>
</P>
</TD>
<TD>
<P>395 (294/101)</P>
</TD>
<TD>
<P>--</P>
</TD>
<TD>
<P>Symptoms of hypocalcaemia or &lt; 7.8 mg/dL</P>
</TD>
<TD>
<P>--</P>
</TD>
<TD>
<P>--</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Malluche-2008" TYPE="STUDY">Malluche 2008</LINK>
</P>
</TD>
<TD>
<P>32 (19/13)</P>
</TD>
<TD>
<P>&lt; 100 pg/mL</P>
</TD>
<TD>
<P>Symptoms of hypocalcaemia or &lt; 7.8 mg/dL</P>
</TD>
<TD>
<P>--</P>
</TD>
<TD>
<P>--</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-OPTIMA-Study-2008" TYPE="STUDY">OPTIMA Study 2008</LINK>
</P>
</TD>
<TD>
<P>552 (368/184)</P>
</TD>
<TD>
<P>&lt; 150 pg/mL</P>
</TD>
<TD>
<P>&lt; 8.0 mg/dL</P>
</TD>
<TD>
<P>&lt; 7.5 mg/dL</P>
</TD>
<TD>
<P>--</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Quarles-2003a" TYPE="STUDY">Quarles 2003a</LINK>
</P>
</TD>
<TD>
<P>71 (36/35)</P>
</TD>
<TD>
<P>&lt; 100 pg/mL</P>
</TD>
<TD>
<P>&lt; 7.8 mg/dL</P>
</TD>
<TD>
<P>--</P>
</TD>
<TD>
<P>--</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES>
<P>PTH - parathyroid hormone</P>
</FOOTNOTES>
</ADDITIONAL_TABLE>
</ADDITIONAL_TABLES>
<ANALYSES_AND_DATA CALCULATED_DATA="YES" MODIFIED="2014-12-08 16:15:06 +1100" MODIFIED_BY="Narelle Willis">
<COMPARISON ID="CMP-001" MODIFIED="2014-12-08 16:15:06 +1100" MODIFIED_BY="Narelle Willis" NO="1">
<NAME>Calcimimetics versus placebo/no treatment</NAME>
<DICH_OUTCOME CHI2="5.200147914049108" CI_END="1.0465499698850111" CI_START="0.8894046093376449" CI_STUDY="95" CI_TOTAL="95" DF="10" EFFECT_MEASURE="RR" EFFECT_SIZE="0.9647830673876394" ESTIMABLE="YES" EVENTS_1="744" EVENTS_2="759" I2="0.0" I2_Q="52.42864493238293" ID="CMP-001.01" LOG_CI_END="0.01975996953778839" LOG_CI_START="-0.0509006241509506" LOG_EFFECT_SIZE="-0.015570327306581096" METHOD="IV" MODIFIED="2014-06-10 16:16:31 +1000" MODIFIED_BY="Narelle Willis" NO="1" P_CHI2="0.8774130477811479" P_Q="0.14709652838144938" P_Z="0.3877137897148021" Q="2.1021053501179816" RANDOM="YES" SCALE="200.0" SORT_BY="WEIGHT" STUDIES="16" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="4038" TOTAL_2="3313" WEIGHT="100.00000000000003" Z="0.8637708560114453">
<NAME>All-cause mortality</NAME>
<GROUP_LABEL_1>Calcimimetic</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo/no treatment</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours calcimimetic</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="3.015230755838342" CI_END="1.0498047960685162" CI_START="0.891989989954479" DF="8" EFFECT_SIZE="0.967685573675313" ESTIMABLE="YES" EVENTS_1="742" EVENTS_2="755" I2="0.0" ID="CMP-001.01.01" LOG_CI_END="0.02110855252560006" LOG_CI_START="-0.04964001931437734" LOG_EFFECT_SIZE="-0.01426573339438861" MODIFIED="2013-06-02 09:38:05 +1000" MODIFIED_BY="Suetonia Palmer" NO="1" P_CHI2="0.9333981060372718" P_Z="0.4292861539640007" STUDIES="14" TAU2="0.0" TOTAL_1="3709" TOTAL_2="3184" WEIGHT="99.75144812932673" Z="0.7904137974486344">
<NAME>GFR category G5 treated with dialysis</NAME>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2013-01-16 21:58:08 +1100" MODIFIED_BY="[Empty name]" ORDER="107" O_E="0.0" SE="0.0" STUDY_ID="STD-Fukagawa-2008" TOTAL_1="72" TOTAL_2="71" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2013-06-02 09:37:41 +1000" MODIFIED_BY="Suetonia Palmer" ORDER="94119" O_E="0.0" SE="0.0" STUDY_ID="STD-Goodman-2002" TOTAL_1="23" TOTAL_2="7" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2013-06-02 09:37:20 +1000" MODIFIED_BY="[Empty name]" ORDER="62" O_E="0.0" SE="0.0" STUDY_ID="STD-Akiba-2008" TOTAL_1="91" TOTAL_2="30" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="94120" O_E="0.0" SE="0.0" STUDY_ID="STD-Lindberg-2003" TOTAL_1="38" TOTAL_2="39" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="94118" O_E="0.0" SE="0.0" STUDY_ID="STD-Goodman-2000" TOTAL_1="16" TOTAL_2="4" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="2.04369981296446" CI_START="0.006040847552086342" EFFECT_SIZE="0.1111111111111111" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="4" LOG_CI_END="0.3104171051871297" LOG_CI_START="-2.21890212406578" LOG_EFFECT_SIZE="-0.9542425094393249" MODIFIED="2013-01-16 22:17:45 +1100" MODIFIED_BY="[Empty name]" ORDER="113" O_E="0.0" SE="1.4857346355952692" STUDY_ID="STD-IMPACT-SHPT-Study-2012" TOTAL_1="134" TOTAL_2="134" VAR="2.2074074074074073" WEIGHT="0.0780453931226253"/>
<DICH_DATA CI_END="7.551751296407412" CI_START="0.03191203286207754" EFFECT_SIZE="0.4909090909090909" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="0.8780476788037255" LOG_CI_START="-1.4960455294742387" LOG_EFFECT_SIZE="-0.3089989253352565" MODIFIED="2013-01-16 20:16:38 +1100" MODIFIED_BY="[Empty name]" ORDER="88" O_E="0.0" SE="1.39455410249339" STUDY_ID="STD-El-Shafey-2011" TOTAL_1="55" TOTAL_2="27" VAR="1.944781144781145" WEIGHT="0.08858476407755045"/>
<DICH_DATA CI_END="3.0400144257856936" CI_START="0.08734840123818612" EFFECT_SIZE="0.5153061224489796" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="2" LOG_CI_END="0.4828756444719969" LOG_CI_START="-1.0587450396196638" LOG_EFFECT_SIZE="-0.2879346975738335" ORDER="94121" O_E="0.0" SE="0.9055556209809013" STUDY_ID="STD-Lindberg-2005" TOTAL_1="294" TOTAL_2="101" VAR="0.8200309826901057" WEIGHT="0.2100871583263227"/>
<DICH_DATA CI_END="4.0465633374992125" CI_START="0.13900684434798108" EFFECT_SIZE="0.75" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="2" LOG_CI_END="0.6070863424330394" LOG_CI_START="-0.8569638156496394" LOG_EFFECT_SIZE="-0.12493873660829995" MODIFIED="2013-01-17 09:40:34 +1100" MODIFIED_BY="[Empty name]" ORDER="121" O_E="0.0" SE="0.8599903100229288" STUDY_ID="STD-Malluche-2008" TOTAL_1="32" TOTAL_2="16" VAR="0.7395833333333333" WEIGHT="0.23293923906646477"/>
<DICH_DATA CI_END="4.762374132113708" CI_START="0.20517993441819418" EFFECT_SIZE="0.9885057471264368" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="3" LOG_CI_END="0.6778235105837638" LOG_CI_START="-0.6878651133338654" LOG_EFFECT_SIZE="-0.005020801375050797" MODIFIED="2013-06-02 09:38:05 +1000" MODIFIED_BY="[Empty name]" ORDER="46" O_E="0.0" SE="0.802212257956932" STUDY_ID="STD-ACHIEVE-Study-2008" TOTAL_1="87" TOTAL_2="86" VAR="0.6435445068163592" WEIGHT="0.26770173168779327"/>
<DICH_DATA CI_END="2.519406108250838" CI_START="0.2900439905330611" EFFECT_SIZE="0.8548324990373508" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="7" LOG_CI_END="0.4012981779613377" LOG_CI_START="-0.5375361283186658" LOG_EFFECT_SIZE="-0.06811897517866407" ORDER="94117" O_E="0.0" SE="0.5514759188136409" STUDY_ID="STD-Block-2004a" TOTAL_1="371" TOTAL_2="370" VAR="0.3041256890313494" WEIGHT="0.5664696706207798"/>
<DICH_DATA CI_END="2.4396149221465278" CI_START="0.34443049603846826" EFFECT_SIZE="0.9166666666666666" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="6" LOG_CI_END="0.3873212810990408" LOG_CI_START="-0.46289840287784045" LOG_EFFECT_SIZE="-0.0377885608893998" MODIFIED="2013-01-17 09:46:25 +1100" MODIFIED_BY="[Empty name]" ORDER="126" O_E="0.0" SE="0.499423251023332" STUDY_ID="STD-OPTIMA-Study-2008" TOTAL_1="368" TOTAL_2="184" VAR="0.24942358366271408" WEIGHT="0.6907044488859204"/>
<DICH_DATA CI_END="2.166299084001057" CI_START="0.46161677645777555" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="12" LOG_CI_END="0.33571841607710684" LOG_CI_START="-0.33571841607710684" LOG_EFFECT_SIZE="0.0" MODIFIED="2013-01-15 16:10:55 +1100" MODIFIED_BY="[Empty name]" ORDER="57" O_E="0.0" SE="0.3944053188733077" STUDY_ID="STD-ADVANCE-Study-2010" TOTAL_1="180" TOTAL_2="180" VAR="0.15555555555555553" WEIGHT="1.1075012928829688"/>
<DICH_DATA CI_END="1.0565412036032564" CI_START="0.8952809768484423" EFFECT_SIZE="0.9725745425634749" ESTIMABLE="YES" EVENTS_1="703" EVENTS_2="718" LOG_CI_END="0.023886438585297903" LOG_CI_START="-0.04804064340558369" LOG_EFFECT_SIZE="-0.0120771024101429" MODIFIED="2013-01-16 21:42:44 +1100" MODIFIED_BY="[Empty name]" ORDER="97" O_E="0.0" SE="0.042250324006241895" STUDY_ID="STD-EVOLVE-study-2007" TOTAL_1="1948" TOTAL_2="1935" VAR="0.00178508987863242" WEIGHT="96.50941443065632"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.08281180809278404" CI_END="1.4774667693561407" CI_START="0.05651906293656206" DF="1" EFFECT_SIZE="0.28897238159367195" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="4" I2="0.0" ID="CMP-001.01.02" LOG_CI_END="0.1695177216700068" LOG_CI_START="-1.247805047192444" LOG_EFFECT_SIZE="-0.5391436627612185" MODIFIED="2014-06-10 16:16:31 +1000" MODIFIED_BY="Narelle Willis" NO="2" P_CHI2="0.7735225011497767" P_Z="0.1359288818132876" STUDIES="2" TAU2="0.0" TOTAL_1="329" TOTAL_2="129" WEIGHT="0.24855187067329046" Z="1.4911242304434449">
<NAME>GFR category G3a to G4</NAME>
<DICH_DATA CI_END="3.9804702774957645" CI_START="0.010049063857139322" EFFECT_SIZE="0.2" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="2" LOG_CI_END="0.5999343853540574" LOG_CI_START="-1.9978743940260948" LOG_EFFECT_SIZE="-0.6989700043360187" MODIFIED="2013-06-02 09:36:54 +1000" MODIFIED_BY="Suetonia Palmer" ORDER="69" O_E="0.0" SE="1.5259657363687524" STUDY_ID="STD-Charytan-2005" TOTAL_1="27" TOTAL_2="27" VAR="2.3285714285714287" WEIGHT="0.073984408113518"/>
<DICH_DATA CI_END="2.3669796203127653" CI_START="0.048193885214011384" EFFECT_SIZE="0.33774834437086093" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="2" LOG_CI_END="0.37419451867102976" LOG_CI_START="-1.3170080610614958" LOG_EFFECT_SIZE="-0.47140677119523305" MODIFIED="2013-06-02 09:36:56 +1000" MODIFIED_BY="Suetonia Palmer" ORDER="76" O_E="0.0" SE="0.9934207669226706" STUDY_ID="STD-Chonchol-2009" TOTAL_1="302" TOTAL_2="102" VAR="0.9868848201532269" WEIGHT="0.17456746255977246"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="3.7213188052482478" CI_END="1.4534613944478352" CI_START="0.3208602188838005" CI_STUDY="95" CI_TOTAL="95" DF="3" EFFECT_MEASURE="RR" EFFECT_SIZE="0.6829040497476101" ESTIMABLE="YES" EVENTS_1="379" EVENTS_2="398" I2="19.383418701750518" I2_Q="0.0" ID="CMP-001.02" LOG_CI_END="0.16240350091488262" LOG_CI_START="-0.4936841245692273" LOG_EFFECT_SIZE="-0.16564031182717232" METHOD="IV" MODIFIED="2014-06-02 16:30:34 +1000" MODIFIED_BY="Narelle Willis" NO="2" P_CHI2="0.2931719216334241" P_Q="0.4499101014783444" P_Z="0.3223445101150636" Q="0.5708786363262943" RANDOM="YES" SCALE="200.0" SORT_BY="WEIGHT" STUDIES="9" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.1925751069779086" TOTALS="YES" TOTAL_1="2651" TOTAL_2="2349" WEIGHT="100.0" Z="0.9896514823906079">
<NAME>Cardiovascular mortality</NAME>
<GROUP_LABEL_1>Calcimimetic</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo/no treatment</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours calcimimetic</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="1.5913575570945118" CI_END="2.8722265222611782" CI_START="0.15678637796913" DF="1" EFFECT_SIZE="0.671063330194849" ESTIMABLE="YES" EVENTS_1="377" EVENTS_2="394" I2="37.16057113991451" ID="CMP-001.02.01" LOG_CI_END="0.45821868817772093" LOG_CI_START="-0.8046916727091676" LOG_EFFECT_SIZE="-0.17323649226572338" MODIFIED="2013-06-02 09:44:40 +1000" MODIFIED_BY="Suetonia Palmer" NO="1" P_CHI2="0.2071323330803544" P_Z="0.5907799878852134" STUDIES="7" TAU2="0.6726926959203879" TOTAL_1="2322" TOTAL_2="2220" WEIGHT="81.51623146691125" Z="0.5377060734705302">
<NAME>GFR category G5 treated with dialysis</NAME>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2013-06-02 09:44:30 +1000" MODIFIED_BY="Suetonia Palmer" ORDER="139" O_E="0.0" SE="0.0" STUDY_ID="STD-Goodman-2002" TOTAL_1="23" TOTAL_2="7" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2013-06-02 09:44:05 +1000" MODIFIED_BY="Suetonia Palmer" ORDER="135" O_E="0.0" SE="0.0" STUDY_ID="STD-Akiba-2008" TOTAL_1="91" TOTAL_2="30" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2013-06-02 09:44:20 +1000" MODIFIED_BY="Suetonia Palmer" ORDER="137" O_E="0.0" SE="0.0" STUDY_ID="STD-Fukagawa-2008" TOTAL_1="72" TOTAL_2="71" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2013-06-02 09:44:00 +1000" MODIFIED_BY="Suetonia Palmer" ORDER="138" O_E="0.0" SE="0.0" STUDY_ID="STD-Goodman-2000" TOTAL_1="16" TOTAL_2="4" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2013-06-02 09:44:40 +1000" MODIFIED_BY="Suetonia Palmer" ORDER="141" O_E="0.0" SE="0.0" STUDY_ID="STD-Lindberg-2003" TOTAL_1="38" TOTAL_2="39" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="2.7391792651609856" CI_START="0.007450466468139938" EFFECT_SIZE="0.14285714285714285" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="3" LOG_CI_END="0.43762045551887224" LOG_CI_START="-2.127816535547386" LOG_EFFECT_SIZE="-0.8450980400142568" MODIFIED="2013-06-02 09:44:35 +1000" MODIFIED_BY="Suetonia Palmer" ORDER="140" O_E="0.0" SE="1.5069503876702346" STUDY_ID="STD-IMPACT-SHPT-Study-2012" TOTAL_1="134" TOTAL_2="134" VAR="2.2708994708994705" WEIGHT="6.029076747811087"/>
<DICH_DATA CI_END="1.0871482208246759" CI_START="0.8437707376857498" EFFECT_SIZE="0.9577598113613806" ESTIMABLE="YES" EVENTS_1="377" EVENTS_2="391" LOG_CI_END="0.03628875944773406" LOG_CI_START="-0.073775540203215" LOG_EFFECT_SIZE="-0.018743390377740466" MODIFIED="2013-06-02 09:44:15 +1000" MODIFIED_BY="Suetonia Palmer" ORDER="136" O_E="0.0" SE="0.06465231444203763" STUDY_ID="STD-EVOLVE-study-2007" TOTAL_1="1948" TOTAL_2="1935" VAR="0.004179921762712108" WEIGHT="75.48715471910016"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.08281180809278404" CI_END="1.4774667693561407" CI_START="0.05651906293656206" DF="1" EFFECT_SIZE="0.28897238159367195" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="4" I2="0.0" ID="CMP-001.02.02" LOG_CI_END="0.1695177216700068" LOG_CI_START="-1.247805047192444" LOG_EFFECT_SIZE="-0.5391436627612185" MODIFIED="2013-06-02 09:46:25 +1000" MODIFIED_BY="Suetonia Palmer" NO="2" P_CHI2="0.7735225011497767" P_Z="0.1359288818132876" STUDIES="2" TAU2="0.0" TOTAL_1="329" TOTAL_2="129" WEIGHT="18.483768533088742" Z="1.4911242304434449">
<NAME>GFR category G3a to G4</NAME>
<DICH_DATA CI_END="3.9804702774957645" CI_START="0.010049063857139322" EFFECT_SIZE="0.2" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="2" LOG_CI_END="0.5999343853540574" LOG_CI_START="-1.9978743940260948" LOG_EFFECT_SIZE="-0.6989700043360187" MODIFIED="2013-06-02 09:46:20 +1000" MODIFIED_BY="Suetonia Palmer" ORDER="142" O_E="0.0" SE="1.5259657363687524" STUDY_ID="STD-Charytan-2005" TOTAL_1="27" TOTAL_2="27" VAR="2.3285714285714287" WEIGHT="5.891159869875633"/>
<DICH_DATA CI_END="2.3669796203127653" CI_START="0.048193885214011384" EFFECT_SIZE="0.33774834437086093" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="2" LOG_CI_END="0.37419451867102976" LOG_CI_START="-1.3170080610614958" LOG_EFFECT_SIZE="-0.47140677119523305" MODIFIED="2013-06-02 09:46:25 +1000" MODIFIED_BY="Suetonia Palmer" ORDER="143" O_E="0.0" SE="0.9934207669226706" STUDY_ID="STD-Chonchol-2009" TOTAL_1="302" TOTAL_2="102" VAR="0.9868848201532269" WEIGHT="12.592608663213108"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="3.648914850166133" CI_END="0.5911509045758995" CI_START="0.40326762199577804" CI_STUDY="95" CI_TOTAL="95" DF="4" EFFECT_MEASURE="RR" EFFECT_SIZE="0.48825405224020013" ESTIMABLE="YES" EVENTS_1="141" EVENTS_2="287" I2="0.0" I2_Q="0.0" ID="CMP-001.03" LOG_CI_END="-0.22830164152315274" LOG_CI_START="-0.3944066457162838" LOG_EFFECT_SIZE="-0.31135414361971825" METHOD="IV" MODIFIED="2014-06-02 16:30:57 +1000" MODIFIED_BY="Narelle Willis" NO="3" P_CHI2="0.45559957564031506" P_Q="1.0" P_Z="2.0168207139781333E-13" Q="0.0" RANDOM="YES" SCALE="500.0" SORT_BY="WEIGHT" STUDIES="5" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="2564" TOTAL_2="2329" WEIGHT="100.0" Z="7.347676379724565">
<NAME>Parathyroidectomy</NAME>
<GROUP_LABEL_1>Calcimimetic</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo/no treatment</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours calcimimetic</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_DATA CI_END="7.979054649018689" CI_START="0.013610660834980807" EFFECT_SIZE="0.32954545454545453" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.9019514395919436" LOG_CI_START="-1.8661207880943689" LOG_EFFECT_SIZE="-0.48208467425121254" MODIFIED="2013-01-15 09:10:05 +1100" MODIFIED_BY="[Empty name]" ORDER="53" O_E="0.0" SE="1.625979328721453" STUDY_ID="STD-ACHIEVE-Study-2008" TOTAL_1="87" TOTAL_2="86" VAR="2.643808777429467" WEIGHT="0.36008961537080947"/>
<DICH_DATA CI_END="4.1368200379647675" CI_START="0.009669262775008026" EFFECT_SIZE="0.2" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="2" LOG_CI_END="0.6166666284084851" LOG_CI_START="-2.0146066370805227" LOG_EFFECT_SIZE="-0.6989700043360187" MODIFIED="2013-01-15 16:13:47 +1100" MODIFIED_BY="[Empty name]" ORDER="59" O_E="0.0" SE="1.545622941160972" STUDY_ID="STD-ADVANCE-Study-2010" TOTAL_1="180" TOTAL_2="180" VAR="2.388950276243094" WEIGHT="0.3985047722616026"/>
<DICH_DATA CI_END="1.4284145810307411" CI_START="0.0033478194497163533" EFFECT_SIZE="0.06915254237288136" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="2" LOG_CI_END="0.15485427475294178" LOG_CI_START="-2.4752379718574704" LOG_EFFECT_SIZE="-1.1601918485522642" ORDER="94144" O_E="0.0" SE="1.5449292048255472" STUDY_ID="STD-Lindberg-2005" TOTAL_1="294" TOTAL_2="101" VAR="2.3868062479228978" WEIGHT="0.3988627424647583"/>
<DICH_DATA CI_END="1.045576525437653" CI_START="0.01440543384882307" EFFECT_SIZE="0.12272727272727273" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="4" LOG_CI_END="0.01935582420204444" LOG_CI_START="-1.8414736575284822" LOG_EFFECT_SIZE="-0.9110589166632189" MODIFIED="2013-01-16 20:22:00 +1100" MODIFIED_BY="[Empty name]" ORDER="95" O_E="0.0" SE="1.0930604488230031" STUDY_ID="STD-El-Shafey-2011" TOTAL_1="55" TOTAL_2="27" VAR="1.194781144781145" WEIGHT="0.7968054148970787"/>
<DICH_DATA CI_END="0.6068081181234781" CI_START="0.41238145900140843" EFFECT_SIZE="0.500236361219033" ESTIMABLE="YES" EVENTS_1="140" EVENTS_2="278" LOG_CI_END="-0.21694861767989176" LOG_CI_START="-0.38470086917511764" LOG_EFFECT_SIZE="-0.3008247434275047" MODIFIED="2013-01-16 21:48:13 +1100" MODIFIED_BY="[Empty name]" ORDER="102" O_E="0.0" SE="0.0985385029153329" STUDY_ID="STD-EVOLVE-study-2007" TOTAL_1="1948" TOTAL_2="1935" VAR="0.009709836556795073" WEIGHT="98.04573745500575"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="3.6955120273228386" CI_END="2.2715452208560585" CI_START="0.12086504697177324" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="0.5239755908601798" ESTIMABLE="YES" EVENTS_1="240" EVENTS_2="260" I2="72.94015030646685" I2_Q="0.0" ID="CMP-001.04" LOG_CI_END="0.3563213869674039" LOG_CI_START="-0.9176992748382846" LOG_EFFECT_SIZE="-0.28068894393544036" METHOD="IV" MODIFIED="2014-06-02 16:31:32 +1000" MODIFIED_BY="Narelle Willis" NO="4" P_CHI2="0.05455926361149521" P_Q="1.0" P_Z="0.38779205967982244" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="WEIGHT" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.8785674421959276" TOTALS="YES" TOTAL_1="2003" TOTAL_2="1962" WEIGHT="100.0" Z="0.8636284127328415">
<NAME>Fractures</NAME>
<GROUP_LABEL_1>Calcimimetic</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo/no treatment</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours calcimimetic</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.9474605617067361" CI_START="0.04069686828599134" EFFECT_SIZE="0.19636363636363635" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="5" LOG_CI_END="-0.023438858604861567" LOG_CI_START="-1.3904390094097268" LOG_EFFECT_SIZE="-0.7069389340072941" MODIFIED="2013-01-16 20:17:36 +1100" MODIFIED_BY="[Empty name]" ORDER="89" O_E="0.0" SE="0.8029826553426572" STUDY_ID="STD-El-Shafey-2011" TOTAL_1="55" TOTAL_2="27" VAR="0.6447811447811447" WEIGHT="36.764515979825816"/>
<DICH_DATA CI_END="1.0934967149924466" CI_START="0.7860317779100922" EFFECT_SIZE="0.9271047227926078" ESTIMABLE="YES" EVENTS_1="238" EVENTS_2="255" LOG_CI_END="0.03881748269803045" LOG_CI_START="-0.10455989582824994" LOG_EFFECT_SIZE="-0.03287120656510973" MODIFIED="2013-01-16 21:43:28 +1100" MODIFIED_BY="[Empty name]" ORDER="98" O_E="0.0" SE="0.0842205818758072" STUDY_ID="STD-EVOLVE-study-2007" TOTAL_1="1948" TOTAL_2="1935" VAR="0.007093106411499543" WEIGHT="63.23548402017418"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="9.49221256786978" CI_END="10.033153435422435" CI_START="5.433857359607931" CI_STUDY="95" CI_TOTAL="95" DF="13" EFFECT_MEASURE="RR" EFFECT_SIZE="7.383679613522367" ESTIMABLE="YES" EVENTS_1="540" EVENTS_2="40" I2="0.0" I2_Q="62.47977934902429" ID="CMP-001.05" LOG_CI_END="1.0014374538937383" LOG_CI_START="0.7351082338705652" LOG_EFFECT_SIZE="0.8682728438821518" METHOD="IV" MODIFIED="2014-06-10 16:16:55 +1000" MODIFIED_BY="Narelle Willis" NO="5" P_CHI2="0.7348367578314445" P_Q="0.10256308670179926" P_Z="2.1330600968457177E-37" Q="2.665229528638167" RANDOM="YES" SCALE="1000.0" SORT_BY="WEIGHT" STUDIES="14" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="3685" TOTAL_2="3179" WEIGHT="100.0" Z="12.77954782892479">
<NAME>Hypocalcaemia</NAME>
<GROUP_LABEL_1>Calcimimetic</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo/no treatment</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours calcimimetic</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="4.780574177660701" CI_END="9.5330771922356" CI_START="5.104692576582756" DF="11" EFFECT_SIZE="6.975917744296836" ESTIMABLE="YES" EVENTS_1="353" EVENTS_2="39" I2="0.0" ID="CMP-001.05.01" LOG_CI_END="0.9792331096513632" LOG_CI_START="0.7079695923947336" LOG_EFFECT_SIZE="0.8436013510230485" MODIFIED="2013-06-02 10:04:38 +1000" MODIFIED_BY="Suetonia Palmer" NO="1" P_CHI2="0.9413255596647224" P_Z="3.48977667167969E-34" STUDIES="12" TAU2="0.0" TOTAL_1="3363" TOTAL_2="3052" WEIGHT="96.3950775809744" Z="12.19056865468773">
<NAME>GFR category G5 treated with dialysis</NAME>
<DICH_DATA CI_END="134.4786900959109" CI_START="0.38329519809910845" EFFECT_SIZE="7.17948717948718" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="0" LOG_CI_END="2.1286534701600854" LOG_CI_START="-0.41646662152864533" LOG_EFFECT_SIZE="0.85609342431572" ORDER="94129" O_E="0.0" SE="1.495016140405601" STUDY_ID="STD-Lindberg-2003" TOTAL_1="38" TOTAL_2="39" VAR="2.23507326007326" WEIGHT="1.095017539729989"/>
<DICH_DATA CI_END="161.9002827422392" CI_START="0.48669477553128865" EFFECT_SIZE="8.876712328767123" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="0" LOG_CI_END="2.2092476072048073" LOG_CI_START="-0.31274331570453207" LOG_EFFECT_SIZE="0.9482521457501374" MODIFIED="2013-01-16 22:01:12 +1100" MODIFIED_BY="[Empty name]" ORDER="109" O_E="0.0" SE="1.4814299521733545" STUDY_ID="STD-Fukagawa-2008" TOTAL_1="72" TOTAL_2="71" VAR="2.194634703196347" WEIGHT="1.1151944416066868"/>
<DICH_DATA CI_END="224.67556768636527" CI_START="0.7351974936891306" EFFECT_SIZE="12.852272727272727" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="0" LOG_CI_END="2.351555847693242" LOG_CI_START="-0.13359598214266857" LOG_EFFECT_SIZE="1.1089799327752867" MODIFIED="2013-01-15 09:05:03 +1100" MODIFIED_BY="[Empty name]" ORDER="48" O_E="0.0" SE="1.4597904865455706" STUDY_ID="STD-ACHIEVE-Study-2008" TOTAL_1="87" TOTAL_2="86" VAR="2.130988264608954" WEIGHT="1.1485020649847757"/>
<DICH_DATA CI_END="40.46378681853882" CI_START="0.13455103618601583" EFFECT_SIZE="2.3333333333333335" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="0" LOG_CI_END="1.6070665239473412" LOG_CI_START="-0.8711129533581522" LOG_EFFECT_SIZE="0.36797678529459443" ORDER="94128" O_E="0.0" SE="1.4556948921555022" STUDY_ID="STD-Goodman-2002" TOTAL_1="23" TOTAL_2="7" VAR="2.119047619047619" WEIGHT="1.1549737723504685"/>
<DICH_DATA CI_END="111.30181942540933" CI_START="0.3795984667466691" EFFECT_SIZE="6.5" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="0" LOG_CI_END="2.0465022637053925" LOG_CI_START="-0.42067555041968113" LOG_EFFECT_SIZE="0.8129133566428556" MODIFIED="2013-01-16 20:19:25 +1100" MODIFIED_BY="[Empty name]" ORDER="91" O_E="0.0" SE="1.4492324607442124" STUDY_ID="STD-El-Shafey-2011" TOTAL_1="55" TOTAL_2="27" VAR="2.1002747252747254" WEIGHT="1.1652972789269607"/>
<DICH_DATA CI_END="419.0783308322443" CI_START="1.4913679711351748" EFFECT_SIZE="25.0" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="0" LOG_CI_END="2.6222952054693005" LOG_CI_START="0.17358481187477465" LOG_EFFECT_SIZE="1.3979400086720377" MODIFIED="2013-01-15 16:12:54 +1100" MODIFIED_BY="[Empty name]" ORDER="58" O_E="0.0" SE="1.4383846065093626" STUDY_ID="STD-ADVANCE-Study-2010" TOTAL_1="180" TOTAL_2="180" VAR="2.0689502762430942" WEIGHT="1.1829401849163346"/>
<DICH_DATA CI_END="107.98803344332717" CI_START="0.38794679879608057" EFFECT_SIZE="6.472527472527473" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="0" LOG_CI_END="2.0333756323622296" LOG_CI_START="-0.4112278274302137" LOG_EFFECT_SIZE="0.8110739024660081" MODIFIED="2013-01-15 18:14:15 +1100" MODIFIED_BY="[Empty name]" ORDER="63" O_E="0.0" SE="1.4359721732643695" STUDY_ID="STD-Akiba-2008" TOTAL_1="90" TOTAL_2="30" VAR="2.0620160823895968" WEIGHT="1.186918202657979"/>
<DICH_DATA CI_END="892.5059002780299" CI_START="3.3893333355641295" EFFECT_SIZE="55.0" ESTIMABLE="YES" EVENTS_1="27" EVENTS_2="0" LOG_CI_END="2.950611095876354" LOG_CI_START="0.5301142831121338" LOG_EFFECT_SIZE="1.7403626894942439" MODIFIED="2013-01-16 22:20:35 +1100" MODIFIED_BY="[Empty name]" ORDER="115" O_E="0.0" SE="1.4218118094701637" STUDY_ID="STD-IMPACT-SHPT-Study-2012" TOTAL_1="134" TOTAL_2="134" VAR="2.021548821548821" WEIGHT="1.2106778704887196"/>
<DICH_DATA CI_END="64.56775514053398" CI_START="0.3014456330052958" EFFECT_SIZE="4.411764705882353" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="0" LOG_CI_END="1.8100156873346533" LOG_CI_START="-0.5207910033078011" LOG_EFFECT_SIZE="0.6446123420134261" ORDER="94127" O_E="0.0" SE="1.3691273877625738" STUDY_ID="STD-Goodman-2000" TOTAL_1="16" TOTAL_2="4" VAR="1.8745098039215689" WEIGHT="1.3056450370339652"/>
<DICH_DATA CI_END="19.131537700472972" CI_START="1.0526698590407244" EFFECT_SIZE="4.487671232876712" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="2" LOG_CI_END="1.2817498779202205" LOG_CI_START="0.022292188015629304" LOG_EFFECT_SIZE="0.652021032967925" MODIFIED="2013-01-17 09:48:52 +1100" MODIFIED_BY="[Empty name]" ORDER="128" O_E="0.0" SE="0.7398116814660693" STUDY_ID="STD-OPTIMA-Study-2008" TOTAL_1="365" TOTAL_2="182" VAR="0.5473213240336529" WEIGHT="4.471677449591243"/>
<DICH_DATA CI_END="13.31222063202275" CI_START="1.5546818344216482" EFFECT_SIZE="4.549315068493151" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="4" LOG_CI_END="1.1242505068489903" LOG_CI_START="0.19164152410686852" LOG_EFFECT_SIZE="0.6579460154779293" MODIFIED="2013-06-02 10:04:38 +1000" MODIFIED_BY="Suetonia Palmer" ORDER="94126" O_E="0.0" SE="0.5478191329516406" STUDY_ID="STD-Block-2004a" TOTAL_1="365" TOTAL_2="369" VAR="0.3001058024278873" WEIGHT="8.155271915976385"/>
<DICH_DATA CI_END="10.326757678837883" CI_START="5.042914911869811" EFFECT_SIZE="7.2164368139600334" ESTIMABLE="YES" EVENTS_1="240" EVENTS_2="33" LOG_CI_END="1.0139639862609393" LOG_CI_START="0.7026816404539643" LOG_EFFECT_SIZE="0.8583228133574519" MODIFIED="2013-01-16 21:44:49 +1100" MODIFIED_BY="[Empty name]" ORDER="99" O_E="0.0" SE="0.18284879079947977" STUDY_ID="STD-EVOLVE-study-2007" TOTAL_1="1938" TOTAL_2="1923" VAR="0.033433680296831914" WEIGHT="73.20296182271088"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="1.1857518594791896" CI_END="192.59908770164768" CI_START="5.283165233588201" DF="1" EFFECT_SIZE="31.89879001100433" ESTIMABLE="YES" EVENTS_1="187" EVENTS_2="1" I2="15.665323060153263" ID="CMP-001.05.02" LOG_CI_END="2.2846542256385747" LOG_CI_START="0.72289419367263" LOG_EFFECT_SIZE="1.5037742096556024" MODIFIED="2014-06-10 16:16:55 +1000" MODIFIED_BY="Narelle Willis" NO="2" P_CHI2="0.27618819245882564" P_Z="1.6040166703175143E-4" STUDIES="2" TAU2="0.2918968155192888" TOTAL_1="322" TOTAL_2="127" WEIGHT="3.604922419025592" Z="3.7743868859226053">
<NAME>GFR category G3a to G4</NAME>
<DICH_DATA CI_END="159.4334025543886" CI_START="0.5080491208382004" EFFECT_SIZE="9.0" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="0" LOG_CI_END="2.2025793147095825" LOG_CI_START="-0.29409429583093266" LOG_EFFECT_SIZE="0.9542425094393249" MODIFIED="2013-06-02 10:03:56 +1000" MODIFIED_BY="Suetonia Palmer" ORDER="71" O_E="0.0" SE="1.4665584375651899" STUDY_ID="STD-Charytan-2005" TOTAL_1="27" TOTAL_2="27" VAR="2.150793650793651" WEIGHT="1.137926188994742"/>
<DICH_DATA CI_END="436.96924601593327" CI_START="8.806579808559988" EFFECT_SIZE="62.03389830508475" ESTIMABLE="YES" EVENTS_1="183" EVENTS_2="1" LOG_CI_END="2.640450872312356" LOG_CI_START="0.9448072751921773" LOG_EFFECT_SIZE="1.7926290737522665" MODIFIED="2013-06-02 10:03:56 +1000" MODIFIED_BY="Suetonia Palmer" ORDER="78" O_E="0.0" SE="0.9960294425195685" STUDY_ID="STD-Chonchol-2009" TOTAL_1="295" TOTAL_2="100" VAR="0.9920746503658424" WEIGHT="2.4669962300308503"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="12.943820337945603" CI_END="0.9688123991183868" CI_START="0.054176944781347415" CI_STUDY="95" CI_TOTAL="95" DF="3" EFFECT_MEASURE="RR" EFFECT_SIZE="0.22910106034351205" ESTIMABLE="YES" EVENTS_1="36" EVENTS_2="73" I2="76.82291686940897" I2_Q="0.0" ID="CMP-001.06" LOG_CI_END="-0.013760311613314232" LOG_CI_START="-1.2661854899269607" LOG_EFFECT_SIZE="-0.6399729007701375" METHOD="IV" MODIFIED="2014-06-02 16:32:14 +1000" MODIFIED_BY="Narelle Willis" NO="6" P_CHI2="0.004759698199490403" P_Q="1.0" P_Z="0.045173856988730846" Q="0.0" RANDOM="YES" SCALE="200.0" SORT_BY="WEIGHT" STUDIES="4" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="1.5528226422319464" TOTALS="YES" TOTAL_1="2339" TOTAL_2="2323" WEIGHT="100.0" Z="2.0030319707880757">
<NAME>Hypercalcaemia</NAME>
<GROUP_LABEL_1>Calcimimetic</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo/no treatment</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours cinacalcet</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.694913956187942" CI_START="0.023600018074052938" EFFECT_SIZE="0.2" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="5" LOG_CI_END="0.22914765575368418" LOG_CI_START="-1.6270876644257217" LOG_EFFECT_SIZE="-0.6989700043360187" MODIFIED="2013-06-02 10:05:48 +1000" MODIFIED_BY="Suetonia Palmer" ORDER="147" O_E="0.0" SE="1.0903618155864083" STUDY_ID="STD-ADVANCE-Study-2010" TOTAL_1="180" TOTAL_2="180" VAR="1.1888888888888889" WEIGHT="19.740448942749076"/>
<DICH_DATA CI_END="0.4357476497022724" CI_START="0.007940852038607572" EFFECT_SIZE="0.058823529411764705" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="17" LOG_CI_END="-0.3607649466714096" LOG_CI_START="-2.100132896085138" LOG_EFFECT_SIZE="-1.2304489213782739" MODIFIED="2013-06-02 10:05:28 +1000" MODIFIED_BY="Suetonia Palmer" ORDER="149" O_E="0.0" SE="1.0217133434958343" STUDY_ID="STD-IMPACT-SHPT-Study-2012" TOTAL_1="134" TOTAL_2="134" VAR="1.0438981562774365" WEIGHT="20.842678399197055"/>
<DICH_DATA CI_END="0.5590752694517975" CI_START="0.031071741037585098" EFFECT_SIZE="0.1318007662835249" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="15" LOG_CI_END="-0.2525297182191725" LOG_CI_START="-1.507634411314329" LOG_EFFECT_SIZE="-0.8800820647667508" MODIFIED="2013-06-02 10:05:34 +1000" MODIFIED_BY="Suetonia Palmer" ORDER="146" O_E="0.0" SE="0.7372547095925256" STUDY_ID="STD-ACHIEVE-Study-2008" TOTAL_1="87" TOTAL_2="86" VAR="0.5435445068163592" WEIGHT="25.817336681891554"/>
<DICH_DATA CI_END="1.414017897540004" CI_START="0.5501626100512412" EFFECT_SIZE="0.8820089439284485" ESTIMABLE="YES" EVENTS_1="32" EVENTS_2="36" LOG_CI_END="0.15045490645781986" LOG_CI_START="-0.25950892830511574" LOG_EFFECT_SIZE="-0.05452701092364797" MODIFIED="2013-06-02 10:05:43 +1000" MODIFIED_BY="Suetonia Palmer" ORDER="148" O_E="0.0" SE="0.24081478589345945" STUDY_ID="STD-EVOLVE-study-2007" TOTAL_1="1938" TOTAL_2="1923" VAR="0.05799176110491272" WEIGHT="33.59953597616232"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="34.05087347935816" CI_END="2.7470314783362464" CI_START="1.5360141147804092" CI_STUDY="95" CI_TOTAL="95" DF="13" EFFECT_MEASURE="RR" EFFECT_SIZE="2.0541370753848365" ESTIMABLE="YES" EVENTS_1="1046" EVENTS_2="438" I2="61.82183106732732" I2_Q="0.0" ID="CMP-001.07" LOG_CI_END="0.43886363604575435" LOG_CI_START="0.1863952065438526" LOG_EFFECT_SIZE="0.31262942129480353" METHOD="IV" MODIFIED="2014-06-10 16:17:14 +1000" MODIFIED_BY="Narelle Willis" NO="7" P_CHI2="0.0011823295977858583" P_Q="0.7360897445354697" P_Z="1.2098834707032767E-6" Q="0.11359332139973538" RANDOM="YES" SCALE="500.0" SORT_BY="WEIGHT" STUDIES="14" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.1094237591625772" TOTALS="YES" TOTAL_1="3799" TOTAL_2="3100" WEIGHT="100.0" Z="4.8540121032503105">
<NAME>Nausea</NAME>
<GROUP_LABEL_1>Calcimimetic</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo/no treatment</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours calcimimetic</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="32.46128409153107" CI_END="2.813605330832827" CI_START="1.4514049879769504" DF="11" EFFECT_SIZE="2.020811918850763" ESTIMABLE="YES" EVENTS_1="960" EVENTS_2="423" I2="66.11347853959411" ID="CMP-001.07.01" LOG_CI_END="0.4492631781511834" LOG_CI_START="0.16178861126801408" LOG_EFFECT_SIZE="0.3055258947095988" MODIFIED="2013-06-02 10:13:15 +1000" MODIFIED_BY="Suetonia Palmer" NO="1" P_CHI2="6.429619115634333E-4" P_Z="3.098940174125896E-5" STUDIES="12" TAU2="0.12584664889409417" TOTAL_1="3477" TOTAL_2="2973" WEIGHT="84.77001276761493" Z="4.166071151738113">
<NAME>GFR category G5 treated with dialysis</NAME>
<DICH_DATA CI_END="22.17521362005882" CI_START="0.045095394215072616" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.3458678122045942" LOG_CI_START="-1.3458678122045942" LOG_EFFECT_SIZE="0.0" ORDER="94132" O_E="0.0" SE="1.5811388300841898" STUDY_ID="STD-Goodman-2002" TOTAL_1="23" TOTAL_2="7" VAR="2.5" WEIGHT="0.8428392435280069"/>
<DICH_DATA CI_END="323.1866250834904" CI_START="1.1170016701858896" EFFECT_SIZE="19.0" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="0" LOG_CI_END="2.5094533794149605" LOG_CI_START="0.04805382249069707" LOG_EFFECT_SIZE="1.2787536009528289" MODIFIED="2013-01-16 22:21:43 +1100" MODIFIED_BY="[Empty name]" ORDER="116" O_E="0.0" SE="1.4458382838616224" STUDY_ID="STD-IMPACT-SHPT-Study-2012" TOTAL_1="134" TOTAL_2="134" VAR="2.0904483430799217" WEIGHT="0.9997511877961694"/>
<DICH_DATA CI_END="86.8969933491733" CI_START="0.3004819376227723" EFFECT_SIZE="5.1098901098901095" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="0" LOG_CI_END="1.9390047500452976" LOG_CI_START="-0.5221816289075771" LOG_EFFECT_SIZE="0.7084115605688603" MODIFIED="2013-01-15 18:16:04 +1100" MODIFIED_BY="[Empty name]" ORDER="64" O_E="0.0" SE="1.4457130620659804" STUDY_ID="STD-Akiba-2008" TOTAL_1="90" TOTAL_2="30" VAR="2.0900862578281934" WEIGHT="0.999915767706105"/>
<DICH_DATA CI_END="317.7752708443197" CI_START="1.1103509418574342" EFFECT_SIZE="18.78409090909091" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="0" LOG_CI_END="2.502120097548125" LOG_CI_START="0.04546026529443286" LOG_EFFECT_SIZE="1.2737901814212789" MODIFIED="2013-01-15 09:05:50 +1100" MODIFIED_BY="[Empty name]" ORDER="49" O_E="0.0" SE="1.443054146128113" STUDY_ID="STD-ACHIEVE-Study-2008" TOTAL_1="87" TOTAL_2="86" VAR="2.082405268657537" WEIGHT="1.0034198467587296"/>
<DICH_DATA CI_END="72.35806441813861" CI_START="0.3455039904817166" EFFECT_SIZE="5.0" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="0" LOG_CI_END="1.859486940943929" LOG_CI_START="-0.4615469322718913" LOG_EFFECT_SIZE="0.6989700043360189" ORDER="94131" O_E="0.0" SE="1.3633867864299423" STUDY_ID="STD-Goodman-2000" TOTAL_1="16" TOTAL_2="4" VAR="1.858823529411765" WEIGHT="1.1174026556437573"/>
<DICH_DATA CI_END="26.534831734223687" CI_START="0.44502242032656286" EFFECT_SIZE="3.4363636363636365" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="1" LOG_CI_END="1.4238163379752085" LOG_CI_START="-0.35161810861720794" LOG_EFFECT_SIZE="0.5360991146790003" MODIFIED="2013-01-16 20:20:17 +1100" MODIFIED_BY="[Empty name]" ORDER="92" O_E="0.0" SE="1.0428989824706358" STUDY_ID="STD-El-Shafey-2011" TOTAL_1="55" TOTAL_2="27" VAR="1.0876382876382877" WEIGHT="1.8372687974648143"/>
<DICH_DATA CI_END="28.051806113184508" CI_START="4.853197144196855" EFFECT_SIZE="11.667945205479452" ESTIMABLE="YES" EVENTS_1="117" EVENTS_2="5" LOG_CI_END="1.4479608285061873" LOG_CI_START="0.6860279333712984" LOG_EFFECT_SIZE="1.066994380938743" MODIFIED="2013-01-17 09:49:40 +1100" MODIFIED_BY="[Empty name]" ORDER="129" O_E="0.0" SE="0.44756315423089266" STUDY_ID="STD-OPTIMA-Study-2008" TOTAL_1="365" TOTAL_2="182" VAR="0.2003127770251058" WEIGHT="7.1006306659409635"/>
<DICH_DATA CI_END="1.4852272140740088" CI_START="0.31520028712455445" EFFECT_SIZE="0.6842105263157895" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="12" LOG_CI_END="0.171792898279607" LOG_CI_START="-0.5014133955715914" LOG_EFFECT_SIZE="-0.16481024864599217" ORDER="94133" O_E="0.0" SE="0.3954447094330932" STUDY_ID="STD-Lindberg-2003" TOTAL_1="38" TOTAL_2="39" VAR="0.15637651821862347" WEIGHT="8.274350835467363"/>
<DICH_DATA CI_END="3.2091822090829525" CI_START="1.0450761898478342" EFFECT_SIZE="1.8313492063492063" ESTIMABLE="YES" EVENTS_1="26" EVENTS_2="14" LOG_CI_END="0.5063943759153139" LOG_CI_START="0.01914795324545962" LOG_EFFECT_SIZE="0.26277116458038674" MODIFIED="2013-01-16 22:01:48 +1100" MODIFIED_BY="[Empty name]" ORDER="110" O_E="0.0" SE="0.2862109605849634" STUDY_ID="STD-Fukagawa-2008" TOTAL_1="72" TOTAL_2="71" VAR="0.08191671395896748" WEIGHT="11.494299723088506"/>
<DICH_DATA CI_END="2.068228385262711" CI_START="0.9129974722130809" EFFECT_SIZE="1.3741496598639455" ESTIMABLE="YES" EVENTS_1="88" EVENTS_2="22" LOG_CI_END="0.3155984942781825" LOG_CI_START="-0.039530424881287156" LOG_EFFECT_SIZE="0.13803403469844766" ORDER="94134" O_E="0.0" SE="0.20860448503077358" STUDY_ID="STD-Lindberg-2005" TOTAL_1="294" TOTAL_2="101" VAR="0.043515831174954236" WEIGHT="14.380349406996414"/>
<DICH_DATA CI_END="2.188001207357555" CI_START="1.3049536593199835" EFFECT_SIZE="1.6897455968688846" ESTIMABLE="YES" EVENTS_1="117" EVENTS_2="70" LOG_CI_END="0.34004755730882424" LOG_CI_START="0.11559508956015682" LOG_EFFECT_SIZE="0.2278213234344905" MODIFIED="2013-06-02 10:13:15 +1000" MODIFIED_BY="Suetonia Palmer" ORDER="94130" O_E="0.0" SE="0.13184449061320147" STUDY_ID="STD-Block-2004a" TOTAL_1="365" TOTAL_2="369" VAR="0.017382969705054572" WEIGHT="17.343912005745196"/>
<DICH_DATA CI_END="2.117698744610607" CI_START="1.6483948800978998" EFFECT_SIZE="1.8683692804705054" ESTIMABLE="YES" EVENTS_1="563" EVENTS_2="299" LOG_CI_END="0.32586417916204885" LOG_CI_START="0.217061256939251" LOG_EFFECT_SIZE="0.2714627180506499" MODIFIED="2013-01-16 21:45:48 +1100" MODIFIED_BY="[Empty name]" ORDER="100" O_E="0.0" SE="0.06391137509682258" STUDY_ID="STD-EVOLVE-study-2007" TOTAL_1="1938" TOTAL_2="1923" VAR="0.0040846638667667535" WEIGHT="19.3758726314789"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="1.0615011505827414" CI_END="3.953088559605842" CI_START="1.2917489604841665" DF="1" EFFECT_SIZE="2.2597340634624903" ESTIMABLE="YES" EVENTS_1="86" EVENTS_2="15" I2="5.793790289250143" ID="CMP-001.07.02" LOG_CI_END="0.5969365437933425" LOG_CI_START="0.11117812072579147" LOG_EFFECT_SIZE="0.35405733225956704" MODIFIED="2014-06-10 16:17:14 +1000" MODIFIED_BY="Narelle Willis" NO="2" P_CHI2="0.3028734430794886" P_Z="0.0042747885637359345" STUDIES="2" TAU2="0.018867239839706656" TOTAL_1="322" TOTAL_2="127" WEIGHT="15.229987232385065" Z="2.8571388029007228">
<NAME>GFR category G3a to G4</NAME>
<DICH_DATA CI_END="18.92330245718707" CI_START="1.0701091971559675" EFFECT_SIZE="4.5" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="2" LOG_CI_END="1.2769969308911184" LOG_CI_START="0.029428096659568897" LOG_EFFECT_SIZE="0.6532125137753437" MODIFIED="2013-06-02 10:12:12 +1000" MODIFIED_BY="Suetonia Palmer" ORDER="70" O_E="0.0" SE="0.73282810879294" STUDY_ID="STD-Charytan-2005" TOTAL_1="27" TOTAL_2="27" VAR="0.5370370370370372" WEIGHT="3.402100730850021"/>
<DICH_DATA CI_END="3.4529257796924804" CI_START="1.1675176921778883" EFFECT_SIZE="2.0078226857887875" ESTIMABLE="YES" EVENTS_1="77" EVENTS_2="13" LOG_CI_END="0.538187243331665" LOG_CI_START="0.06726347044329918" LOG_EFFECT_SIZE="0.30272535688748214" MODIFIED="2013-06-02 10:12:14 +1000" MODIFIED_BY="Suetonia Palmer" ORDER="79" O_E="0.0" SE="0.27662295530489756" STUDY_ID="STD-Chonchol-2009" TOTAL_1="295" TOTAL_2="100" VAR="0.07652025940161535" WEIGHT="11.827886501535044"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="8.303987792221497" CI_END="2.1796378510511145" CI_START="1.7374651015891098" CI_STUDY="95" CI_TOTAL="95" DF="9" EFFECT_MEASURE="RR" EFFECT_SIZE="1.9460330676286037" ESTIMABLE="YES" EVENTS_1="849" EVENTS_2="365" I2="0.0" I2_Q="0.0" ID="CMP-001.08" LOG_CI_END="0.3383843411479727" LOG_CI_START="0.23991609018906487" LOG_EFFECT_SIZE="0.28915021566851884" METHOD="IV" MODIFIED="2014-06-02 16:32:54 +1000" MODIFIED_BY="Narelle Willis" NO="8" P_CHI2="0.5038258232402478" P_Q="0.758794879185056" P_Z="1.1639807792290865E-30" Q="0.0942881380746975" RANDOM="YES" SCALE="200.0" SORT_BY="WEIGHT" STUDIES="10" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="3695" TOTAL_2="3023" WEIGHT="99.99999999999997" Z="11.510796694637913">
<NAME>Vomiting</NAME>
<GROUP_LABEL_1>Calcimimetic</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo/no treatment</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours calcimimetic</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="8.22648499461503" CI_END="2.2439963779802965" CI_START="1.7326744761686912" DF="8" EFFECT_SIZE="1.9718304310313934" ESTIMABLE="YES" EVENTS_1="802" EVENTS_2="356" I2="2.7531198897619613" ID="CMP-001.08.01" LOG_CI_END="0.35102215159284034" LOG_CI_START="0.23871697789973245" LOG_EFFECT_SIZE="0.2948695647462864" MODIFIED="2013-06-02 10:21:27 +1000" MODIFIED_BY="Suetonia Palmer" NO="1" P_CHI2="0.41166516453852453" P_Z="7.640924402304973E-25" STUDIES="9" TAU2="0.0017480808573042022" TOTAL_1="3400" TOTAL_2="2923" WEIGHT="97.18856245204941" Z="10.292201294644192">
<NAME>GFR category G5 treated with dialysis</NAME>
<DICH_DATA CI_END="193.70187095740064" CI_START="0.6105548925028673" EFFECT_SIZE="10.875" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="0" LOG_CI_END="2.287133815569657" LOG_CI_START="-0.21427528431630696" LOG_EFFECT_SIZE="1.036429265626675" MODIFIED="2013-01-15 09:06:34 +1100" MODIFIED_BY="[Empty name]" ORDER="50" O_E="0.0" SE="1.469340087447757" STUDY_ID="STD-ACHIEVE-Study-2008" TOTAL_1="87" TOTAL_2="86" VAR="2.158960292580982" WEIGHT="0.15496120926303567"/>
<DICH_DATA CI_END="76.36262164820675" CI_START="0.2568304292682669" EFFECT_SIZE="4.428571428571429" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="0" LOG_CI_END="1.8828808299862319" LOG_CI_START="-0.5903535223462001" LOG_EFFECT_SIZE="0.6462636538200158" MODIFIED="2013-01-15 18:16:36 +1100" MODIFIED_BY="[Empty name]" ORDER="65" O_E="0.0" SE="1.4527901012675624" STUDY_ID="STD-Akiba-2008" TOTAL_1="90" TOTAL_2="30" VAR="2.110599078341014" WEIGHT="0.15851191309729717"/>
<DICH_DATA CI_END="14.598239348158726" CI_START="0.6165127030291616" EFFECT_SIZE="3.0" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="2" LOG_CI_END="1.1643004799290968" LOG_CI_START="-0.21005797048977184" LOG_EFFECT_SIZE="0.47712125471966244" MODIFIED="2013-01-16 22:22:42 +1100" MODIFIED_BY="[Empty name]" ORDER="117" O_E="0.0" SE="0.8073049569600934" STUDY_ID="STD-IMPACT-SHPT-Study-2012" TOTAL_1="134" TOTAL_2="134" VAR="0.6517412935323382" WEIGHT="0.5133249972178205"/>
<DICH_DATA CI_END="5.921628510667102" CI_START="0.25435542678744594" EFFECT_SIZE="1.2272727272727273" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="2" LOG_CI_END="0.7724411587392137" LOG_CI_START="-0.5945589920656514" LOG_EFFECT_SIZE="0.08894108333678108" MODIFIED="2013-01-16 20:21:09 +1100" MODIFIED_BY="[Empty name]" ORDER="94" O_E="0.0" SE="0.8029826553426572" STUDY_ID="STD-El-Shafey-2011" TOTAL_1="55" TOTAL_2="27" VAR="0.6447811447811447" WEIGHT="0.5188661306198445"/>
<DICH_DATA CI_END="11.220844884060785" CI_START="1.3865838210997552" EFFECT_SIZE="3.9444444444444446" ESTIMABLE="YES" EVENTS_1="16" EVENTS_2="4" LOG_CI_END="1.0500255587624767" LOG_CI_START="0.14194612846906185" LOG_EFFECT_SIZE="0.5959858436157692" MODIFIED="2013-01-16 22:02:18 +1100" MODIFIED_BY="[Empty name]" ORDER="111" O_E="0.0" SE="0.5334103524200272" STUDY_ID="STD-Fukagawa-2008" TOTAL_1="72" TOTAL_2="71" VAR="0.2845266040688576" WEIGHT="1.1758306355361463"/>
<DICH_DATA CI_END="3.4441578763106047" CI_START="1.100323451383865" EFFECT_SIZE="1.9467120181405895" ESTIMABLE="YES" EVENTS_1="68" EVENTS_2="12" LOG_CI_END="0.5370830508068867" LOG_CI_START="0.0415203692513069" LOG_EFFECT_SIZE="0.28930171002909677" ORDER="94136" O_E="0.0" SE="0.29109597222058387" STUDY_ID="STD-Lindberg-2005" TOTAL_1="294" TOTAL_2="101" VAR="0.08473686504304692" WEIGHT="3.948164680381673"/>
<DICH_DATA CI_END="5.876962972103343" CI_START="1.9385755559798803" EFFECT_SIZE="3.3753424657534246" ESTIMABLE="YES" EVENTS_1="88" EVENTS_2="13" LOG_CI_END="0.7691529544438775" LOG_CI_START="0.2874827322999864" LOG_EFFECT_SIZE="0.5283178433719319" MODIFIED="2013-01-17 09:50:28 +1100" MODIFIED_BY="[Empty name]" ORDER="130" O_E="0.0" SE="0.28293547279337483" STUDY_ID="STD-OPTIMA-Study-2008" TOTAL_1="365" TOTAL_2="182" VAR="0.08005248176481054" WEIGHT="4.1791970756400705"/>
<DICH_DATA CI_END="2.5182739580302753" CI_START="1.436501101415315" EFFECT_SIZE="1.9019735314604134" ESTIMABLE="YES" EVENTS_1="111" EVENTS_2="59" LOG_CI_END="0.4011029743774322" LOG_CI_START="0.1573059633167656" LOG_EFFECT_SIZE="0.27920446884709893" MODIFIED="2013-06-02 10:21:27 +1000" MODIFIED_BY="Suetonia Palmer" ORDER="94135" O_E="0.0" SE="0.14320757111170354" STUDY_ID="STD-Block-2004a" TOTAL_1="365" TOTAL_2="369" VAR="0.02050840842371363" WEIGHT="16.31306977982671"/>
<DICH_DATA CI_END="2.1385971206027854" CI_START="1.6316498637134782" EFFECT_SIZE="1.8680047377802795" ESTIMABLE="YES" EVENTS_1="497" EVENTS_2="264" LOG_CI_END="0.33012897775584754" LOG_CI_START="0.2126269690186213" LOG_EFFECT_SIZE="0.2713779733872344" MODIFIED="2013-01-16 21:47:17 +1100" MODIFIED_BY="[Empty name]" ORDER="101" O_E="0.0" SE="0.06902126157657057" STUDY_ID="STD-EVOLVE-study-2007" TOTAL_1="1938" TOTAL_2="1923" VAR="0.004763934549621377" WEIGHT="70.22663603046682"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="3.4806824428123866" CI_START="0.9003311212935459" DF="0" EFFECT_SIZE="1.7702448210922788" ESTIMABLE="YES" EVENTS_1="47" EVENTS_2="9" I2="0.0" ID="CMP-001.08.02" LOG_CI_END="0.5416644025933138" LOG_CI_START="-0.04559773755685456" LOG_EFFECT_SIZE="0.2480333325182296" MODIFIED="2013-06-02 10:20:36 +1000" MODIFIED_BY="Suetonia Palmer" NO="2" P_CHI2="1.0" P_Z="0.09780229871394308" STUDIES="1" TAU2="0.0" TOTAL_1="295" TOTAL_2="100" WEIGHT="2.8114375479505633" Z="1.6556027213907165">
<NAME>GFR category G3a to G4</NAME>
<DICH_DATA CI_END="3.4806824428123866" CI_START="0.9003311212935459" EFFECT_SIZE="1.7702448210922788" ESTIMABLE="YES" EVENTS_1="47" EVENTS_2="9" LOG_CI_END="0.5416644025933138" LOG_CI_START="-0.04559773755685456" LOG_EFFECT_SIZE="0.2480333325182296" MODIFIED="2013-06-02 10:20:36 +1000" MODIFIED_BY="Suetonia Palmer" ORDER="80" O_E="0.0" SE="0.344960688118686" STUDY_ID="STD-Chonchol-2009" TOTAL_1="295" TOTAL_2="100" VAR="0.11899787634731739" WEIGHT="2.8114375479505633"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="5.441036909072242" CI_END="1.29104513777942" CI_START="1.0219218641510157" CI_STUDY="95" CI_TOTAL="95" DF="7" EFFECT_MEASURE="RR" EFFECT_SIZE="1.148628422903878" ESTIMABLE="YES" EVENTS_1="579" EVENTS_2="415" I2="0.0" I2_Q="0.0" ID="CMP-001.09" LOG_CI_END="0.1109414264227642" LOG_CI_START="0.009417691038116323" LOG_EFFECT_SIZE="0.06017955873044024" METHOD="IV" MODIFIED="2014-06-02 16:33:12 +1000" MODIFIED_BY="Narelle Willis" NO="9" P_CHI2="0.6063052182777406" P_Q="1.0" P_Z="0.02014747936375989" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="WEIGHT" STUDIES="8" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="3151" TOTAL_2="2488" WEIGHT="100.00000000000001" Z="2.323589991449662">
<NAME>Diarrhoea</NAME>
<GROUP_LABEL_1>Calcimimetic</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo/no treatment</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours calcimimetic</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_DATA CI_END="24.44164672388626" CI_START="0.04273194393180568" EFFECT_SIZE="1.021978021978022" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.3881304625772635" LOG_CI_START="-1.3692473501115807" LOG_EFFECT_SIZE="0.009441556232841484" MODIFIED="2013-01-15 18:18:34 +1100" MODIFIED_BY="[Empty name]" ORDER="67" O_E="0.0" SE="1.619697376413732" STUDY_ID="STD-Akiba-2008" TOTAL_1="90" TOTAL_2="30" VAR="2.6234195911615266" WEIGHT="0.13556345334541975"/>
<DICH_DATA CI_END="13.50322122851976" CI_START="0.16062283088821697" EFFECT_SIZE="1.4727272727272727" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="1" LOG_CI_END="1.13043738293166" LOG_CI_START="-0.7941927241628483" LOG_EFFECT_SIZE="0.16812232938440588" MODIFIED="2013-01-16 20:22:39 +1100" MODIFIED_BY="[Empty name]" ORDER="96" O_E="0.0" SE="1.1305372519799948" STUDY_ID="STD-El-Shafey-2011" TOTAL_1="55" TOTAL_2="27" VAR="1.2781144781144782" WEIGHT="0.27825349406614874"/>
<DICH_DATA CI_END="4.724017763609372" CI_START="0.4762894875909387" EFFECT_SIZE="1.5" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="4" LOG_CI_END="0.6743115220115501" LOG_CI_START="-0.3221290039001876" LOG_EFFECT_SIZE="0.17609125905568124" MODIFIED="2013-01-16 12:56:18 +1100" MODIFIED_BY="[Empty name]" ORDER="72" O_E="0.0" SE="0.5853140973807077" STUDY_ID="STD-Charytan-2005" TOTAL_1="27" TOTAL_2="27" VAR="0.34259259259259256" WEIGHT="1.0380837970271262"/>
<DICH_DATA CI_END="1.9715455538013602" CI_START="0.2998214099973789" EFFECT_SIZE="0.768837803320562" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="9" LOG_CI_END="0.2948068161726204" LOG_CI_START="-0.5231373577728581" LOG_EFFECT_SIZE="-0.11416527080011885" MODIFIED="2013-01-15 09:12:01 +1100" MODIFIED_BY="[Empty name]" ORDER="56" O_E="0.0" SE="0.48046445666453474" STUDY_ID="STD-ACHIEVE-Study-2008" TOTAL_1="87" TOTAL_2="86" VAR="0.23084609411794657" WEIGHT="1.5405927516805986"/>
<DICH_DATA CI_END="3.4806824428123866" CI_START="0.9003311212935459" EFFECT_SIZE="1.7702448210922788" ESTIMABLE="YES" EVENTS_1="47" EVENTS_2="9" LOG_CI_END="0.5416644025933138" LOG_CI_START="-0.04559773755685456" LOG_EFFECT_SIZE="0.2480333325182296" MODIFIED="2013-01-16 13:28:46 +1100" MODIFIED_BY="[Empty name]" ORDER="83" O_E="0.0" SE="0.344960688118686" STUDY_ID="STD-Chonchol-2009" TOTAL_1="295" TOTAL_2="100" VAR="0.11899787634731739" WEIGHT="2.9886232449551033"/>
<DICH_DATA CI_END="3.2452223612718507" CI_START="1.0014323081773857" EFFECT_SIZE="1.8027397260273972" ESTIMABLE="YES" EVENTS_1="47" EVENTS_2="13" LOG_CI_END="0.5112444598312419" LOG_CI_START="6.215984837196304E-4" LOG_EFFECT_SIZE="0.2559330291574808" MODIFIED="2013-01-17 09:52:27 +1100" MODIFIED_BY="[Empty name]" ORDER="133" O_E="0.0" SE="0.29994239637946324" STUDY_ID="STD-OPTIMA-Study-2008" TOTAL_1="365" TOTAL_2="182" VAR="0.08996544114585503" WEIGHT="3.953071477472226"/>
<DICH_DATA CI_END="2.0193122722466255" CI_START="0.8161201441281517" EFFECT_SIZE="1.2837450769781598" ESTIMABLE="YES" EVENTS_1="71" EVENTS_2="19" LOG_CI_END="0.30520348468253633" LOG_CI_START="-0.08824590240907305" LOG_EFFECT_SIZE="0.10847879113673163" ORDER="94147" O_E="0.0" SE="0.23111411758348804" STUDY_ID="STD-Lindberg-2005" TOTAL_1="294" TOTAL_2="101" VAR="0.05341373534639434" WEIGHT="6.658209111299179"/>
<DICH_DATA CI_END="1.2514032538552295" CI_START="0.9687977586769421" EFFECT_SIZE="1.1010706914344686" ESTIMABLE="YES" EVENTS_1="397" EVENTS_2="360" LOG_CI_END="0.09739727988038206" LOG_CI_START="-0.013766874608359042" LOG_EFFECT_SIZE="0.041815202636011496" MODIFIED="2013-06-02 10:27:55 +1000" MODIFIED_BY="[Empty name]" ORDER="103" O_E="0.0" SE="0.0652983746181259" STUDY_ID="STD-EVOLVE-study-2007" TOTAL_1="1938" TOTAL_2="1935" VAR="0.004263877727769109" WEIGHT="83.4076026701542"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="9.977831601633955" CI_END="4.824740935095555" CI_START="0.5455117641841868" CI_STUDY="95" CI_TOTAL="95" DF="3" EFFECT_MEASURE="RR" EFFECT_SIZE="1.622329479247554" ESTIMABLE="YES" EVENTS_1="62" EVENTS_2="26" I2="69.93334704597817" I2_Q="0.0" ID="CMP-001.10" LOG_CI_END="0.6834739988240537" LOG_CI_START="-0.26319587923661847" LOG_EFFECT_SIZE="0.21013905979371766" METHOD="IV" MODIFIED="2014-06-02 16:33:30 +1000" MODIFIED_BY="Narelle Willis" NO="10" P_CHI2="0.01875555517177041" P_Q="1.0" P_Z="0.38422699750460265" Q="0.0" RANDOM="YES" SCALE="500.0" SORT_BY="WEIGHT" STUDIES="4" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.6761677829330632" TOTALS="YES" TOTAL_1="543" TOTAL_2="288" WEIGHT="100.0" Z="0.8701343488070696">
<NAME>Abdominal pain</NAME>
<GROUP_LABEL_1>Calcimimetic</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo/no treatment</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours calcimimetic</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_DATA CI_END="34.516840930887824" CI_START="0.08405229393009792" EFFECT_SIZE="1.7032967032967032" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" LOG_CI_END="1.5380310411258957" LOG_CI_START="-1.0754504294275" LOG_EFFECT_SIZE="0.23129030584919788" MODIFIED="2013-01-15 18:17:33 +1100" MODIFIED_BY="[Empty name]" ORDER="66" O_E="0.0" SE="1.535171952744988" STUDY_ID="STD-Akiba-2008" TOTAL_1="90" TOTAL_2="30" VAR="2.35675292449486" WEIGHT="10.195564229444837"/>
<DICH_DATA CI_END="255.6870873876233" CI_START="0.8600959111205981" EFFECT_SIZE="14.829545454545455" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="0" LOG_CI_END="2.4077087960048136" LOG_CI_START="-0.06545311695655089" LOG_EFFECT_SIZE="1.1711278395241311" MODIFIED="2013-01-15 09:11:29 +1100" MODIFIED_BY="[Empty name]" ORDER="55" O_E="0.0" SE="1.4527475500224165" STUDY_ID="STD-ACHIEVE-Study-2008" TOTAL_1="87" TOTAL_2="86" VAR="2.1104754440961337" WEIGHT="11.096626068045515"/>
<DICH_DATA CI_END="4.770926533670897" CI_START="1.0318439254423415" EFFECT_SIZE="2.21875" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="8" LOG_CI_END="0.678602729016065" LOG_CI_START="0.013614011782273781" LOG_EFFECT_SIZE="0.3461083703991693" MODIFIED="2013-01-16 22:03:19 +1100" MODIFIED_BY="[Empty name]" ORDER="112" O_E="0.0" SE="0.39061766425036787" STUDY_ID="STD-Fukagawa-2008" TOTAL_1="72" TOTAL_2="71" VAR="0.15258215962441313" WEIGHT="37.31202415528385"/>
<DICH_DATA CI_END="1.1253794495232547" CI_START="0.3964972549790825" EFFECT_SIZE="0.667989417989418" ESTIMABLE="YES" EVENTS_1="35" EVENTS_2="18" LOG_CI_END="0.051298980268711845" LOG_CI_START="-0.4017598150338021" LOG_EFFECT_SIZE="-0.17523041738254513" ORDER="94146" O_E="0.0" SE="0.26612897903790284" STUDY_ID="STD-Lindberg-2005" TOTAL_1="294" TOTAL_2="101" VAR="0.07082463348375653" WEIGHT="41.3957855472258"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="14.92098497122323" CI_END="2.332657647371445" CI_START="0.38910158501569486" CI_STUDY="95" CI_TOTAL="95" DF="3" EFFECT_MEASURE="RR" EFFECT_SIZE="0.9527018357761315" ESTIMABLE="YES" EVENTS_1="105" EVENTS_2="72" I2="79.89408872278987" I2_Q="0.0" ID="CMP-001.11" LOG_CI_END="0.3678510042170003" LOG_CI_START="-0.4099370000824873" LOG_EFFECT_SIZE="-0.02104299793274352" METHOD="IV" MODIFIED="2014-06-02 16:33:52 +1000" MODIFIED_BY="Narelle Willis" NO="11" P_CHI2="0.0018854364713776217" P_Q="1.0" P_Z="0.9155400106892897" Q="0.0" RANDOM="YES" SCALE="500.0" SORT_BY="WEIGHT" STUDIES="4" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.5646864795851043" TOTALS="YES" TOTAL_1="1117" TOTAL_2="739" WEIGHT="100.00000000000001" Z="0.10605336633360399">
<NAME>Upper respiratory tract infection</NAME>
<GROUP_LABEL_1>Calcimimetic</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo/no treatment</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours calcimimetic</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.3294412289134039" CI_START="0.004350281027746335" EFFECT_SIZE="0.07604895104895106" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="6" LOG_CI_END="0.12366914307956836" LOG_CI_START="-2.361482686756342" LOG_EFFECT_SIZE="-1.118906771838387" MODIFIED="2013-01-15 09:07:51 +1100" MODIFIED_BY="[Empty name]" ORDER="52" O_E="0.0" SE="1.4597904865455706" STUDY_ID="STD-ACHIEVE-Study-2008" TOTAL_1="87" TOTAL_2="86" VAR="2.130988264608954" WEIGHT="7.743373286561529"/>
<DICH_DATA CI_END="6.640571508774597" CI_START="1.012414313504991" EFFECT_SIZE="2.592876712328767" ESTIMABLE="YES" EVENTS_1="26" EVENTS_2="5" LOG_CI_END="0.82220545774547" LOG_CI_START="0.005358276581328489" LOG_EFFECT_SIZE="0.4137818671633992" MODIFIED="2013-01-17 09:50:41 +1100" MODIFIED_BY="[Empty name]" ORDER="131" O_E="0.0" SE="0.4798200776745756" STUDY_ID="STD-OPTIMA-Study-2008" TOTAL_1="365" TOTAL_2="182" VAR="0.23022730693963572" WEIGHT="26.258968151386075"/>
<DICH_DATA CI_END="2.459114626222863" CI_START="0.7976903687312762" EFFECT_SIZE="1.400575614861329" ESTIMABLE="YES" EVENTS_1="53" EVENTS_2="13" LOG_CI_END="0.3907787728931801" LOG_CI_START="-0.09816565156430501" LOG_EFFECT_SIZE="0.14630656066443753" ORDER="94143" O_E="0.0" SE="0.28720837524026216" STUDY_ID="STD-Lindberg-2005" TOTAL_1="294" TOTAL_2="101" VAR="0.08248865080815122" WEIGHT="32.253426967700406"/>
<DICH_DATA CI_END="0.8514753882196953" CI_START="0.3427265512710046" EFFECT_SIZE="0.5402066486972147" ESTIMABLE="YES" EVENTS_1="26" EVENTS_2="48" LOG_CI_END="-0.06982790074289896" LOG_CI_START="-0.46505224916274135" LOG_EFFECT_SIZE="-0.2674400749528202" ORDER="94142" O_E="0.0" SE="0.23215673865389236" STUDY_ID="STD-Block-2004a" TOTAL_1="371" TOTAL_2="370" VAR="0.05389675130241168" WEIGHT="33.744231594352"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="5.337501505430584" CI_END="2.5846376978527723" CI_START="0.9271599024436245" CI_STUDY="95" CI_TOTAL="95" DF="5" EFFECT_MEASURE="RR" EFFECT_SIZE="1.5480221044265778" ESTIMABLE="YES" EVENTS_1="99" EVENTS_2="19" I2="6.3232114330496545" I2_Q="0.0" ID="CMP-001.12" LOG_CI_END="0.41239967437355907" LOG_CI_START="-0.03284535888659524" LOG_EFFECT_SIZE="0.18977715774348192" METHOD="IV" MODIFIED="2014-06-02 16:34:07 +1000" MODIFIED_BY="Narelle Willis" NO="12" P_CHI2="0.37609355903362063" P_Q="0.8809989045217073" P_Z="0.09476234814824397" Q="0.022411006943843976" RANDOM="YES" SCALE="100.0" SORT_BY="WEIGHT" STUDIES="5" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.03209590193591562" TOTALS="YES" TOTAL_1="1017" TOTAL_2="362" WEIGHT="100.0" Z="1.6707941312318653">
<NAME>Asthenia, muscle weakness or paraesthesia</NAME>
<GROUP_LABEL_1>Calcimimetic</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo/no treatment</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours calcimimetic</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="4.259495613766379" CI_END="8.97952056089854" CI_START="0.2647989841981706" DF="1" EFFECT_SIZE="1.542001272085247" ESTIMABLE="YES" EVENTS_1="36" EVENTS_2="8" I2="76.52304191209699" ID="CMP-001.12.01" LOG_CI_END="0.9532531492157779" LOG_CI_START="-0.5770836852367764" LOG_EFFECT_SIZE="0.18808473198950068" MODIFIED="2013-01-16 13:28:13 +1100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.03903167191683765" P_Z="0.6299655263665802" STUDIES="2" TAU2="1.2467154900896098" TOTAL_1="589" TOTAL_2="201" WEIGHT="37.66107717489258" Z="0.4817753744693244">
<NAME>Asthenia</NAME>
<DICH_DATA CI_END="17.13493236147121" CI_START="0.9918093185795697" EFFECT_SIZE="4.122448979591836" ESTIMABLE="YES" EVENTS_1="24" EVENTS_2="2" LOG_CI_END="1.2338823944327784" LOG_CI_START="-0.0035718155965580845" LOG_EFFECT_SIZE="0.61515528941811" ORDER="94138" O_E="0.0" SE="0.7268867284683626" STUDY_ID="STD-Lindberg-2005" TOTAL_1="294" TOTAL_2="101" VAR="0.528364316023439" WEIGHT="12.204741344314726"/>
<DICH_DATA CI_END="1.7589539436447135" CI_START="0.26131328606307225" EFFECT_SIZE="0.6779661016949152" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="6" LOG_CI_END="0.2452544680630206" LOG_CI_START="-0.5828385086913843" LOG_EFFECT_SIZE="-0.1687920203141818" MODIFIED="2013-01-16 13:28:13 +1100" MODIFIED_BY="[Empty name]" ORDER="82" O_E="0.0" SE="0.4864259136718822" STUDY_ID="STD-Chonchol-2009" TOTAL_1="295" TOTAL_2="100" VAR="0.2366101694915254" WEIGHT="25.456335830577853"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.4180097535821421" CI_END="3.144997415181176" CI_START="1.003293000743018" DF="3" EFFECT_SIZE="1.7763315833498423" ESTIMABLE="YES" EVENTS_1="63" EVENTS_2="11" I2="0.0" ID="CMP-001.12.02" LOG_CI_END="0.49762029284233283" LOG_CI_START="0.0014277824952892665" LOG_EFFECT_SIZE="0.24952403766881104" MODIFIED="2013-01-16 13:27:43 +1100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.9364974989311459" P_Z="0.04869603200224733" STUDIES="4" TAU2="0.0" TOTAL_1="428" TOTAL_2="161" WEIGHT="62.33892282510742" Z="1.9712434867903665">
<NAME>Muscle weakness or paraesthesia</NAME>
<DICH_DATA CI_END="24.44164672388626" CI_START="0.04273194393180568" EFFECT_SIZE="1.021978021978022" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.3881304625772635" LOG_CI_START="-1.3692473501115807" LOG_EFFECT_SIZE="0.009441556232841484" MODIFIED="2013-01-15 18:20:56 +1100" MODIFIED_BY="[Empty name]" ORDER="68" O_E="0.0" SE="1.619697376413732" STUDY_ID="STD-Akiba-2008" TOTAL_1="90" TOTAL_2="30" VAR="2.6234195911615266" WEIGHT="2.575873502433819"/>
<DICH_DATA CI_END="70.53181155968163" CI_START="0.12760199690014357" EFFECT_SIZE="3.0" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.8483850385343752" LOG_CI_START="-0.8941425290950501" LOG_EFFECT_SIZE="0.47712125471966244" MODIFIED="2013-01-16 12:55:23 +1100" MODIFIED_BY="[Empty name]" ORDER="71" O_E="0.0" SE="1.6109742689559308" STUDY_ID="STD-Charytan-2005" TOTAL_1="27" TOTAL_2="27" VAR="2.5952380952380953" WEIGHT="2.603503019155406"/>
<DICH_DATA CI_END="49.0108998342363" CI_START="0.21356735059105986" EFFECT_SIZE="3.235294117647059" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="0" LOG_CI_END="1.6902926761803703" LOG_CI_START="-0.6704651399484305" LOG_EFFECT_SIZE="0.5099137681159699" ORDER="94139" O_E="0.0" SE="1.386720827133716" STUDY_ID="STD-Goodman-2000" TOTAL_1="16" TOTAL_2="4" VAR="1.9229946524064172" WEIGHT="3.4986982975185805"/>
<DICH_DATA CI_END="3.1611892547455724" CI_START="0.9420981580652359" EFFECT_SIZE="1.7257318952234206" ESTIMABLE="YES" EVENTS_1="56" EVENTS_2="11" LOG_CI_END="0.4998504970516247" LOG_CI_START="-0.025903845311999935" LOG_EFFECT_SIZE="0.23697332586981237" MODIFIED="2013-01-16 13:27:43 +1100" MODIFIED_BY="[Empty name]" ORDER="81" O_E="0.0" SE="0.3088307032303608" STUDY_ID="STD-Chonchol-2009" TOTAL_1="295" TOTAL_2="100" VAR="0.09537640325775919" WEIGHT="53.66084800599961"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.7826231412650057" CI_END="2.118660172015707" CI_START="0.48967141086471183" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="1.018551577277167" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="13" I2="0.0" I2_Q="0.0" ID="CMP-001.13" LOG_CI_END="0.32606130250885285" LOG_CI_START="-0.3100952512322289" LOG_EFFECT_SIZE="0.00798302563831199" METHOD="IV" MODIFIED="2014-06-02 16:35:26 +1000" MODIFIED_BY="Narelle Willis" NO="13" P_CHI2="0.37634013304784053" P_Q="1.0" P_Z="0.9607674487798106" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="WEIGHT" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="125" TOTAL_2="125" WEIGHT="100.0" Z="0.04919054168895504">
<NAME>Dyspnoea</NAME>
<GROUP_LABEL_1>Calcimimetic</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo/no treatment</GROUP_LABEL_2>
<GRAPH_LABEL_1>Less with calcimimetic</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Less with placebo</GRAPH_LABEL_2>
<DICH_DATA CI_END="4.135291243972951" CI_START="0.4992430069988482" EFFECT_SIZE="1.436842105263158" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="5" LOG_CI_END="0.6165061018440947" LOG_CI_START="-0.3016880096682406" LOG_EFFECT_SIZE="0.15740904608792708" ORDER="94137" O_E="0.0" SE="0.5393517662365008" STUDY_ID="STD-Lindberg-2003" TOTAL_1="38" TOTAL_2="39" VAR="0.290900327742433" WEIGHT="48.001963773273125"/>
<DICH_DATA CI_END="2.047123282610565" CI_START="0.2684954474781056" EFFECT_SIZE="0.7413793103448276" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="8" LOG_CI_END="0.31114399769194834" LOG_CI_START="-0.5710630736586498" LOG_EFFECT_SIZE="-0.12995953798335072" MODIFIED="2013-01-15 09:07:09 +1100" MODIFIED_BY="[Empty name]" ORDER="51" O_E="0.0" SE="0.5182128007067746" STUDY_ID="STD-ACHIEVE-Study-2008" TOTAL_1="87" TOTAL_2="86" VAR="0.2685445068163592" WEIGHT="51.99803622672687"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="2.6783005673573093" CI_END="1.9055912664235735" CI_START="0.6488604217673848" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="RR" EFFECT_SIZE="1.111963467407021" ESTIMABLE="YES" EVENTS_1="74" EVENTS_2="29" I2="25.325782162925474" I2_Q="0.0" ID="CMP-001.14" LOG_CI_END="0.28002975371429994" LOG_CI_START="-0.18784871548871152" LOG_EFFECT_SIZE="0.04609051911279422" METHOD="IV" MODIFIED="2014-06-02 16:35:03 +1000" MODIFIED_BY="Narelle Willis" NO="14" P_CHI2="0.2620684410163091" P_Q="1.0" P_Z="0.6993851959544335" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="WEIGHT" STUDIES="3" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.06732733237347589" TOTALS="YES" TOTAL_1="746" TOTAL_2="369" WEIGHT="100.0" Z="0.38615052171009456">
<NAME>Headache</NAME>
<GROUP_LABEL_1>Calcimimetic</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo/no treatment</GROUP_LABEL_2>
<GRAPH_LABEL_1>Less with calcimimetic</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Less with placebo</GRAPH_LABEL_2>
<DICH_DATA CI_END="3.7417295611462684" CI_START="0.3760525121959416" EFFECT_SIZE="1.186206896551724" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="5" LOG_CI_END="0.5730723950436805" LOG_CI_START="-0.4247515056985325" LOG_EFFECT_SIZE="0.074160444672574" MODIFIED="2013-01-15 09:10:50 +1100" MODIFIED_BY="[Empty name]" ORDER="54" O_E="0.0" SE="0.5861266986039446" STUDY_ID="STD-ACHIEVE-Study-2008" TOTAL_1="87" TOTAL_2="86" VAR="0.3435445068163593" WEIGHT="18.38378569027072"/>
<DICH_DATA CI_END="6.533219139540061" CI_START="0.7706458586588524" EFFECT_SIZE="2.243835616438356" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="4" LOG_CI_END="0.815127225692777" LOG_CI_START="-0.11314515108488928" LOG_EFFECT_SIZE="0.35099103730394376" MODIFIED="2013-01-17 09:51:35 +1100" MODIFIED_BY="[Empty name]" ORDER="132" O_E="0.0" SE="0.5452717891415737" STUDY_ID="STD-OPTIMA-Study-2008" TOTAL_1="365" TOTAL_2="182" VAR="0.29732132403365286" WEIGHT="20.714130451642163"/>
<DICH_DATA CI_END="1.3696068974146935" CI_START="0.5385576132478513" EFFECT_SIZE="0.858843537414966" ESTIMABLE="YES" EVENTS_1="50" EVENTS_2="20" LOG_CI_END="0.1365959344691747" LOG_CI_START="-0.2687678303841289" LOG_EFFECT_SIZE="-0.0660859479574771" ORDER="94145" O_E="0.0" SE="0.23811268205782826" STUDY_ID="STD-Lindberg-2005" TOTAL_1="294" TOTAL_2="101" VAR="0.05669764935677241" WEIGHT="60.90208385808711"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="125.13702369373617" CI_END="4.983221660718768" CI_START="1.885148938836232" CI_STUDY="95" CI_TOTAL="95" DF="10" EFFECT_MEASURE="RR" EFFECT_SIZE="3.0649820596032384" ESTIMABLE="YES" EVENTS_1="1112" EVENTS_2="230" I2="92.00875991387308" I2_Q="0.0" ID="CMP-001.15" LOG_CI_END="0.6975102056310127" LOG_CI_START="0.27534566794205106" LOG_EFFECT_SIZE="0.48642793678653184" METHOD="IV" MODIFIED="2014-12-08 16:15:06 +1100" MODIFIED_BY="Narelle Willis" NO="15" P_CHI2="-4.440892098500626E-16" P_Q="1.0" P_Z="6.283052531303507E-6" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="WEIGHT" STUDIES="11" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.5626223094705849" TOTALS="YES" TOTAL_1="1728" TOTAL_2="1125" WEIGHT="100.00000000000001" Z="4.516633454788909">
<NAME>Achievement of PTH target</NAME>
<GROUP_LABEL_1>Calcimimetic</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo/no treatment</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours placebo</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours calcimimetic</GRAPH_LABEL_2>
<DICH_DATA CI_END="72.84807564378515" CI_START="4.568536273085197" EFFECT_SIZE="18.243055555555557" ESTIMABLE="YES" EVENTS_1="37" EVENTS_2="2" LOG_CI_END="1.8624180839258626" LOG_CI_START="0.659777077455779" LOG_EFFECT_SIZE="1.2610975806908207" MODIFIED="2013-06-02 14:19:03 +1000" MODIFIED_BY="[Empty name]" ORDER="108" O_E="0.0" SE="0.7064372803695206" STUDY_ID="STD-Fukagawa-2008" TOTAL_1="72" TOTAL_2="71" VAR="0.49905363109588463" WEIGHT="5.792242380907117"/>
<DICH_DATA CI_END="15.341907512134597" CI_START="1.4951894445721066" EFFECT_SIZE="4.7894736842105265" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="3" LOG_CI_END="1.185879360296913" LOG_CI_START="0.17469622243961636" LOG_EFFECT_SIZE="0.6802877913682647" ORDER="94123" O_E="0.0" SE="0.5939739806146351" STUDY_ID="STD-Lindberg-2003" TOTAL_1="38" TOTAL_2="39" VAR="0.3528050896471949" WEIGHT="6.717610138897897"/>
<DICH_DATA CI_END="7.090456930116108" CI_START="1.2693117084984007" EFFECT_SIZE="3.0" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="5" LOG_CI_END="0.8506742233119523" LOG_CI_START="0.10356828612737265" LOG_EFFECT_SIZE="0.47712125471966244" MODIFIED="2013-01-15 19:00:15 +1100" MODIFIED_BY="[Empty name]" ORDER="70" O_E="0.0" SE="0.43885372573625553" STUDY_ID="STD-Charytan-2005" TOTAL_1="27" TOTAL_2="27" VAR="0.1925925925925926" WEIGHT="8.142694696487988"/>
<DICH_DATA CI_END="6.821124531436914" CI_START="1.3194305364930923" EFFECT_SIZE="3.0" ESTIMABLE="YES" EVENTS_1="30" EVENTS_2="5" LOG_CI_END="0.8338559784011349" LOG_CI_START="0.12038653103818997" LOG_EFFECT_SIZE="0.47712125471966244" MODIFIED="2013-06-02 14:19:04 +1000" MODIFIED_BY="[Empty name]" ORDER="90" O_E="0.0" SE="0.4190954851117173" STUDY_ID="STD-El-Shafey-2011" TOTAL_1="52" TOTAL_2="26" VAR="0.17564102564102566" WEIGHT="8.32966244600086"/>
<DICH_DATA CI_END="4.569465075420672" CI_START="1.1667906834934167" EFFECT_SIZE="2.3090277777777777" ESTIMABLE="YES" EVENTS_1="19" EVENTS_2="8" LOG_CI_END="0.6598653623476455" LOG_CI_START="0.06699295274010199" LOG_EFFECT_SIZE="0.3634291575438737" ORDER="94125" O_E="0.0" SE="0.3482561881692299" STUDY_ID="STD-Quarles-2003a" TOTAL_1="36" TOTAL_2="35" VAR="0.12128237259816206" WEIGHT="8.991727266929832"/>
<DICH_DATA CI_END="8.441575498420399" CI_START="3.0178983500805847" EFFECT_SIZE="5.047357404500262" ESTIMABLE="YES" EVENTS_1="191" EVENTS_2="13" LOG_CI_END="0.9264235089971472" LOG_CI_START="0.47970460762560474" LOG_EFFECT_SIZE="0.7030640583113761" ORDER="94124" O_E="0.0" SE="0.26240489395986916" STUDY_ID="STD-Lindberg-2005" TOTAL_1="294" TOTAL_2="101" VAR="0.06885632837409018" WEIGHT="9.738230257048095"/>
<DICH_DATA CI_END="2.7177499515068115" CI_START="1.3173846678636563" EFFECT_SIZE="1.8921739130434783" ESTIMABLE="YES" EVENTS_1="51" EVENTS_2="23" LOG_CI_END="0.4342094966656765" LOG_CI_START="0.11971260467938477" LOG_EFFECT_SIZE="0.27696105067253063" MODIFIED="2013-01-15 09:03:56 +1100" MODIFIED_BY="[Empty name]" ORDER="47" O_E="0.0" SE="0.1847370311374706" STUDY_ID="STD-ACHIEVE-Study-2008" TOTAL_1="75" TOTAL_2="64" VAR="0.03412777067348678" WEIGHT="10.304957774373282"/>
<DICH_DATA CI_END="3.593261276570576" CI_START="1.8907660294488668" EFFECT_SIZE="2.6065333983422723" ESTIMABLE="YES" EVENTS_1="216" EVENTS_2="28" LOG_CI_END="0.5554887971788627" LOG_CI_START="0.2766377909254416" LOG_EFFECT_SIZE="0.41606329405215214" MODIFIED="2013-01-16 13:21:05 +1100" MODIFIED_BY="[Empty name]" ORDER="77" O_E="0.0" SE="0.1637984614080022" STUDY_ID="STD-Chonchol-2009" TOTAL_1="293" TOTAL_2="99" VAR="0.026829935959628785" WEIGHT="10.432540422761997"/>
<DICH_DATA CI_END="0.9200468032230286" CI_START="0.5073553866771886" EFFECT_SIZE="0.6832208293153327" ESTIMABLE="YES" EVENTS_1="39" EVENTS_2="61" LOG_CI_END="-0.036190079323486654" LOG_CI_START="-0.2946877242876369" LOG_EFFECT_SIZE="-0.16543890180556176" MODIFIED="2013-06-02 14:19:05 +1000" MODIFIED_BY="[Empty name]" ORDER="114" O_E="0.0" SE="0.15184279623592126" STUDY_ID="STD-IMPACT-SHPT-Study-2012" TOTAL_1="102" TOTAL_2="109" VAR="0.0230562347687435" WEIGHT="10.49976038600731"/>
<DICH_DATA CI_END="7.619515308996764" CI_START="4.226934362981568" EFFECT_SIZE="5.67513797972019" ESTIMABLE="YES" EVENTS_1="239" EVENTS_2="42" LOG_CI_END="0.8819273459691164" LOG_CI_START="0.626025504035256" LOG_EFFECT_SIZE="0.7539764250021863" ORDER="94122" O_E="0.0" SE="0.1503180086864968" STUDY_ID="STD-Block-2004a" TOTAL_1="371" TOTAL_2="370" VAR="0.022595503735473733" WEIGHT="10.508026650879236"/>
<DICH_DATA CI_END="4.324696959590378" CI_START="2.461191234774554" EFFECT_SIZE="3.2625" ESTIMABLE="YES" EVENTS_1="261" EVENTS_2="40" LOG_CI_END="0.6359556809595305" LOG_CI_START="0.3911453597331444" LOG_EFFECT_SIZE="0.5135505203463374" MODIFIED="2013-06-02 14:19:06 +1000" MODIFIED_BY="[Empty name]" ORDER="127" O_E="0.0" SE="0.14380279451901343" STUDY_ID="STD-OPTIMA-Study-2008" TOTAL_1="368" TOTAL_2="184" VAR="0.020679243711477596" WEIGHT="10.542547579706389"/>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="9.156441576704937" CI_END="-234.93768641944308" CI_START="-325.8442160562784" CI_STUDY="95" CI_TOTAL="95" DF="6" EFFECT_MEASURE="MD" EFFECT_SIZE="-280.39095123786075" ESTIMABLE="YES" I2="34.47236079936659" I2_Q="0.0" ID="CMP-001.16" MODIFIED="2014-06-02 16:38:56 +1000" MODIFIED_BY="Narelle Willis" NO="16" P_CHI2="0.1649692724933689" P_Q="1.0" P_Z="1.1845290691570906E-33" Q="0.0" RANDOM="YES" SCALE="1000.0" SORT_BY="WEIGHT" STUDIES="7" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="1116.5269374440693" TOTALS="YES" TOTAL_1="1173" TOTAL_2="762" UNITS="pg/mL" WEIGHT="100.0" Z="12.090576292210667">
<NAME>PTH</NAME>
<GROUP_LABEL_1>Calcimimetic</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo/no treatment</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours calcimimetic</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<CONT_DATA CI_END="-210.97677748179956" CI_START="-833.0232225182004" EFFECT_SIZE="-522.0" ESTIMABLE="YES" MEAN_1="307.0" MEAN_2="829.0" MODIFIED="2013-01-17 09:36:48 +1100" MODIFIED_BY="[Empty name]" ORDER="117" SD_1="218.0" SD_2="543.0" SE="158.6882335448569" STUDY_ID="STD-Malluche-2008" TOTAL_1="19" TOTAL_2="13" WEIGHT="2.045047015265362"/>
<CONT_DATA CI_END="115.10630311422119" CI_START="-317.1063031142212" EFFECT_SIZE="-101.0" ESTIMABLE="YES" MEAN_1="451.0" MEAN_2="552.0" MODIFIED="2013-06-02 14:25:52 +1000" MODIFIED_BY="Suetonia Palmer" ORDER="94152" SD_1="444.0" SD_2="444.0" SE="110.2603439751139" STUDY_ID="STD-Quarles-2003a" TOTAL_1="34" TOTAL_2="31" WEIGHT="4.051691884906227"/>
<CONT_DATA CI_END="-72.71374323550836" CI_START="-409.28625676449167" EFFECT_SIZE="-241.0" ESTIMABLE="YES" MEAN_1="460.0" MEAN_2="701.0" ORDER="94150" SD_1="289.7" SD_2="437.1" SE="85.8619128167212" STUDY_ID="STD-Lindberg-2003" TOTAL_1="38" TOTAL_2="37" WEIGHT="6.335602742324776"/>
<CONT_DATA CI_END="-203.4428838791913" CI_START="-449.5571161208087" EFFECT_SIZE="-326.5" ESTIMABLE="YES" MEAN_1="525.5" MEAN_2="852.0" MODIFIED="2013-06-02 14:26:16 +1000" MODIFIED_BY="Suetonia Palmer" ORDER="94151" SD_1="510.81" SD_2="551.0" SE="62.78539661517637" STUDY_ID="STD-Lindberg-2005" TOTAL_1="288" TOTAL_2="100" WEIGHT="10.631863686644405"/>
<CONT_DATA CI_END="-162.52331227247956" CI_START="-359.47668772752047" EFFECT_SIZE="-261.0" ESTIMABLE="YES" MEAN_1="334.0" MEAN_2="595.0" MODIFIED="2013-01-16 19:53:11 +1100" MODIFIED_BY="[Empty name]" ORDER="84" SD_1="189.0" SD_2="225.0" SE="50.24413127194784" STUDY_ID="STD-El-Shafey-2011" TOTAL_1="55" TOTAL_2="27" WEIGHT="14.771117247139504"/>
<CONT_DATA CI_END="-265.788089207839" CI_START="-372.211910792161" EFFECT_SIZE="-319.0" ESTIMABLE="YES" MEAN_1="374.0" MEAN_2="693.0" MODIFIED="2013-06-02 14:26:34 +1000" MODIFIED_BY="Suetonia Palmer" ORDER="94149" SD_1="366.0" SD_2="373.0" SE="27.149432954834772" STUDY_ID="STD-Block-2004a" TOTAL_1="371" TOTAL_2="370" WEIGHT="29.014400035944053"/>
<CONT_DATA CI_END="-210.91904083427954" CI_START="-299.08095916572046" EFFECT_SIZE="-255.0" ESTIMABLE="YES" MEAN_1="264.0" MEAN_2="519.0" MODIFIED="2013-01-17 09:42:20 +1100" MODIFIED_BY="[Empty name]" ORDER="122" SD_1="168.0" SD_2="281.0" SE="22.490698560496746" STUDY_ID="STD-OPTIMA-Study-2008" TOTAL_1="368" TOTAL_2="184" WEIGHT="33.15027738777568"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="7.282511162379882" CI_END="-0.7719023010639332" CI_START="-0.9603490731742668" CI_STUDY="95" CI_TOTAL="95" DF="6" EFFECT_MEASURE="MD" EFFECT_SIZE="-0.8661256871191" ESTIMABLE="YES" I2="17.610836891058952" I2_Q="0.0" ID="CMP-001.17" MODIFIED="2014-06-10 15:35:04 +1000" MODIFIED_BY="Narelle Willis" NO="17" P_CHI2="0.2955091637243511" P_Q="1.0" P_Z="1.4462098959769826E-72" Q="0.0" RANDOM="YES" SCALE="2.0" SORT_BY="WEIGHT" STUDIES="7" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.002848345900126126" TOTALS="YES" TOTAL_1="1050" TOTAL_2="506" UNITS="mg/dL" WEIGHT="99.99999999999999" Z="18.016494884237453">
<NAME>Serum calcium</NAME>
<GROUP_LABEL_1>Calcimimetic</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo/no treatment</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours calcimimetic</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<CONT_DATA CI_END="0.09566566310449065" CI_START="-1.2956656631044936" EFFECT_SIZE="-0.6000000000000014" ESTIMABLE="YES" MEAN_1="9.2" MEAN_2="9.8" MODIFIED="2013-01-17 09:37:44 +1100" MODIFIED_BY="[Empty name]" ORDER="118" SD_1="0.83" SD_2="1.08" SE="0.35493798283632455" STUDY_ID="STD-Malluche-2008" TOTAL_1="19" TOTAL_2="13" WEIGHT="1.793934268820121"/>
<CONT_DATA CI_END="-0.42023436181388746" CI_START="-0.9797656381861146" EFFECT_SIZE="-0.7000000000000011" ESTIMABLE="YES" MEAN_1="9.2" MEAN_2="9.9" ORDER="94155" SD_1="0.58" SD_2="0.57" SE="0.142740193387669" STUDY_ID="STD-Quarles-2003a" TOTAL_1="34" TOTAL_2="31" WEIGHT="9.951782532686106"/>
<CONT_DATA CI_END="-0.7217601757551566" CI_START="-1.2782398242448434" EFFECT_SIZE="-1.0" ESTIMABLE="YES" MEAN_1="9.1" MEAN_2="10.1" MODIFIED="2013-06-02 14:29:32 +1000" MODIFIED_BY="Suetonia Palmer" ORDER="94154" SD_1="1.71" SD_2="1.0" SE="0.14196170258206964" STUDY_ID="STD-Lindberg-2005" TOTAL_1="288" TOTAL_2="100" WEIGHT="10.047676020510822"/>
<CONT_DATA CI_END="-0.49734443827334524" CI_START="-1.0226555617266544" EFFECT_SIZE="-0.7599999999999998" ESTIMABLE="YES" MEAN_1="8.88" MEAN_2="9.64" MODIFIED="2013-01-16 19:55:13 +1100" MODIFIED_BY="[Empty name]" ORDER="85" SD_1="0.72" SD_2="0.48" SE="0.13401040212904325" STUDY_ID="STD-El-Shafey-2011" TOTAL_1="55" TOTAL_2="27" WEIGHT="11.107312042847704"/>
<CONT_DATA CI_END="-0.7090925755827723" CI_START="-1.19090742441723" EFFECT_SIZE="-0.9500000000000011" ESTIMABLE="YES" MEAN_1="9.29" MEAN_2="10.24" MODIFIED="2013-01-16 21:54:13 +1100" MODIFIED_BY="[Empty name]" ORDER="104" SD_1="0.82" SD_2="0.64" SE="0.12291420981072908" STUDY_ID="STD-Fukagawa-2008" TOTAL_1="72" TOTAL_2="71" WEIGHT="12.870802205268339"/>
<CONT_DATA CI_END="-0.8303679285308925" CI_START="-1.1696320714691075" EFFECT_SIZE="-1.0" ESTIMABLE="YES" MEAN_1="8.9" MEAN_2="9.9" MODIFIED="2013-01-16 13:16:41 +1100" MODIFIED_BY="[Empty name]" ORDER="73" SD_1="0.8" SD_2="0.6" SE="0.08654856558954328" STUDY_ID="STD-Chonchol-2009" TOTAL_1="214" TOTAL_2="80" WEIGHT="22.353353828820403"/>
<CONT_DATA CI_END="-0.6699585842568212" CI_START="-0.9300414157431802" EFFECT_SIZE="-0.8000000000000007" ESTIMABLE="YES" MEAN_1="9.0" MEAN_2="9.8" MODIFIED="2013-01-17 09:43:19 +1100" MODIFIED_BY="[Empty name]" ORDER="123" SD_1="0.8" SD_2="0.7" SE="0.0663488802697037" STUDY_ID="STD-OPTIMA-Study-2008" TOTAL_1="368" TOTAL_2="184" WEIGHT="31.875139101046493"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="58.55931728271693" CI_END="0.11876201317484508" CI_START="-0.5751554616521051" CI_STUDY="95" CI_TOTAL="95" DF="7" EFFECT_MEASURE="MD" EFFECT_SIZE="-0.22819672423863002" ESTIMABLE="YES" I2="88.04630872623584" I2_Q="0.0" ID="CMP-001.18" MODIFIED="2014-06-10 15:35:20 +1000" MODIFIED_BY="Narelle Willis" NO="18" P_CHI2="2.925545361520676E-10" P_Q="1.0" P_Z="0.19737048453154968" Q="0.0" RANDOM="YES" SCALE="2.0" SORT_BY="WEIGHT" STUDIES="8" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.203672930462386" TOTALS="YES" TOTAL_1="1423" TOTAL_2="877" UNITS="mg/dL" WEIGHT="100.0" Z="1.2890793995619458">
<NAME>Serum phosphorous</NAME>
<GROUP_LABEL_1>Calcimimetic</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo/no treatment</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours calcimimetic</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<CONT_DATA CI_END="0.7575027846311889" CI_START="-1.1575027846311876" EFFECT_SIZE="-0.1999999999999993" ESTIMABLE="YES" MEAN_1="5.9" MEAN_2="6.1" MODIFIED="2013-01-17 09:38:38 +1100" MODIFIED_BY="[Empty name]" ORDER="119" SD_1="1.57" SD_2="1.19" SE="0.4885308057616609" STUDY_ID="STD-Malluche-2008" TOTAL_1="19" TOTAL_2="13" WEIGHT="7.084478674744121"/>
<CONT_DATA CI_END="0.65438552613208" CI_START="-0.4543855261320807" EFFECT_SIZE="0.09999999999999964" ESTIMABLE="YES" MEAN_1="5.8" MEAN_2="5.7" ORDER="94158" SD_1="1.17" SD_2="1.11" SE="0.2828549557568418" STUDY_ID="STD-Quarles-2003a" TOTAL_1="34" TOTAL_2="31" WEIGHT="11.046659737270488"/>
<CONT_DATA CI_END="-0.013189622265495582" CI_START="-0.9868103777345044" EFFECT_SIZE="-0.5" ESTIMABLE="YES" MEAN_1="5.55" MEAN_2="6.05" MODIFIED="2013-01-16 21:55:36 +1100" MODIFIED_BY="[Empty name]" ORDER="105" SD_1="1.48" SD_2="1.49" SE="0.24837720569071806" STUDY_ID="STD-Fukagawa-2008" TOTAL_1="72" TOTAL_2="71" WEIGHT="11.80911080335248"/>
<CONT_DATA CI_END="-0.39553810507686554" CI_START="-1.0844618949231348" EFFECT_SIZE="-0.7400000000000002" ESTIMABLE="YES" MEAN_1="4.55" MEAN_2="5.29" MODIFIED="2013-01-16 19:56:12 +1100" MODIFIED_BY="[Empty name]" ORDER="86" SD_1="0.87" SD_2="0.68" SE="0.17574909418754942" STUDY_ID="STD-El-Shafey-2011" TOTAL_1="55" TOTAL_2="27" WEIGHT="13.359932795038302"/>
<CONT_DATA CI_END="-0.12279564134120585" CI_START="-0.6772043586587948" EFFECT_SIZE="-0.40000000000000036" ESTIMABLE="YES" MEAN_1="5.6" MEAN_2="6.0" ORDER="94156" SD_1="1.93" SD_2="1.92" SE="0.14143339410588515" STUDY_ID="STD-Block-2004a" TOTAL_1="371" TOTAL_2="370" WEIGHT="14.010041976866756"/>
<CONT_DATA CI_END="-0.02281923513006423" CI_START="-0.5771807648699354" EFFECT_SIZE="-0.2999999999999998" ESTIMABLE="YES" MEAN_1="5.5" MEAN_2="5.8" ORDER="94157" SD_1="1.7" SD_2="1.0" SE="0.1414213562373095" STUDY_ID="STD-Lindberg-2005" TOTAL_1="289" TOTAL_2="100" WEIGHT="14.010255251440764"/>
<CONT_DATA CI_END="-0.028527068798245014" CI_START="-0.5714729312017564" EFFECT_SIZE="-0.3000000000000007" ESTIMABLE="YES" MEAN_1="5.1" MEAN_2="5.4" MODIFIED="2013-01-17 09:44:05 +1100" MODIFIED_BY="[Empty name]" ORDER="124" SD_1="1.6" SD_2="1.5" SE="0.13850914268991651" STUDY_ID="STD-OPTIMA-Study-2008" TOTAL_1="368" TOTAL_2="184" WEIGHT="14.061505008876553"/>
<CONT_DATA CI_END="0.7027454189941967" CI_START="0.29725458100580326" EFFECT_SIZE="0.5" ESTIMABLE="YES" MEAN_1="4.5" MEAN_2="4.0" MODIFIED="2013-01-16 13:17:47 +1100" MODIFIED_BY="[Empty name]" ORDER="74" SD_1="1.0" SD_2="0.7" SE="0.10344344110066649" STUDY_ID="STD-Chonchol-2009" TOTAL_1="215" TOTAL_2="81" WEIGHT="14.618015752410535"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="80.31070647850602" CI_END="-1.3356010837368237" CI_START="-9.162566302513888" CI_STUDY="95" CI_TOTAL="95" DF="7" EFFECT_MEASURE="MD" EFFECT_SIZE="-5.249083693125356" ESTIMABLE="YES" I2="91.28385204546363" I2_Q="0.0" ID="CMP-001.19" MODIFIED="2014-06-10 15:35:59 +1000" MODIFIED_BY="Narelle Willis" NO="19" P_CHI2="1.1657341758564144E-14" P_Q="1.0" P_Z="0.008567052209899081" Q="0.0" RANDOM="YES" SCALE="20.0" SORT_BY="WEIGHT" STUDIES="8" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="26.5574790761016" TOTALS="YES" TOTAL_1="1500" TOTAL_2="895" UNITS="mg²/dL²" WEIGHT="99.99999999999999" Z="2.6288643689589977">
<NAME>Calcium x phosphorous</NAME>
<GROUP_LABEL_1>Calcimimetic</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo/no treatment</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours calcimimetic</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<CONT_DATA CI_END="4.098707273947994" CI_START="-16.098707273947994" EFFECT_SIZE="-6.0" ESTIMABLE="YES" MEAN_1="54.1" MEAN_2="60.1" MODIFIED="2013-01-17 09:39:30 +1100" MODIFIED_BY="[Empty name]" ORDER="120" SD_1="15.3" SD_2="13.6" SE="5.152496348711154" STUDY_ID="STD-Malluche-2008" TOTAL_1="19" TOTAL_2="13" WEIGHT="7.507399299881361"/>
<CONT_DATA CI_END="2.226339145614441" CI_START="-9.22633914561444" EFFECT_SIZE="-3.5" ESTIMABLE="YES" MEAN_1="53.1" MEAN_2="56.6" ORDER="94161" SD_1="10.5" SD_2="12.81" SE="2.921655291006913" STUDY_ID="STD-Quarles-2003a" TOTAL_1="34" TOTAL_2="31" WEIGHT="11.360654374422806"/>
<CONT_DATA CI_END="5.654249810405708" CI_START="-4.054249810405714" EFFECT_SIZE="0.7999999999999972" ESTIMABLE="YES" MEAN_1="53.5" MEAN_2="52.7" MODIFIED="2013-01-16 20:15:45 +1100" MODIFIED_BY="[Empty name]" ORDER="87" SD_1="11.2" SD_2="10.2" SE="2.4767035765429433" STUDY_ID="STD-El-Shafey-2011" TOTAL_1="55" TOTAL_2="27" WEIGHT="12.195377813517364"/>
<CONT_DATA CI_END="-5.382977649984219" CI_START="-15.037022350015782" EFFECT_SIZE="-10.21" ESTIMABLE="YES" MEAN_1="51.62" MEAN_2="61.83" MODIFIED="2013-01-16 21:56:46 +1100" MODIFIED_BY="[Empty name]" ORDER="106" SD_1="14.71" SD_2="14.74" SE="2.462811759854119" STUDY_ID="STD-Fukagawa-2008" TOTAL_1="72" TOTAL_2="71" WEIGHT="12.221029492664758"/>
<CONT_DATA CI_END="-4.981057587308246" CI_START="-11.218942412691757" EFFECT_SIZE="-8.100000000000001" ESTIMABLE="YES" MEAN_1="50.0" MEAN_2="58.1" ORDER="94160" SD_1="15.43" SD_2="13.06" SE="1.5913263903283812" STUDY_ID="STD-Lindberg-2005" TOTAL_1="288" TOTAL_2="100" WEIGHT="13.705343273931204"/>
<CONT_DATA CI_END="-4.6867790437738535" CI_START="-9.91322095622614" EFFECT_SIZE="-7.299999999999997" ESTIMABLE="YES" MEAN_1="45.7" MEAN_2="53.0" MODIFIED="2013-01-17 09:44:52 +1100" MODIFIED_BY="[Empty name]" ORDER="125" SD_1="14.9" SD_2="14.7" SE="1.3333004977840908" STUDY_ID="STD-OPTIMA-Study-2008" TOTAL_1="368" TOTAL_2="184" WEIGHT="14.070347475252975"/>
<CONT_DATA CI_END="-6.782366313776372" CI_START="-11.217633686223628" EFFECT_SIZE="-9.0" ESTIMABLE="YES" MEAN_1="51.0" MEAN_2="60.0" ORDER="94159" SD_1="15.41" SD_2="15.39" SE="1.1314665492407203" STUDY_ID="STD-Block-2004a" TOTAL_1="371" TOTAL_2="370" WEIGHT="14.32179168330198"/>
<CONT_DATA CI_END="2.8584915343230968" CI_START="-0.4584915343230913" EFFECT_SIZE="1.2000000000000028" ESTIMABLE="YES" MEAN_1="40.1" MEAN_2="38.9" MODIFIED="2013-01-16 13:18:31 +1100" MODIFIED_BY="[Empty name]" ORDER="75" SD_1="8.3" SD_2="6.9" SE="0.8461846990072591" STUDY_ID="STD-Chonchol-2009" TOTAL_1="293" TOTAL_2="99" WEIGHT="14.618056587027539"/>
</CONT_OUTCOME>
</COMPARISON>
</ANALYSES_AND_DATA>
<FIGURES MODIFIED="2014-12-08 16:15:08 +1100" MODIFIED_BY="Narelle Willis">
<FIGURE FILENAME="Flowchart.png" FILE_TYPE="PNG" ID="FIG-01" MODIFIED="2014-12-08 16:15:06 +1100" MODIFIED_BY="Narelle Willis" NO="1" SHORT_VERSION_FIGURE="YES" TYPE="OTHER">
<CAPTION>
<P>Study flow diagram.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAooAAAI1CAYAAABR6NssAAB6oklEQVR42uydD6RVS9j/L9d15boS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</FILE>
</FIGURE>
<FIGURE FILENAME="Risk of bias summary.png" FILE_TYPE="PNG" ID="FIG-02" MODIFIED="2014-12-08 16:15:07 +1100" MODIFIED_BY="Narelle Willis" NO="2" SHORT_VERSION_FIGURE="YES" TYPE="QUALITY_TABLE_PLOT">
<CAPTION>
<P>Risk of bias summary: review authors' judgements about each risk of bias item for each included study.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAXkAAANxCAIAAACOrV4uAAA9AUlEQVR42u2dv27jSLaHCRgwHHTg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=
</FILE>
</FIGURE>
<FIGURE FILENAME="Risk of bias graph.png" FILE_TYPE="PNG" ID="FIG-03" MODIFIED="2014-12-08 16:15:08 +1100" MODIFIED_BY="Narelle Willis" NO="3" SHORT_VERSION_FIGURE="YES" TYPE="QUALITY_GRAPH_PLOT">
<CAPTION>
<P>Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAl4AAAEACAMAAABVk4iuAAADAFBMVEUAAADAAAAAwAAAAMDg4ADA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</FILE>
</FIGURE>
</FIGURES>
<FEEDBACK/>
<APPENDICES MODIFIED="2014-12-08 16:15:06 +1100" MODIFIED_BY="Narelle Willis">
<APPENDIX ID="APP-01" MODIFIED="2014-12-08 16:15:06 +1100" MODIFIED_BY="Narelle Willis" NO="1">
<TITLE MODIFIED="2014-05-28 12:20:21 +1000" MODIFIED_BY="[Empty name]">Electronic search strategies</TITLE>
<APPENDIX_BODY MODIFIED="2014-05-28 12:26:30 +1000" MODIFIED_BY="[Empty name]">
<TABLE COLS="2" ROWS="4">
<TR>
<TH>
<P>Database</P>
</TH>
<TH>
<P>Search terms</P>
</TH>
</TR>
<TR>
<TD>
<P>CENTRAL</P>
</TD>
<TD>
<OL>
<LI>KIDNEY DISEASES single term</LI>
<LI>KIDNEY FAILURE single term</LI>
<LI>KIDNEY FAILURE CHRONIC single term</LI>
<LI>RENAL DIALYSIS explode all trees</LI>
<LI>(hemodialysis or haemodialysis)</LI>
<LI>dialysis</LI>
<LI>(capd or ccpd or apd)</LI>
<LI>predialysis</LI>
<LI>((chronic next renal) or (chronic next kidney))</LI>
<LI>(kidney next disease*)</LI>
<LI>(kidney next failure)</LI>
<LI>(#1 or #2 or #3 or #4 or #5 or #6 or #7 or #8 or #9 or #10 or #11)</LI>
<LI>BONE DISEASES explode all trees</LI>
<LI>RENAL OSTEODYSTROPHY single term</LI>
<LI>(bone next disease*)</LI>
<LI>(bone* and (atroph* or formation or deform* or destruct* or necrosis or resorption or metabol* or turnover or demineral* or decalcif* or density))</LI>
<LI>(osteo* or hyperparathyroid*)</LI>
<LI>(#13 or #14 or #15 or #16 or #17)</LI>
<LI>(#12 and #18)</LI>
<LI>calcimimetic*</LI>
<LI>cinacalcet</LI>
<LI>NAPHTHALENES single term</LI>
<LI>(#20 or #21 or #22)</LI>
<LI>(#19 and #23)</LI>
</OL>
</TD>
</TR>
<TR>
<TD>
<P>MEDLINE</P>
</TD>
<TD>
<OL>
<LI>Kidney Diseases/</LI>
<LI>Kidney Failure/</LI>
<LI>Kidney Failure Chronic/</LI>
<LI>exp Renal Dialysis/</LI>
<LI>((kidney$ or renal) and (dialysis or failure)).tw.</LI>
<LI>(hemodialysis or haemodialysis).tw.</LI>
<LI>(peritoneal dialysis or CAPD or CCPD or APD).tw.</LI>
<LI>or/1-7</LI>
<LI>exp Bone Diseases/</LI>
<LI>bone disease$.tw.</LI>
<LI>(bone$ and (atroph$ or formation or deform$ or destruct$ or necrosis or resorption or metabol$ or turnover or demineral$ or decalcif$ or density)).tw.</LI>
<LI>(osteo$ or hyperparathyroid$).tw.</LI>
<LI>or/9-12</LI>
<LI>8 and 13</LI>
<LI>Renal Osteodystrophy/</LI>
<LI>14 or 15</LI>
</OL>
</TD>
</TR>
<TR>
<TD>
<P>EMBASE</P>
</TD>
<TD>
<OL>
<LI>Kidney Disease/</LI>
<LI>2. Kidney Failure/</LI>
<LI>3. Chronic Kidney Failure/</LI>
<LI>4. exp hemodialysis/</LI>
<LI>5. (hemodialysis or haemodialysis).tw.</LI>
<LI>6. dialysis.tw.</LI>
<LI>7. (CAPD or CCPD or APD).tw.</LI>
<LI>8. predialysis.tw.</LI>
<LI>9. (chronic renal or chronic kidney).tw.</LI>
<LI>10. or/1-9</LI>
<LI>11. exp Bone Disease/</LI>
<LI>12. bone disease$.tw.</LI>
<LI>13. (bone$ and (atroph$ or formation or deform$ or destruct$ or necrosis or resorption or metabol$ or turnover or demineral$ or decalcif$ or density)).tw.</LI>
<LI>14. (osteo$ or hyperparathyroid$).tw.</LI>
<LI>15. Renal Osteodystrophy/</LI>
<LI>16. or/11-15</LI>
<LI>17. 10 and 16</LI>
<LI>18. Calcimimetic Agent/</LI>
<LI>19. Cinacalcet/</LI>
<LI>20. naphthalene derivative/ or naphthalene/</LI>
<LI>21. ("R-568" or "AMG 074" or "AMG 073" or "KRN 1493").tw.</LI>
<LI>22. calcimimetic$.tw.</LI>
<LI>23. cinacalcet.tw.</LI>
<LI>24. or/18-23</LI>
<LI>25. and/17,24</LI>
</OL>
<P/>
</TD>
</TR>
</TABLE>
<P/>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-02" MODIFIED="2014-12-08 16:15:06 +1100" MODIFIED_BY="Narelle Willis" NO="2">
<TITLE MODIFIED="2013-06-01 19:03:22 +1000" MODIFIED_BY="Suetonia Palmer">Risk of Bias Assessment Tool</TITLE>
<APPENDIX_BODY MODIFIED="2014-05-28 12:22:04 +1000" MODIFIED_BY="[Empty name]">
<TABLE COLS="2" ROWS="22">
<TR>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>
<B>Potential source of bias</B>
</P>
</TH>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>
<B>Assessment criteria</B>
</P>
</TH>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>
<B>Random sequence generation</B>
</P>
<P>Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence</P>
</TD>
<TD>
<P>
<I>Low risk of bias: </I>Random number table; computer random number generator; coin tossing; shuffling cards or envelopes; throwing dice; drawing of lots; minimisation (minimisation may be implemented without a random element, and this is considered to be equivalent to being random)</P>
</TD>
</TR>
<TR>
<TD>
<P>
<I>High risk of bias: </I>Sequence generated by odd or even date of birth; date (or day) of admission; sequence generated by hospital or clinic record number; allocation by judgement of the clinician; by preference of the participant; based on the results of a laboratory test or a series of tests; by availability of the intervention</P>
</TD>
</TR>
<TR>
<TD>
<P>
<I>Unclear: </I>Insufficient information about the sequence generation process to permit judgement</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>
<B>Allocation concealment</B>
</P>
<P>Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment</P>
</TD>
<TD>
<P>
<I>Low risk of bias: </I>Randomisation method described that would not allow investigator/participant to know or influence intervention group before eligible participant entered in the study (e.g. central allocation, including telephone, web-based, and pharmacy-controlled, randomisation; sequentially numbered drug containers of identical appearance; sequentially numbered, opaque, sealed envelopes)</P>
</TD>
</TR>
<TR>
<TD>
<P>
<I>High risk of bias: </I>Using an open random allocation schedule (e.g. a list of random numbers); assignment envelopes were used without appropriate safeguards (e.g. if envelopes were unsealed or non-opaque or not sequentially numbered); alternation or rotation; date of birth; case record number; any other explicitly unconcealed procedure</P>
</TD>
</TR>
<TR>
<TD>
<P>
<I>Unclear</I>: Randomisation stated but no information on method used is available</P>
</TD>
</TR>
<TR>
<TD ROWSPAN="3" VALIGN="TOP">
<P>
<B>Blinding of participants and personnel</B>
</P>
<P>Performance bias due to knowledge of the allocated interventions by participants and personnel during the study</P>
</TD>
<TD>
<P>
<I>Low risk of bias</I>: No blinding or incomplete blinding, but the review authors judge that the outcome is not likely to be influenced by lack of blinding; blinding of participants and key study personnel ensured, and unlikely that the blinding could have been broken</P>
</TD>
</TR>
<TR>
<TD>
<P>
<I>High risk of bias</I>: No blinding or incomplete blinding, and the outcome is likely to be influenced by lack of blinding; blinding of key study participants and personnel attempted, but likely that the blinding could have been broken, and the outcome is likely to be influenced by lack of blinding</P>
</TD>
</TR>
<TR>
<TD>
<P>
<I>Unclear</I>: Insufficient information to permit judgement</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>
<B>Blinding of outcome assessment</B>
</P>
<P>Detection bias due to knowledge of the allocated interventions by outcome assessors.</P>
</TD>
<TD>
<P>
<I>Low risk of bias: </I>No blinding of outcome assessment, but the review authors judge that the outcome measurement is not likely to be influenced by lack of blinding; blinding of outcome assessment ensured, and unlikely that the blinding could have been broken</P>
</TD>
</TR>
<TR>
<TD>
<P>
<I>High risk of bias: </I>No blinding of outcome assessment, and the outcome measurement is likely to be influenced by lack of blinding; blinding of outcome assessment, but likely that the blinding could have been broken, and the outcome measurement is likely to be influenced by lack of blinding</P>
</TD>
</TR>
<TR>
<TD>
<P>
<I>Unclear: </I>Insufficient information to permit judgement</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>
<B>Incomplete outcome data</B>
</P>
<P>Attrition bias due to amount, nature or handling of incomplete outcome data.</P>
</TD>
<TD>
<P>
<I>Low risk of bias: </I>No missing outcome data; reasons for missing outcome data unlikely to be related to true outcome (for survival data, censoring unlikely to be introducing bias); missing outcome data balanced in numbers across intervention groups, with similar reasons for missing data across groups; for dichotomous outcome data, the proportion of missing outcomes compared with observed event risk not enough to have a clinically relevant impact on the intervention effect estimate; for continuous outcome data, plausible effect size (difference in means or standardised difference in means) among missing outcomes not enough to have a clinically relevant impact on observed effect size; missing data have been imputed using appropriate methods</P>
</TD>
</TR>
<TR>
<TD>
<P>
<I>High risk of bias: </I>Reason for missing outcome data likely to be related to true outcome, with either imbalance in numbers or reasons for missing data across intervention groups; for dichotomous outcome data, the proportion of missing outcomes compared with observed event risk enough to induce clinically relevant bias in intervention effect estimate; for continuous outcome data, plausible effect size (difference in means or standardised difference in means) among missing outcomes enough to induce clinically relevant bias in observed effect size; &#8216;as-treated&#8217; analysis done with substantial departure of the intervention received from that assigned at randomisation; potentially inappropriate application of simple imputation</P>
</TD>
</TR>
<TR>
<TD>
<P>
<I>Unclear: </I>Insufficient information to permit judgement</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>
<B>Selective reporting</B>
</P>
<P>Reporting bias due to selective outcome reporting</P>
</TD>
<TD>
<P>
<I>Low risk of bias: </I>The study protocol is available and all of the study&#8217;s pre-specified (primary and secondary) outcomes that are of interest in the review have been reported in the pre-specified way; the study protocol is not available but it is clear that the published reports include all expected outcomes, including those that were pre-specified (convincing text of this nature may be uncommon)</P>
</TD>
</TR>
<TR>
<TD>
<P>
<I>High risk of bias: </I>Not all of the study&#8217;s pre-specified primary outcomes have been reported; one or more primary outcomes is reported using measurements, analysis methods or subsets of the data (e.g. subscales) that were not pre-specified; one or more reported primary outcomes were not pre-specified (unless clear justification for their reporting is provided, such as an unexpected adverse effect); one or more outcomes of interest in the review are reported incompletely so that they cannot be entered in a meta-analysis; the study report fails to include results for a key outcome that would be expected to have been reported for such a study</P>
</TD>
</TR>
<TR>
<TD>
<P>
<I>Unclear: </I>Insufficient information to permit judgement</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>
<B>Other bias</B>
</P>
<P>Bias due to problems not covered elsewhere in the table</P>
</TD>
<TD>
<P>
<I>Low risk of bias: </I>The study appears to be free of other sources of bias</P>
</TD>
</TR>
<TR>
<TD>
<P>
<I>High risk of bias:</I> Had a potential source of bias related to the specific study design used; stopped early due to some data-dependent process (including a formal-stopping rule); had extreme baseline imbalance; has been claimed to have been fraudulent; had some other problem</P>
</TD>
</TR>
<TR>
<TD>
<P>
<I>Unclear: </I>Insufficient information to assess whether an important risk of bias exists; insufficient rationale or evidence that an identified problem will introduce bias</P>
</TD>
</TR>
</TABLE>
</APPENDIX_BODY>
</APPENDIX>
</APPENDICES>
<EXTENSIONS>
<EXTENSION ID="AFF_33825053211215209688111117004628_1" NAME="PERSON" REVMAN_VERSION="5.1.0" TYPE="ADDRESS">
<ALIAS ALIAS_ID="33825053211215209688111117004628">
<ADDRESS>
<DEPARTMENT>European Renal Best Practice Methods Support Team</DEPARTMENT>
<ORGANISATION>Ghent University Hospital</ORGANISATION>
<ADDRESS_1/>
<ADDRESS_2/>
<CITY>Ghent</CITY>
<ZIP/>
<REGION/>
<COUNTRY CODE="BE">Belgium</COUNTRY>
<PHONE_1/>
<PHONE_2/>
<FAX_1/>
<FAX_2/>
</ADDRESS>
</ALIAS>
</EXTENSION>
<EXTENSION ID="AFF_16154_1" NAME="PERSON" REVMAN_VERSION="5.1.0" TYPE="ADDRESS">
<ALIAS ALIAS_ID="16154">
<ADDRESS>
<DEPARTMENT>Department of Emergency and Organ Transplantation</DEPARTMENT>
<ORGANISATION>University of Bari</ORGANISATION>
<ADDRESS_1/>
<ADDRESS_2/>
<CITY>Bari</CITY>
<ZIP>70100</ZIP>
<REGION/>
<COUNTRY CODE="IT">Italy</COUNTRY>
<PHONE_1/>
<PHONE_2/>
<FAX_1/>
<FAX_2/>
</ADDRESS>
</ALIAS>
</EXTENSION>
<EXTENSION ID="AFF_16154_2" NAME="PERSON" REVMAN_VERSION="5.1.0" TYPE="ADDRESS">
<ALIAS ALIAS_ID="16154">
<ADDRESS>
<DEPARTMENT>Department of Clinical Pharmacology and Epidemiology</DEPARTMENT>
<ORGANISATION>Mario Negri Sud Consortium</ORGANISATION>
<ADDRESS_1/>
<ADDRESS_2/>
<CITY>Santa Maria Imbaro</CITY>
<ZIP/>
<REGION/>
<COUNTRY CODE="IT">Italy</COUNTRY>
<PHONE_1/>
<PHONE_2/>
<FAX_1/>
<FAX_2/>
</ADDRESS>
</ALIAS>
</EXTENSION>
<EXTENSION ID="AFF_16154_3" NAME="PERSON" REVMAN_VERSION="5.1.0" TYPE="ADDRESS">
<ALIAS ALIAS_ID="16154">
<ADDRESS>
<DEPARTMENT>Sydney School of Public Health</DEPARTMENT>
<ORGANISATION>The University of Sydney</ORGANISATION>
<ADDRESS_1/>
<ADDRESS_2/>
<CITY>Sydney</CITY>
<ZIP/>
<REGION/>
<COUNTRY CODE="AU">Australia</COUNTRY>
<PHONE_1/>
<PHONE_2/>
<FAX_1/>
<FAX_2/>
</ADDRESS>
</ALIAS>
</EXTENSION>
<EXTENSION ID="AFF_16154_4" NAME="PERSON" REVMAN_VERSION="5.1.0" TYPE="ADDRESS">
<ALIAS ALIAS_ID="16154">
<ADDRESS>
<DEPARTMENT>Medical-Scientific Office</DEPARTMENT>
<ORGANISATION>Diaverum</ORGANISATION>
<ADDRESS_1/>
<ADDRESS_2/>
<CITY>Lund</CITY>
<ZIP/>
<REGION/>
<COUNTRY CODE="SE">Sweden</COUNTRY>
<PHONE_1/>
<PHONE_2/>
<FAX_1/>
<FAX_2/>
</ADDRESS>
</ALIAS>
</EXTENSION>
<EXTENSION ID="AFF_16154_5" NAME="PERSON" REVMAN_VERSION="5.1.0" TYPE="ADDRESS">
<ALIAS ALIAS_ID="16154">
<ADDRESS>
<DEPARTMENT>Division of Nephrology and Transplantation, Department of Translational Medicine</DEPARTMENT>
<ORGANISATION>Amedeo Avogadro University of Eastern Piedmont</ORGANISATION>
<ADDRESS_1/>
<ADDRESS_2/>
<CITY>Novara</CITY>
<ZIP>28100</ZIP>
<REGION/>
<COUNTRY CODE="IT">Italy</COUNTRY>
<PHONE_1/>
<PHONE_2/>
<FAX_1/>
<FAX_2/>
</ADDRESS>
</ALIAS>
</EXTENSION>
<EXTENSION ID="AFF_4552_1" NAME="PERSON" REVMAN_VERSION="5.1.0" TYPE="ADDRESS">
<ALIAS ALIAS_ID="4552">
<ADDRESS>
<DEPARTMENT>Cochrane Renal Group, Centre for Kidney Research</DEPARTMENT>
<ORGANISATION>The Children's Hospital at Westmead</ORGANISATION>
<ADDRESS_1/>
<ADDRESS_2/>
<CITY>Westmead</CITY>
<ZIP>2145</ZIP>
<REGION>NSW</REGION>
<COUNTRY CODE="AU">Australia</COUNTRY>
<PHONE_1>+61 2 98451469</PHONE_1>
<PHONE_2/>
<FAX_1>+61 2 98451491</FAX_1>
<FAX_2/>
</ADDRESS>
</ALIAS>
</EXTENSION>
<EXTENSION ID="FLOW_1" NAME="FIGURE" REVMAN_VERSION="5.1.0" TYPE="FLOWCHART">
<ALIAS ALIAS_ID="1">
<FLOWCHARTBOX TEXT="&lt;p&gt;2014 review update&lt;/p&gt;&lt;p&gt;Total included studies: 18 studies (88 reports; 7446 participants)&lt;/p&gt;&lt;p&gt;Total excluded studies:18 studies (26 reports)&lt;/p&gt;&lt;p&gt;Ongoing studies: 0&lt;/p&gt;&lt;p&gt;Studies awaiting assessment: 4 studies (4 reports)&lt;/p&gt;" WIDTH="450">
<FLOWCHARTBOX TEXT="&lt;p&gt;Included studies: 8 (8 reports)&lt;/p&gt;&lt;p&gt;Excluded studies: 17 (8 reports)&lt;/p&gt;&lt;p&gt;Studies awaiting assessment: 11 (8 reports)&lt;/p&gt;&lt;p&gt;Ongoing studies: 2 (2 reports)&lt;/p&gt;" WIDTH="300">
<FLOWCHARTBOX TEXT="&lt;p&gt;Excluded after title and abstract review: 148&lt;/p&gt;&lt;p&gt;Reports excluded after full text review: 17 (not RCT; wrong population; wrong intervention)&lt;/p&gt;" WIDTH="300">
<FLOWCHARTBOX TEXT="&lt;p&gt;2006 review: 186 reports screened&lt;/p&gt;&lt;p&gt;CENTRAL (12); MEDLINE (61); EMBASE (113)&lt;/p&gt;" WIDTH="300"/>
</FLOWCHARTBOX>
</FLOWCHARTBOX>
<FLOWCHARTBOX TEXT="&lt;p&gt;New included studies: 10 (43 reports)&lt;/p&gt;&lt;p&gt;Existing included studies: 6 (40 new reports)&lt;/p&gt;&lt;p&gt;New studies awaiting assessment: 2 (2 reports)&lt;/p&gt;&lt;p&gt;Excluded studies: 18 (26 reports) (not RCT; wrong population or intervention)&lt;/p&gt;" WIDTH="300">
<FLOWCHARTBOX TEXT="&lt;p&gt;Excluded after title and abstract review: 134 (duplicates; not RCT; wrong population or intervention)&lt;/p&gt;" WIDTH="300">
<FLOWCHARTBOX TEXT="&lt;p&gt;2014 review update: 245 records screened&lt;/p&gt;&lt;p&gt;Renal Group Register (78); EMBASE (167)&lt;/p&gt;" WIDTH="300"/>
</FLOWCHARTBOX>
</FLOWCHARTBOX>
</FLOWCHARTBOX>
</ALIAS>
</EXTENSION>
</EXTENSIONS>
</COCHRANE_REVIEW>